Stereoselective synthesis of secondary and tertiary amines through bronsted base assisted mannich, nitro-mannich and a-amination reactions. by Bastida Saiz, Iñaki
Stereoselective Synthesis of 
Secondary and Tertiary Amines 
through Brønsted Base Assisted 
Mannich, Nitro-Mannich and 
α-Amination Reactions 
DOCTORAL THESIS 
Iñaki Bastida Saiz 
Donostia, 2018
(cc)2018 IÑAKI BASTIDA SAIZ (cc by-nc 4.0)
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ama, Aita… zuei esker eta zuentzat
  
 
  
 
ESKERRAK 
Esta Tesis Doctoral ha sido realizada en el Departamento de Química Orgánica I de la 
Facultad de Química de Donostia, Universidad del País Vasco (UPV/EHU), bajo la 
dirección del Dr. Claudio Palomo Nicolau, a quien expreso mi gratitud por la 
oportunidad, dedicación y esfuerzo brindados, y la Dra. Rosa Mª López Álvarez, pilar 
fundamental de este trabajo, a quien estoy totalmente agradecido por todo su apoyo, 
tanto en lo profesional como en lo personal, por su dedicación y pasión con la que me 
ha enseñado todo lo aprendido y por toda la confianza depositada en mí desde el primer 
día. ¡¡Muchísimas gracias!! 
I also want to thank Prof. Phil S. Baran and his group for giving me the opportunity to 
do a short but unforgettable stay in his laboratory at The Scripps Research Institute in 
La Jolla (California, USA) and participate in one of their research projects. Thank you very 
much for your kindness and hospitality. 
La financiación de este trabajo ha provenido de una beca predoctoral del Gobierno 
Vasco, así como la ayuda para la realización de estancias predoctorales en centros 
distintos al de aplicación para el personal investigador en formación. 
Labokideei, eskerrik asko guztiagatik!! Zuen laguntza, barreak, negarrak, bazkariak, 
karameloak, abestiak, dantzak, besarkadak, marmarrak, juergak, eztulak, oihuak… ez 
ditut inoiz ahaztuko. Zuek ezagutu eta bidelagun izatea, ibilbide honetako onena izan 
da!! Eskerrik asko benetan!!! 
Kuadrilako lagunei, lana dela eta, zuekin oso gutxitan egon arren, beti hor egoteagatik 
eta nahiz eta zuek ez konturatu, lanaren zama arintzen laguntzeagatik, eskerrik asko!! 
Nire gurasoei, 27 urte hauetan eman didazuen guztiagatik. Tesi honen egileak zuek 
zarete!! Zuen maitasun, laguntza eta jakintzek ekarri naute honaino, eta zuen babesa 
une oro sentitzeak beldurrik gabe aurrera egitera bultzatu nau. Aneri, nigan, nik baino 
mila aldiz gehiago konfiatzeagatik. Jaio nintzen unetik nire alboan egoteagatik eta nire 
babeslerik onena izateagatik. Urkiri, gure familian hain gogor sartzeagatik eta lehen 
momentutik zure babesa eta animoak emateagatik. Marisa, Kepa, Amaia eta Jokini, zuen 
baldintzarik gabeko maitasun, animo eta babes guztiagatik. Eta azkenik, Maitaneri, 
nirekin bizitza konpartitzeagatik, momentu on zein txarrenetan beti hor egoteagatik, tesi 
honen bultzatzaile sutsuena izateagatik, egunero irribarre bat ateratzeagatik… azken 
finean, ZU izateagatik!! 
Matte zaituztet!!
  
 
SUMMARY 
Chiral amines, structures with a carbon stereocenter adjacent to an amino group, are 
widely present as pharmaceutical or agrochemical compounds as well as natural 
products. In addition, they are also employed as ligands or catalysts in organic synthesis. 
 
Figure 1. Representative examples of chiral amines as drugs, natural products, ligands and catalysts. 
The interest of chiral amines has led to the development of several catalytic 
asymmetric methodologies for their synthesis during the last years. The main strategies 
are based, on the one hand, on reductive methods which provide exclusively secondary 
amines and, on the other hand, on C–C or C–N bond forming methodologies for the 
synthesis of secondary and tertiary amines (Scheme 1). Hydroamination and amination 
reactions are among the most popular approaches for C–N generation, whereas the 
stereoselective addition of carbon (pro)nucleophiles to azomethine groups is the one 
for C–C bond formations. 
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Scheme 1. Main strategies for chiral amine synthesis. 
In this context, the main objective of this Ph. D. Thesis has been the development of 
new Brønsted base catalyzed methodologies for the synthesis of enantiomerically 
enriched secondary and tertiary amines of synthetic utility and with possible biological 
activity. 
Many structures derived from enantiomerically pure γ-sulfonyl allyl amines have 
shown capacity to inhibit a wide variety of enzymatic processes. The structural 
requirements for an optimal enzyme-substrate recognition are still unknown and the 
elaboration of this type of structures could lead to the identification of more specific 
inhibitors or ones with better pharmacological properties. Nevertheless, there are 
practically no methodologies for their synthesis through catalytic enantioselective 
procedures. For that purpose, we envisioned that 2-nitroethyl sulfones could be 
employed as vinyl sulfone anion synthetic equivalents in chiral Brønsted base catalyzed 
nitro-Mannich type reactions to produce, after nitrous acid elimination, 
enantiomerically enriched secondary amines (Scheme 2). This approach would lead to 
the formation of the C–C bond and the new stereogenic center in a single step, which is 
a great advantage over the methodologies described to date.  
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Scheme 2. Synthetic plan for the enantioselective preparation of γ-sulfonyl allyl amines. *BB: chiral 
Brønsted base. 
Based on this hypothesis, we have developed an enantioselective methodology for the 
nitro-Mannich reaction of 2-nitroethyl sulfones with N-Boc imines, catalyzed by a 
ureidopeptide-based bifunctional Brønsted base. The subsequent nitrous acid 
elimination affords the corresponding γ-sulfonyl allyl amines in variable yields and with 
generally excellent enantioselectivities (Scheme 3). 
 
Scheme 3. Enantioselective synthesis of γ-sulfonyl allyl amines. 
On the other hand, ortho-substituted pyridines are common fragments in chiral 
compounds with biological activity. In particular, α- and/or β-functionalized pyridines 
containing amino groups constitute a relevant family (Figure 2).  
 
Figure 2. Representative examples of pyridines containing amino groups with biological activity.  
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In order to address the stereoselective synthesis of this type of chiral amines, we 
considered that 2-alkyl pyridines could be employed as pronucleophiles in chiral 
Brønsted base-catalyzed C–N and C–C bond forming reactions; in particular, the α-
amination reaction for the preparation of tertiary amines and the Mannich-type reaction 
for the synthesis of secondary amines (Scheme 4). 
 
Scheme 4. Synthetic plan for the stereoselective preparation of pyridine based amines. EWG: electron-
withdrawing group. 
To date, the main limitation of 2-alkyl azaarenes as pronucleophiles in catalytic 
asymmetric reactions is their low acidity, thus, generally stoichiometric amounts of base 
are required. On the other hand, no methodologies for the generation of 
tetrasubstituted stereogenic centers, which would afford chiral tertiary amines, have 
been described. 
In order to enhance the low reactivity of 2-alkyl pyridines under basic conditions, we 
considered to employ 2-alkyl pyridine N-oxides as their synthetic equivalents. It is well 
known that the oxidation of the pyridine increases the acidity of the carbon at α position 
(Figure 3). Moreover, the N-oxide group could act as an additional coordinating site for 
the catalyst binding and provide more rigid transition states.  
 
Figure 3. pKa values for pyridine derivatives and their N-oxides. 
Hence, we have developed a methodology for the enantioselective synthesis of tertiary 
amines through α-amination of 2-cyanoalkyl pyridine N-oxides catalyzed by a novel 
squaramide-based Brønsted base bearing a bulky silyl group. The reduction of the 
adducts affords the corresponding enantiomerically enriched pyridine based tertiary 
amines (Scheme 5). 
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Scheme 5. Enantioselective synthesis of pyridine based tertiary amines (JACS 2016, 138, 3282–3285). 
Likewise, we have developed a highly stereoselective Mannich-type reaction of 2-
azaaryl acetate N-oxides with N-carbamoyl aldimines for the synthesis of pyridine based 
chiral secondary amines (Scheme 6). In this case, the ureidopeptide-based Brønsted 
base employed, not only provides excellent levels of asymmetric induction but is also 
able to preserve the configurational stability of the new generated tertiary 
stereocenters during the reaction.  
 
Scheme 6. Stereoselective synthesis of pyridine based secondary amines (Chem. Eur. J. 2017, 23, 
13332–13336). 
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In both cases, the dual role of the N-oxide functionality as an activating and 
stereodirecting group has been proved since the parent 2-alkyl pyridines reacted 
sluggishly and with diminished stereoselectivities. 
Finally, during a short stay at The Scripps Research Institute in La Jolla (California, USA), 
under the supervision of Prof. Baran, a synthetic strategy for the enantio- and 
diastereoselective modular preparation of trans-disubstituted cyclopropanes has been 
developed by the combination of the following reactions: i) desymmetrization of the 
caronic or 1,2-cyclopropanecarboxylic anhydride, ii) formation of the redox-active ester, 
iii) C–C cross-coupling, iv) hydrolysis, v) formation of the redox-active ester, and vi) 
subsequent C–C cross-coupling (Scheme 7). 
 
Scheme 7. Synthetic plan for the modular and stereoselective preparation of trans-disubstituted 
cyclopropanes. RAE: redox-active ester. 
For that purpose, the optimization of nickel catalyzed Negishi and Suzuki 
decarboxylative cross-coupling reactions has been carried out and the synthesis of a 
series of highly enantioenriched trans-disubstituted cyclopropanes has been 
successfully accomplished (Figure 4). 
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Figura 4. Synthetized trans-disubstituted cyclopropanes (Nature 2018, 560, 350–354).
   
 RESUMEN 
Las aminas quirales, por la presencia de un carbono estereogénico en la posición α, 
son estructuras muy frecuentes tanto en productos farmacéuticos y agroquímicos, como 
en productos naturales. Asimismo, también son ampliamente empleadas como ligandos 
y catalizadores en síntesis orgánica (Figura 1). 
 
Figura 1. Ejemplos representativos de aminas quirales como fármacos, productos naturales, ligandos y 
catalizadores. 
En los últimos años, el interés por estas estructuras ha motivado el desarrollo de un 
gran número de metodologías catalíticas y asimétricas. Las principales estrategias para 
la síntesis de este tipo de aminas quirales se centran, por un lado, en métodos 
reductores que conducen exclusivamente a la formación de aminas secundarias y, por 
otro lado, en metodologías de formación de enlaces C–C o C–N para la síntesis de aminas 
secundarias y terciarias (Esquema 1). Las reacciones de hidroaminación y aminación son 
las transformaciones más empleadas para la generación de enlaces C–N, mientras que 
la adición de (pro)nucleófilos carbonados a grupos azometino constituye la estrategia 
más relevante para la formación de enlaces C–C. 
Resumen 
 
 
 
Esquema 1. Estrategias principales para la síntesis de aminas quirales. 
En este contexto, el objetivo principal de esta Tesis Doctoral ha sido el desarrollo de 
nuevas metodologías de formación de enlaces C–C y C–N, catalizadas por bases de 
Brønsted quirales, para la síntesis de aminas secundarias y terciarias 
enantioméricamente enriquecidas con utilidad sintética y posible actividad biológica. 
Varias estructuras derivadas de γ-sulfonil alil aminas enantioméricamente puras han 
demostrado tener capacidad para inhibir una amplia variedad de procesos enzimáticos. 
Los requisitos estructurales para un reconocimiento enzima–sustrato óptimo son aún 
desconocidos y la elaboración de este tipo de estructuras podría llevar a la identificación 
de inhibidores más específicos o con mejores propiedades farmacológicas. Sin embargo, 
no existen prácticamente metodologías que permitan su síntesis mediante 
procedimientos catalíticos y asimétricos. Con este propósito, consideramos que las 2-
nitroetil sulfonas podrían emplearse como equivalentes sintéticos del anión vinil sulfona 
en reacciones de tipo nitro-Mannich catalizadas por bases de Brønsted quirales, para 
producir, tras la eliminación del ácido nitroso, aminas secundarias enantioméricamente 
enriquecidas (Esquema 2). Esta aproximación conduciría a la formación del enlace C–C 
y el nuevo centro estereogénico en una sola etapa, lo que supone una gran ventaja sobre 
las metodologías descritas hasta la fecha. 
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Esquema 2. Plan sintético para la preparación enantioselectiva de γ-sulfonil alil aminas. BB*: base de 
Brønsted quiral. 
Basada en esta hipótesis, ha sido posible desarrollar una metodología enantioselectiva 
para la reacción nitro-Mannich entre 2-nitroetil sulfonas y N-Boc iminas, catalizada por 
una base de Brønsted bifunctional de tipo ureidopeptídico. La posterior eliminación del 
ácido nitroso proporciona las γ-sulfonil alil aminas correspondientes con rendimientos 
variables y enantioselectividades generalmente excelentes (Esquema 3). 
 
Esquema 3. Síntesis enantioselectiva de γ-sulfonil alil aminas. 
Por otro lado, las piridinas orto-sustituidas son fragmentos muy comunes en 
compuestos quirales con actividad biológica. En particular, las piridinas α- y/o β-
funcionalizadas que contienen grupos amino constituyen una familia importante (Figura 
2). 
 
Figura 2. Ejemplos representativos de piridinas con actividad biológica que contienen grupos amino. 
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Para abordar la síntesis estereoselectiva de este tipo de aminas quirales, consideramos 
factible el empleo de 2-alquil piridinas como pronucleófilos en reacciones de formación 
de enlaces C–N y C–C catalizadas por bases de Brønsted quirales; en concreto, la 
reacción de α-aminación para producir aminas terciarias y la reacción de tipo Mannich 
para la obtención de aminas secundarias (Esquema 4). 
 
Esquema 4. Plan sintético para la síntesis estereoselectiva de aminas terciarias y secundarias. EWG: 
grupo electron-atractor. 
Hasta la fecha, el empleo de 2-alquil azaarenos como pronucleófilos en reacciones 
catalíticas y asimétricas presenta como principal limitación su baja acidez, lo que 
generalmente requiere el empleo de cantidades estequiométricas de base. Por otro 
lado, no se han descrito métodos para la generación de centros estereogénicos 
tetrasubstituidos que darían lugar a aminas terciarias quirales. 
Con el objeto de aumentar la baja reactividad de las 2-alquil piridinas en condiciones 
básicas, se eligieron los N-óxidos de 2-alquil piridina como equivalentes sintéticos. Es 
conocido que la oxidación de la piridina produce un aumento de la acidez del carbono 
en la posición α (Figura 3). Además, el grupo N-óxido podría funcionar como un punto 
de anclaje adicional en la coordinación con el catalizador y, de este modo, proporcionar 
mayor rigidez a los estados de transición. 
 
Figura 3. Valores de pKa de derivados de piridina y sus correspondientes N-óxidos. 
De este modo, se ha desarrollado una metodología que permite la síntesis 
enantioselectiva de aminas terciarias mediante la α-aminación de N-óxidos de 2-
cianoalquil piridina promovida por una nueva base de Brønsted bifuncional de tipo 
escuaramida que contiene un grupo sililo voluminoso. La reducción de los aductos 
proporciona las correspondientes aminas terciarias de piridina altamente 
enantioenriquecidas (Esquema 5). 
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Esquema 5. Síntesis enantioselectiva de aminas terciarias (JACS 2016, 138, 3282–3285). 
De forma análoga, se ha desarrollado una reacción de tipo Mannich altamente 
estereoselectiva entre N-óxidos de acetato de 2-azaarilo y N-carbamoil aldiminas que 
proporciona aminas secundarias altamente enantioenriquecidas (Esquema 6). En este 
caso, la base de Brønsted de tipo ureidopeptídico empleada no solo proporciona 
excelentes niveles de inducción asimétrica, sino que es capaz de preservar la estabilidad 
configuracional de los estereocentros terciarios generados durante la reacción. 
 
Esquema 6. Síntesis enantioselectiva de aminas secundarias (Chem. Eur. J. 2017, 23, 13332–13336). 
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En ambos casos, el papel dual del N-óxido como grupo activante y estereodirector ha 
sido corroborado, puesto que, empleando las mismas condiciones de reacción, las 2-
alquil piridinas análogas reaccionaron más lentamente y con enantioselectividades 
inferiores. 
Finalmente, durante una estancia realizada en The Scripps Research Institute en La 
Jolla (California, USA), bajo la supervisión del Prof. Baran, se ha desarrollado una 
estrategia sintética para la preparación modular diastereo- y enantioselectiva de 
ciclopropanos trans-disustituidos mediante la combinación de las siguientes reacciones: 
i) desimetrización del anhídrido carónico o 1,2-ciclopropanodicarboxílico, ii) formación 
del éster redox-activo, iii) acoplamiento cruzado C–C, iv) desprotección, v) formación del 
éster redox-activo y vi) segundo acoplamiento cruzado C–C (Esquema 7). 
 
Esquema 7. Plan sintético para la preparación modular y estereoselectiva de ciclopropanos trans-
disustituidos. RAE: éster redox-activo. 
Con este propósito, se ha llevado a cabo la optimización de reacciones de 
acoplamiento cruzado descarboxilativo de tipo Negishi y Suzuki catalizadas por níquel y 
se ha logrado la síntesis de una serie de ciclopropanos trans-disubstituidos altamente 
enantioenriquecidos (Figura 4). 
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Figura 4. Ciclopropanos trans-disustituidos sintetizados (Nature 2018, 560, 350–354). 
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AA Amino acid 
Ac Acetyl group 
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APAQ Acetyl-protected aminoethyl quinoline 
Ar Aryl group 
B Base 
BB* Chiral Brønsted base 
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Cat. Catalyst 
Cbz Carboxybenzyl group 
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d Days 
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Abbreviations and acronyms 
 
 
(DHQD)2Pyr Hydroquinidine-2,5-diphenyl-4,6-pyrimidinediyl diether 
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h Hours 
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Piv Pivaloyl group 
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1. INTRODUCTION 
1.1. Chiral amines 
1.1.1. General considerations 
A vast majority of bioactive compounds, such as agrochemicals and active 
pharmaceutical ingredients, are amines or contain functional groups derived from 
amines. As an illustration, from 1086 unique small-molecule drugs approved by U.S. FDA 
in 2012, 910 (84%) contained at least one nitrogen atom, being 2.3 the average number 
of nitrogen atoms per drug.1 
During the past decades, the number of chiral and non-racemic amines that show 
biological activity has been increasing continuously. In fact, chiral amines are powerful 
pharmacophores for defining new pharmaceutical drugs due to their high density of 
structural information and inherent ability for hydrogen bonding.2 
 
Figure 1. Examples of chiral amine-based pharmaceutical drugs. 
                                                     
1 Vitaku, E.; Smith, D. T.; Njardarson, J. T. J. Med. Chem. 2014, 57, 10257–10274. 
2 a) Chiral Amine Synthesis – Methods, Developments and Applications; Nugent, T. C., Ed.; WILEY-VCH 
Verlag: Weinheim, 2010. b) Stereoselective Formation of Amines; Wang, C., Xiao, J., Eds.; Topics in Current 
Chemistry 343; Springer: Heidelberg, 2014. 
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Figure 1 shows some examples of chiral amines used for the treatment of different 
diseases. Cinacalcet is used against hyperparathyroidism and hypercalcemia –high levels 
of calcium in the blood–.3 Codeine is an opioid used to treat severe pain,4 whereas 
amoxicillin is a penicillin antibiotic used against different types of infection caused by 
bacteria.5 In contrast, crizotinib is a cancer medication that interferes with the growth 
and spread of cancer cells in the body6 and cipargamin is an experimental synthetic 
antimalarial molecule.7 
In addition, chiral amines can also be found in a wide variety of natural products (Figure 
2). For instance, (–)-adaline acts as part of the defence system of the European ladybird, 
Adalia bipunctata, and has also been isolated from Quadrimaculata and Patherina L.8 
The sesquiterpene aminobisabolene is an antimicrobial metabolite isolated from the 
tropical sponge, Halichondria sp.9 and the aminocyclopentitol pactamycin, which was 
isolated from Streptomyces pactum var. pactum, has recently displayed antitumor, 
antimicrobial, antiviral and antiprotozoal properties by acting as a universal inhibitor of 
translocation.10  
 
Figure 2. Examples of chiral amines found in nature. 
                                                     
3 https://www.drugs.com/mtm/cinacalcet.html (accessed May 3, 2018). 
4 https://www.drugs.com/codeine.html (accessed May 3, 2018). 
5 https://www.drugs.com/amoxicillin.html (accessed May 3, 2018). 
6 https://www.drugs.com/mtm/crizotinib.html (accessed May 3, 2018). 
7 Rottmann, M.; McNamara, C.; Yeung, B. K. S.; Lee, M. C. S.; Zou, B.; Russell, B.; Seitz, P.; Plouffe, D. M.; 
Dharia, N. V; Tan, J.; Coher, S. B.; Spencer, K. R.; González-Páez, G. E.; Lakshminarayana, S. B.; Goh, A.; 
Suwanarusk, R.; Jegla, T.; Schimtt, E. K.; Beck, H.-P.; Brun, R.; Nosten, F.; Renia, L.; Dartois, V.; Keller, T. H.; 
Fidock, D. A.; Winzeler, E. A.; Diagana, T. T.; Science 2010, 329, 1175–1180. 
8 Davison, E. C.; Holmes, A. B. Tetrahedron Lett. 1995, 36, 9047–9050. 
9 Sullivan, B. W.; Faulkner, D. J.; Okamoto, K. T.; Chen, M. H. M.; Clardy, J. J. Org. Chem. 1986, 51, 5134–
5136.  
10 Malinowski, J. T.; Sharpe, R. J.; Johnson, J. S. Science 2013, 340, 180–182. 
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In this context, naturally occurring L-α-amino acids also constitute a very important 
type of chiral amines, which have an essential role as building blocks of oligopeptides 
and proteins.11 
Furthermore, chiral amines are also broadly used as chiral ligands or organocatalysts 
in asymmetric synthesis (Figure 3). For instance, chiral ferrocene P,N ligand PPFA was 
first developed by Hayashi and Kumada12 and has been used in several metal catalyzed 
enantioselective transformations.13 Likewise, chiral acetyl-protected aminoethyl 
quinoline (APAQ) has been employed in enantioselective Pd catalized C(sp3)–H bond 
activations.14 On the other hand, diarylprolinol silyl ethers developed by Jørgensen and 
Hayashi15 and Takemoto’s thiourea16 represent well-known organocatalysts used in 
asymmetric reactions. 
 
Figure 3. Examples of ligands and organocatalysts bearing chiral amines. 
                                                     
11 α-Amino acid synthesis is a well-developed and extensively reviewed field that will not be discussed in 
the present thesis. For selected reviews, see: a) Nájera, C.; Sansano, J. M. Chem. Rev. 2007, 107, 4584–
4671. b) Martens, J. ChemCatChem 2010, 2, 379–381. c) Luo, Y.-C.; Zhang, H.-H.; Wang, Y.; Xu, P.-F. Acc. 
Chem. Res. 2010, 43, 1317–1330. d) Jakubowska, A.; Kulig, K. Curr. Org. Synth. 2013, 10, 547–563. e) 
Sorochinsky, A. E.; Aceña, J. L.; Moriwaki, H.; Sato, T.; Soloshonok, V. Amino Acids 2013, 45, 1017–1033. 
f) Aceña, J. L.; Sorochinsky, A. E.; Soloshonok, V. Amino Acids 2014, 46, 2047–2073. For leading books on 
the topic, see: g) Asymmetric Synthesis and Application of α-Amino Acids; Soloshonok V. A., Izawa K., Eds.; 
ACS Symposium Series 1009; American Chemical Society: Washington, DC, 2009.  
12 Hayashi, T.; Mise, T.; Fukushima, M.; Kagotani, M.; Nagashima, N.; Hamada, Y.; Matsumoto, A.; 
Kawakami, S.; Konishi, M.; Yamamoto, K.; Kumada, M. Bull. Chem. Soc. Jpn. 1980, 53, 1138–1151. 
13 a) Carroll, M. P.; Guiry, P. J. Chem. Soc. Rev. 2014, 43, 819–833. b) Han, J. W.; Tokunaga, N.; Hayashi, T. 
Synlett 2002, 871–874. c) Standfest-Hauser, C.; Slugovc, C.; Mereiter, K.; Schmid, R.; Kirchner, K.; Xiao, L.; 
Weissensteiner, W. J. Chem. Soc. Dalton Trans. 2001, 2989–2995. d) Xu, S.; Zhang, Z. M.; Xu, B.; Liu, B.; 
Liu, Y.; Zhang, J. J. Am. Chem. Soc. 2018, 140, 2272–2283. 
14 Chen, G.; Gong, W.; Zhuang, Z.; Andrä, M. S.; Chen, Y. Q.; Hong, X.; Yang, Y. F.; Liu, T.; Houk, K. N.; Yu, J. 
Q. Science 2016, 353, 1023–1027. 
15 Klier, L.; Tur, F.; Poulsen, P. H.; Jørgensen, K. A. Chem. Soc. Rev. 2017, 46, 1080–1102. 
16 Okino, T.; Hoashi, Y.; Takemoto, Y. J. Am. Chem. Soc. 2003, 125, 12672–12673. 
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These examples reveal the wide structural variety of synthetically interesting chiral 
amines, therefore standing their stereoselective preparation at the forefront of modern 
synthetic methodologies. 
1.1.2. Stereoselective synthesis of chiral amines 
A “chiral amine”, which is better described as an “α-chiral amine”, is a structure 
bearing an amino group adjacent to a stereogenic carbon. In this context, two generic 
structural features of chiral amines are useful to point out: first, the nitrogen can be 
primary, secondary, tertiary or even quaternary (ammonium salt), and second, the α-
stereogenic carbon, by necessity, can only be secondary or tertiary.2a 
The main strategies for chiral amine synthesis are summarized in Scheme 1. On the 
one hand, secondary amines are exclusively produced by stereoselective reduction of 
azomethine groups and enamines. On the other hand, secondary and tertiary amines 
can be prepared by the construction of C–N or C–C bonds. Hydroamination and 
amination reactions are among the most popular approaches for C–N bond generation, 
whereas the stereoselective addition of carbon (pro)nucleophiles to azomethine groups 
is the one for C–C bond formations. 
 
Scheme 1. Main strategies for chiral amine synthesis. 
Since the overall aim of this investigation, as explained later in detail, is focused on the 
preparation of enantiomerically pure secondary and tertiary amines through C–N and 
C–C bond formation, only the state of art for aminations and Mannich-type reactions is 
presented in the following sections. Concerning the asymmetric reduction of imines and 
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the enantioselective hydrogenation of enamines, the reader can be directed to several 
reviews on the topic.17 
1.1.2.1. Enantioselective C–N bond formation 
The enantioselective generation of new C–N bonds, through nucleophilic or 
electrophilic addition of nitrogen sources to carbon substrates, to afford optically pure 
α-chiral amines, is underexplored compared to reduction or C–C bond forming 
strategies. Nevertheless, significant advances have been made in this field during the 
past two decades. 
1.1.2.1.1. Catalytic enantioselective hydroamination 
The nucleophilic asymmetric addition of an amine N–H bond across an unsaturated 
carbon–carbon bond, the so-called hydroamination, provides a simple and highly atom-
economical access to α-chiral amines.18 Alkylic linear amines are obtained by means of 
the intermolecular version of the reaction, whereas the intramolecular version affords 
N-heterocyclic compounds (Scheme 2). Currently, most studies involve the latter whilst, 
in general, the intermolecular hydroamination remains significantly less investigated. 
                                                     
17 a) Nugent, T. C.; El-Shazly, M. Adv. Synth. Catal. 2010, 352, 753–819. b) Xie, J.-H.; Zhu, S.-F.; Zhou, Q.-L. 
Chem. Rev. 2011, 111, 1713–1760. For reviews and book chapters about asymmetric reduction of imines, 
see: c) Zhu, Q.-C.; Hutchins, R. O.; Hutchins, M. K. Org. Prep. Proc. Int. 1994, 26, 193–236. d) Rossi, S.; 
Benaglia, M.; Massolo, E.; Raimondi, L. Catal. Sci. Technol. 2014, 4, 2708–2723. e) Li, W.; Zhang, X. 
Asymmetric Hydrogenation of Imines. In Stereoselective Formation of Amines; Wang, C., Xiao, J., Eds.; Top. 
Curr. Chem. 343; Springer: Heidelberg, 2014; pp 103–144. For book chapters about enantioselective 
enamine hydrogenation, see: f) Zhou, Q.-L.; Xie, J.-H. Enantioselective Hydrogenation of Enamines with 
Monodentate Phosphorus Ligands. In Chiral Amine Synthesis – Methods, Developments and Applications; 
Nugent, T. C., Ed.; WILEY-VCH Verlag: Weinheim, 2010; pp 247–271. g) Hu, X.-P.; Zheng, Z. Bidentate 
Ligands for Enantioselective Enamide Reduction. In Chiral Amine Synthesis – Methods, Developments and 
Applications; Nugent, T. C., Ed.; WILEY-VCH Verlag: Weinheim, 2010; pp 273–298. h) Zhou Q.-L.; Xie, J.-H. 
Transition Metal-Catalyzed Enantioselective Hydrogenation of Enamides and Enamines. In Stereoselective 
Formation of Amines; Wang, C., Xiao, J., Eds.; Top. Curr. Chem. 343; Springer: Heidelberg, 2014; pp 75–
102. 
18 For book chapters on the topic, see: a) Reznichenko, A. L.; Hultzsch, K. C. Asymmetric Hydroamination. 
In Chiral Amine Synthesis – Methods, Developments and Applications; Nugent, T. C., Ed.; WILEY-VCH 
Verlag: Weinheim, 2010; pp 299–339. b) Reznichenko, A. L.; Nawara-Hultzsch, A. J.; Hultzsch, K. C. 
Asymmetric Hydroamination. In Stereoselective Formation of Amines; Wang, C., Xiao, J., Eds.; Top. Curr. 
Chem. 343; Springer: Heidelberg, 2014; pp 75–102. c) Reznichenko, A. L.; Hultzsch, K. C. Hydroamination 
of Alkenes. In Organic Reactions; John Wiley & Sons, Inc.: Hoboken, NJ, USA, 2015; Vol. 88, pp 1–554. 
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Scheme 2. Inter- and intramolecular hydroaminations. 
In 1992, the group of Marks described the first enantioselective intramolecular 
hydroamination of terminal aminoalkenes assisted by a chiral lantanocene catalyst, 
which afforded 2-methyl pyrrolidines with moderate enantioselectivities (Scheme 3).19 
Since then, several metal-based catalytic systems were introduced for this reaction.20 In 
addition, this intramolecular reaction was extended to other unsaturated substrates 
such as aminodienes,21 aminoallenes22 and aminoalkynes.23 
 
Scheme 3. Marks’ pioneering asymmetric intramolecular hydroamination. 
As noted above, the enantioselective intermolecular hydroamination, has been less 
developed although it represents a high interesting and challenging approach towards 
the synthesis of chiral alkyl amines. An important difficulty to overcome, besides the 
negative entropy, is the competition between amines and alkenes for coordinating with 
the catalysts, since amines are usually much more chelating agents and could poison the 
catalytic center. The first intermolecular example was reported by the group of Togni in 
1997, in which norbornene was asymmetrically hydroaminated with phenylamine 
                                                     
19 Gagné, M. R.; Brard, L.; Conticello, V. P.; Giardello, M. A.; Stern, C. L.; Marks, T. J. Organometallics 1992, 
11, 2003–2005. 
20 a) Giardello, M. A.; Conticello, V. P.; Brard, L.; Gagné, M. R.; Marks, T. J. J. Am. Chem. Soc. 1994, 116, 
10241–10254. b) Knight, P. D.; Munslow, I.; O’Shaughnessy, P. N.; Scott, P. Chem. Commun. 2004, 894–
895. c) Horrillo Martínez, P.; Hultzsch, K. C.; Hampel, F. Chem. Commun. 2006, 2221–2223. d) Zhang, X.; 
Emge, T. J.; Hultzsch, K. C. Angew. Chem. Int. Ed. 2012, 51, 394–398. For a recent review in metal-catalyzed 
asymmetric hydroamination of alkenes, see: e) Michon, C.; Abadie, M.-A.; Medina, F.; Agbossou-
Niedercorn, F. J. Organomet. Chem. 2017, 847, 13–27. 
21 Hong, S.; Kawaoka, A. M.; Marks, T. J. J. Am. Chem. Soc. 2003, 125, 15878–15892. 
22 Hoover, J. M.; Petersen, J. R.; Pikul, J. H.; Johnson, A. R. Organometallics 2004, 23, 4614–4620. 
23 Patil, N. T.; Lutete, L. M.; Wu, H.; Pahadi, N. K.; Gridnev, I. D.; Yamamoto, Y. J. Org. Chem. 2006, 71, 
4270–4279. 
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employing Ir-BINAP catalyst, albeit with low yield (22% yield, 95% ee).24 Thereafter, 
some methodologies were developed for the intermolecular enantioselective 
hydroamination of alkenes,25 allenes26 and alkynes27 (Table 1). 
Table 1. Pioneering intermolecular asymmetric hydroaminations. 
Ent. Author 
Unsaturated 
substrate 
Amine 
Catalytic 
system 
Product 
1 
Togni 
199724 
 
PhNH2 Ir, BINAP 
 
2 
Hartwig 
200025a 
 
PhNH2 Pd, BINAP 
 
3 
Hartwig 
200125b 
 
ArNH2 
Pd, 
Trost ligand  
 
4 
Widenhoefer 
200925c  
 
Au, 
MeOBIPHEP 
 
5 
Widenhoefer 
201226a  
CbzNH2 
Au, 
MeOBIPHEP 
 
6 
Breit  
201226b  
ArNH2 Rh, JosiPhos 
 
                                                     
24 Dorta, R.; Egli, P.; Zurcher, F.; Togni, A. J. Am. Chem. Soc. 1997, 119, 10857–10858. 
25 For pioneering examples with alkenes, see: a) Kawatsura, M.; Hartwig, J. F. J. Am. Chem. Soc. 2000, 122, 
9546–9547. b) Löber, O.; Kawatsura, M.; Hartwig, J. F. J. Am. Chem. Soc. 2001, 123, 4366–4367. c) Zhang, 
Z.; Lee, S. D.; Widenhoefer, R. A. J. Am. Chem. Soc. 2009, 131, 5372–5373. 
26 For pioneering examples with allenes, see: a) Butler, K. L.; Tragni, M.; Widenhoefer, R. A. Angew. Chem. 
Int. Ed. 2012, 51, 5175–5178. b) Cooke, M. L.; Xu, K.; Breit, B. Angew. Chem. Int. Ed. 2012, 51, 10876–
10879. 
27 For the pioneering example with alkynes, see: Chen, Q.-A.; Chen, Z.; Dong, V. M. J. Am. Chem. Soc. 2015, 
137, 8392–8395. 
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Ent. Author 
Unsaturated 
substrate 
Amine 
Catalytic 
system 
Product 
7 
Dong 
201527  
 
Rh, BDPP 
 
 
On the other hand, metal-free catalyzed enantioselective hydroaminations are rather 
limited and mainly consist of intramolecular transformations.28 In 2011, Beauchemin 
and co-workers reported the only intermolecular organocatalytic enantioselective 
hydroamination so far, where a chiral aldehyde is used as a tethering precatalyst in order 
to enable, through temporary intramolecularity, the asymmetric synthesis of chiral 
vicinal diamines.29 
 
Scheme 4. Beauchemin’s organocatalytic enantioselective intermolecular hydroamination. 
1.1.2.1.2. Catalytic enantioselective allylic amination 
The catalytic allylic amination, is the most explored nucleophilic amination reaction for 
the stereoselective generation of new C–N bonds.30 In 1989, Hayashi, Ito and co-workers 
described the first asymmetric allylic amination of 1,3-symmetrically disubstituted 
                                                     
28 a) Ackermann, L.; Althammer, A. Synlett 2008, 995–998. b) Shapiro, N. D.; Rauniyar, V.; Hamilton, G. L.; 
Wu, J.; Toste, F. D. Nature 2011, 470, 245–249. c) Brown, A. R.; Uyeda, C.; Brotherton, C. A.; Jacobsen, E. 
N. J. Am. Chem. Soc. 2013, 135, 6747–6749. d) Lin, J.-S.; Yu, P.; Huang, L.; Zhang, P.; Tan, B.; Liu, X.-Y. 
Angew. Chem. Int. Ed. 2015, 54, 7847–7851. 
29 a) MacDonald, M. J.; Schipper, D. J.; Ng, P. J.; Moran, J.; Beauchemin, A. M. J. Am. Chem. Soc. 2011, 133, 
20100–20103. b) Guimond, N.; Macdonald, M. J.; Lemieux, V.; Beauchemin, A. J. Am. Chem. Soc. 2012, 
134, 16571–16577. 
30 For selected reviews on aminations via nucleophilic substitution, see: a) Johannsen, M.; Jørgensen, K. 
A. Chem. Rev. 1998, 98, 1689–1708. b) Grange, R. L.; Clizbe, E. A.; Evans, P. A. Synthesis 2016, 2911–2968. 
For selected book chapters, see: c) Takemoto, Y.; Miyabe, H. C–N Bond Formation through Amination. In 
Comprehensive Organometallic Chemistry III; Elsevier, 2007; Vol. 10, pp 695–724. d) Takemoto, Y.; 
Miyabe, H. Asymmetric Carbon-Heteroatom Bond-Forming Reactions. In Catalytic Asymmetric Synthesis, 
3rd ed.; Ojima, I., Ed.; John Wiley and Sons: Hoboken, NJ, 2010; pp 227–267. 
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substrates employing a ferrocenylphosphine-palladium complex (Table 2, entry 1).31 
One year later, the same authors applied the same system to the regio- and 
enantioselective amination of terminal allylic substrates (entry 2).32 
In addition, other structures that also generate π-allylic intermediates have been 
employed in asymmetric aminations. For instance, palladium-catalyzed asymmetric 
cycloadditions of vinyloxirane33 and vinylaziridine,34 with heterocumulenes, were 
developed by the groups of Alper and Trost, respectively (Table 2, entries 3 and 4). 
Furthermore, the group of Trost reported the dynamic kinetic asymmetric allylic 
amination of racemic allene acetates through vinyl-allyl palladium intermediates (entry 
5).35 More recently, van Maarseveen and co-workers described the enantioselective 
copper-catalyzed substitution reaction of propargylic acetates with aryl amines (entry 
6).36 
Table 2. Pioneering works in asymmetric nucleophilic amination. 
Ent. Author 
Allylic 
substrate 
Nitrogen 
source 
Catalyst Product 
1 
Hayashi, 
Ito 
198931 
 
 
 
 
2 
Hayashi, 
Ito 
199032 
 BnNH2 
 
3 
Alper 
199733 
  
Pd, TolBINAP 
 
                                                     
31 Hayashi, T.; Yamamoto, A.; Ito, Y.; Nishioka, E.; Miura, H.; Yanagi, K. J. Am. Chem. Soc. 1989, 111, 6301–
6311. 
32 a) Hayashi, T.; Kishi, K.; Yamamoto, A.; Ito, Y. Tetrahedron Lett. 1990, 31, 1743–1746. For further 
examples with the same ligand, see: b) You, S.-L.; Zhu, X.-Z.; Luo, Y.-M.; Hou, X.-L.; Dai, L.-X. J. Am. Chem. 
Soc. 2001, 123, 7471–7472. 
33 Larksarp, C.; Alper, H. J. Am. Chem. Soc. 1997, 119, 3709–3715. 
34 Trost, B. M.; Fandrick, D. R. J. Am. Chem. Soc. 2003, 125, 11836–11837. 
35 Trost, B. M.; Fandrick, D. R.; Dinh, D. C. J. Am. Chem. Soc. 2005, 127, 14186–14187. 
36 Detz, R. J.; Delville, M. M. E.; Hiemstra, H.; van Maarseveen, J. H. Angew. Chem. Int. Ed. 2008, 47, 3777–
3780. 
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Ent. Author 
Allylic 
substrate 
Nitrogen 
source 
Catalyst Product 
4 
Trost 
200334 
  
 
 
5 
Trost 
200535 
 
 
 
 
6 
van 
Maarseven 
200836  
Ar2NH2 
 
 
 
Alternatively, some organocatalytic methods have also been designed for the 
enantioselective allylic amination. Krische and co-workers reported the first regio- and 
enantioselective amination of Morita-Baylis-Hillman derived acetates with phthalimide, 
via nucleophilic phosphine catalysis, albeit only one example was reported with a 
moderate enantiomeric excess (Table 3, entry 1).37 Subsequent to this work, other 
approaches involving related amino compounds were described,38,39 as shown in Table 
3 (entries 2 and 3). 
                                                     
37 Cho, C.-W.; Kong, J.-R.; Krische, M. J. Org. Lett. 2004, 6, 1337–1339. 
38 Lin, A.; Mao, H.; Zhu, X.; Ge, H.; Tan, R.; Zhu, C.; Cheng, Y. Chem. Eur. J. 2011, 17, 13676–13679. 
39 Zhuang, M.; Du, H. Org. Biomol. Chem. 2014, 12, 4590–4593. 
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Table 3. Organocatalytic asymmetric nucleophilic aminations. 
Ent. Author Allylic substrate 
Nitrogen 
source 
Catalyst Product 
1 
Krische 
200437 
  
 
 
2 
Zhu, 
Cheng 
201138 
 
 
 
 
3 
Du 
201439 
 
TsNH2 
 
 
1.1.2.1.3. Catalytic enantioselective C–H amination 
In the last two decades, C–H functionalization has emerged as a powerful tool for the 
synthesis of complex organic molecules. Particularly, metallonitrene chemistry allows 
the direct transformation of a C–H bond into a C–N bond. During the reaction, the amine 
binds to the metallic center forming a metallonitrene, which performs the insertion into 
a well-diferenciated C–H bond –tipically benzylic, allylic, tertiary or contiguous to a 
heteroatom– (Scheme 5). 
 
Scheme 5. Metal-catalyzed C–H amination. 
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In 1997, the group of Müller described the first enantioselective intermolecular C–H 
amination of indanes employing iminoiodane and a chiral dirhodium catalyst.40 
Thereafter, the groups of Hashimoto41 and Davies42 were able to improve the catalytic 
system, by using different chiral ligands and/or oxidants, and higher enantioselectivities 
were obtained (Scheme 6). 
 
Scheme 6. Indan enantioselective C–H aminations. 
Additionally, the groups of Katsuki43 and Clark44 reported the manganese- and copper-
catalyzed enantioselective C–H amination of cyclohexene, respectively. Nevertheless, 
the corresponding cyclohexenyl amine was obtained in low to moderate yields and with 
moderate enantioselectivities (Scheme 7). 
                                                     
40 Nägeli, I.; Baud, C.; Bernardinelli, G.; Jacquier, Y.; Moran, M.; Müller, P. Helv. Chim. Acta 1997, 80, 1087–
1105. 
41 Yamawaki, M.; Tsutsui, H.; Kitagaki, S.; Anada, M.; Hashimoto, S. Tetrahedron Lett. 2002, 43, 9561–
9564. 
42 Reddy, R. P.; Davies, H. M. L. Org. Lett. 2006, 8, 5013–5016. 
43 Kohmura, Y.; Katsuki, T. Tetrahedron Lett. 2001, 42, 3339–3342. 
44 Clark, J. S.; Roche, C. Chem. Commun. 2005, 5175–5177. 
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Scheme 7. Cyclohexene enantioselective C–H aminations. 
Intramolecular enantioselective C–H aminations have also been developed. As a 
representative example, diverse catalytic systems performed satisfactorily for the 
asymmetric synthesis of 6-membered cyclic chiral sulfonamides (Scheme 8).45 
 
Scheme 8. Intramolecular enantioselective C–H amination. 
                                                     
45 a) Liang, J.-L.; Yuan, S.-X.; Huang, J.-S.; Yu, W.-Y.; Che, C.-M. Angew. Chem. Int. Ed. 2002, 41, 3465–3468. 
b) Milczek, E.; Boudet, N.; Blakey, S. Angew. Chem. Int. Ed. 2008, 47, 6825–6828. c) Zalatan, D. N.; Du Bois, 
J. J. Am. Chem. Soc. 2008, 130, 9220–9221. 
Introduction 
48 
 
As illustrated, catalytic enantioselective C–H amination constitutes a new emerging 
field for the synthesis of α-chiral amines46 still restricted to very specific substrates. 
Thus, the search for additional suitable structures and efficient catalytic systems 
represents the forthcoming steps in this field. 
1.1.2.1.4. Catalytic enantioselective electrophilic amination 
The catalytic asymmetric electrophilic amination has been stablished as a fruitful 
methodology for the construction of nitrogen-bearing tri- and tetrasubstituted carbon 
stereocenters. In 1997, Evans and co-workers documented the first enantioselective 
electrophilic amination of N-acyloxazolidinones with tert-butyl azodicarboxylate 
catalyzed by a chiral magnesium bis(sulfonamide) complex via Lewis acid activation 
(Scheme 9).47 After this seminal work, several nucleophiles have been employed in 
metal-catalyzed reactions, particularly, α-carbonyl species.48 
 
Scheme 9. Evans’ first enantioselective electrophilic amination. 
                                                     
46 For recent examples, see: a) Ichinose, M.; Suematsu, H.; Yasutomi, Y.; Nishioka, Y.; Uchida, T.; Katsuki, 
T. Angew. Chem. Int. Ed. 2011, 50, 9884–9887. b) Nishioka, Y.; Uchida, T.; Katsuki, T. Angew. Chem. Int. 
Ed. 2013, 52, 1739–1742. c) Höke, T.; Herdtweck, E.; Bach, T. Chem. Commun 2013, 49, 8009–8011. d) 
Wang, P. S.; Shen, M. L.; Wang, T. C.; Lin, H. C.; Gong, L. Z. Angew. Chem. Int. Ed. 2017, 56, 16032–16036. 
47 Evans, D. A.; Nelson, S. G. J. Am. Chem. Soc. 1997, 119, 6452–6453. 
48 For examples with silyl enol ethers, see: a) Evans, D. A.; Johnson, D. S. Org. Lett. 1999, 1, 595–598. 2-
Ketoesters: b) Juhl, K.; Jørgensen, K. A. J. Am. Chem. Soc. 2002, 124, 2420–2421. β-Keto phosphonate 
esters: c) Bernardi, L.; Zhuang, W.; Jørgensen, K. A. J. Am. Chem. Soc. 2005, 127, 5772–5773. Succinimides: 
d) Mashiko, T.; Hara, K.; Tanaka, D.; Fujiwara, Y.; Kumagai, N.; Shibasaki, M. 2007, 129, 11342–11343. α-
Cyanoacetates: e) Hasegawa, Y.; Watanabe, M.; Gridnev, I. D.; Ikariya, T. J. Am. Chem. Soc. 2008, 130, 
2158–2159. Ketones: f) Trost, B. M.; Tracy, J. S.; Saget, T. Chem. Sci. 2018, 9, 2975–2980. 
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In addition, organocatalytic enantioselective electrophilic aminations have been 
extensively studied. The groups of List and Jørgensen, independently, reported the first 
proline-catalyzed amination of aldehydes in 2002 via a dual activation exerted by the 
catalyst (Scheme 10).49 
 
Scheme 10. Pioneer organocatalytic asymmetric electrophilic amination. 
After these pioneering works via enamine catalysis, other organocatalytic activation 
modes have been applied in asymmetric amination reactions (Table 4).50–53 
Table 4. Pioneering organocatalytic asymmetric electrophilic amination reactions. 
Ent. Author Nucleophile Electrophile Catalyst Product 
1 
Chen 
200750 
  
  
2 
Jørgensen 
200451 
  
 
 
                                                     
49 a) List, B. J. Am. Chem. Soc. 2002, 124, 5656–5657. b) Bøgevig, A.; Juhl, K.; Kumaragurubaran, N.; Zhuang, 
W.; Jørgensen, K. A. Angew. Chem. Int. Ed. 2002, 41, 1790–1793. 
50 Liu, T. Y.; Cui, H. L.; Zhang, Y.; Jiang, K.; Du, W.; He, Z. Q.; Chen, Y. C. Org. Lett. 2007, 9, 3671–3674. 
51 Saaby, S.; Bella, M.; Jørgensen, K. A. J. Am. Chem. Soc. 2004, 126, 8120–8121. 
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Ent. Author Nucleophile Electrophile Catalyst Product 
3 
Maruoka 
200852 
  
 
 
4 
Fu 
200853 
  
 
 
 
While electrophilic aminations have been developed with a wide variety of carbonyl 
derived pronucleophiles as shown in Table 4, the variety of aminating reagents is still 
quite limited. Azodicarboxylates are the most popular aminating reagents, due to their 
high reactivity and tunable level of steric hindrance, in spite of their low atom economy. 
In this context, nitroso compounds are another type of promising electrophilic 
amination reagents with high reactivity and higher atom-economy. Both nitrogen and 
oxygen atoms are highly reactive towards nucleophile attack, thus, chemoselective 
control is crutial to achieve productive α-aminations. In 2004, the group of Yamamoto 
described the first chemoselective and enantioselective amination employing 
nitrosobenzene, under metal catalysis, to afford the corresponding cyclic α-amino 
ketones in high yield and enantiomeric excess (Scheme 11).54 
                                                     
52 He, R.; Wang, X. Hashimoto, T.; Maruoka, K. Angew. Chem. Int. Ed. 2008, 47, 9466–9468. 
53 Berlin, J. M.; Fu, G. C. Angew. Chem. Int. Ed. 2008, 47, 7048–7050. 
54 Momiyama, N.; Yamamoto, H. J. Am. Chem. Soc. 2004, 126, 5360–5361. 
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Scheme 11. Yamamoto’s pioneering enantioselective amination with nitrosobenzene. 
Despite the progress made with nitroso aryl compounds,55 a mild cleavage of the 
nitrogen–aryl bond, in the resulting products, remains unsolved. For that reason, the 
use of nitrocarbonyl compounds, formed in situ by oxidation of hydroxamic acid 
derivatives, is emerging as a promising alternative since the previous oxidation step for 
the formation of, sometimes toxic and unstable, nitroso compounds is avoided.56  In this 
context, Luo and co-workers disclosed an appealing procedure for the asymmetric 
catalytic α-amination of β-keto carbonyls, using N-hydroxycarbamate, under primary  
amine catalysis and copper(I)-catalyzed aerobic oxidation (Scheme 12).57 
 
Scheme 12. Luo’s enantioselective α-amination with N-hydroxycarbamate. 
                                                     
55 For selected examples, see: a) Guo, H.-M.; Cheng, L.; Cun, L.-F.; Gong, L.-Z.; Mi, A.-Q. Chem. Commun. 
2006, 429–431. b) López-Carretero, J.; Cid, M. B.; Poulsen, T. B.; Bella, M.; Ruano, J. L. G.; Jørgensen, K. A. 
J. Org. Chem. 2007, 72, 7062–7065. c) Shen, K.; Liu, X.; Wang, G.; Lin, L.; Feng, X. Angew. Chem. Int. Ed. 
2011, 50, 4684–4688. d) Companyó, X.; Valero, G.; Pineda, O.; Calvet, T.; Font-Bardía, M.; Moyano, A.; 
Rios, R. Org. Biomol. Chem. 2012, 10, 431–439. 
56 For a review in the topic, see: Palmer, L. I.; Frazier, C. P.; Read de Alaniz, J. Synthesis 2014, 46, 269–280. 
57 Xu, C.; Zhang, L.; Luo, S. Angew. Chem. Int. Ed. 2014, 53, 4149–4153. 
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On the other hand, azido compounds are also attractive reagents for catalytic 
asymmetric amination, as demonstrated by the enantioselective iron-catalyzed 
azidation of β-keto esters developed by Gade and co-workers in 2013 (Scheme 13).58 
 
Scheme 13. Gade’s enantioselective electrophilic azidation reactions. 
As a conclusion, although significant advances have been made in catalytic 
enantioselective electrophilic amination reactions during the past two decades, there is 
still ample room for progress. The development of new aminating reagents to afford 
enantioenriched products with better atom- and step-economy is greatly important, as 
well as the search for new catalytic systems that could allow the activation of less 
reactive substrates such as esters, amides, nitriles and aromatic alkanes. 
1.1.2.2. Enantioselective C–C bond formation 
The enantioselective formation of carbon–carbon bonds by means of nucleophilic 
addition to imines and related C=N systems represents an effective strategy for the 
                                                     
58 Deng, Q. H.; Bleith, T.; Wadepohl, H.; Gade, L. H. J. Am. Chem. Soc. 2013, 135, 5356–5359. 
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synthesis of α-chiral amines.59 Imines are generally much less electrophilic than the 
corresponding aldehydes, a drawback that can often be overcome by employing Lewis 
or Brønsted acids and the introduction of activating electron-withdrawing groups at 
either one or both the nitrogen and the iminic carbon (Figure 4). On the other hand, 
imines derived from enolizable aldehydes have been barely employed due to their 
inherent instability and tendency to imine-enamine isomerization.60 
 
Figure 4. Reactivity of representative imines as electrophiles. 
The group of Tomioka reported the first catalytic enantioselective alkylation of imines 
employing organolithium reagents and a chiral Lewis base organocatalyst (Scheme 14).61 
Since then, most efforts have been addressed towards the development of catalytic and 
enantioselective versions for which the most representative examples are disclosed 
below.  
 
Scheme 14. Tomioka’s pioneering catalytic enantioselective alkylation of imines. 
                                                     
59 For general reviews on the topic, see: a) Kobayashi, S.; Ishitani, H. Chem. Rev. 1999, 99, 1069–1094. b) 
Vilaivan, T.; Bhanthumnavin, W.; Sritana-Anant, Y. Curr. Org. Chem. 2005, 9, 1315–1392. c) Kobayashi, S.; 
Mori, Y.; Fossey, J. S.; Salter, M. M. Chem. Rev. 2011, 111, 2626–2704. 
60 For further information about aliphatic imine decomposition and isomerization, see: a) Katritzky, A. R.; 
Harris, P. A.; Tetrahedron 1990, 46, 987–996. b) Nolen, E. G.; Allocco, A.; Broody, A. M.; Zuppa, A. 
Tetrahedron Lett. 1991, 32, 73–74. c) Marson, C. M.; Fallah, A. Chem. Commun. 1998, 83–84. 
61 Tomioka, K.; Inoue, I.; Shindo, M.; Koga, K. Tetrahedron Lett. 1991, 32, 3095–3098. 
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 Mannich reaction 
Among the different carbon nucleophilic species that have been employed in the 
asymmetric addition to imines, α-carbonyl moieties constitute the most used ones. The 
addition of these substrates to azomethine groups is named the Mannich reaction.62 The 
first catalytic enantioselective reaction of this type was described by Kobayashi and co-
workers in 1997. High enantioselectivities were obtained in the addition of silyl enol 
ethers to aryl amines employing a chiral zirconium catalyst derived from BINOL (Scheme 
15).63  
 
Scheme 15. Kobayashi’s pioneering catalytic enantioselective Mannich reaction. 
The authors assumed a catalytic cycle in which the catalyst coordinates the aldimine 
to produce an intermediate, whose trimethylsilylated oxygen atom attacks the 
zirconium center to afford the product along with the regeneration of the catalyst. Then, 
the final Mannich adduct is obtained after acidic treatment (Scheme 16). 
                                                     
62 For general reviews on asymmetric Mannich reaction, see: a) Arend, M.; Westermann, B.; Risch, N. 
Angew. Chem. Int. Ed. 1998, 37, 1044–1070. b) Syamala, M. Org. Prep. Proced. Int. 2009, 41, 1–68. c) 
Bhadury, P. S.; Song, B.-A. Curr. Org. Chem. 2010, 14, 1989–2006. d) Greco, S. J.; Lacerda, V.; Bezerra dos 
Santos, R. Aldrichimica Acta 2011, 44, 15–23. e) Xiao-Hua, C.; Hui, G.; Bing, X. Eur. J. Chem. 2012, 3, 258–
266. 
63 Ishitani, H.; Ueno, M.; Kobayashi, S. J. Am. Chem. Soc. 1997, 119, 7153–7154. 
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Scheme 16. Assumed catalytic cycle for Kobayashi’s Mannich reaction. 
This work inspired many subsequent catalytic non-direct examples in which either the 
metal center, the chiral ligands or the nature of the catalyst were modified.64 A similar 
approach was employed by the group of Hoveyda and Snapper for the silver-catalyzed 
enantioselective indirect Mannich reaction of enol ethers with aryl, alkyl, alkenyl and 
alkynyl N-aryl imines.65  
In 1999, Shibasaki and co-workers described the first direct catalytic asymmetric 
Mannich reaction with ethyl and propyl phenyl ketones employing a lanthanum–lithium 
heterobimetallic chiral catalyst and an aminomethyl ether as a synthetic equivalent of 
[Et2NCH2+].66 Based on this reaction, they reported in 2003 the zinc-catalyzed 
enantioselective anti67 and syn68 Mannich reactions of 2-hydroxy-1-(2-
                                                     
64 For examples on the use of metal catalysis, see: a) D. Ferraris, B. Young, T. Dudding, T. Lecta, J. Am. 
Chem. Soc. 1998, 120, 4548–4549. b) A. Fuji, E. Hagiwara, M. Sodeoka, J. Am. Chem. Soc. 1999, 121, 5450–
5458. c) S. Nakamura, H. Sano, H. Nakashima, K. Kubo, N. Shibata, T. Toru, Tetrahedron Lett. 2007, 48, 
5565–5568. For an example on the use of organocatalysis, see: d) A. G. Wenzel, E. N. Jacobsen, J. Am. 
Chem. Soc. 2002, 124, 12964–12965; For an example on the use of ternary complex ligand, see: d) H. 
Fujieda, M. Kanai, T. Kambara, A. Iida, K. Tomioka, J. Am. Chem. Soc. 1997, 119, 2060–2061. 
65 Josephsohn, N. S.; Snapper, M. L.; Hoveyda, A. H. J. Am. Chem. Soc. 2004, 126, 3734–3735. 
66 Yamasaki, S.; Iida, T.; Shibasaki, M. Tetrahedron Lett. 1999, 40, 307–310. 
67 Matsunaga, S.; Kumagai, N.; Harada, S.; Shibasaki, M. J. Am. Chem. Soc. 2003, 125, 4712–4713. 
68 Sugita, M.; Yamaguchi, A.; Yamagiwa, N.; Handa, S.; Matsunaga, S.; Shibasaki, M. Org. Lett. 2005, 7, 
5339–5342. 
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methoxyphenyl)ethanone with N-phosphinoyl and N-Boc imines, respectively (Scheme 
17). 
 
Scheme 17. Shibasaki’s stereoselective Mannich reactions with N-phosphinoyl and N-Boc imines. 
Since then, several groups have worked in the search of suitable catalytic systems for 
the Mannich reaction with α-hydroxy ketones. For instance, Trost and co-workers 
introduced the use of chiral dinuclear Zn complexes in the reaction with N-
methoxyphenyl imines as electrophiles (Scheme 18).69 Likewise, under similar reaction 
conditions, switch to the anti Mannich adducts by using N-phosphinoyl imines was 
accomplished.70 
 
Scheme 18. Trost’s zinc-catalyzed enantioselective syn-Mannich reaction. 
On the other hand, in 2001, Jørgensen and co-workers disclosed the metal-catalyzed 
asymmetric Mannich reaction of ethyl N-tosyl α-iminoester and α-oxoesters promoted 
                                                     
69 Trost, B. M.; Terrell, L. M. J. Am. Chem. Soc. 2003, 125, 338–339. 
70 Trost, B. M.; Jaratjaroonphong, J.; Reutrakul, V. J. Am. Chem. Soc. 2006, 128, 27782779. 
Chapter 1 
57 
 
by a chiral Cu(II)–bis(oxazolidine) in a highly syn-diastereo- and enantioselective way.71 
This methodology was later expanded to other activated carbonylic pronucleophiles, 
such as malonates and β-ketoesters.72 The latter allowed the construction of quaternary 
stereocenters for the first time through a metal-catalyzed Mannich reaction (Scheme 
19). Nevertheless, while the system was versatile regarding the pronucleophile, it was 
limited to the use of highly activated N-tosyl iminoesters.73 
 
Scheme 19. Jørgensen’s Cu-catalyzed enantioselective Mannich reactions with N-tosyl imines. 
Thereafter, several groups have described metal-catalyzed direct Mannich reactions 
with a wide variety of pronucleophiles and N-protected imines.74 Noteworthy, Kumagai, 
Shibasaki and co-workers and the group of Shimizu and Kanai have been able to address 
                                                     
71 Juhl, K.; Gathergood, N.; Jørgensen, K. A. Angew. Chem. Int. Ed. 2001, 40, 2995–2997.  
72 Marigo, M.; Kjaersgaard, A.; Juhl, K.; Gathergood, N.; Jørgensen, K. A. Chem. Eur. J. 2003, 9, 2359–2367. 
73 The procedure was later extended to a family of aryl and alkyl-substituted N-tosyl imines with variable 
results: Bernardi, L.; Gothelf, A. S.; Hazell, R. G.; Jørgensen, K. A. J. Org. Chem. 2003, 68, 2583–2591. 
74 For selected examples, see: a) Hamashima, Y.; Samamoto, N.; Hotta, D.; Somei, H.; Umebayashi, N.; 
Sodeoka, M. Angew. Chem. Int. Ed. 2005, 44, 15251529. b) Lu, G.; Morimoto, H.; Matsunaga, S.; 
Shibasaki, M. Angew. Chem. Int. Ed. 2008, 47, 6847–6850. c) Yan, X.-X.; Peng, Q.; Li, Q.; Zhang, K.; Yao, J.; 
Hou, X.-L.; Wu, Y.-D. J. Am. Chem. Soc. 2008, 130, 14362–14363. d) Liang, G.; Tong, M.-C.; Tao, H.; Wang, 
C.-J. Adv. Synth. Catal. 2010, 352, 1851–1855. e) Hatano, M.; Moriyama, K.; Maki, T.; Ishihara, K. Angew. 
Chem. Int. Ed. 2010, 49, 3823–3826. f) Poisson, T.; Tsubogo, T.; Yamashita, Y.; Kobayashi, S. J. Org. Chem. 
2010, 75, 963–965. f) Hatano, M.; Horibe, T.; Ishihara, K. J. Am. Chem. Soc. 2010, 132, 56–57. g) Karimi, 
B.; Jafari, E.; Enders, D. Chem. Eur. J. 2013, 19, 10142–10145. 
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Mannich reactions using more challenging pronucleophiles such as thioamides75 and 
carboxylic acids,76 respectively (Scheme 20). 
 
Scheme 20. Asymmetric Mannich reactions with thioamides and carboxylic acids. 
In 2000, List disclosed the first organocatalytic Mannich reaction using proline as the 
promoter. This three-component procedure afforded the corresponding syn Mannich 
adducts with good to excellent yields and stereoselectivities (Scheme 21a).77 On the 
other hand, the same year, the group of Barbas III described the first anti-selective 
asymmetric Mannich reaction using chiral amine catalysis (Scheme 21b).78 Subsequent 
                                                     
75 Suzuki, Y.; Yazaki, R.; Kumagai, N.; Shibasaki, M. Angew. Chem. Int. Ed. 2009, 48, 5026–5029. 
76 Morita, Y.; Yamamoto, T.; Nagai, H.; Shimizu, Y.; Kanai, M. J. Am. Chem. Soc. 2015, 137, 7075–7078. 
77 List, B. J. Am. Chem. Soc. 2000, 122, 9336–9337. 
78 Córdova, A.; Barbas III, C. F. Tetrahedron Lett. 2002, 43, 7749–7752. 
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to these works, many groups have exploited the ability of chiral secondary and primary 
amines to produce highly enantioenriched syn79 and anti80 Mannich adducts.  
 
Scheme 21. Pioneering organocatalytic enantio- and diastereoselective Mannich reactions. 
In 2005, Jørgensen and co-workers developed the first Brønsted base assisted 
asymmetric Mannich reaction. α-Aryl cyanoacetates were added to N-Boc iminoesters 
in a highly stereoselective manner via deprotonative activation with (DHQD)2Pyr 
                                                     
79 For selected syn-Mannich examples, see: a) List, B.; Pojarliev, P.; Biller, W. T.; Martin, H. J. J. Am. Chem. 
Soc. 2002, 124, 827–833. b) Córdova, A.; Notz, W.; Zhong, G.; Barbas III, C. F. J. Am. Chem. Soc. 2002, 124, 
1842–1843. c) Hayashi, Y.; Yamaguchi, J.; Hibino, K.; Sumiya, T.; Urushima, T.; Shoji, M. Hashizume, D.; 
Koshino, H. Adv. Synth. Catal. 2004, 346, 1435–1439. d) Wang, W.; Wang, J.; Li, H. Tetrahedron Lett. 2004, 
45, 7243–7246. e) Cobb, A. J. A.; Shaw, D. M.; Longbottom, D. A.; Gold, J. B.; Ley, S. V. Org. Biomol. Chem. 
2005, 3, 84–96. f) Yang, H.; Carter, R. G. J. Org. Chem. 2009, 74, 2246–2249. For primary amine-catalyzed 
syn-Mannich reactions, see: g) Ibrahem, I.; Zou, W.; Engqvist, M.; Xu, Y.; Córdova, A. Chem. Eur. J. 2005, 
11, 7024–7029. h) Valero, G.; Balaguer, A.-N.; Moyano, A.; Rios, R. Tetrahedron Lett. 2008, 48, 6559–6562. 
80 For selected anti-Mannich examples with pyrrolidinic amines, see: a) Franzén, J.; Marigo, M.; 
Fielenbach, D.; Wabnitz, T. C.; Kjaersgaard, A.; Jørgensen, K. A.; J. Am. Chem. Soc. 2005, 127, 18296–18304. 
b) Mitsumori, S.; Zhang, H.; Cheong, P. H.-Y.; Houk, K. N.; Tanaka, F.; Barbas III, C. F. J. Am. Chem. Soc. 
2006, 128, 1040–1041. c) Zhang, H.; Mitsumori, S.; Utsumi, N.; Imai, M.; Garcia-Delgado, N.; Mifsud, M.; 
Albertshofer, K.; Cheong, P. H.-Y.; Houk, K. N.; Tanaka, F.; Barbas III, C. F. J. Am. Chem. Soc. 2008, 130, 
875–886. d) Martín-Rapún, R.; Fan, X.; Sayalero, S.; Bahramnejad, M.; Cuevas, F.; Pericàs, M. A. Chem. Eur. 
J. 2011, 17, 8780–8783. e) Gómez-Bengoa, E.; Jiménez, J.; Lapuerta, I.; Mielgo, A.; Oiarbide, M.; Velilla, I.; 
Vera, S.; Palomo, C. Chem. Sci. 2012, 3, 2949–For non-pyrrolidinic amines, see: f) Kano, T.; Yamaguchi, Y.; 
Tokuda, O.; Maruoka, K. J. Am. Chem. Soc. 2005, 127, 16408–16409. g) Ramasatry, S. S. V.; Zhang, H. 
Tanaka, F.; Barbas III, C. F. J. Am. Chem. Soc. 2007, 129, 228–289. h) Cheng, L.; Wu, X.; Lu, Y. Org. Biomol. 
Chem. 2007, 5, 1018–1020. 
Introduction 
60 
 
generating α-chiral aminoesters with an adjacent quaternary stereocenter (Scheme 
22).81  
 
Scheme 22. Jørgensen’s pioneering Brønsted base-catalyzed asymmetric Mannich reaction. 
Thereafter, many enantioselective Mannich procedures catalyzed by chiral Brønsted 
bases, in general bifunctional ones, have been developed (Figure 5). Deng’s and 
Takemoto’s groups described the enantioselective addition of N-Boc imines to 
malonates82 and β-keto esters,83 respectively, whereas the groups of Lu84 and Jiang85 
disclosed the reaction with α-fluorinated β-keto esters. In addition, Lambert and co-
workers reported the highly diastereo- and enantioselective Mannich reaction of the 
less reactive glycinates to N-Boc imines.86 
                                                     
81 Poulsen, T.; Alemparte, C.; Saaby, S.; Bella, M.; Jørgensen, K. A. Angew. Chem. Int. Ed. 2005, 44, 2896–
2899. 
82 Song, J.; Wang, Y.; Deng, L. J. Am. Chem. Soc. 2006, 128, 6048–6049.  
83 Yamaoka, Y.; Miyabe, H.; Yasui, Y.; Takemoto, Y. Synthesis, 2007, 16, 2571–2575. 
84 Han, X.; Kwiatkowski, J.; Xue, F.; Huang, K.-W.; Lu, Y. Angew. Chem. Int. Ed. 2009, 48, 7604–7607. 
85 Pan, Y.; Zhao, Y.; Ma, T.; Yang, Y.; Liu, H.; Jiang, Z.; Tan, C.-H. Chem. Eur. J. 2010, 16, 779–782. 
86 Bandar, J. S.; Lambert, T. H. J. Am. Chem. Soc. 2013, 135, 11799–11802. 
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Figure 5. Representative Brønsted base catalysts for enantioselective Mannich reactions. 
On the other hand, chiral Brønsted acids can also promote enantioselective Mannich 
reactions by protonating the imine and generating an iminium ion with an enantiopure 
counterion. In 2004, Terada and co-workers developed the first example of Brønsted 
acid-catalyzed asymmetric Mannich reaction employing a chiral phosphoric acid 
(Scheme 23).87 
 
Scheme 23. Terada’s pioneering Brønsted acid-catalyzed enantioselective Mannich reaction. 
                                                     
87 a) Uraguchi, D.; Terada, M. J. Am. Chem. Soc. 2004, 126, 5356–5357. For more examplesof Brønsted 
acid-catalyzed asymmetric Mannich reactions, see: b) Guo, Q.-X.; Liu, H.; Guo, C.; Luo, S.-W.; Gu, Y.; Gong, 
L.-Z.; J. Am. Chem. Soc. 2007, 129, 3790–3791. c) Hatano, M.; Maki, T.; Moriyama, K.; Arinobe, M.; Ishitara, 
K. J. Am. Chem. Soc. 2008, 130, 16858–16860. d) Chen, Y.-Y.; Jiang, Y.-J.; Fan, Y.-S.; Sha, D.; Wang, G.; 
Zhang, G.; Zheng, L.; Zhang, S. Tetrahedron: Asymmetry 2012, 23, 904–909.  
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The same year, Maruoka and co-workers described the first example of an asymmetric 
direct Mannich reaction under phase transfer conditions (Scheme 24a).88 However, the 
first phase transfer catalyzed (PTC) enantioselective Mannich reaction, involving the in 
situ formation of N-Cbz and N-Boc imines, was developed by Ricci and co-workers in 
2006. This example represents the first successful asymmetric direct-Mannich reaction 
with imines derived from enolizable aldehydes (Scheme 24b).89 Since then, only one 
additional PTC Mannich approach has been reported, employing tert-butyl glycinate and 
in situ prepared aryl, alkyl, E-alkenyl and alkynyl N-Boc imines.90 
 
Scheme 24. Pioneering phase transfer catalyzed enantioselective Mannich reactions. 
                                                     
88 a) Ooi, T.; Kameda, M.; Fujii, J.-I.; Maruoka, K. Org. Lett. 2004, 6, 2397–2399. For a similar PTC approach, 
see: Okada, A.; Shibuguchi, T.; Ohshima, T.; Masu, H.; Yamaguchi, K.; Shibasaki, M. Angew. Chem. Int. Ed. 
2005, 44, 4564–4567. 
89 Fini, F.; Bernardi, L.; Herrera, R. P.; Pettersen, D.; Ricci, A.; Sgarzani, V. Adv. Synth. Catal. 2006, 348, 
2043–2046. 
90 Kano, T.; Kobayashi, R.; Maruoka, K. Angew. Chem. Int. Ed. 2015, 54, 8471–8474. 
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Regarding the generation of tertiary amines, procedures are restricted to very 
particular active ketimines (Scheme 25).91 The group of Jørgensen was pioneer in using 
ketimines A in the zirconium-catalyzed enantioselective indirect Mannich reaction92 and 
the diastereo- and enantioselective direct Mannich reaction with aldehydes via enamine 
catalysis.93 Isatin-derived scaffolds B are the most employed electrophiles of this type94 
whereas ketimines bearing an electron-withdrawing trifluoromethyl substituent C have 
also been employed in reactions with acetone95 and diaryl diketones.96 More recently, 
Terada and co-workers have reported a bis(guanidino)iminophosphorane-catalyzed 
asymmetric addition of thionolactones to iminoesters D97 and Ma’s group have 
developed a chiral phosphoric acid-catalyzed Mannich reaction of imines E with simple 
ketones.98 
 
Scheme 25. Ketimines in asymmetric Mannich reactions. 
Importantly, Shibasaki and co-workers reported the use of simple N-phosphinoyl 
ketimines in the enantioselective indirect Mannich reaction99 as well as in the enantio- 
and diastereoselective direct Mannich reaction with an α-isothiocyanate ester in which 
thioxoimidazolidines were afforded after cyclization of the Mannich adduct (Scheme 
                                                     
91 For a review on asymmetric addition to ketimines, see: Kumagai, N.; Shibasaki, M. Bull. Chem. Soc. Jpn. 
2015, 88, 503–517. 
92 Saaby, S.; Nakama, K.; Lie, M. A.; Hazell, R. A.; Jørgensen, K. A. Chem. Eur. J. 2003, 9, 6145–6154. 
93 Zhuang, W.; Saaby, S.; Jørgensen, K. A. Angew. Chem. Int. Ed. 2004, 43, 4476–4478. 
94 a) Yan, W.; Wang, D.; Feng, J.; Li, P.; Zhao, D.; Wang, R. Org. Lett. 2012, 14, 2512–2515. b) Tang, Z.; Shi, 
Y.; Mao, H.; Zhu, X.; Li, W.; Cheng, Y.; Zheng, W.-H.; Zhu, C. Org. Biomol. Chem. 2014, 12, 6085–6088. c) 
Engl, O. D.; Fritz, S. P.; Wennemers, H. Angew. Chem. Int. Ed. 2015, 54, 8193–8194. d) Dai, J.; Xiong, D.; 
Yuan, T.; Liu, J.; Chen, T.; Shao, Z. Angew. Chem. Int. Ed. 2017, 56, 12697–12701. e) Sawa, M.; Miyazaki, 
S.; Yonesaki, R.; Morimoto, H.; Ohshima, T. Org. Lett. 2018, 20, 5393–5397. 
95 a) Sukach, V. A.; Golovach, N. M.; Pirozhenko, V. V.; Rusanov, E. B.; Vovk, M. V. Tetrahedron: Asymmetry 
2008, 19, 761–764. b) Hara, N.; Tamura, R.; Funahashi, Y.; Nakamura, S. Org. Lett. 2011, 13, 1662–1665. 
c) Rassunaka, Y.; Yelenich, I. P.; Vlasenko, Y. G.; Onys’ko, P. P. Tetrahedron: Asymmetry 2014, 25, 1234–
1238. 
96 Sawa, M.; Morisaki, K.; Kondo, Y.; Morimoto, H.; Ohshima, T. Chem. Eur. J. 2017, 23, 17022–17028.  
97 Takeda, T.; Kondoh, A.; Terada, M. Angew. Chem. Int. Ed. 2016, 55, 4734–4737. 
98 Li, J. S.; Liu, Y.-J.; Li, S.; Ma, J.-A. Chem. Commun. 2018, 54, 9151–9154. 
99 a) Suto, Y.; Kanai, M.; Shibasaki, M. J. Am. Chem. Soc. 2007, 129, 500–501. b) For an additional similar 
indirect example, see: Du, Y.; Xu, L.-W.; Shimizu, Y.; Oisaki, K.; Kanai, M.; Shibasaki, M. J. Am. Chem. Soc. 
2008, 130. 16146–16147. 
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26).100 Other groups have described the addition of isonitriles to N-phosphinoyl 
ketimines for the preparation of imidazolines101 but surprisingly, no direct Mannich 
reactions affording acyclic tertiary amines have been reported yet. 
 
Scheme 26. Shibasaki’s asymmetric Mannich reactions with N-phosphinoyl ketimines. 
Despite the advances made in the catalytic asymmetric Mannich reaction, this 
transformation still presents some limitations such as the scarcity of methods for 
reactions with less activated pronucleophiles and/or imines derived from enolyzable 
aldehydes.86,102 Moreover, as stated above, the generation of tertiary amines is 
restricted to the use of very particular active ketimines. Thus, the search for additional 
                                                     
100 Lu, G.; Yoshino, T.; Morimoto, H.; Matsunaga, S.; Shibasaki, M. Angew. Chem. Int. Ed. 2011, 50, 4382–
4385. 
101 a) Nakamura, S.; Yamaji, R.; Iwanaga, M. Chem. Commun. 2016, 52, 7462–7465. b) de la Campa, R.; 
Yamagata, A. D. G.; Ortín, I.; Franchino, A.; Thompson, A. L.; Odell, B.; Dixon, D. J. Chem. Commun. 2016, 
52, 10632–10635. 
102 For examples of catalytic enantioselective Mannich reactions with aliphatic imines, see: a) Arai, T.; 
Moribatake, T.; Masu, H. Chem. Eur. J. 2015, 21, 10671–10675. b) Bae, H. Y.; Kim, M. J.; Sim, J. H.; Song, 
C. E. Angew. Chem. Int. Ed. 2016, 55, 10825–10829. c) Echave, H.; Bastida, I.; López, R.; Palomo, C. Chem. 
Eur. J. 2018, 24, 11554–11558. 
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suitable substrates and more effective catalytic systems constitutes a challenge for next 
years. 
 Nitro-Mannich reaction 
Alternatively, there is a variant of the Mannich reaction which provides access to chiral 
diamines: the nitro-Mannich or aza-Henry reaction.103 This transformation is based on 
the use of nitro alkanes as pronucleophiles in the addition to imines to produce β-nitro 
amines, which after reduction affords the mentioned diamines. In 1999, Shibasaki and 
co-workers described the first asymmetric nitro-Mannich reaction between 
nitromethane and N-phosphinoyl imines promoted by a heterobimetallic chiral complex 
of ytterbium and potassium, which works as a Lewis acid and a Brønsted base. The 
corresponding adducts were obtained with variable yields and enantioselectivities 
(Scheme 27).104 
 
Scheme 27. Shibasaki’s pioneering metal-catalyzed asymmetric nitro-Mannich reaction. 
A further improvement of the methodology with N-phosphinoyl imines was achieved 
employing an aluminium-lithium-binaphthoxide–potassium tert-butoxide complex 
(Figure 6) for the reaction with linear nitro alkanes to afford, for the first time, anti β-
nitro amines with moderate to good diastereo- and enantioselectivities.105 The same 
authors, also described, in 2007, the first and only metal-catalyzed syn-selective nitro-
Mannich reaction of linear nitroalkanes to N-Boc imines employing a heterobimetallic 
samarium-copper complex,106 which after further optimization of the catalytic system 
                                                     
103 a) For a general review on nitro-Mannich reaction, see: Noble, A.; Anderson, J. C. Chem. Rev. 2013, 
113, 2887–2939. b) For a review on catalytic enantioselective nitro-Mannich reactions, see: Marqués-
López, E.; Merino, P.; Tejero, T.; Herrera, R. P. Eur. J. Org. Chem. 2009, 2401–2420. 
104 Yamada, K.-I.; Harwood, S. J.; Gröger, H.; Shibasaki, M. Angew. Chem. Int. Ed. 1999, 38, 3504–3506. 
105 a) Yamada, K.-I.; Moll, G.; Shibasaki, M. Synlett 2001, 980–982. b) This procedure was also employed 
for the synthesis of bioactive compound CP-99994: Tsuritani, N.; Yamada, K.-I.; Yoshikawa, N.; Shibasaki, 
M. Chem. Lett. 2002, 34, 276–277. 
106 Handa, S.; Gnanadesikan, V.; Matsunaga, S.; Shibasaki, M. J. Am. Chem. Soc. 2007, 129, 4900–4901. 
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was extended to N-Boc aliphatic imines with excellent yields and diastereo- and 
enantioselectivities.107 Finally, in 2008, they designed a homodinuclear nickel catalyst 
for the asymmetric addition of nitro acetates to N-Boc imines for the preparation of α-
quaternary anti-α,β-diamino acids.108 
 
Figure 6. Metal catalysts employed in asymmetric nitro-Mannich reactions by Shibasaki’s group. 
Several groups have also developed metal-catalyzed asymmetric nitro-Mannich 
methodologies (Figure 7). For instance, in 2001, Jørgensen and co-workers described the 
direct109 and indirect110 anti-selective nitro-Mannich reactions promoted by Cu(II)-
bisoxazoline complexes with N-PMP iminoesters and linear nitroalkanes. The group of 
Anderson described, in 2005, a similar indirect approach where non-activated aromatic, 
heteroaromatic and aliphatic N-PMP imines were added for the first time to propyl 
nitronates with high yields and anti-stereoselectivities.111 Thereafter, several metal 
based catalytic systems, such as zinc,112 copper,113 cobalt113 and iron,114 have been 
reported. 
 
                                                     
107 Handa, S.; Gnanadesikan, V.; Matsunaga, S.; Shibasaki, M. J. Am. Chem. Soc. 2010, 132, 4925–4934. 
108 Chen, Z.; Morimoto, H.; Matsunaga, S.; Shibasaki, M. J. Am. Chem. Soc. 2008, 130, 2170–2171. 
109 Nishiwaki, N.; Knudsen, K. R.; Gothelf, K. V.; Jørgensen, K. A. Angew. Chem. Int. Ed. 2001, 40, 2992–
2995. 
110 Knudsen, K. R.; Risgaard, T.; Nishiwaki, N.; Gothelf, K. V; Jørgensen, K. A. J. Am. Chem. Soc. 2001, 123, 
5843–5844. 
111 Anderson, J. C.; Howell, G. P.; Lawrence, R. M.; Wilson, C. S. J. Org. Chem. 2005, 70, 5665–5670. 
112 a) Palomo, C.; Oiarbide, M.; Halder, R.; Laso, A.; López, R. Angew. Chem. Int. Ed. 2006, 45, 117–120. b) 
Trost, B. M.; Lupton, D. W. Org. Lett. 2007, 9, 2023–2026. 
113 Arai, T.; Matsumura, E. Synlett 2014, 25, 1776–1780. 
114 Dudek, A.; Mlynarski, J. J. Org. Chem. 2017, 82, 11218–11224. 
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Figure 7. Representative metal catalysts in enantioselective nitro-Mannich reactions. 
Regarding metal-free approaches, in 2004, Takemoto and co-workers described the 
first organocatalytic enantioselective nitro-Mannich procedure with N-phosphinoyl 
aromatic imines and nitromethane, under chiral Brønsted base catalysis, with good 
yields and moderate enantioselectivities (Scheme 28a).115 Further optimization of the 
method revealed that better stereocontrol could be achieved employing N-Boc imines 
instead (Scheme 28b). In order to explain the observed stereoselectivities, they 
suggested the formation of a trimolecular complex, in which the N-Boc imine is 
coordinated to the thiourea group through hydrogen-bonding interactions while the 
protonated amine approaches the nitronate to the imine inducing the attack to the less 
hindered face.116 
                                                     
115 Okino, T.; Nakamura, S.; Furukawa, T.; Takemoto, Y. Org. Lett. 2004, 6, 625–627. 
116 Xu, X.; Furukawa, T.; Okino, T.; Miyabe, H.; Takemoto, Y. Chem. Eur. J. 2005, 12, 466–476. 
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Scheme 28. Takemoto’s pioneering organocatalytic asymmetric nitro-Mannich reaction. 
In 2009, Wang and co-workers described a Brønsted base catalyzed asymmetric nitro-
Mannich procedure in which N-Boc imines were generated in situ employing 1 
equivalent of potassium carbonate. The rosin-derived thiourea-Brønsted base 
promoted the addition of nitromethane and nitroethane with generally good yield and 
stereoselectivity (Scheme 29).117 
 
Scheme 29. Wang’s asymmetric nitro-Mannich reaction with in situ generated imines. 
                                                     
117 Jiang, X.; Zhang, Y.; Wu, L.; Zhang, G.; Liu, X.; Zhang, H.; Fu, D.; Wang, R. Adv. Synth. Catal. 2009, 351, 
2096–2100. 
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In 2012, the group of Todd reported the first catalytic enantioselective nitro-Mannich 
reaction with a non-activated cyclic imine employing Takemoto’s thiourea. In this case, 
the nitro amine intermediate is trapped through acylation to produce the corresponding 
adducts with moderate enantioselectivities. Nevertheless, single recrystallization of the 
products provided the corresponding enantiopure compounds (Scheme 30).118 
 
Scheme 30. Todd’s asymmetric nitro-Mannich reaction with non-activated cyclic imines. 
Furthermore, the catalytic nitro-Mannich reaction has been employed in the context 
of cascade processes with very high success.119 
Other structurally diverse bifunctional Brønsted base organocatalysts have also been 
designed for the stereoselective nitro-Mannich reaction (Figure 8). In 2011, Johnston 
and co-workers reported the first highly diastereo- and enantioselective addition of aryl 
nitromethanes to N-Boc imines employing the pyrrolidine BisAMidine (PBAM) 
catalyst.120 In 2014, Gong, Meggers and co-workers designed a very efficient iridium-
templated chiral Brønsted base organocatalyst for the reaction of aryl or thiopenyl 
nitromethanes with N-Boc imines.121 In addition, Ooi and co-workers employed a chiral 
ammonium betaine catalyst for the same reaction with aryl nitromethanes. They 
proposed that the aryloxy basic moiety promotes the nitronate generation, which is 
stabilized by the quaternary amine via ionic interaction.122 
                                                     
118 Amarasinghe, N. R.; Turner, P.; Todd, M. H. Adv. Synth. Catal. 2012, 354, 2954–2958. 
119 For selected examples, see: a) Barber, D. M.; Sanganee, H. J.; Dixon, D. J. Org. Lett. 2012, 14, 5290–
5293. b) Barber, D. M.; Ďuriš, A.; Thompson, A. L.; Sanganee, H. J.; Dixon, D. J. ACS Catal. 2014, 4, 634–
638. c) Hahn, R.; Jafari, E.; Raabe, G.; Enders, D. Synthesis 2015, 47, 472–480. d) Maity, R.; Pan, S. C. Org. 
Biomol. Chem. 2015, 13, 6825–6831. 
120 a) Davis, T. A.; Johnston, J. N. Chem. Sci. 2011, 2, 1076–1079. For further applications of this reaction, 
see: b) Dobish, M. C.; Villalta, F.; Waterman, M. R.; Lepesheva, G. I.; Johnston, J. N. Org. Lett. 2012, 14, 
6322–6325. c) Tsukanov, S. V; Johnson, M. D.; May, S. A.; Rosemeyer, M.; Watkins, M. A.; Kolis, S. P.; Yates, 
M. H.; Johnston, J. N. Org. Process Res. Dev. 2016, 20, 215–226. 
121 Ma, J.; Ding, X.; Hu, Y.; Huang, Y.; Gong, L.; Meggers, E. Nat. Commun. 2014, 5, 4531–4536. 
122 a) Uraguchi, D.; Oyaizu, K.; Noguchi, H.; Ooi, T. Chem. Asian J. 2015, 10, 334–337. b) A similar catalytic 
system was employed for the asymmetric Mannich-type reaction with α-nitro esters: Uraguchi, D.; 
Koshimoto, K.; Ooi, T. J. Am. Chem. Soc. 2008, 130, 10878–10879. 
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Figure 8. Structurally diverse bifunctional Brønsted bases in asymmetric nitro-Manich reactions. 
Besides bifunctional Brønsted bases, purely hydrogen-bonding chiral catalysts have 
also been employed, along with external achiral bases, in asymmetric nitro-Mannich 
reactions (Figure 9).123–125 Although with catalysts such as those represented in Figure 8 
good results have been obtained, the competitive racemic pathway promoted by the 
base alone constitutes the major problem of this approach. 
   
Jacobsen, 2005123 Ellman, 2007124 Kozlowski, 2015125 
 
Figure 9. Representative H-bonding organocatalysts. 
                                                     
123 Yoon, T. P.; Jacobsen, E. N. Angew. Chem. Int. Ed. 2005, 44, 466–468. 
124 Robak, M. T.; Trincado, M.; Ellman, J. A. J. Am. Chem. Soc. 2007, 129, 15110–15111. 
125 Walvoord, R. R.; Kozlowski, M. C. Tetrahedron Lett. 2015, 56, 3070–3074. 
Chapter 1 
71 
 
In 2013, the group of de Armas and García-Tellado described the water-compatible 
stereoselective multicomponent nitro-Mannich reaction. Aromatic and aliphatic N-
phenyl imines were synthetized in situ and reacted with several nitroalkanes including 
symmetric tertiary nucleophiles, such as 2-nitropropane, nitrocyclopentane and 
nitrocyclohexane, employing a variety of squaramide- or thiourea-type H-bonding 
organocatalysts and substoichiometric amounts of N,N-dimethyl cyclohexylamine as 
Brønsted base. (Scheme 31).126 
 
Scheme 31. Garcia-Delgado’s water-compatible asymmetric multicomponent nitro-Mannich reaction. 
Anderson and co-workers developed an interesting approach to β-nitro amines 
consisting of nitroolefin reduction, employing the Hantzsch ester, and subsequent 
nitronate addition to imines via hydrogen-bonding activation (Scheme 32).127 
                                                     
126 Cruz-Acosta, F.; De Armas, P.; García-Tellado, F. Chem. Eur. J. 2013, 19, 16550–16554. 
127 a) Anderson, J. C.; Koovits, P. J. Chem. Sci. 2013, 4, 2897–2901. b) For the intramolecular version of the 
reaction, see: Anderson, J. C.; Barham, J. P.; Rundell, C. D. Org. Lett. 2015, 17, 4090–4093. 
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Scheme 32. Anderson’s asymmetric tandem reduction/nitro-Mannich reactions. 
On the other hand, Johnston and co-workers reported, in 2004, the first 
stereoselective example of Brønsted acid catalyzed nitro-Mannich reaction. They 
designed a protonated version of the BisAMidine catalyst, able to promote the addition 
of nitroalkanes to N-Boc imines (Scheme 33).128 
 
Scheme 33. Johnston’s Brønsted acid-catalyzed asymmetric nitro-Mannich reaction. 
Finally, the use of chiral organic salts, generally quaternary ammonium salts, in 
combination with inorganic bases in biphasic systems has also been effective for 
                                                     
128 a) Nugent, B. M.; Yoder, R. A.; Johnston, J. N. J. Am. Chem. Soc. 2004, 126, 3418–3419. b) Davis, T. A.; 
Wilt, J. C.; Johnston, J. N. J. Am. Chem. Soc. 2010, 132, 2880–2882. c) Schwieter, K. E.; Johnston, J. N. ACS 
Catal. 2015, 5, 6559–6562. d) Vara, B. A.; Johnston, J. N. J. Am. Chem. Soc. 2016, 138, 13794–13797. For 
an example employing chiral phosphoric acid catalyst, see: e) Rueping, M.; Antonchick, A. P. Org. Lett. 
2008, 10, 1731–1734. 
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asymmetric nitro-Mannich procedures. Those basic reaction conditions are suitable for 
nitronate generation as well as to promote in situ formation of N-acyl or N-sulfonyl 
imines from the corresponding N-protected amino sulfones. This type of catalysis, 
moreover, allows the expansion of the methodology to imines coming from enolizable 
aldehydes. In fact, the first catalytic asymmetric nitro-Mannich procedure compatible 
with these imines was developed under phase transfer conditions. In 2005, our research 
group129 and Herrera, Bernardi and co-workers,130 concurrently, described the N-benzyl 
quininium chloride-catalyzed nitromethane addition to N-carbamoyl imines in phase 
transfer conditions. Both methodologies employed α-amido sulfones as starting 
material, providing the corresponding β-nitroamines with good yields and excellent 
stereoselectivities (Scheme 34). 
 
Scheme 34. Pioneering phase transfer catalyzed asymmetric nitro-Mannich reactions. 
After these pioneering works, other phase-transfer catalytic systems were developed 
for the asymmetric nitro-Mannich reaction (Figure 10).131-134 All of them, in combination 
with inorganic salts, successfully allowed the use of aliphatic imines in the reaction. 
                                                     
129 Palomo, C.; Oiarbide, M.; Laso, A.; López, R. J. Am. Chem. Soc. 2005, 127, 17622–17623. 
130 Fini, F.; Sgarzani, V.; Pettersen, D.; Herrera, R. P.; Bernardi, L.; Ricci, A. Angew. Chem. Int. Ed. 2005, 44, 
7975–7978.  
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Dixon, 2012133 
 
Lin, Duan, 2014134 
Figure 10. Phase transfer catalysts in asymmetric nitro-Mannich reactions. 
Finally, the asymmetric synthesis of tertiary amines employing ketimines has been 
underexplored and the few examples described, mainly consist of the addition of 
nitromethane, nitroethane or (nitromethyl)benzene to particularly active isatin-derived 
ketimines.135 In 2008, Feng and co-workers described the first enantioselective nitro-
Mannich reaction with N-tosyl ketimines employing a chiral copper(I) catalyst (Figure 
11). The reaction was very slow –generally required more than 10 days to go to 
completion– and moderate yields were obtained.136 Later, Dixon and co-workers 
designed a bifunctional iminophosphorane organocatalyst for the reaction with N-
phosphinoyl ketimines. The reactions were faster –24 to 96 hours to completion– and 
high yields and enantioselectivities were achieved.137 More recently, the group of Lin 
                                                     
131 a) Takada, K.; Nagasawa, K. Adv. Synth. Catal. 2009, 351, 345–347. b) Huang, W.; Peng, C.; Guo, L.; Hu, 
R.; Han, B. Synlett 2011, 2981–2984. 
132 Wei, Y.; He, W.; Liu, Y.; Liu, P.; Zhang, S. Org. Lett. 2012, 14, 704–707. 
133 a) Johnson, K. M.; Rattley, M. S.; Sladojevich, F.; Barber, D. M.; Nuñez, M. G.; Goldys, A. M.; Dixon, D. 
J. Org. Lett. 2012, 14, 2492–2495. b) Clark, P. G. K.; Vieira, L. C. C.; Tallant, C.; Fedorov, O.; Singleton, D. 
C.; Rogers, C. M.; Monteiro, O. P.; Bennett, J. M.; Baronio, R.; Müller, S.; Daniels, D. L.; Méndez, J.; Knapp, 
S.; Brennan, P. E.; Dixon, D. J. Angew. Chem. Int. Ed. 2015, 54, 6217–6221. 
134 Wang, B.; Liu, Y.; Sun, C.; Wei, Z.; Cao, J.; Liang, D.; Lin, Y.; Duan, H. Org. Lett. 2014, 16, 6432–6435. 
135 a) Arai, T.; Matsumura, E.; Masu, H. Org. Lett. 2014, 16, 2768–2771. b) Liu, Y.; Liu, Y.; Wang, J.; Wei, Z.; 
Cao, J.; Liang, Y.; Lin, Y.; Duan, H. Tetrahedron Lett. 2017, 58, 2400–2403. c) Liu, Y.; Wang, J.; Wei, Z.; Cao, 
J.; Liang, D.; Lin, Y.; Duan, H. New. J. Chem. 2018, 42, 1608–1611. 
136 Tan, C.; Liu, X.; Wang, L.; Wang, J.; Feng, X. Org. Lett. 2008, 10, 5305–5308. 
137 Núñez, M. G.; Farley, A. J. M.; Dixon, D. J. J. Am. Chem. Soc. 2013, 135, 16348–16351. 
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and Duan have reported a phase-tranfer-catalyzed nitro-Mannich reaction of N-6-
methyl-2-pyridylsulfonyl protected ketimines with nitromethane.138 
 
Figure 11. Enantioselective nitro-Mannich reactions with ketimines. 
In conclusion, the nitro-Mannich reaction still presents some limitations for its 
application in the stereoselective synthesis of chiral amines. Regarding the azomethine 
component, imines derived from enolizable aldehydes have been scarcely explored, 
mainly under phase transfer conditions, and the use of ketimines to produce chiral 
tertiary amines is generally restricted to isatin-derived ketimines. With respect to the 
nucleophilic component, linear and non-functionalized nitroalkanes are used in most 
nitro-Mannich transformations. 
Furthermore, the synthesis of α-chiral amines through nucleophilic asymmetric 
additions to imines is mainly limited to highly acidic pronucleophiles, such as α-carbonyl 
compounds in the Mannich reaction and nitroalkanes in the nitro-Mannich reaction. In 
consequence, the search of structurally different suitable pronucleophiles for their 
addition to azomethine scaffolds is also at the forefront of current research. 
                                                     
138 Wang, B.; Xu, T.; Zhu, L.; Lan, Y.; Wang, J.; Lu, N.; Wei, Z.; Lin, Y.; Duan, H. Org. Chem. Front. 2017, 4, 
1266–1271. 
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1.2. Objectives 
As mentioned in the first section, the structural diversity of α-chiral amines and the 
arousing interest for their potential as therapeutic agents, chiral ligands and, in general, 
synthetically valuable molecules, prompt the development of new catalytic 
methodologies with enhanced efficiency, sustainability and production cost. In this 
context, the overall aim of this Ph. D. work consists of the development of new Brønsted 
base catalyzed methodologies for the synthesis of enantiomerically enriched amines of 
synthetic utility and with possible biological activity. 
Chiral Brønsted base catalyzed transformations are a straightforward way to assembly 
simple starting materials into optically active functionalized fragments, since only 
proton transfer occurs between substrates and products.139 Due to the intrinsic non-
directional nature of the ionic interactions stablished with reactants, bifunctional 
Brønsted base catalysts, bearing hydrogen bond donor groups, have become much more 
suitable catalysts for asymmetric reactions. Among them, Cinchona alkaloids,140 
thiourea-115 and squaramide-based141 Brønsted bases are the most representative 
bifunctional organocatalysts (Figure 12).  
 
Figure 12.  Most representative bifunctional Brønsted base organocatalysts. 
                                                     
139 For selected reviews, see: a) Palomo, C.; Oiarbide, M.; López, R. Chem. Soc. Rev. 2009, 38, 632–653. b) 
Ting, A.; Goss, J. M.; McDougal, N. T.; Schaus, S. E. Top. Curr. Chem. 2010, 291, 145–200. c) Teng, B.; Lim, 
W. C.; Tan, C.-H. Synlett 2017, 28, 1272–1277. For a book chapter, see: d) Ting, A.; Schaus, S. E. Brønsted 
Bases. In Comprehensive Enantioselective Organocatalysis: Catalysts, Reactions, and Applications; Dalko, 
P. I., Ed. Wiley-VCH: Weinheim, 2013. Vol. 2, pp 343–363. 
140 Wynberg, H.; Helder, R. Tetrahedron Lett. 1975, 16, 4057–4060. 
141 Malerich, J. P.; Hagihara, K.; Rawal, V. H. J. Am. Chem. Soc. 2008, 130, 14416–14417. 
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In spite of the developments made based on these pioneering works,142 bifunctional 
Brønsted-base catalyzed reactions still show strong dependence on both substrate and 
catalyst structures. Thus, research on this field is centered on the design of more 
efficient and general organocatalysts able to activate less reactive pronucleophiles in 
a stereocontrolled manner. At the same time, the search for minimally modified 
pronucleophiles in order to enhance their reactivity and favor their interaction with 
the catalysts has attracted much attention.   
In this context, this Ph. D. work will try to give evidence of the potential of Brønsted 
base catalyzed carbon–carbon and carbon–heteroatom bond forming reactions by 
properly setting subtle modifications in the reaction counterparts. 
Many structures derived from enantiomerically pure γ-sulfonyl allyl amines have 
shown capacity to inhibit a wide variety of enzymatic processes. Nevertheless, the 
structural requirements for an optimal enzyme-substrate recognition are still unknown 
and the elaboration of this type of structures could lead to the identification of more 
specific inhibitors or ones with better pharmacological properties. Thus, the first 
objective of this work is the preparation of optically active γ-sulfonyl allyl amines by 
developing a Brønsted base catalyzed nitro-Mannich reaction with 2-nitroethyl sulfones 
as vinyl sulfone anion equivalents (Scheme 35). 
 
Scheme 35. Synthetic plan for the asymmetric preparation of γ-sulfonyl allyl amines. 
On the other hand, ortho-substituted pyridines are common fragments in chiral 
compounds with biological activity. In particular, α- and/or β-functionalized pyridines 
containing amino groups constitute a relevant family. Thus, the second objective of the 
present thesis is to explore the potential of 2-alkyl pyridines as pronucleophiles in 
Brønsted base catalyzed α-aminations and Mannich type reactions to produce 
enantiomerically enriched tertiary and secondary amines, respectively (Scheme 36). 
                                                     
142 For selected reviews in bifunctional Brønsted base organocatalysis, see: a) Marcelli, T.; van 
Maarseveen, J. H.; Hiemstra, H. Angew. Chem. Int. Ed. 2006, 45, 7496–7504. b) Connon, S. J. Chem. 
Commun. 2008, 2499–2510. c) Lattanzi, A. Chem. Commun. 2009, 1452–1463. d) Cucinotta, C.S.; Kosa, M.; 
Melchiorre, P.; Cavalli, A.; Gervasio, F. Chem. Eur. J. 2009, 15, 7913–7921. e) Lu, L.-Q.; An, X.-L.; Chen, J.-
R.; Xiao, W.-J. Synlett 2012, 23, 490–508. f) Fang, X.; Wang, C.-J. Chem. Commun. 2015, 51, 1185–1197. 
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Scheme 36. Synthetic plan for the asymmetric preparation of ortho-substituted pyridyl amines. 
Finally, the results obtained during a short stay carried out at The Scripps Research 
Institute in La Jolla (California, USA), under the supervision of Prof. Baran are also 
included in this Ph.D. thesis. The main objective of the project consists of the 
preparation of a library of trans-disubstituted cyclopropanes through cycloaddition 
followed by desymmetrization and two consecutive cross coupling reactions (Scheme 
37). 
 
Scheme 37. Synthetic plan for the stereoselective modular preparation of trans-disubstituted 
cyclopropanes. 
Challenges for each particular objective, working hypothesis and the state of the art 
along with the results obtained for each project will be presented in three different 
chapters: 
 Chapter 2: Enantioselective synthesis of γ-sulfonyl allyl amines. 
 Chapter 3: Stereoselective synthesis of pyridine based tertiary and secondary 
amines. 
 Chapter 4: Stereoselective modular synthesis of trans-disubstituted cyclopropanes. 
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2. ENANTIOSELECTIVE SYNTHESIS OF γ-SULFONYL ALLYL 
AMINES 
2.1. Introduction 
2.1.1. γ-Sulfonyl allyl amines 
Many structures derived from enantiomerically pure γ-sulfonyl allyl amines –also 
known as γ-amino vinyl sulfones– have shown capacity to act as cysteine protease 
inhibitors (Figure 13).143 
 
Figure 13. γ-Sulfonyl allyl amines with inhibitory activity. 
                                                     
143 For a review about cistein proteases and its inhibition, see: Lecaille, F.; Kaleta, J.; Brömme, D. Chem. 
Rev. 2002, 102, 4459–4488. 
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Structures A144 and B145 have exhibit activity against dipeptidyl aminopeptidase I (DPP-
I) and cruzipain, respectively. Peptidyl vinyl sulfones C146 and D147 act as site-selective 
proteasome inhibitors; C is a β5 specific inhibitor whilst compound D is active in trypsin-
like sites. Additionally, γ-sulfonyl allyl amines E148 and F149 have recently shown activity 
as anti-trypanosomal agents to treat African trypanosomiasis –an African sleeping 
sickness caused by protozoan parasite Trypanosoma brucei transmitted by the tsetse 
fly.– 
Cysteine proteases are proteolytic enzymes involved in the degradation of proteins, 
implicated in very diverse processes ranging from cardiovascular, neurological, 
respiratory, musculoskeletal, immunological, CNS and other disorders to cancer. 
Moreover, they are essential for the life cycle of several parasites such as falcipain –the 
causing agent of malaria– and rodhesain from Trypanosoma brucei. The activity of these 
cysteine proteases is based on a nucleophilic cysteine residue within the active site, 
which assists in the peptide bond hydrolysis (Scheme 38).148,150 
 
Scheme 38. Cysteine protease-based peptide hydrolysis. 
Of the several types of compounds developed as cysteine protease inhibitors, most 
rely on covalent derivatization of the key cysteine residue. Among them, Michael-type 
                                                     
144 Thompson, S. A.; Andrews, P. R.; Hanzlik, R. P. J. Med. Chem. 1986, 29, 104–111. 
145 Palmer, J. T.; Rasnik, D.; Klaus, J. L.; Brömme, D. J. Med. Chem. 1995, 38, 3193–3196. 
146 a) Screen, M.; Britton, M.; Downey, S. L.; Verdoes, M.; Voges, M. J.; Blom, A. E. M.; Geurink, P. P.; 
Risseeuw, M. D. P.; Florea, B. I.; van der Linden, W. A.; Pletnev, A. A.; Overkleeft, H. S.; Kisselev, A. F. J. 
Biol. Chem. 2010, 285, 40125–40134. b) Verdoes, M.; Willems, L. I.; van der Linden, W. A.; Duivenvoorden, 
B. A.; van der Marel, G. A.; Florea, B. I.; Kisselev, A. F.; Overkleeft, H. S. Org. Biomol. Chem. 2010, 8, 2719–
2727. 
147 Geurink, P. P.; van der Linden, W. A.; Mirabella, A. C.; Gallastegui, N.; de Briun, G.; Blom, A. E. M.; 
Voges, M. J.; Mock, E. D.; Florea, B. I.; van der Marel, G. A.; Driessen, C.; van der Stelt, M.; Groll, M.; 
Overkleeft, H. S.; Kisselev, A. F. J. Med. Chem. 2013, 56, 1262–1275. 
148 Dunny, E. Doherty, W.; Evans, P.; Malthouse, J. P. G.; Nolan, D.; Knox, A. J. S. J. Med. Chem. 2013, 56, 
6638–6650. 
149 Zhang, H.; Collins, J.; Nyamwihura, R.; Ware, S.; Kaiser, M.; Ogungbe, I. V. Bioorg. Med. Chem. 2018, 
28, 1647–1651. 
150 Santos, M. M. M.; Moreira, R. Mini-Rev. Med. Chem. 2007, 7, 1040–1050. 
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acceptors have shown to be potent inhibiting agents due to the irreversible C–S bond 
formation (Scheme 39).148,150, In particular, the interest in γ-sulfonyl allyl amines 
principally relies on the absence of reactivity towards other proteases, such as serin- or 
metallo-proteases, and even other circulating nucleophiles such as glutathione. It is 
noteworthy the fact that inhibitors of enzymes from the same and related families have 
important structural differences.151 Since the structural requirements for an optimal 
enzyme-substrate recognition are still unknown, the elaboration of this type of 
structures could lead to the identification of more specific inhibitors or ones with better 
pharmacological properties. 
 
Scheme 39. Mechanism of cysteine protease inhibition by γ-sulfonyl allyl amines. 
Despite the interest for the preparation of structurally diverse γ-sulfonyl allyl amines, 
very few procedures have been reported for the synthesis of this type of compounds 
and most of them are based on olefination reactions of α-amino aldehydes derived from 
synthetic152 or naturally available amino acids.144–149,153 Enantioenriched γ-sulfonyl allyl 
amines have also been synthesized employing chiral auxiliaries. The group of Sato 
reported in 2003 the first diastereoselective allylation of imines employing a chiral N-
protecting group, although only one example was reported with low yield (Scheme 
40).154 
                                                     
151 Simple achiral vinyl sulfones have also shown activity as sortase and tyrosine phosphatase inhibitors. 
a) Sortase inhibitor: Frankel, B. A.; Bentley, M.; Kruger, R. G.; McCafferty, D. G. J. Am. Chem. Soc., 2004, 
126, 3404–3405. b) Tyrosine phosphatase inhibitor: Liu, S.; Zhou, B.; Yang, H.; He, Y.; Jiang, Z.-X.; Kumar, 
S.; Wu, L.; Zhang, Z.-X. J. Am. Chem. Soc. 2008, 130, 8251–8260. 
152 de Bruin, G.; van Rooden, E. J.; Ward, D.; Wesseling, C.; van den Nieuwendijk, A. M. C. H.; van Boeckel, 
C. A. A.; Driessen, C.; Kisselev, A. F.; Florea, B. I.; van der Stelt, M.; Overkleeft, H. S. Eur. J. Org. Chem. 2017, 
5921–5934. 
153 Kim, M.; Jeon, J.; Baek, J.; Choi, J.; Park, E. J.; Song, J.; Bang, H.; Suh, K. H.; Kim, Y. H.; Kim, J.; Kim, D.; 
Min, K. H.; Lee, K.-O. Bull. Korean Chem. Soc. 2014, 35, 345–346. 
154 Fukuhara, K.; Okamoto, S.; Sato, F. Org. Lett. 2003, 5, 2145–2148. 
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Scheme 40. Diastereoselective asymmetric synthesis of γ-sulfonyl allyl amines. 
On the other hand, Love and co-workers have recently reported the total synthesis of 
compound B, performing, as the key stereoselective step, the alkynylation of the chiral 
sulfinyl N-protected imine shown Scheme 41.155 
 
Scheme 41. Asymmetric synthesis of γ-sulfonyl allyl amines employing chiral sulfoxides . 
Nevertheless, to the best of our knowledge, only one procedure has been reported, to 
date, for the synthesis of enantioenriched γ-sulfonyl allyl amines based on a catalytic 
enantioselective strategy. In 2003, Moyano and co-workers reported the synthesis of 
such structures starting from 3-amino-1,2-alkanediols prepared from allylic alcohols,156 
being the key stereoselective step their asymmetric epoxidation described previously.157 
Additionally, this work is the only example in which amines with R1 as an aromatic group 
have been produced in good yields (Scheme 42). 
                                                     
155 Kiemele, E. R.; Wathier, M.; Bichler, P.; Love, J. A. Org. Lett. 2016, 18, 492–495. 
156 a) Picó, A.; Moyano, A.; Pericàs M. A. J. Org. Chem. 2003, 68, 5075–5083. b) Moyano, A.; Pericàs, M. 
A.; Picó, A. Stereoselective Method of Preparing gamma-Amino Vinyl Sulphones. WO 2004101504 A1, 
2004. For preparation of peptidyl aryl vinyl sulfones with this procedure, see: c) Mendieta, L.; Picó, A.; 
Tarragó, T.; Teixidó, M.; Castillo, M.; Rafecas, L.; Moyano, A.; Giralt, E. ChemMedChem 2010, 5, 1556–
1567. 
157 a) Caron, M.; Carlier, P. R.; Sharpless, K. B. J. Org. Chem. 1988, 53, 5187–5189. b) Canas, M.; Poch, M.; 
Verdaguer, X.; Moyano, A.; Pericàs, M. A.; Riera, A. Tetrahedron Lett. 1991, 32, 6931–6934. c) Martín, R.; 
Islas, G.; Moyano, A.; Pericàs, M. A.; Riera, A. Tetrahedron, 2001, 57, 6367–6374. 
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Scheme 42. Enantioselective synthesis of γ-sulfonyl allyl amines. 
In view of the scarcity of methodologies described to prepare these type of potential 
protease inhibitors, in this chapter, we present our attempts to develop an alternative 
strategy which could provide γ-sulfonyl allyl amines in a more efficient way.   
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2.2. Working hypothesis and objectives 
As mentioned in the introduction, it is relevant the fact that structurally diverse 
enantiopure γ-sulfonyl allyl amines show potential to act as irreversible protease 
inhibitors. Thus, a concise and general methodology for their preparation could facilitate 
the identification of novel inhibitors with improved activity. 
Due to the experience of our group in the catalytic asymmetric C–C bond forming 
reactions, and more particularly in the nitro-Mannich reaction,158 we considered that 
the base promoted addition of a synthetic equivalent of the vinyl sulfone anion to N-
protected imines, followed by nitrous acid elimination, would represent a practical and 
short stereoselective route to γ-sulfonyl allyl amines. Both, the carboncarbon bond and 
the new stereogenic center could be generated in a single operation, which is a clear 
advantage over traditional olefination methods (Scheme 43).  
 
Scheme 43. Retrosynthetic analysis for the preparation of γ-sulfonyl allyl amines. 
As previously disclosed, our group reported the preparation of highly enantioenriched 
α,β-unsaturated γ-amino esters under catalytic phase transfer conditions. This 
methodology represents a unique example of the use of 3-nitropropionates as β-acryloyl 
anion equivalents, through their organocatalytic asymmetric addition to N-Boc α-amino 
sulfones followed by basic treatment (Scheme 44).159 
                                                     
158 a) Ref. 112a, page 66. b) Ref. 129, page 73. 
159 Gomez-Bengoa, E.; Linden, A.; López, R.; Múgica-Mendiola, I.; Oiarbide, M.; Palomo, C. J. Am. Chem. 
Soc. 2008, 130, 7955–7966. 
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Scheme 44. Enantioselective synthesis of α,β-unsaturated γ-amino esters. 
In fact, this umpolung strategy for the olefination reaction was successfully applied 
later in Michael-type reactions employing 2-nitroethyl sulfones as vinyl sulfone anion 
equivalents.160 In particular, the asymmetric Michael addition of 2-nitroethyl sulfones to 
α,β-unsaturated aldehydes, via iminium ion catalysis, followed by nitrous acid 
elimination, provided access to highly enantioenriched γ-substituted vinyl sulfones in a 
one-pot process (Scheme 45). 
 
Scheme 45. Enantioselective synthesis of γ-substituted vinyl sulfones. 
Encouraged by these results, we envisioned, as mentioned before, that the 
organocatalyzed asymmetric nitro-Mannich reaction with 2-nitroethyl sulfones followed 
by nitrous acid elimination could represent a general procedure for the synthesis of 
enantioenriched γ-sulfonyl allyl amines (Scheme 46). The present strategy would reduce 
significantly the number of synthetic steps required for the synthesis of this type of 
scaffolds, providing access to a wide variety of structures from economic achiral 
substrates. 
                                                     
160 López, R.; Zalacain, M.; Palomo, C. Chem. Eur. J. 2011, 17, 2450–2457. 
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Scheme 46. Synthetic plan for the preparation of enantioenriched γ-sulfonyl allyl amines. 
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2.3. Results and discussion 
2.3.1. Initial experiments  
Several organocatalytic systems have shown their efficiency for the stereoselective 
addition of linear nitroalkanes to imines. However, protocols with functionalized 
nitroalkanes have been scarcely explored. Due to the structural similarities between 2-
nitroethyl sulfones and ethyl 3-nitropropionates, it seemed appropriate to evaluate first 
their behavior in the phase transfer catalyzed nitro-Mannich reaction employing the 
optimal conditions established before for the analogous reaction (Scheme 44 in page 
91).159 Specifically, we studied the addition of 2-nitroethyl sulfone 2a to α-amido sulfone 
1, in the presence of catalytic amounts of N-benzyl quininium chloride and 
suprastoichiometric amounts of cesium hydroxide, in toluene at –50 °C.161 
Unfortunately, only traces of adduct 3 were detected after 72 hours (Scheme 47). 
 
Scheme 47. Nitro-Mannich reaction of 1 and 2a under phase transfer conditions. 
Higher cesium hydroxide quantities –up to 3 equivalents– provided similar results 
whereas the use of other inorganic bases such as potassium carbonate or sodium 
bicarbonate led to total absence of reactivity. On the other hand, rise of reaction 
temperature up to –10 °C provided better transformations at the expense of the 
formation of complex mixtures. This low reactivity was attributed to a lower solubility 
of 2-nitroethyl sulfone 2a in comparison with ethyl 3-nitropropionate. 
In view of these results, we decided to explore the asymmetric nitro-Mannich reaction 
of N-Boc imines and 2-nitroethyl sulfones, under homogeneous conditions, employing 
                                                     
161 This part of the work was carried out by Dr. Maitane Zalacain: Zalacain, M. Reacción de Michael 
enantioselectiva de 2-nitroetil sulfonas. Ph.D. Thesis, University of the Basque Country, Donostia-San 
Sebastian, 2014. 
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chiral Brønsted base catalysis. One critical issue to address in this approach would be 
the tendency of such nitroalkanes to eliminate nitrous or sulphinic acid in the presence 
of base. Consequently, the chiral Brønsted base used in the reaction should promote the 
addition reaction –C–C bond formation– rather than the nitrous or sulfinic acid 
elimination in the starting pronucleophile (Scheme 48). 
 
Scheme 48. Possible reaction pathways under Brønsted base catalysis. 
Preliminary assays with catalytic amounts of DBU, DABCO and triethylamine showed 
that nitrous acid elimination in the starting material competed with the addition 
reaction especially at temperatures above –10 °C. Nevertheless, quinine-mediated 
nitro-Mannich addition of 2-nitroethyl sulfone 2a to N-Boc imine 4a worked 
satisfactorily at 0 °C and the addition product 5aa was obtained (Scheme 49).161 
 
Scheme 49. Quinine-catalyzed addition of 2-nitroethyl sulfone 2a to imine 4a. 
This result suggests that certain Brønsted bases may be compatible with the proposed 
reaction pathway and favor the new C–C bond formation instead of the elimination of 
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nitrous or sulfinic acid in the starting 2-nitroethyl sulfone. Further studies with chiral 
Brønsted bases showed that bases lacking hydrogen-bond donors, such as (DHQD)2Pyr, 
(DHQD)2AQN and (DHQD)2PHAL, gave no reaction while bifunctional organocatalysts 
provided total transformations. Quinine, as previously shown, and cinchonine promoted 
complete transformation of 4a into the corresponding adducts at –40 °C after 72 hours, 
whereas the reaction with Takemoto’s thiourea only required 15 hours to completion. 
After elimination of nitrous acid by adding magnesium methoxide,162 the highest 
enantioselectivity was obtained with Takemoto’s thiourea although the desired γ-
sulfonyl allyl amine 5aa was produced in low global yield (20%) (Scheme 50).161 The 
nitro-Mannich reaction proceeded to completion but the basic conditions, for the 
nitrous acid elimination, promoted retroaddition and the isomerization of the double 
bond to afford the corresponding achiral γ-sulfonyl vinyl amine. 
 
Scheme 50. Takemoto’s thiourea-catalyzed synthesis of γ-sulfonyl allyl amine 5aa. 
2.3.2. Optimization of nitrous acid elimination in the Mannich adducts 
Nitro-Mannich adduct 5aa, obtained by the addition of 2-nitroethyl sulfone 2a to N-
Boc imine 3a, seemed to be more sensitive to basic conditions than the adducts 
produced in the reaction with ethyl 3-propionate (only aliphatic adducts were tested, 
see Scheme 44 in page 91)159 and in the amine-catalyzed conjugate addition of 2-
nitroethyl sulfones (see Scheme 45 in page 91).160 Thus, we decided to focus on the 
optimization of the nitrous acid elimination. Several bases were tested, although the 
traditional organic ones were excluded from the study since previous experiments 
                                                     
162 Nitrous acid elimination under these conditions provided satisfactory results for the enantioselective 
Michael reaction with 2-nitroethyl sulfones (see Scheme 45 in page 76).  
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already showed that they favored the isomerization of the double bond. Most 
representative results are depicted in Table 5.  
Table 5. Optimization of nitrous acid elimination step. 
 
Entry Base Equiv. Solvent t (h) Conv. (%)b 5aa:7aa:8ab 
1 Mg(MeO)2 2 MeOH 2 60 0:100:0 
2c Mg(MeO)2 2 MeOH 2 >95 0:100:0 
3 Mg 3 MeOH 1.5 >95 0:100:0 
4c AcOK 5 CH2Cl2 24 70 0:100:0 
5 CsF 5 CH2Cl2 5 >95 0:100:0 
6 DMAP 2 CH2Cl2 2 >95 0:100:0 
7 CsOH·H2O 2 CH2Cl2 1.5 >95 61:39:0 
8 
Cs2CO3  
(0.2 M aq.) 
4 CH2Cl2 20 >95 0:0:100 
9 K2CO3 2 CH2Cl2 24 60 0:0:100 
10 t-BuOK 2 CH2Cl2 2 >95 0:100:0 
11 KOH 2 CH2Cl2 2 >95 100:0:0 
12 Amberlyst A-21 1 mg/mmol CH2Cl2 48 N.R. - 
13 Basic silica gel 0.1 g/mmol CH2Cl2 24 N.R. - 
a Reactions conducted on 0.5 mmol scale in 20 mL of the indicated solvent at room temperature.           
b Reaction conversion and 5aa:7aa:8a ratio determined by 1H NMR of the crude product. c Reactions 
carried out at 40 °C. 
Isomerization of adduct 5aa into 7aa was observed with bases of different nature 
(entries 1–6). Cesium hydroxide monohydrate provided a mixture of desired adduct 5aa 
and isomerized 7aa (entry 7), which could not be improved decreasing neither reaction 
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time nor temperature. On the other hand, cesium or potassium carbonates induced 
sulfinic acid elimination to produce compound 8a (entries 8 and 9). When potassium 
tert-butoxide was employed, the desired γ-sulfonyl allyl amine 5aa was detected in 
initial assays but these results were later irreproducible, giving rise only to the 
isomerized product 7aa (entry 10). We attributed the lack of reproducibility to the non-
homogeneity of some commercial inorganic bases, which were usually stored under 
non-anhydrous conditions. Considering that hydroxide species could be present in the 
used potassium tert-butoxide, we carried out a last experiment employing potassium 
hydroxide. To our satisfaction, treatment of 6aa with 2 equivalents of potassium 
hydroxide for 2 hours, in methylene chloride at room temperature, provided only the 
desired γ-sulfonyl allyl amine 5aa (entry 11). As reaction time seemed to be crucial to 
avoid isomerization, the reactions were always monitorized by IR spectroscopy and 
quenched when the NO2 band (1560 cm-1) disappeared. In addition, other basic agents 
such as resins and basic silica gel (entries 12 and 13) were assayed but no transformation 
was observed in any case regardless temperature or reaction time. 
On the other hand, attempts to perform the one-pot nitro-Mannich and potassium 
hydroxide-promoted elimination reactions produced adduct 5aa in low yield. 
With these results in hand, we decided to proceed with the optimization of the 
asymmetric nitro-Mannich reaction step promoted by a chiral Brønsted base. 
2.3.3. Catalyst screening for the asymmetric nitro-Mannich reaction 
Encouraged by the results obtained using bifunctional Takemoto’s thiourea (see 
Scheme 50 in page 95), we decided to explore the use of bifunctional Brønsted bases, 
particularly, ureidopeptide-type bifunctional catalysts developed by our group, which 
had previously demonstrated a great efficiency in conjugate additions.163 Their design 
was inspired by observations made by the group of Zhong164 and later corroborated by 
Schreiner and co-workers.165 Based on exhaustive studies on NMR and IR spectroscopy, 
mass-spectrometry and DFT calculations, they suggested that the success of 
                                                     
163 For pioneering ureidopeptide-type catalyst promoted asymmetric Michael reaction, see: a) Diosdado, 
S.; Etxabe, J.; Izquierdo, J.; Landa, A.; Mielgo A.; Olaizola, I.; López, R.; Palomo, C. Angew. Chem. Int. Ed. 
2013, 52, 11846–11851. For ureidopeptide-type catalyst promoted asymmetric Mannich reaction, see: b) 
Diosdado, S.; López, R.; Palomo, C. Chem. Eur. J. 2014, 20, 6526–6531. For ureidopeptide-type catalyst 
promoted asymmetric aldol reaction, see: c) Echave, H.; López, R.; Palomo, C. Angew. Chem. Int. Ed. 2016, 
55, 3364–3368. 
164 Tan, B.; Lu, Y.; Zeng, X.; Chua, P. J.; Zhong, G. Org. Lett. 2010, 12, 2682–2685. 
165 Lippert, K. M.; Hof, K.; Gerbig, D.; Ley, D.; Hausmann, H.; Guenther, S.; Schreiner, P. R. Eur. J. Org. Chem. 
2012, 5919–5927. 
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electronically deficient thioureas may be a consequence of the participation of three 
contiguous H-bond donors during the electrophile activation event: both N–H bonds in 
thiourea unit and the ortho C–H bond in the aryl group (Figure 14). 
 
Figure 14. Activation mode proposal. 
Based on these appreciations and given the efficacy of flexible synthetic peptides for 
the fine-tuning of reactivity and selectivity in several synthetic transformations,166 our 
group developed a new class of organocatalysts, the so-called ureidopeptide-based 
Brønsted base catalysts. These compounds are distinguished by the presence of an N,N-
diacyl aminal unit, in place of the bis(trifluoromethyl)-phenyl group, and a urea moiety 
as hydrogen bond donors, both in close proximity to an additional stereodirecting group. 
This type of structures closely resembles to ureidopeptides, which have been recognized 
for their ability to develop hydrogen bond interactions.167 It was expected that 
replacement of the α-amino acid terminus in ureidopeptides by a group bearing a 
tertiary amine would result in novel bifunctional Brønsted base catalysts with several 
sites amenable for structural modification (Figure 15). 
                                                     
166 Selected review: Davie, E. A. C.; Mennen, S. M.; Xu, Y.; Miller, S. J. Chem. Rev. 2007, 107, 5759–5812. 
167 a) Schoonbeek, F. S.; van Esch, J. H.; Hulst, R.; Kellogg, R. M.; Feringa, B. L. Chem. Eur. J. 2000, 6, 2633–
2643. b) Semetey, V.; Rognan, D.; Hemmerlin, C.; Graff, R.; Briand, J.-P.; Marraud, M.; Guichard, G. Angew. 
Chem. Int. Ed. 2002, 41, 1893–1895. c) Myers, A. C.; Kowalski, J. A.; Lipton, M. Bioorg. Med. Chem. Lett. 
2004, 14, 5219–5222. d) Sureshbabu, V. V; Patil, B. S.; Venkataramanarao, R. J. Org. Chem. 2006, 71, 7697–
7705. 
Enantioselective synthesis of γ-sulfonyl allyl amines 
 
99 
 
 
Figure 15. Design of ureidopeptide-based bifunctional Brønsted bases. 
The first synthesis and subsequent optimization of these organocatalysts was 
conducted by Dr. Diosdado in our research group.168 The proposed general synthetic 
sequence involves carbamate protection of the α-amino acid, followed by Curtius 
rearrangement and coupling of the resulting isocyanate with the primary amino group 
of the corresponding Brønsted base (Scheme 51). Hence, from a synthetic point of view, 
these structures can be easily tuned in several sites facilitating the modulation of 
catalyst properties. 
 
Scheme 51. Synthesis of ureidopeptide-based bifunctional Brønsted base catalysts. 
Following the methodology described above, we synthetized a series of ureidopeptide-
based organocatalysts (Figure 16) that were tested in the nitro-Mannich reaction of 2-
nitroethyl sulfone 2a with N-Boc imine 4a (Table 6). 
                                                     
168 Diosdado, S. Adición de Fosfonoacetatos, Malonatos y Sulfonilacetonitrilos a Iminas. Desarrollo de 
Bases de Brønsted Bifuncionales, Ureidopéptido-Cinchona. Ph.D. Thesis, University of the Basque Country, 
Donostia-San Sebastian, 2014. 
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Figure 16. Bifunctional ureidopeptide-based Brønsted base organocatalysts. 
Results in Table 6 show the high capacity of the synthetized catalysts C1–C8 to promote 
the addition of 2-nitroethyl sulfone 2a to imine 4a. The transformation resulted 
complete with each catalyst after 15 hours at –40 or –60 °C. In addition, this study 
permitted the evaluation of the effect that each tunable group from the catalyst had in 
the asymmetric induction of the reaction. First, a higher enantiomeric excess was 
obtained with 9-epi-9-amino-9-deoxyquinine (catalyst C2, entry 2) than when employing 
9-epi-9-amino-9-deoxyquinidine (catalyst C1, entry 1) as the Brønsted base fragment. 
Likewise, we observed that a higher volume of the aminal geminal group provided better 
enantioselectivity since the substitution of the iso-propyl and benzyl groups (catalysts 
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C2 and C3) with a bulkier tert-butyl group (catalyst C4) increased the enantiomeric 
excess of γ-sulfonyl allyl amine 5aa up to 82 % (entries 2–4). On the other hand, the 
impact of the N-protecting group was tested, observing a drastic drop in the 
enantioselectivity when the Fmoc group was replaced by Boc or Cbz groups (catalysts 
C4–C6, entries 4–6). In addition, the convenient use of 9-epi-9-amino-9-deoxyquinine 
fragment was corroborated as the matched pair, since catalysts C7 provided a lower 
enantiomeric excess (entry 7). Finally, the highest enantiomeric excess was obtained 
with catalyst C8, prepared from Fmoc-protected L-tert-leucine and 9-epi-9-amino-9-
deoxyhydroquinine, at –60 °C (entry 8). Under these reaction conditions followed by 
nitrous acid elimination, compound 5aa was obtained with 85% ee. The use of apolar 
solvents, such as toluene, decreased drastically the enantioselectivity of the reaction 
(entry 9). 
Table 6. Catalyst screening for the asymmetric nitro-Mannich reaction of 2a with 4a. 
 
Entry Cat. Solvent T (°C) Conv. (%)b ee (%)c 
1 C1 CH2Cl2 –40 >95 13 
2 C2 CH2Cl2 –40 >95 75 
3 C3 CH2Cl2 –60 >95 70 
4 C4 CH2Cl2 –40 >95 82 
5 C5 CH2Cl2 –40 >95 20 
6 C6 CH2Cl2 –40 >95 49 
7 C7 CH2Cl2 –60 >95 42 
8 C8 CH2Cl2 –60 >95 85d 
9 C8 Toluene –60 >95 40 
a Reactions conducted on 0.5 mmol scale employing 1.5 equiv. of 2a. b Conversion 
determined for addition step by 1H NMR spectroscopy. c Enantiomeric excess of product 5aa 
was determined by chiral HPLC on the reaction crude. d Diastereomeric ratio of addition 
product 6aa was 4:1, determined by 1H NMR spectroscopy on the reaction crude. 
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2.3.4. Evaluation of the sulfone group in 2-nitroethyl sulfones 
As already mentioned, since reactivity and stereoselectivity in Brønsted base catalyzed 
reaction is promoted through non-covalent interactions, the stereochemical outcome 
shows strong dependence not only on catalyst but also on substrate structure. For 
this reason, we decide to evaluate the impact of the sulfone moiety in the 
stereoselectivity of the reaction and 2-nitroethyl sulfones 2b–2d were synthetized 
following the same procedure as for 2a (Figure 17).  
 
Figure 17. 2-Nitroethyl sulfones 2b–2d employed in the study.  
These 2-nitroethyl sulfones were tested in the nitro-Mannich reaction with N-Boc 
imine 4a, in the presence of catalyst C8, under the optimized conditions. (Table 7). The 
substitution of the phenyl ring with a bulkier 2-naphthyl group decreased 
enantioselectivity, whereas the inclusion of nitrogen in the ring increased the 
enantiomeric excess up to 92%. Nevertheless, adduct 5ca was isolated in very low yield 
due to the low efficiency of the elimination step. Surprisingly, 2-nitroethyl sulfone 2d, 
bearing a 3,5-bis(trifluoromethyl)phenyl group, provided γ-sulfonyl allyl amine 5da as 
only one detectable enantiomer in moderate yield after two steps. 
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Table 7. Effect of sulfone substituents in the asymmetric nitro-Mannich reaction. 
 
a Reactions conducted on 0.5 mmol scale employing 1.5 equiv. of 2(a–d). b Yields refer to isolated adducts 
after 2 steps. c Enantiomeric excess was determined by chiral HPLC.  
2.3.5. Reaction scope 
A selection of N-Boc imines was evaluated in order to stablish the generality of this 
asymmetric route to γ-sulfonyl allyl amines. As data in Table 8 show, catalyst C8 
promoted the addition reaction of 2d within 15 hours at –60 °C to afford the 
corresponding enantioenriched amines in variable yields over two steps. The 
enantiomeric excesses were excellent for aryl N-Boc imines with electron-donating and 
electron-withdrawing groups, irrespective of their number. For example, the reaction 
with imines 4(a–c), 4e and 4h led to the corresponding products with 99% enantiomeric 
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excess. The method also worked well for imines with bulkier groups (4i) and 
heteroaromatic azomethines such as 4i, to afford adducts with 88% and 94% ee, 
respectively. 
Nevertheless, the overall yields were variable from moderate to low. In spite of having 
optimized the base promoted nitrous acid elimination step, we realized that during 
purification, the γ-sulfonyl allyl amines tended to isomerize into the corresponding 
achiral vinyl amines. All attempts to minimize the isomerization event during purification 
resulted fruitless and consequently, compounds 5dd, 5dh and 5dj could not be 
completely characterized (only 1H NMR and UPLC-MS analysis were conducted). 
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Table 8. N-Boc imine reaction scope. 
 
a Reactions conducted on 0.5 mmol scale employing 1.5 equiv. of 2d. b Yields refer to isolated adducts 
after 2 steps. c Enantiomeric excess was determined by chiral HPLC. 
On the other hand, the nitro-Mannich reaction with N-Boc aliphatic imines was also 
investigated. Unfortunately, no addition reaction was observed neither employing pre-
formed imines 4k–4m (Scheme 52a) nor preparing them in situ from amido sulfone 9 in 
the presence of stoichiometric amounts of cesium carbonate (Scheme 52b). For the last 
case, the imine formation was confirmed since hydrocinnamaldehyde was obtained 
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after acid treatment. Additionally, the use of higher reaction temperatures resulted in 
nitrous acid elimination from 2-nitroethyl sulfone 2a. 
 
Scheme 52. Unsuccessful asymmetric nitro-Mannich reaction with aliphatic imines. 
Moreover, attempts to promote the nitro-Mannich reaction of 2-nitroethyl sulfone 2d 
with isatin-derived ketimine 10 were also fruitless. 
 
Scheme 53. Unsuccessful asymmetric nitro-Mannich reaction with isatin-derived ketimine 10. 
2.3.6. Elaboration of adducts 
The fact that small γ-sulfonyl allyl amines are effective inhibitors of several proteases 
strongly supported our interest for developing this method but, at the same time, γ-
sulfonyl allyl amines are interesting frameworks that could be easily transformed into 
enantiomerically enriched allylic amines or exploited as easily available chiral Michael 
acceptors. 
For that purpose, the elimination of the sulfone group from the adducts was examined, 
first. To our disappointment, desulfonylation of adduct 5da, employing standard 
conditions (magnesium, sodium hydrosulfite or sodium amalgam), did not produce the 
corresponding allyl amine. (Table 9). In all cases, the reactions resulted in messy crude 
mixtures, in which either isomerization and/or decomposition of adduct 5da was 
observed. 
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Table 9. Unsuccessfull desulfonilation of adduct 5da. 
 
Entry Reagent (equiv.) Solvent T (°C) t (h) 
1 Mg (15), TMSCl (0.5), DBE (0.5) MeOH rt 2 h 
2 Na2S2O4 (4), NaHCO3 (12) DMF:THF:H2O (1:1:1) 50 2 h 
3 Na(Hg) 5% (6) MeOH –20 4 h 
 
On the other hand, attempts to employ the γ-sulfonyl allyl amines as Michael acceptors 
were also disappointing. The use of Grignard or organocuprate reagents did not 
promote the reaction at low temperature and only isomerization of the double bond 
was detected at higher temperatures. (Table 10, entries 1–3). Otherwise, since 
thiomalonate 11 was found to perform the Mannich reaction with N-Boc imines in 
absence of an external base,168 we considered this pronucleophile as an alternative. 
Unfortunately, no reaction was observed in the stated conditions (entry 4) and further 
addition of 20 mol% of Et3N resulted in adduct isomerization. 
Table 10. Unsuccessfull conjugate addition to adduct 5da. 
 
Entry Reagent (equiv.) Solvent T (°C) t (h) 
1 MeMgBr (3) THF –40 48 
2 Me2CuLi (2) Et2O 0 48 
3 n-Bu2CuLi (2) Et2O 0 48 
4 
  
CH2Cl2 rt to 40 72 
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Other chemical transformations such as iodocyclocarbamation169 and photochemical 
substitutions,170 previously described for vinyl sulfones lacking α-stereogenic centers, 
went also without success. 
We were able only to produce the corresponding free secondary amines in excellent 
yield (Scheme 54).156c 
 
Scheme 54. Amine deprotection in final adduct 5da. 
In spite of the difficulties, mainly related to the purification and manipulation of the 
adducts, our initial hypothesis resulted correct and we have been able to develop a 
catalytic methodology for the synthesis of highly enantioenriched γ-sulfonyl allyl 
amines. Nevertheless, the inconvenients found out during the work made us focus on 
other projects that were being developed in parallel with greater success.
 
 
  
  
                                                     
169 Dell’Uomo, N.; Di Giovani, M. C.; Misiti, D.; Zappia, G.; Delle Monache, G. Liebigs Ann. Chem. 1994, 
641–644. 
170 Amaoka, Y.; Nagamoto, M.; Watanabe, M.; Tao, K.; Kamijo, S.; Inoue, M. Chem. Sci. 2014, 5, 4339–
4345. 
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3. STEREOSELECTIVE SYNTHESIS OF PYRIDINE BASED TERTIARY 
AND SECONDARY AMINES 
3.1. Pyridine based amines 
3.1.1. General considerations 
Nitrogen-containing heterocycles are one of the most significant structural 
components in pharmaceuticals.171,172 For instance, from 1086 unique small-molecule 
drugs approved by U.S. FDA in 2012, 640 (59%) contained at least one nitrogen 
heterocycle.173 Moreover, from the top 6 prescribed drugs in the U.S. in 2016, 5 of them 
also incorporated this type of moiety (Figure 18).174 
                                                     
171 For selected books about nitrogen-containing heterocycles, see: a) Royer, J., Ed. Asymmetric Synthesis 
of Nitrogen Heterocycles; Wiley-VCH: Weinheim, 2009. b) Majumdar, K. C.; Chattopadhyay, S. K., Eds. 
Heterocycles in Natural Product Synthesis; Wiley-VCH: Weinheim, 2011. c) Eicher, T.; Hauptmann, S.; 
Speicher, A. The Chemistry of Heterocycles, 3rd ed.; Wiley-VCH: Weinheim, 2012. 
172 For a survey of the heterocyclic drugs approved by the U.S. FDA from 2000 to 2012, see: a) Wu, Y.-J. 
Prog. Heterocycl. Chem. 2012, 24, 1–53. For a study in anticancer activity of nitrogen-containing 
heterocyclic moieties, see: b) Akhtar, J.; Khan, A. A.; Ali, Z.; Haider, R.; Shahar Yar, M. Eur. J. Med. 2017, 
125, 143–149. 
173 Ref. 1, page 35. 
174 a) https://njardarson.lab.arizona.edu/content/top-pharmaceuticals-poster (accessed Jul 26, 2018). b)  
McGrath, N. A.; Brichacek, M.; Njardarson, J. T. J. Chem. Educ. 2010, 87, 1348–1349. 
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Figure 18. Top N-heterocycle-containing pharmaceuticals by prescriptions in 2016. 
Among the nitrogen-containing heterocycles, pyridine represents the second most 
common moiety, appearing in 62 drugs (Figure 19a). In addition, C2-position results the 
preferred one for substitution with a frequency of 66% (Figure 19b).173 
 
Figure 19. Most frequent N-heterocycles and substituted pyridines in U.S. FDA approved drugs (2012). 
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Furthermore, C-2 or ortho-substituted pyridines are frequent structures in chiral 
molecules. Among them, chiral α-functionalized 2-pyridyl amines present interesting 
properties due to their high density of structural information. Figure 20 shows some 
examples of biologically active compounds175 and chiral ligands176 bearing this structural 
moiety, including some α-chiral amines. 
 
Figure 20. Ortho-substituted pyridines as bioactive compounds or chiral ligands. 
3.1.2. Enantioselective synthesis of α-functionalized 2-pyridyl amines 
The synthesis of ortho-substituted chiral pyridine-containing building blocks has 
recently attracted much attention. Actually, there are three main catalytic approaches 
for the preparation of α-functionalized chiral 2-alkyl pyridines: the reduction of 2-pyridyl 
based carbonyls and olefins (Scheme 55a), the nucleophilic addition to 2-pyridyl 
carbonyls, azomethines and alkenes (Scheme 55b), and the use of 2-alkyl pyridines as 
pronucleophiles in nucleophilic additions (Scheme 55c). 
                                                     
175 For information about disopyramide, see: a) Mokler, C. M.; van Arman, C. G. J. Pharmacol. Exp. Ther. 
1962, 136, 114–124. b) https://www.drugs.com/mtm/disopyramide.html (accessed August 10, 2018). For 
information about the anti-Alzheimer and antipsychotic agent, see: Kolczewski, S.; Marty, H.-P-; 
Narquizian, R.; Pinard, E.; Stader, H. Preparation of cyclic amines or amino alcohols as therapeutic GlyT-1 
inhibitors. US 20100210592 A1, 2010. 
176 Uenishi, J.; Hamada, M. Tetrahedron: Asymmetry 2001, 12, 2999–3006. 
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Scheme 55. Main approaches for the synthesis of α-functionalized chiral 2-alkylpyridines. 
These three approaches constitute straightforward methodologies for the preparation 
of pyridine based tertiary and secondary amines, but all remain underexplored. For 
instance, whereas general enantioselective reductive methods have been described for 
ketones and olefins, only isolated examples of the use of ketimines has been reported 
with very low efficiency.177 At the same time, regarding the use of 2-pyridyl imines as 
electrophiles, only few examples appear as particular cases of enantioselective 
nucleophilic additions to aromatic imines.178 The third approach, towards the synthesis 
of pyridine based tertiary and secondary amines, constitutes the main objective of this 
chapter, therefore the state of the art for this particular strategy is presented. 
                                                     
177 For selected examples, see: a) Malkov, A. V.; Vranková, K.; Stončius, S.; Kočovský, P. J. Org. Chem. Soc. 
2009, 74, 5839–5849. b) Huang, K.; Merced, F. G.; Ortiz-Marciales, M.; Meléndez, H. J.; Correa, W.; De 
Jesús, M. J. Org. Chem. 2008, 73, 4017–4026. c) Adams, M. R.; Tien, C.-H.; McDonald, R.; Speed, A. W. H. 
Angew. Chem. Int. Ed. 2017, 56, 16660–16663.  
178 For selected examples, see: a) Okino, T.; Nakamura, S.; Furukawa, T.; Takemoto, Y. Org. Lett. 2004, 6, 
625–627. b) Budragchaa, T.; Abraham, M.; Schöfberger, W.; Roller, A.; Widhalm, M. Asym. Catal. 2016, 3, 
1–14. For catalytic asymmetric [2+3] cycloaddition with 2-pyridyl imines, see: c) Padilla, S.; Tejero, R.; 
Adrio, J.; Carretero, J. C. Org. Lett. 2010, 12, 5608–5611. d) Pascual-Escudero, A.; González-Esguevillas, 
M.; Padilla, S.; Adrio, J.; Carretero, J. C. Org. Lett. 2014, 16, 2228–2231. e) Takizawa, S.; Arteaga, F. A.; 
Yoshida, Y.; Suzuki, M.; Sasai, H. Asian J. Org. Chem. 2014, 3, 412–415. f) Takizawa, S.; Kishi, K.; Abozeid, 
M. A.; Murai, K.; Fujioka, H.; Sasai, H. Org. Biomol. Chem. 2015, 14, 761–767. 
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 2-Alkyl pyridines as pronucleophiles 
α-Deprotonation of 2-alkyl pyridines presents a remarkable parallelism with the 
enolization of carbonyl compounds since C=N moiety exhibits electron-withdrawing 
properties resembling those of the carbonyl group (Scheme 56).179 Nevertheless, 
although the latter has been employed in many direct catalytic enantioselective bond 
forming reactions (Scheme 56b),180 the use of 2-alkyl pyridines in analogous processes 
has been scarcely explored (Scheme 56a). The principal obstacle in the development of 
such reactions is the lower acidity of 2-alkyl pyridines compared to carbonyl compounds. 
 
Scheme 56. α-Deprotonation of 2-alkyl pyridines and enolization of carbonyl compounds. 
Despite this difficulty, several non-asymmetric methods have been reported for the α-
functionalization of 2-alkyl pyridines employing transition-metal catalysis. Normally, 
harsh reaction conditions, such as suprastoichiometric amounts of strong bases, high 
reaction temperatures or microwave radiation were required.181 These issues have 
compromised the development of asymmetric versions of these reactions and only a 
few precedents concerning catalytic enantioselective approaches that employ 2-
alkylazaarenes as pronucleophiles have been found in the literature. 
In 2009, the group of Trost described the palladium-catalyzed stereoselective allylation 
of 2-alkyl pyridines with excellent yields, diastereo- and enantioselectivities (Scheme 
                                                     
179 For a perspective in the matter, see: Best, D.; Lam, H. W. J. Org. Chem. 2014, 79, 831–845. 
180 For selected reviews in the matter, see: a) MacMillan, D. W. C.; Watson, A. J. B. α-Functionalization of 
Carbonyl Compounds. In Science of Synthesis: Stereoselective Synthesis; De Vries, J. G., Molander, G. A., 
Evans, P. A., Eds.; Thieme: Stuttgart, Germany, 2011; Vol. 3, pp 675−745. b) Melchiorre, P. Angew. Chem. 
Int. Ed. 2012, 51, 9748–9770. c) Hodgson, D. M.; Charlton, A. Tetrahedron 2014, 70, 2207–2236. 
181 For selected examples, see: a) Campeau, L.-C.; Schipper, D. J.; Fagnou, K. J. Am. Chem. Soc. 2008, 130, 
3266–3267. b) Qian, B.; Guo, S.; Shao, J.; Zhu, Q.; Yang, L.; Xia, C.; Huang, H. J. Am. Chem. Soc. 2010, 132, 
3650–3651. c) Qian, B.; Guo, S.; Xia, C.; Huang, H. Adv. Synth. Catal. 2010, 352, 3195–3200. d) Yan, Y.; Xu, 
K.; Fang, Y.; Wang, Z. J. Org. Chem. 2011, 76, 6849–6855. e) Qian, B.; Shi, D.; Yang, L.; Huang, H. Adv. Synth. 
Catal. 2012, 354, 2146–2150. f) Liu, X.-J.; You, S.-L. Angew. Chem. Int. Ed. 2017, 56, 4002–4005. g) Suzuki, 
H.; Igarashi, R.; Yamashita, Y.; Kobayashi, S. Angew. Chem. Int. Ed. 2017, 56, 4520–4524. h) Zhai, D.-D.; 
Zhang, X.-Y.; Liu, Y.-F.; Zheng, L.; Guan, B.-T. Angew. Chem. Int. Ed. 2018, 57, 1650–1653. i) Zhang, G.; 
Irrgang, T.; Dietel, T.; Kallmeier, F.; Kempe, R. Angew. Chem. Int. Ed. 2018, 57, 9131–9135. 
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57). The reactive nucleophiles were generated by coordination to BF3·OEt2 followed by 
deprotonation with 3.5 equivalents of LiHMDS and 1 equivalent of n-BuLi.182 
 
Scheme 57. Trost’s asymmetric allylation of 2-alkyl pyridines. 
Otherwise, the installation of an additional activating group into the substrate has 
become a successful strategy to overcome the low acidity of 2-alkyl pyridines. In 2011, 
Melchiorre and co-workers reported the enantioselective addition of nitrobenzyl 
pyridines to α,β-unsaturated aldehydes via iminium ion catalysis. In this process, the 
combination of the electron-withdrawing nitrophenyl and pyridine groups rendered the 
methylene at the benzylic position sufficiently acidic for the reaction to proceed, under 
mild conditions, and the corresponding adducts were obtained with good yields and 
excellent enatioselectivites, albeit with low diastereoselectivities (Scheme 58).183 
                                                     
182 a) Trost, B. M.; Thaisrivongs, D. A. J. Am. Chem. Soc. 2009, 131, 12056–12057. See also: b) Trost, B. M.; 
Thaisrivongs, D. A. J. Am. Chem. Soc. 2008, 130, 14092–14093. c) Trost, B. M.; Thaisrivongs, D. A.; Hartwig, 
J. J. Am. Chem. Soc. 2011, 133, 12439–12441. 
183 Vera, S.; Liu, Y.; Marigo, M.; Escudero-Afán, E. C.; Melchiorre, P. Synlett 2011, 489–494. 
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Scheme 58. Melchiorre’s asymmetric Michael addition of nitrobenzyl pyridine to enals. 
The attachment of an extra activating group, such as an ester or amide group, to the 
α-carbon of the 2-alkyl pyridine, enhances the acidity to an extent that is almost 
comparable to that for 1,3-dicarbonyl compounds. 
 
Scheme 59. Structural homology between 2-pyridyl acetates and 1,3-dicarbonyl compounds. 
Following this principle, the group of Lam verified that certain 2-azaaryl acetates and 
acetamides, which had not previously been used in asymmetric catalysis, behaved as 
excellent pronucleophiles in Michael type additions to nitroalkenes, promoted by a 
chiral nickel (II) complex (Scheme 60).184 This methodology was compatible with a wide 
variety of azarenes, such as pyridines, pyrazines, triazines, isoquinolines, quinazolines, 
benzotiazoles and benzisoxazoles, and represents the first general approach for the 
construction of highly enantioenrichedαsubstituted azaarenes. 
  
                                                     
184 Fallan, C.; Lam, H. W. Chem. Eur. J. 2012, 18, 11214–11218. 
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Scheme 60. Lam’s enantioselective Michael reaction of 2-azaaryl acetates and acetamides. 
The same group also developed a similar approach to increase the acidity of 2-alkyl 
azaarenes; the incorporation of an electron-withdrawing group into the azaarene ring. 
High levels of stereoselectivity were achieved in the reactions of these substituted 2-
alkyl azaarenes with N-Boc imines and nitroalkenes promoted by a chiral Pd(II)-
bis(oxazoline) complex (Scheme 61).185 As far as we know, this is the only catalytic 
asymmetric methodology described, so far, for the synthesis of azaarene derived 
secondary amines based on the use of 2-alkyl azarenes as pronuclephiles. 
                                                     
185 Best, D.; Kujawa, S.; Lam, H. W. J. Am. Chem. Soc. 2012, 134, 18193–18196. 
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Scheme 61. Lam’s asymmetric addition of 2-alkyl azaarenes to N-Boc imines and nitroalkenes. 
More recently, and after the work developed in this thesis, Rios and co-workers 
reported the stereoselective synthesis of 2-alkyl pyridine derivatives, bearing a 
quaternary stereocenter, through Michael/Michael/aldol cascade reactions employing 
2-pyridyl acetonitrile as pronucleophile and iminium ion activation (Scheme 62).186 
 
Scheme 62. Rios’ asymmetric synthesis of 2-alkyl pyridine derivatives bearing a quaternary stereocenter 
via cascade reaction. 
Meanwhile, Jørgensen and co-workers performed the analogous reaction employing 
unactivated alkyl quinolines through synergistic activation of the alkyl quinolone by 
InCl3, and the electrophile, by iminium ion catalysis (Scheme 63),187 although no 
examples with 2-alkylpyridines were included. 
                                                     
186 Meazza, M.; Potter, M.; Pitak, M. B.; Coles, S. J.; Mazzanti, A.; Rios, R. Eur. J. Org. Chem. 2017, 719–
725. 
187 Meazza, M.; Tur, F.; Hammer, N.; Jørgensen, K. A. Angew. Chem. Int. Ed. 2017, 56, 1634–1638. 
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Scheme 63. Jørgensen’s functionalization of alkyl quinolines 
Finally, this year, Hartwig and co-workers reported the stereodivergent allylation of 
azaaryl acetamides and acetates employing a chiral metallacyclic iridium complex and a 
chiral bis-phosphine-ligated copper(I) complex, which individually controlled the 
configuration of the electrophilic and nucleophilic carbon atoms, respectively. Thus, by 
simple permutation of catalysts enantiomers, all four stereoisomers were synthesized 
with excellent diastereo- and enantioselectivity (Scheme 64).188 
                                                     
188 Jiang, X.; Boehm, P.; Hartwig, J. F. J. Am. Chem. Soc. 2018, 140, 1239–1242. 
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Scheme 64. Hartwig’s stereodivergent allylation of 2-pyridyl acetamides. 
In summary, precedents described above show that, although some examples of 
catalytic enantioselective addition of 2-alkyl pyridines to different electrophiles have 
been accomplished, the approach still presents numerous limitations. On the one hand, 
suprastoichiometric amounts of strong bases or substrate pre-activation with electron-
withdrawing groups are required for the reaction to proceed. Likewise, the asymmetric 
generation of quaternary stereocenters remains almost unexplored and no examples 
for the stereoselective synthesis of pyridine based tertiary and secondary amines have 
been reported through C–N bond formation whereas only one example has been 
disclosed for the synthesis of azaarene based secondary amines through C–C bond 
formation under metal catalysis (Scheme 61, page 123). 
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3.2. Working hypothesis and objectives 
Based on the experience of our research group in the development of Brønsted base 
catalyzed C–C and C–heteroatom bond forming reactions, we considered that 2-alkyl 
pyridines could be employed as pronucleophiles to address the stereoselective synthesis 
of pyridine based chiral tertiary and secondary amines through chiral Brønsted base-
catalyzed C–N and C–C bond formation reactions, respectively (Scheme 65).    
 
Scheme 65. Synthetic plan for the preparation of pyridine based tertiary and secondary amines. 
Precedents described above reveal the main limitations that substrates of this type 
present: i) the low acidity of 2-alkylazaarenes, that requires the use of pre-activated 
substrates either in the azarene ring and/or the Cα, ii) the lack of methods to address 
the generation of Cα quaternary stereocentres and iii) the difficulties to maintain the 
configurational stability of tertiary stereocenters generated under basic conditions. 
As mentioned in the general introduction, Brønsted base catalyzed transformations 
usually show a strong dependence on both substrate and catalyst structure. As a result, 
methodologies that imply modifications in the pronucleophile structures to enhance 
reactivity and improve stereoselectivity are of great interest. In this context, and 
following the atom economy principle,189 we envisioned that 2-alkyl azaarene N-oxides 
could be perfect candidates to perform efficiently in chiral Brønsted base catalyzed C–N 
and C–C bond formation reaction. 
The two key elements that make 2-alkyl azaarene N-oxides good candidates a priori, 
are their relatively high CH Brønsted acidity as compared to most alkylazaarenes (Figure 
21)190  and the presence of the N-O group as a potentially coordinating site for catalyst 
binding.191 Considering this, we could expect that bifuncional Brønsted bases might be 
                                                     
189 a) Trost, B. M. Science 1991, 254, 1471–1471 b) Trost, B. M. Angew. Chem. Int. Ed. 1995, 34, 259–381. 
c) Trost, B. M. Acc. Chem. Res. 2002, 35, 695–705. 
190 2-Alkylpyridine N-oxides are more acidic than the parent 2-alkyl pyridines in about 3–4 pKa units in 
DMSO: a) Bordwell, F. G. Acc. Chem. Res. 1988, 21, 456–463. b) 
http://evans.rc.fas.harvard.edu/pdf/evans_pKa_table.pdf (accessed Aug 30, 2018). 
191 Stereoselective methodologies with N-oxides: a) Landa, A.; Minkkilä, A.; Blay, G.; Jørgensen, K. A. Chem. 
Eur. J. 2006, 12, 3472–3483. b) Landa, A.; Richter, B.; Johansen, R. L.; Minkkilä, A.; Jørgensen, K. A. J. Org. 
Chem. 2007, 72, 240–245. c) Holmquist, M.; Blay, G.; Muñoz, M. C.; Pedro, J. R. Org. Lett. 2014, 16, 1204–
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adequate for an effective α-deprotonation and subsequent stereoselective bond 
formation. As far as we know, azaarene N-oxides have not been investigated in the 
context of asymmetric functionalizations.  
 
Figure 21. pKa values of pyridine and pyridine N-oxide derivatives. 
In consequence, we decided to address, as first objective, the stereoselective synthesis 
of pyridine based tertiary amines through Brønsted base-catalyzed stereoselective α-
amination of 2-cyanoalkylazaarene N-oxides with azodicarboxylates (0). 
 
Scheme 66. Synthetic plan for the enantioselective formation of pyridine based tertiary amines. 
As a second objective, we envisioned that pyridine based α-chiral secondary amines 
might be prepared through Brønsted base-catalyzed stereoselective Mannich-type 
reaction of 2-azaaryl acetate N-oxides with N-protected aldimines (0).  
 
Scheme 67. Synthetic plan for the enantioselective formation of pyridine based secondary amines. 
                                                     
1207. For examples reported after the present work, see: d) Xu, Y.; Zhang, S.; Li, L.; Wang, Y.; Zha, Z.; 
Wang, Z. Org. Chem. Front 2018, 5, 376–379. e) He, F.; Chen, G.; Yang, J.; Liang, G.; Deng, P.; Xiong, Y.; 
Zhou, H. RSC Adv. 2018, 8, 9414–9422. 
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3.3. Results and discussion 
3.3.1. Enantioselective α-amination of 2-(cyanomethyl)pyridine N-oxides 
with azodicarboxylates 
3.3.1.1. Initial experiments and catalyst design. 
In order to address our goal on the enantioselective synthesis of pyridine based tertiary 
amines, we first examined the adddition of 2-(cyano(phenyl)methyl)pyridine N-oxide 
13a to di(tert-butyl) azodicarboxylate 14a promoted by the bifunctional squaramide-
type Brønsted base C9. Fortunately, the reaction went smoothly at 0 °C and total 
conversion was achieved in only 16 hours. Adduct 15aa was obtained in 85% yield and 
77% ee (Scheme 68). More gratifiying was to find out that the reaction between the 
pyridine analogue 13’a and 14a went sluggish and with low asymmetric induction, thus 
confirming our initial hypothesis. 
 
Scheme 68. Comparison of the reactivity of 13a and 13’a in the reaction with 14a promoted by C9. 
As mention before, the development of steroselective Brønsted based catalyzed 
transformations is linked to the search of new modes of substrate activation and new 
catalyst design. Accordingly, with this promising result in hand, we decided to focus on 
a way to improve the enantiocontrol by designing new catalysts with additional sites for 
substrate activation. 
For the new catalyst design, we were inspired by the work by Hashimoto and co-
workers on the enantioselective allylation of aldehydes with allyltrichlorosilanes 
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assisted by chiral azaarene N-oxide catalyst.192 The authors suggested that the allylation 
of aromatic and unsaturated aldehydes proceeded via a cyclic chair-like transition state 
model where the N-oxide groups of the catalyst are coordinated to the hypervalent 
silicon (Scheme 69). 
 
Scheme 69. Hashimoto’s allylation with allyltrichorosilanes catalyzed by chiral azaarene N-oxide. 
In addition, Feng and co-workers, developed the enantioselective cyanation of 
carbonyl compounds and imines employing trimethylsilyl cyanide (TMSCN). The 
reactions were promoted by L-proline or L-piperidinamide based N,N’-dioxides, 
activating cooperatively both TMSCN and the electrophile. The possible mechanism 
consists of the generation of a hypervalent silicon intermediate from the bidentate N,N’-
dioxide which enhances the nucleophility of the cyano group as well as the rigidity of 
the reaction environment. Consequently, the electrophile activated by hydrogen 
bonding by the nearby amide is attacked by the cyano group (Scheme 70).193 
                                                     
192 a) Nakajima, M.; Saito, M.; Shiro, M.; Hashimoto, S.-I. J. Am. Chem. Soc. 1998, 120, 6419–6420. For 
further works with similar activation models, see: b) Tao, B.; Lo, M. M.-C.; Fu, G. C. J. Am. Chem. Soc. 2001, 
123, 353–354. c) Denmark, S. E.; Fan, Y. J. Am. Chem. Soc. 2002, 124, 4233–4235. d) Malkov, A. V; Bell, M.; 
Orsini, M.; Pernazza, D.; Massa, A.; Herrmann, P.; Meghani, P.; Kočovský, P. J. Org. Chem. 2003, 68, 9659–
9668. e) Denmark, S. E.; Fan, Y.; Eastgate, M. D. J. Org. Chem. 2005, 70, 5235–5248. f) Chen, J.; Captain, 
B.; Takenaka, N. Org. Lett. 2011, 13, 1654–1657. 
193 a) Wen, Y.; Huang, X.; Huang, J.; Xiong, Y.; Qin, B.; Feng, X. Synlett 2005, 2445–2448. b) Huang, J.; Liu, 
X.; Wen, Y.; Qin, B.; Feng, X. J. Org. Chem. 2007, 72, 204–208. c) Qin, B.; Liu, X.; Shi, J.; Zheng, K.; Zhao, H.; 
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Scheme 70. Feng’s cyanosilylation reaction catalyzed by N,N’-dioxides. 
Taking these works into account and given the high chemical affinity of silicon for 
oxygen, we envisioned a multifunctional catalyst based on N-oxide–silicon interactions 
as a suitable candidate to carry out the reaction satisfactorily (Figure 22). 
 
Figure 22. New design for the multifunctional squaramide-based Brønsted base catalyst. 
The proposed general synthetic sequence for this type of catalysts is depicted in 
Scheme 71. Their preparation involved the amination of the corresponding 
(chloromethyl)silyl derivative in a two-step sequence; first, the corresponding azide was 
prepared by treatment of the alkyl chloride with NaN3 in HMPA194 and subsequent 
reduction with LiAlH4 led to the corresponding amine.195 The coupling with 3,4-
                                                     
Feng, X. J. Org. Chem. 2007, 72, 2374–2378. For further examples employing proline-based N-oxides as 
chiral catalysts, see: d) Traverse, J. F.; Zhao, Y.; Hoveyda, A. H.; Snapper, M. L. Org. Lett. 2005, 7, 3151–
3154. For a review on chiral N,N’-dioxides as ligands and organocatalysts in catalytic asymmetric reactions, 
see: Liu, X.; Lin, L.; Feng, X. Acc. Chem. Res. 2011, 44, 574–587. 
194 Otohiko, T.; Shuji, K.; Koyo, M. Chem. Lett. 1983, 7, 1131–1134. 
195 Lettelier, M.; McPhee, D. J.; Griller, D. Synth. Commun. 1988, 18, 1975–1978. 
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dimethoxy-3-cyclobutadiene-1,2-diene and the amine was carried out at room 
temperature and, finally, the coupling of the second amino group, containing the 
corresponding chiral Brønsted base, was performed to produce the novel 
multifunctional squaramide-based Brønsted base catalysts. 
 
Scheme 71. Synthesis of squaramide-based Brønsted base catalysts bearing a silicon group. 
3.3.1.2. Catalyst screening 
Following the methodology described above, we synthetized a series of silicon-
containing squaramide-based Brønsted base catalysts (Figure 23) and we tested them in 
the reaction of 2-(cyano(phenyl)methyl)pyridine N-oxide 13a with di(tert-butyl) 
azodicarboxylate 14a. 
Chapter 3 
132 
 
 
Figure 23. Silicon-containing squaramide-based Brønsted base catalysts. 
Results obtained for each catalyst are shown in Table 6. The effect of the chiral 
Brønsted base moiety was first examined with catalysts C10 and C11 at room 
temperature. Catalyst C10 bearing the 2-(piperidin-1-yl)cyclohexan-1-amine scaffold 
provided much lower enantioselectivity (38% ee, entry 1) than catalyst C11 with the 9-
amino-9-deoxy-9-epiquinine fragment (70% ee, entry 2). Consequently, the 9-amino-9-
deoxy-9-epiquinine was maintained as the Brønsted base and variations on the silyl 
group were evaluated. First, the inclusion of a phenyl group –catalyst C12– induced a 
modest improvement in the enantioselectivity (72% ee, entry 3), which could not be 
increased at lower temperatures (entries 4 and 5). Replacement of the phenyl group by 
a 2-naphthyl moiety –catalyst C13– provided similar results (76% ee, entry 6) whereas 
the introduction of an additional 2-naphthyl group in the structure –catalyst C14– 
caused a significant drop in the asymmetric induction (57% ee, entry 7). Catalyst C15 
bearing two phenyl groups attached to the silyl atom provided a higher enantiomeric 
excess (81% ee, entry 8). On the other hand, increasing the concentration of the 
reactants, the enantioselectivity significantly decreased (48% ee, entry 9) while it was 
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maintained with dilution (entry 10) and at lower temperatures (entry 10). Apolar 
solvents such as toluene produced the adduct 15aa as a racemic mixture (entry 12). 
Finally, the reaction promoted by catalyst C16, bearing the triphenylsilyl group, in CH2Cl2 
at 0 °C provided the best results in terms of stereocontrol (90% ee, entry 13). 
Table 11. Catalyst screening for asymmetric α-amination of 13a with 14a. 
 
Entry Cat. Solvent (mL) T (°C) t (h) Yield (%) ee (%)b 
1 C10 CH2Cl2 rt 15 80 38 
2 C11 CH2Cl2 rt 15 96 70 
3 C12 CH2Cl2 rt 15 78 72 
4 C12 CH2Cl2 –10 32 97 76 
5 C12 CH2Cl2 –40 56 96 75 
6 C13 CH2Cl2 0 40 92 76 
7 C14 CH2Cl2 0 15 99 57 
8 C15 CH2Cl2 0 15 90 81 
9 C15 CH2Cl2 (0.5) 0 15 92 48 
10 C15 CH2Cl2 (2) 0 15 93 81 
11 C15 CH2Cl2 –10 15 95 81 
12 C15 Toluene 0 24 90 0 
13 C16 CH2Cl2 0 15 88 90 
a Reactions were conducted on 0.2 mmol scale employing 1.5 equiv. of 14a in 1 mL of CH2Cl2 (unless 
otherwise stated). b Enantiomeric excess of adduct 15aa was determined by chiral HPLC. 
3.3.1.3. Reaction scope 
The scope of this α-amination process using either di-tert-butyl or dibenzyl 
azodicarboxylates (14a or 14b), as aminating reagents, was investigated for a range of 
2-cyanomethylpyridine N-oxides. As data collected in Table 12 show, reactions 
proceeded successfully to give adducts 15 with good yield and enantiomeric excess with 
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catalyst C16 providing the best results for all entries. A slight decrease in 
enantioselectivity was observed for nucleophiles containing electron-donating groups 
into the aromatic ring (15ba and 15ca) whereas excellent yields and enantiomeric 
excesses were obtained with electron-withdrawing groups (15da–15fa) as well as with 
heteroaromatic rings (15ga). In addition, dibenzyl azodicarboxylate 14b performed in a 
similar way providing adducts 15db and 15eb with excellent yield and enantioselectivity. 
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Table 12. Enantioselective α-amination reaction scope. 
 
Reactions were conducted on 0.2 mmol scale employing 1.5 equiv. of 14 and 10 mol% of catalyst C16 in 1 
mL of CH2Cl2 (unless otherwise stated). Yields were determined for isolated products. Enantiomeric excess 
of adduct 15 was determined by chiral HPLC. 
Once again, the parent pyridine 13’a proved to be less efficient for this transformation 
(Scheme 72). The reaction of 13’a and 14a in the presence of 10 mol% catalyst C15 
proceeded to a limited extent of 30% conversion after 15 hours at 0 °C. After 120 hours, 
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complete transformation was observed and adduct 15’a was obtained in 85% yield and 
with 50% ee. 
 
Scheme 72. Effect of the N-oxide functionality. 
Transformation of the adduct 15aa into the crystalline compound 16 allowed the 
determination of the absolute configuration by single-crystal X-ray analysis (Scheme 73).  
The configuration of the rest of adducts was stablished by assuming a uniform reaction 
mechanism. 
 
 
Scheme 73. Determination of the absolute configuration. 
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To prove the utility of the N-oxide functionality as a temporary activating and 
stereodirecting group in the stereoselective synthesis of pyridine base tertiary amines, 
the reduction of the N-oxide group was accomplished in adduct 15aa under mild 
conditions by treatment with (Bpin)2.196 In this way, the protected enantioenriched 2-
pyridyl tertiary amine 15’aa was synthetized in 77% yield (Scheme 74). The methodology 
described represents the first catalytic and enantioselective procedure for the synthesis 
of pyridine based tertiary amines by means of α-amination of 2-alkyl pyridines. 
 
Scheme 74. Reduction of N-oxide group on adduct 15aa. 
In parallel, it was proven by Dr. Joseba Izquierdo that 2-cyanomethylazaarene N-oxides 
could also work as enabling substrates for conjugate additions to acrylate surrogates to 
afford elusive 2-tert-alkyl azaaryl adducts with high enantioselectivity (Scheme 75).197 
 
Scheme 75. Enantioselective conjugate addition of 2-(cyanomethyl)azaarene N-oxides to α-hydroxy 
enones. 
                                                     
196 Procedure adapted from: Kokatla, H. P.; Thompson, P. F.; Bae, S.; Doddi, V. R.; Lakshman, M. K. J. Org. 
Chem. 2011, 76, 7842–7848. 
197 Izquierdo, J. New Approach to Optically Active 2-tert-Alkyl Azaaryl Compounds and 5,5-Disubstituted 
Hydantoins. Ph.D. Thesis, University of the Basque Country, Donostia-San Sebastian, 2018. 
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3.3.2. Enantioselective Mannich reaction of 2-azaaryl acetates with N-
carbamoyl imines 
With the satisfactory results obtained in the previous section, we decided to further 
extend the methodology for the stereoselective synthesis of pyridine based secondary 
amines with contiguous quaternary and tertiary stereocenters. For that purpose, we 
envisioned that the addition of 2-(cyanomethyl)pyridine N-oxides to N-Boc imines could 
be an attractive approach for their preparation. Therefore, the Mannich reaction of 2-
(cyano(phenyl)methyl)pyridine N-oxide 13a with N-Boc imine 4a was investigated. 
Unfortunately, the reaction promoted by catalyst C15 did not proceed at room 
temperature (Scheme 76), nor even when 0.5 equivalents of triethylamine were added. 
 
Scheme 76. Unfructuous Mannich reaction of 6a with N-Boc imine 3a. 
Since α-amination worked well for 13a, we attributed the lack of conversion to steric 
reasons. At this point, we became also interested in the generation of configurationally 
labile sterocenters under Brønsted base catalysis, since their stability is easily 
compromised under proton transfer conditions. Therefore, we decide to investigate the 
Mannich reaction of 2-pyridyl acetate N-oxide 17 with N-Boc imine 4a. The reaction 
promoted by C15 provided adduct 18a in very low conversion, after 48 hours at room 
temperature, low enantioselectivity and, as expected for tertiary sterocenters 
generated under Brønsted base catalysis, with low diasteroselectivity (Scheme 77). 
 
Scheme 77. Mannich reaction of 17 with N-Boc imine 4a catalyzed by C15. 
Given the structural differences between pronucleophile 17 and 13a, we decided to 
explore other catalytic systems that could result more appropriate for the reaction.  
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3.3.2.1. Catalyst screening 
A variety of bifunctional Brønsted base catalysts was prepared and tested in the 
enantioselective Mannich reaction of 2-pyridyl acetate N-oxide 17 with N-Boc imine 4a 
(Figure 24). 
 
Figure 24. Catalyst library for the enantioselective Mannich reaction. 
As data in Table 13 show, squaramide- and (thio)urea-based catalysts containing silyl 
groups –C15, C17 and C18– afforded very poor results in terms of reactivity and 
stereoselectivity (entries 1–3) and similar results were achieved with conventional 
catalysts C9, C19, C20 and C21 (entries 4–7). In contrast, it was gratifying to observe that 
after 64 hours of stirring at room temperature, ureidopeptide-based Brønsted base 
catalysts –C22, C4, C6 and C23– exhibited high (88%, entry 8) and complete conversion 
(entries 9-11). Most remarkably, the corresponding Mannich adduct 18a was produced 
with high anti:syn ratio (5.7:19:1) and enantioselectivity (96-99% ee) regardless the 
nature of the R substituent in the catalyst. After some additional screening,198 catalyst 
C6 enabled the production of 18a as the only detectable diastereomer in 99% ee (entry 
12). 
                                                     
198 Reactions performed in THF and toluene at 0 °C provided lower conversions with C6 after 48 hours, 
although similar stereoselectivities were obtained. N-Tosyl imine afforded poor results with C6 after 48 
hours at 0 °C in methylene chloride –40% conv., dr 2.5:1 anti, 44/0% ee–.  
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Table 13. Catalyst screening for the enantioselective Mannich reaction of 17 with 4a.  
 
Entry Cat. T (°C) t (h) Conv. (%)b dr (anti:syn)c ee (%)d 
1 C15 rt 64 21 2:1 30/52 
2 C17 40 48 30 1:1 26/18 
3 C18 rt 64 51 1.7:1 54/28 
4 C9 40 48 20 0.9:1 4/53 
5 C19 40 70 42 0.8:1 3/16 
6 C20 40 48 36 0.7:1 50/74 
7 C21 rt 140 60 0.6:1 17/79 
8 C22 rt 64 88 6.7:1 99/99 
9 C4 rt 64 >95 5.7:1 99/98 
10 C6 rt 64 >95 9:1 96/94 
11 C23 rt 64 >95 9:1 98/55 
12e C6 0 48 >95 99:1 99 
a Reactions conducted on a 0.12 mmol scale in 0.5 mL of CH2Cl2 (molar ratio of 17:4a, 1:1.2). b 
Conversion determined by 1H NMR. c Diastereomeric ratio determined by 1H NMR of crude 
mixture and corroborated by chiral HPLC. d Enantiomeric excess determined by chiral HPLC. e 
Molar ratio of 17:4a, 1:2. 
3.3.2.2. Reaction scope 
Next, we explored the generality of the optimized procedure for N-oxide 17 with a 
range of N-Boc imines under the action of catalyst C6. As data in Table 14 show, N-Boc 
imines 4 with either electron-donating or electron withdrawing groups at ortho, meta 
or para positions in the aromatic ring, and even heteroaromatic and disubstituted ones, 
were equally tolerated to produce the corresponding anti Mannich adducts 18(a–p), as 
sole diastereomers with excellent enantiomeric excess (99%). In this study, we 
employed 20 mol% of catalyst but it is worth mentioning that using 5–10 mol% of 
catalyst loading, the reactions proceeded equally well without compromising either 
stereoselectivity or chemical yield (adducts 18d and 18n). 
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Table 14. Scope of N-Boc imines. 
 
a Reactions conducted on a 0.12 mmol scale in 0.5 mL of CH2Cl2 (molar ratio of 17:4, 1:2).b  Diastereomeric 
ratio determined by 1H NMR of crude mixture and corroborated by chiral HPLC. c Enantiomeric excess 
determined by chiral HPLC. 
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Crystallization of compound 18c allowed the determination of the relative and 
absolute configuration by single-crystal X-ray analysis (Figure 25) and the configuration 
of the rest of adducts was stablished by assuming a uniform reaction mechanism. 
 
 
 
 
 
 
 
Figure 25. ORTEP diagram of compound 18c. 
Furthermore, the reaction with N-Cbz imine 21 produced the corresponding Mannich 
adduct 22 with identical level of stereocontrol and tert-butyl and methyl pyridyl N-oxide 
acetates 19 and 20a were also compatible with the reaction conditions and produced 
the Mannich adducts 23 and 24, respectively, with equal high stereoselectivity. This 
functional group compatibility represents an important advantage for subsequent 
adducts manipulations. Furthermore, the methodology was also suitable for substituted 
pyridyl N-oxide acetates such as 20b and 20c, which reacted with either N-Boc or N-Cbz 
imines using 10 mol% of catalyst C6 to afford adducts 25, 26 and 27 (Table 15). 
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Table 15. Further scope of the enantioselective Mannich reaction with 2-pyridyl acetate N-oxides. 
 
a Reactions conducted on a 0.12 mmol scale in 0.5 mL of CH2Cl2 (molar ratio of 17/19/20:4/21, 
1:2).b  Diastereomeric ratio determined by 1H NMR of crude mixture and corroborated by chiral 
HPLC. c Enantiomeric excess determined by chiral HPLC. 
Moreover, quinoline N-oxide 28 performed well with N-Cbz imine 21 and 10 mol% of 
catalyst C6 to afford the corresponding Mannich adduct 29, albeit with slightly 
diminished diastereoselectivity (Scheme 78).  
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Scheme 78. Enantioselective Mannich reaction with quinoline N-oxide 28.  
The suitability of this stereoselective Mannich reaction to generate quaternary 
stereogenic centers was briefly examined. 2-Pyridyl acetate N-oxide 17 reacted with N-
Boc imine derived isatines 30 and 31 in the presence of either catalyst C6 or C23 to 
produce the corresponding Mannich adducts 32 and 33 in good yields, after 72 hours. 
In this case, catalyst C23 improved the results obtained with C6 and good diastereo- and 
enantioselectivities were achieved although they were not as good as those obtained 
for the reaction with aldimines 4 and 21 (Scheme 79). 
 
Scheme 79. Mannich reaction with imine derived isatines 30 and 31. 
Finally, the role of the N-oxide functionality in the Mannich reactions described above 
was reexamined under the optimized reaction conditions (Scheme 80). Again, the 
presence of the N-oxide was essential to ensure reactivity and selectivity since reactions 
went much slower or did not proceed with the corresponding pyridine analogs and 
lower diastereo- and enantioselectivities were obtained. These results corroborate 
again the dual role of the N-oxide functionality as an activating and sterodirecting group. 
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Scheme 80. Effect of the N-oxide funtionality 
3.3.2.3. Configurational stability of Mannich anti adducts 
We were intringued by  the configurational stability of the anti adducts obtained in the 
reaction. It can be argued that the anti adducts obtained in the Mannich reaction are 
produced under kinetic control since their diastereomeric ratio and enantiomeric excess 
remained constant during the reaction progress despite the basic reaction conditions. 
For instance, upon complete transformation into the Mannich adduct 18a, its 
configurational stability was maintained at 0 °C and slowly diminished at room 
temperature; after 96 hours the diastereomeric ratio turned to 7.3:1 (99% ee) (Figure 
26). This stability of the anti adduct 18a, could be explained by the difficulty of the 
catalyst to remove the remaining hydrogen at the exocyclic tertiary Cαcarbon. Less 
hindered and stronger bases, such as Et3N, DBU, and even the analogous bifunctional 
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urea C20 promoted epimerization at shorter reaction times at room temperature (Figure 
26). 
 
 
Figure 26. Effect of different Brønsted bases on the configurational stability of the anti adducts. 
3.3.2.4. Reaction model proposal 
The capacity of ureidopeptide-based catalyst C6 to exclusively produce anti-R,S-
configured Mannich adducts might be consistent with a tight transition state (TS) in 
which multiple hydrogen-bonding may be operating in unison, as depicted in Figure 27. 
In this way, the Re face of the enolate approaches the Si face of the N-protected imine 
to afford the corresponding anti-R,S-adducts. 
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Figure 27. Plausible TS model for the enantioselective Mannich reaction. 
This transition state proposal would be in accordance with the model proposed by 
Pápai and Soós, for bifunctional thiourea and squaramide-based oraganocatalysts, in 
which the deprotonated nucleophile binds to the H-bond network, while the protonated 
amine activates and orientates the electrophile (Figure 28).199 
 
Figure 28. Pápai and Soós’ transition state model. 
An evidence in favor of the proposed model, wherein the three N–H of the catalyst are 
involved in hydrogen bonding, is the observation that chemical shifts of the ortho-H in 
the pyridine and the methylene of the benzyl group in 15 were affected (Δδ = +0.03 and 
+0.02 ppm, respectively, in CDCl3) by addition of 1 equivalent of C6, as well as the 
chemical shifts of the three N–H in the catalyst. Chemical shifts for Ha and Hb could not 
be exactly determined due to overlapping, whereas for Hc was determined as Δδ = +0.07 
ppm. On the other hand, N–H shifts remained unaffected by addition of N-Boc imine 
(Figure 29).200 
 
                                                     
199 a) Hamza, A.; Schubert, G.; Soós, T.; Pápai, I. J. Am. Chem. Soc. 2006, 128, 13151–13160. b) Kótai, B.; 
Kardos, G.; Hamza, A.; Farkas, V.; Pápai, T.; Soós, T. Chem. Eur. J. 2014, 20, 5631–5639. 
200 All N–H’s of the catalyst were unequivocally assigned based on COSY, HSQC and HMBC experiments. 
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1H NMR spectra of each of the following compounds in CDCl3 (0.02 M) were recorded: (i) Pyridyl N-oxide 
acetate 17, (ii) N-Boc imine 4a and (iii) catalyst C6. Subsequently, 1H NMR spectra of the following mixtures 
were recorded under the same conditions (0.02 M in CDCl3): (iv) C6/17 (1:1 mixture), (v) C6/4a (1:1 
mixture) and (vi) C6/17/4a (1:1:1 mixture).  
Figure 29. Expanded and full 1H NMR (300 MHz) spectra of equimolar mixtures.  
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Additionally, the 1H NMR spectra of catalyst C6 (0.02 M in CDCl3) were recorded in the 
presence of increasing amounts of pyridyl N-oxide acetate 17 (increments of 0.25 
equivalents until saturation) and the chemical shift of the N–H proton Hc was monitored 
and the interaction of N–Hc was corroborated (Figure 30). 
 
 
Figure 30. Expanded and full 1H NMR (300 MHz) spectra of C6 in presence of increasing amounts of 17. To 
a 0.02M solution of catalyst C6 in CDCl3, 0.25 equivalents of 17 were subsequently added until saturation.  
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3.3.2.5. Elaboration of adducts 
We explored the elaboration of Mannich adducts in order to evaluate the utility of the 
present reaction as an effective way to synthetize highly enantioenriched chiral pyridine 
based secondary amines. First, reduction of the N-oxide group on the Mannich adducts 
was accomplished; adduct 18b was successfully reduced by treatment with B(pin)2196 to 
afford the corresponding N-Boc protected secondary amine 18’b in 80% isolated yield 
with unaltered diastereo- and enantioselectivity (Scheme 81).  
 
Scheme 81. Reduction of N-oxide group on adduct 18b. 
On the other hand, cleavage of the benzyl group on adduct 18a by hydrogenation 
under 30 bar pressure for 1.5 hours afforded β2,3-amino acid 34 in very good yield 
(Scheme 82). 
 
Scheme 82. Synthesis of β2,3-amino acid 34. 
In addition, the treatment of compound 24 with lithium aluminium hydride resulted in 
simultaneous reduction of the ester and the N-oxide group to provide the corresponding 
amino alcohol 35 (Scheme 83). 
 
Scheme 83. Synthesis of amino alcohol 35.  
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Enantiopure benzyl amines201 can also be obtained from the Mannich adducts through 
hydrogenation and subsequent N-oxide group reduction, a step that proceeds with 
concomitant in situ decarboxylation, probably through intermediate 37 assisted by the 
pyridine basic nitrogen atom.202 Under the reaction conditions shown in Scheme 84, 
adduct 18a led to benzylic amine 36a in 90% overall yield. 
 
Scheme 84. Synthesis of enantiopure benzyl amine 36a. 
Besides, adduct 18b was easily transformed into Lanicemine (AZD-6765) 38 (Scheme 
85), a potent low-trapping NMDA (N-methyl-D-aspartate) receptor agonist, usually 
prepared by resolutive methods.203 
 
Scheme 85. Synthesis of Lanicemine (AZD-6765).
                                                     
201 For other enantioselective methods for the preparation of chiral benzyl amines, see: a) Chu, L.; Wang, 
X.-C.; Moore, C. E.; Rheingold, A. L.; Yu, J. Q. J. Am. Chem. Soc. 2013, 135, 16344–16347. b) Zhu, Y.; 
Buchwald, S. L. J. Am. Chem. Soc. 2014, 136, 4500–4503. c) Zuo, Z.; Cong, H.; Li, W.; Choi, J.; Fu, G. C.; 
MacMillan, D. W. C. J. Am. Chem. Soc. 2016, 138, 1832–1835. 
202 a) Taylor, P. J. J. Chem. Soc. Perkin Trans. 2 1972, 1077–1086. b) Button, R. G.; Taylor, P. J. J. Chem. Soc. 
Perkin Trans. 2 1973, 557–567. 
203 For further information about lanicemine, see: a) Griffith, R. C.; Murray, R. J.; Balestra, M. Preparation 
of enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders. 
WO 9320052 A1, 1993. b) Sanacora, G.; Smith, M. A.; Pathak, S.; Su, H.-L.; Boeijinga, P. H.; McCarthy, D. 
J.; Quirk, M. C. Mol. Psychiatry 2014, 19, 978–985. c) Sanacora, G.; Johnson, M. R.; Khan, A.; Atkinson, S. 
D.; Riesenberg, R. R.; Schronen, J. P.; Burke, M. A.; Zajecka, J. M.; Barra, L.; Su, H.-L.; Posener, J. A.; Bui, K. 
H.; Quirk, M. C.; Piser, T. M.; Mathew, S. J.; Pathak, S. Neuropsychopharmacology 2017, 42, 844–853. 
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4. STEREOSELECTIVE MODULAR SYNTHESIS OF TRANS-
DISUBSTITUTED CYCLOPROPANES 
4.1. Introduction 
This part of the work has been carried out in the group of Prof. Phil S. Baran at The 
Scripps Research Institute in La Jolla (California, USA) during a 3-months internship. In 
this project, the enantioselective synthesis of trans-disubstituted cyclopropanes by 
combining cycloaddition and C–C cross-coupling reactions has been explored. The work 
has been carried out under the supervision of Dr. Tian Qin and Prof. Phil S. Baran. 
Cycloaddition reactions are considered among the most powerful bond-forming 
reactions in organic synthesis because of their ability to form many bonds in one step 
and also for their potential in generating several stereogenic centers (Scheme 86). The 
reactions happen between two π-systems to form rings by breaking two π bonds and 
making two new σ bonds. They generally proceed through concerted pathways and 
follow precise rules for predicting stereo- and regiochemistry.204 Starting with 
specialized building blocks, that are designed to enable reaction to take place cleanly, 
this process rapidly generates complex ring systems with multiple stereocenters.  
 
Scheme 86. Diels-Alder reaction, the most popular cycloaddition reaction. 
Cycloaddition reactions have featured in numerous total syntheses.205 As an 
illustration, epibatidine, valued for its pronounced analgesic properties, has been 
prepared by total synthesis more than 60 times, from which at least 31 have used 
cycloaddition chemistry as their key ring-constructing step. The vast majority of these 
approaches involve formation of the bridged pyrrolidine core, followed by stepwise, and 
often lengthy, pyridine incorporation (Scheme 87).206 
                                                     
204 Dinda, B. Essentials of Pericyclic and Photochemical Reactions; Lecture Notes in Chemistry 93; Springer: 
Switzerland, 2017. 
205 Nicolaou, K. C.; Snyder, S. A.; Montagnon, T.; Vassilikogiannakis, G. Angew. Chem. Int. Ed. 2002, 41, 
1668–1698. 
206 Olivo, H. F.; Hemenway, M. Org. Prep. Proced. Int. 2002, 34, 1–25. 
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Scheme 87. Synthesis of epibatidine. 
On the other hand, transition metal catalyzed C–C cross-coupling reactions form one 
new sigma bond, between easily accessible building blocks, in a controllable manner 
(Scheme 88).207 Indeed, what C–C cross-coupling lacks in terms of complexity 
generation, it makes up for by its reliability and modularity. 
 
Scheme 88. Cross-coupling reaction. 
This strategy is one of the most recurrent methodologies for C–C bond forming 
reactions in the patent literature.208 For instance, the preparation of the commercial 
antihypertensive medicine Cozaar®, considered as one of the first examples of a 
“blockbuster” drug, has employed C–C cross-coupling reactions –Ullman and Suzuki 
reactions– for the key bond formation, from its initial synthesis to its eventual 
manufacture (Scheme 89).209 This approach facilitated both a convergent assembly and 
a modularity that permitted the rapid exploration of hundreds of analogues. 
                                                     
207 de Meijere, A.; Bräse, S.; Oestreich, M. Metal Catalyzed Cross-Coupling Reactions and More; Wiley-
VCH: New York, 2014.  
208 Schneider, N.; Lowe, D. M.; Sayle, R. A.; Tarselli, M. A.; Landrum, G. A. J. Med. Chem. 2016, 59, 4385–
4402. 
209 a) Carini, D. J.; Duncia, J. V.; Aldrich, P. E.; Chiu, A. T.; Johnson, A. L.; Pierce, M. E.; Price, W. A.; Santella 
III, J. B.; Wells, G. J.; Wexler, R. R.; Wong, P. C.; Yoo, S.-E.; Timmermans, P. B. M. W. M. J. Med. Chem. 
1991, 34, 2525–2547. b) Larsen, R. D.; King, A. O.; Chen, C. Y.; Corley, E. G.; Foster, B. S.; Roberts, F. E.; 
Yang, C.; Lieberman, D. R.; Reamer, R. A.; Tschaen, D. M.; Verhoeven, T. R.; Reider, P. J. J. Org. Chem. 1994, 
59, 6391–6394. c) Dolitzky, B.-Z.; Nisnevich, G.; Ruchman, I.; Kaftanov, J. Processes for preparing losartan 
and losartan potassium. CA 2482857 A1, 2003. 
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Scheme 89. Synthesis of Cozaar®. 
In this context, the group of Prof. Baran has recently developed novel C–C cross-
coupling reactions that enable to couple simple alkyl carboxylic acids with a wide variety 
of reagents under nickel or iron catalysis. These transformations represent a great 
contribution into the C–C cross-coupling field, since previous methodologies were 
generally based on the use of alkyl halides.210 The only example with alkyl carboxylic 
acids reported until then, by MacMillan and co-workers, was limited to α-nitrogen or 
oxygen substituted carboxylic acids and employed a combination of photocatalysis and 
metal catalysis. A carbon-centered radical was generated through an Ir-photomediated 
oxidation event whereas a Ni(0) catalyst promoted the cross-coupling reaction with aryl 
halide coupling partners (Scheme 90).211 
 
Scheme 90. Cross-coupling with carboxylic acids merging photoredox with nickel catalysis. 
Alternatively, Baran’s methodology is based on the activation of alkyl carboxylic acids 
with N-hydroxyphthalimide (NHPI) or tetrachloro-N-hydroxyphthalimide (TCNHPI) to 
form a redox-active ester (RAE) able to participate efficiently in Ni or Fe-catalyzed 
decarboxylative cross-coupling reactions with several coupling partners. In 
                                                     
210 For reviews in the field, see: a) Jana, R.; Pathak, T. P.; Sigman, M. S. Chem. Rev. 2011, 111, 1417–1492. 
b) Tasker, S. Z.; Standley, E. A.; Jamison, T. F. Nature, 2014, 509, 299–309. 
211 Zuo, Z.; Ahneman, D. T.; Chu, L.; Terrett, J. A.; Doyle, A. G.; Macmillan, D. W. C. Science 2014, 345, 437–
440. 
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consequence, a wide range of functionalities can be installed, such as aryl or heteroaryl 
systems,212,213 alkynyl,214 alkenyl215 and alkyl groups216 (Table 16). 
Table 16. C–C cross-coupling reactions developed by Baran and co-workers. 
 
Reaction R4-Y C–C cross-coupling conditions Product 
Arylation 
(Negishi)212  
20 mol% NiCl2·glyme 
40 mol% di-t-Bubipy 
THF:DMF (3:2) 
25 °C, 16 h 
 
Arylation 
(Suzuki)213 
 
10–20 mol% NiCl2·6H2O 
10–20 mol% di-t-Bubipy/BPhen 
Et3N (10 equiv.) 
1,4-dioxane:DMF (10:1) 
75 °C, 12 h 
 
Alkynylation214 
 
20 mol% NiCl2·6H2O  
20 mol% di-MeObipy 
THF:DMF (3:2) 
rt, 12 h  
 
20 mol% FeBr2·H2O  
NMP:THF (3:2) 
–15 °C, 15 min 
 
                                                     
212 Cornella, J.; Edwards, J. T.; Qin, T.; Kawamura, S.; Wang, J.; Pan, C.-M.; Gianatassio, R.; Schmidt, M.; 
Eastgate, M. D.; Baran, P. S. J. Am. Chem. Soc. 2016, 138, 2174–2177. 
213 Wang, J.; Qin, T.; Chen, T.-G.; Wimmer, L.; Edwards, J. T.; Cornella, J.; Vokits, B.; Shaw, S. A.; Baran, P. 
S. Angew. Chem. Int. Ed. 2016, 55, 9676–9679. 
214 Smith, J. M.; Qin, T.; Merchant, R. R.; Edwards, J. T.; Malins, L. R.; Liu, Z.; Che, G.; Shen, Z.; Shaw, S. A.; 
Eastgate, M. D.; Baran, P. S. Angew. Chem. Int. Ed. 2017, 56, 11906–11910. 
215 Edwards, J. T.; Merchant, R. R.; McClymont, K. S.; Knouse, K. W.; Qin, T.; Malins, L. R.; Vokits, B.; Shaw, 
S. A.; Bao, D.-H.; Wei, F.-L.; Zhou, T.; Eastgate, M. D.; Baran, P. S. Nature 2017, 545, 213–218. 
216 Qin, T.; Cornella, J.; Li, C.; Malins, L. R.; Edwards, J. T.; Kawamura, S.; Maxwell, B. D.; Eastgate, M. D.; 
Baran, P. S. Science, 2016, 352, 801–805. 
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Reaction R4-Y C–C cross-coupling conditions Product 
Alkenylation215 
 
10 mol% Ni(acac)2·xH2O 
10 mol% bipy 
THF:DMF (3:2) 
rt, 12 h  
Alkylation216 
 
20 mol% NiCl2·glyme 
40 mol% bipy/di-t-Bubipy 
THF:DMF (3:2) 
25 °C, 8–14 h 
 
 
A possible reaction mechanism was postulated for the decarboxylative C–C cross-
coupling reaction (Scheme 91). The authors proposed that Ni(I)-X complex A 
transmetalates with the coupling partner to produce Ni(I)-R4 complex B. Then, this 
complex acts as a reducing agent and deliver an electron into the redox-active ester, 
thus generating the radical anion of the activated ester with concomitant formation of 
[Ni(II)-R4]+ complex C. Fragmentation of the former, followed by extrusion of CO2, 
generates the phtalimide anion and the desired radical species. At this point, 
recombination of the radical species and the phthalimide anion with [Ni(II)-R4]+ complex 
C renders the Ni(III) intermediate D, which upon reductive elimination affords the 
desired cross-coupling product and close the catalytic cycle. 
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Scheme 91. Plausible mechanism for the decarboxylative C–C cross-coupling reaction. 
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4.2. Working hypothesis and objectives 
In this work, we considered to combine the innate complexity generated by 
cycloaddition reactions with the simplicity and modularity of C–C cross-coupling 
reactions in order to achieve the rapid generation of challenging complex chemical 
structures. 
For instance, building block 39, of hypothetical value in medicinal chemistry, 
represents the manifestation of this idea (Scheme 92). The Diels-Alder reaction of the 
relevant building blocks 40 and 41, which are not electronically matched, is expected to 
not take place. But, even a workable enantioselective Diels-Alder reaction could be 
invented to achieve this transformation, the strategy would suffer from lack of 
modularity. In the same way, although the use of vicinal (pseudo)haloethylenes 42 could 
overcome the modularity issue through C-C cross-coupling reactions, the cycloaddition 
with 40 would not take place neither. We envisioned that the use of a vicinal 
(pseudo)haloethylene surrogate, such as 43, would solve this problem since the 
electronics are favorable for the cycloaddition reaction, and the subsequent 
decarboxylative cross-coupling reactions have been widely explored in the group, as 
previously commented.  
 
Scheme 92. Case study. 
In order to address the stereoselective challenge in the overall process, we considered 
a combination of transformations (Scheme 93). First, we thought that maleic anhydride 
44 could act as a surrogate of 43 in the C-C cross-coupling reactions, and take advantage 
of its inexpensive nature, ready participation in most cycloaddition reactions ([2+1], 
[2+2], [3+2], [4+2]), and its easy desymmetrization through chiral Lewis base-mediated 
alcoholysis. Thus, the sequence that we proposed for the enantioselective modular 
synthesis of trans-disubstituted cycles would involve five steps: 
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1. Cycloaddition to build the scaffold. 
2. Desymmetrization to set the absolute configuration. 
3. First decarboxylative cross-coupling. 
4. Hydrolysis of the ester group. 
5. Second decarboxylative cross-coupling. 
 
Scheme 93. Synthetic plan. 
In consequence, the total project would involve the development of a synthetic 
strategy for the modular preparation of structures bearing 6-, 5-, 4- and 3-membered 
rings. During my 3-months internship, I was involved in the enantioselective modular 
synthesis of trans-disubstituted cyclopropanes. Following this strategy, interesting 3-
membered cyclic scaffolds, not affordable through conventional methodologies, could 
be produced. In general, the methodologies employed for their synthesis, to date, 
involve late-stage cyclopropanations of olefins which usually suffer from lack of 
enantiocontrol.217 
                                                     
217 For a review on asymmetric cyclopropanation reactions, see: Bartoli, G.; Bencivenni, G.; Dalpozzo, R. 
Synthesis 2014, 46, 979–1029. 
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4.3. Results and discussion 
For the particular case of cyclopropane construction, caronic anhydride 45 and 1,2-
cyclopropanedicarboxylic anhydride 46 are commercially available compounds (Figure 
31), thus the [2+1] cycloaddition reaction was not explored. 
 
Figure 31. Starting materials. 
4.3.1. Desymmetrization step  
The desymmetrization of anhydrides 45 and 46 was conducted by quinidine-mediated 
alcoholisis with benzyl alcohol at low temperature.218 Then, the corresponding free 
carboxylic acid was activated with tetrachloro-N-hydroxyphthalimide (TCNHPI). As a 
result, redox-active esters 47 and 48 were prepared in high yield and with excellent 
enantioselectivity (Scheme 94). 
 
Scheme 94. Desymmetrization of anhydrides 45 and 46. 
                                                     
218 Procedure adapted from: Bolm, C.; Schiffers, I.; Atodiresei, I.; Hackenberger, C. P. R. Tetrahedron: 
Asymmetry, 2003, 14, 3455–3467. 
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4.3.2. Decarboxylative cross-coupling reactions 
Next, the decarboxylative cross-coupling reaction, employing different coupling 
partners and conditions, was studied for redox-active esters 47 and 48.  
4.3.2.1. Negishi cross-coupling reactions 
4.3.2.1.1. Negishi arylation 
First, the nickel-catalyzed Negishi arylation reaction was explored employing similar 
conditions to those developed previously in the group for the same reaction (Table 
17).212 Unfortunately, aryl adducts 49a and 50a were obtained in low yields and product 
51a was not even detected. Furthermore, large amounts of the decarboxylated product 
were observed, indicating that hydrogen abstraction from the solvent was occurring as 
side-reaction, which was not observed in cross-couplings with larger carbocycles carried 
out by other colleagues in the group. 
Table 17. Preliminary experiments for Negishi arylation. 
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Then, we decided to evaluate the arylation reaction of 47 in other solvents to minimize 
the H-abstraction side-reaction (Table 18). First, we observed that the reaction 
temperature had an irrelevant effect (compare entries 1 and 2), whereas a remarkable 
solvent-dependence was confirmed. Different solvent systems provided significant 
variations in the 49a:52 ratio and in the reaction yield. Among all the solvents screened, 
acetonitrile afforded the best results, since the production of 52 was almost completely 
suppressed (entry 10). Nevertheless, the presence of DMF in the solvent system was 
required to obtain high yields. Hence, MeCN:DMF (3:2) resulted to be the optimal 
solvent system for the Negishi arylation with cyclopropanes, affording product 49a in 
56% isolated yield (entry 6). 
Table 18. Optimization of the Negishi arylation reaction. 
 
Entry Solvent system T (°C) 49a:52b Yieldc 
1 THF:DMF (3:2) rt 64:36 45 (40) 
2 THF:DMF (3:2) 60 62:38 45 
3 DMF rt 71:29 52 
4 dioxane:DMF (3:2) rt 66:34 50 
5 toluene:DMF (3:2) rt 76:24 54 
6 MeCN:DMF (3:2) rt 91:9 60 (56) 
7 Et2O:DMF (3:2) rt 73:27 56 
8 CH2Cl2:DMF (3:2) rt 78:22 42 
9 CHCl3:DMF (3:2) rt 46:54 18 
10 MeCN rt 92:8 19 
a Reactions were carried out on 0.1 mmol scale in 2 mL of solvent. b 49a:52 ratio determined 
by GC/MS. c Yield determined on crude mixture by GC/MS. Isolated yields indicated in 
parentheses. 
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With these optimal conditions in hand, the scope of the transformation was then 
explored (Table 19). Acceptable yields were obtained in the reactions with both 
electron-rich and electron-poor aryl groups for redox-active esters 47 and 48, being the 
use of heteroaryl groups an exception; compounds 51a and 51b were not detected 
under these reaction conditions. On the other hand, the reactions were completely 
trans-diastereoselective and no significant decrease of the optical purity in adducts      
49–50 was observed. 
Table 19. Negishi arylation scope. 
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4.3.2.1.2. Negishi alkenylation 
For the study of the nickel-catalyzed Negishi alkenylation reaction, we focused on the 
search of the most appropriate Ni source and solvent system since, in a previous study, 
different ligands and reaction temperatures had been already screened.215 The 
alkenylation reaction of 47 with the organozinc reagent 53 was studied and, as data in 
Table 20 show, among all nickel sources tested, Ni(acac)2·H2O provided the best results. 
Again, the solvent system MeCN:DMF afforded the highest 54a:52 ratio and yield (entry 
5). On the other hand, previous deoxigenation of the solvent or the absence of light had 
meaningless impact in the reaction outcome (entries 9 and 10).  
Table 20. Optimization of Negishi alkenylation. 
 
Entry Ni source Solvent system 54a:52b Yieldc 
1 Ni(acac)2·H2O DMF 55:45 36 (35) 
2 NiCl2·glyme DMF 20:80 17 
3 NiBr2·glyme DMF 68:32 14 
4 NiCl2·6H2O DMF 69:31 33 (30) 
5 Ni(acac)2·H2O MeCN:DMF (3:1) 82:18 42 (40) 
6 Ni(acac)2·H2O toluene:DMF (3:1) 63:37 27 (25) 
7 NiCl2·6H2O MeCN:DMF (3:1) 78:22 24 
8 Ni(ClO4)2·H2O MeCN:DMF (3:1) 75:25 29 
9d Ni(acac)2·H2O MeCN:DMF (3:1) 86:14 32 
10e Ni(acac)2·H2O MeCN:DMF (3:1) 89:11 31 
a Reactions were carried out on 0.1 mmol scale in 3.5 mL of solvent. b 54a:52 ratio 
determined by GC/MS. c Yield determined on crude mixture by GC/MS. Isolated yields 
indicated in parentheses. d MeCN was previously purged. e Reaction carried out in absence 
of light. 
Chapter 4 
170 
 
The reaction with redox-active ester 47 was performed in the presence of several 
alkenylzinc reagents and the corresponding adducts 54(a–c) were produced as only one 
detectable diasteroisomer and with almost unaltered enantiomeric excess (Table 21). 
Table 21. Negishi alkenylation scope. 
 
4.3.2.2. Suzuki cross-coupling reactions 
The reaction of the redox-active ester 47 with phenylboronic acid, employing similar 
conditions to that reported previously by the group213 did not produce the 
corresponding trans-disubstituted cyclopronane 49b. Furthermore, the evaluation of 
other ligands, bases and solvent systems resulted ineffective. (Scheme 95). 
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Scheme 95. Preliminary experiments for the Suzuki cross-coupling reaction. 
On the other hand, the Suzuki cross-coupling employing aryl, heteroaryl and alkenyl 
pinacol boronate esters showed to be highly substrate-dependent (Table 22). 
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Table 22. Preliminary experiments for Suzuki cross-coupling with pinacol boronate esters. 
 
Yields determined on crude mixtures by GC/MS. n.d. = not detected. 
Thus, a further optimization of the reaction conditions was carried out for adducts 49c, 
54f and 56 to improve the moderate yields obtained. First, the effect of the nickel source 
and the ligand was evaluated for the reaction of redox-active ester 47 with pinacol 
boronate ester 60 (Table 23). Unfortunately, the previous result could not be improved 
employing neither different nickel sources nor ligands. Moreover, the use of 
stoichiometric amounts of nickel and ligand afforded product 49c in lower yield than 
when catalytic amounts were used (entries 1 and 8). Likewise, maintaining NiCl2·glyme 
and di-Meobipy as the catalytic system, variations in the stoichiometry of the reagents, 
the use of additives (MgBr2·OEt2, LiBr and ZnCl2) or different solvents were also 
detrimental. 
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Table 23. Ni source and ligand screening for the Suzuki cross-coupling reaction with 62. 
 
Entry Ni source Ligand Yieldb 
1 NiCl2·glyme di-Meobipy 26 
2 NiBr2·glyme di-Meobipy 10 
3 Ni(acac)2·H2O di-Meobipy 0 
4 NiCl2·6H2O di-Meobipy 0 
5 NiCl2·glyme di-t-Bubipy 24 
6 NiCl2·glyme bipy 16 
7 NiCl2·glyme Bphen 10 
8 NiCl2·glymec di-Meobipyc 11 
a Reactions were carried out on 0.1 mmol scale in 2 mL of solvent. b Yield 
determined on crude mixture by GC/MS. c 100 mol% of NiCl2·glyme and 
di-Meobipy was used. 
Meanwhile, we also studied the reaction of the redox-active ester 47 with (trans)-2-
cyclopropylvinylboronic acid pinacol ester 61 (Table 24) and we found that the highest 
yield for adduct 54f was produced in the presence of 40 mol% of the catalytic system in 
a toluene:DMF solvent mixture (entry 6). 
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Table 24. Optimization of the Suzuki cross-coupling reaction with 63. 
 
Entry [Ni+L] (mol%) Solvent Yieldb 
1 40 dioxane:DMF (1:1) 33 
2 20 dioxane:DMF (1:1) 14 
3 60 dioxane:DMF (1:1) 44 
4 40 dioxane:DMF (1:2)c 20 
5 40 THF:DMF (1:1) 26 
6 40 toluene:DMF (1:1) 56(55) 
7 40 MeCN:DMF (1:1) 0 
a Reactions were carried out on 0.1 mmol scale in 2 mL of solvent. b Yield 
determined on crude mixture by GC/MS. Isolated yield indicated in 
parentheses. c Reaction conducted in 3 mL of solvent. 
4.3.2.3. Unsuccessful cross-coupling reactions 
Other cross-coupling reaction types were explored with no success. For instance, the 
iron-catalyzed alkynylation of redox-active ester 47 with the Grignard reagent 62 and 
the nickel-promoted alkylation of 47 with the dialkylzinc reagent 64 did not afford the 
desired products (Scheme 96).214,216 
Stereoselective modular synthesis of trans-disubstituted cyclopropanes 
 
175 
 
 
Scheme 96. Unsuccessful cross-coupling reactions. 
4.3.3. Synthesis of trans-disubstituted cyclopropanes 
Finally, with the above adducts in hand, completion of the synthesis of trans-
disubstituted cyclopropanes 66–70 was carried out. To this end, products 49a and 50d 
were debenzylated via Pd-catalyzed hydrogenation and activated with tetrachloro-N-
hydroxyphthalimide. Then, the resulting redox-active esters were subjected to further 
cross-coupling with the corresponding organozinc or organoboron compounds under 
the conditions shown in Table 25. In these cases, slightly higher catalytic charges were 
employed in order to increase the reaction yields. Accordingly, trans-disubstituted 
cyclopropanes 66–70 were successfully synthetized in acceptable yields and with 
excellent enantiomeric excesses (Table 25). 
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Table 25. Synthesis of trans-α,β-disubstituted cyclopropanes 66–70. 
 
This strategy has also been employed by other co-workers in the group for the 
enantioselective modular synthesis of trans-α,β-disubstituted 4-, 5- and 6-membered 
rings, which has efficiently allowed the preparation of a great library of interesting 
structures.219
                                                     
219 Chen, T.-G.; Barton, L. M.; Lin, Y.; Tsien, J.; Kossler, D.; Bastida, I.; Asai, S.; Bi, C.; Chen, J. S.; Shan, M.; 
Fang, H.; Fang, F. G.; Choi, H.-W.; Hawkins, L.; Qin, T.; Baran, P. S. Nature 2018, 560, 350–354. 
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5. CONCLUSIONS 
Three new Brønsted base catalyzed methodologies have been developed for the 
synthesis of enantiomerically enriched secondary and tertiary amines. 
First, the ureidopeptide-based Brønsted base catalyzed enantioselective nitro-
Mannich reaction with N-Boc imines and 2-nitroethyl sulfones, as synthetic equivalents 
of vinyl sulfone anions, followed by nitrous acid elimination, afforded γ-sulfonyl allyl 
amines in variable yields and with generally excellent enantioselectivities. 
Second, the enantioselective α-amination of 2-cyanoalkylpyridine N-oxides with 
azodicarboxylates has been described for the synthesis of pyridine based α-chiral 
tertiary amines. The N-oxide functionality plays a strategic role as a removable activating 
and stereodirecting group, in conjunction with a newly designed multifunctional 
squaramide-based Brønsted base catalyst bearing a bulky silyl group.  
Third, the ureidopeptide-based Brønsted base catalyzed highly stereoselective 
Mannich-type reaction of 2-azaaryl acetate N-oxides with N-carbamoyl aldimines has 
been developed for the synthesis of pyridine based chiral secondary amines. The N-
oxide functionality and the ureidopeptide-based Brønsted base, able to preserve the 
configurational stability of the final adducts, are the key elements for the efficient 
preparation of pyridine based β-amino esters in high yield and with excellent diastereo- 
and enantioselectivity. 
Finally, a synthetic strategy for the stereoselective modular preparation of trans-
disubstituted cyclopropanes has been developed, which consists of [2+1] cycloaddition 
with maleic anhydride, desymmetrization of the corresponding meso-anhydrides and 
two subsequent nickel catalyzed decarboxylative C–C cross-coupling reactions.
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6. EXPERIMENTAL SECTION 
6.1. Materials and general techniques 
6.1.1. General experimental 
All non-aqueous reactions were performed using oven-dried glassware and were 
magnetically stirred unless otherwise stated. Yields refer to chromatographically 
purified and spectroscopically pure compounds, unless otherwise stated.  
Heat requiring reactions were performed using a hotplate with an oil or sand bath and 
a condenser. Reactions requiring low temperatures were performed using cooling bath 
circulators Huber T100E and acetone or isopropanol baths.  
Organic layers washed with aqueous phases were dried over MgSO4 or Na2SO4 and 
filtered through cotton or a filter funnel.  
Organic solvents were evaporated under reduced pressure using rotavapors Büchi R-
110, R-200 and R-210, the latter equipped with a Büchi V-700 vacuum pump and a Büchi 
V-850 vacuum controller, appropriate for the evaporation of solvents when products 
were volatile compounds. For the complete removal of solvents vacuum pump Telstar 
Top-3 (≈0.5 mmHg) was employed. IKA RV8 rotary evaporators equipped with a dry ice 
condenser were employed for the work in chapter 4. 
6.1.2. Reagents and solvents 
Reagents were purchased from different commercial suppliers (Sigma-Aldrich, Acros, 
Alfa Aesar, Fluka, TCI, Merck, Fluorochem, etc.), stored as specified by the manufacturer 
and used without previous purification unless otherwise stated. Imines 4 and 21220 and 
N-Boc isatin ketimines 30 and 31221 were synthesized following described procedures. 
Azodicarboxylates 14 were purchased from Sigma-Aldrich, stored at –30 °C and used 
without previous purification. NiCl2·glyme and Ni(acac)2·xH2O were purchased from 
Strem, bipyridine ligands (2,2’-bipyridine, 4,4’-di-tert-butylbipyridine and 4,4’-di-OMe-
                                                     
220 Wang, W.; van Gemmeren, M.; List, B. Angew. Chem. Int. Ed. 2014, 53, 13592–13595. b) Mbofana, C. 
T.; Miller, S. J. J. Am. Chem. Soc. 2014, 136, 3285–3292. 
221 Holmquist, M.; Blay, G.; Muñoz, M. C.; Pedro, J. R. Adv. Synth. Cat. 2015, 357, 3857–3862. 
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bipyridine) were purchased from Sigma-Aldrich and bathophenanthroline was 
purchased from Combi-Blocks. 
Triethylamine, DBU, DIPA and DIPEA were purified by distillation. Liquid aldehydes 
were purified by distillation before usage and stored in the fridge at –30 °C under 
nitrogen. 
When anhydrous solvents were required, they were dried following established 
procedures.222 Dichloromethane was dried over CaH2, and diethyl ether and 
tetrahydrofuran were dried by filtration through activated alumina (powder ≈ 150 mesh, 
pore size 58 Å, basic, Sigma-Aldrich) columns. For the work in chapter 4, etrahydrofuran 
(THF), N,N-dimethylformamide (DMF), toluene, acetonitrile (CH3CN), and 
dichloromethane (CH2Cl2) were obtained by passing the previously degassed solvents 
through an activated alumina column. N-Methyl-2-pyrrolidone (NMP) (anhydrous, 
99.5%) and carbon tetrachloride (CCl4) (anhydrous, ≥99.5%) were purchased from 
Sigma-Aldrich and used without further purification. 
6.1.3. Chromatography 
Reactions were monitored by 1H NMR, GC/MS, LC/MS or thin layer chromatography 
(TLC) using Merck silica gel (60F-254) plates and visualized by fluorescence quenching 
under UV light, Ficher Bioblock lamp VL-4LC, λ= 254 and 365 nm. A solution of potassium 
permanganate or phosphomolybdic acid and heat were employed as developing agents.  
Purification of reaction products was carried out by flash column chromatography 
using ROCC silica gel 60 (40-63 μm, 230-400 mesh). Preparative thin layer 
chromatography (pTLC) was performed on Merck silica plates (60F-254). 
Non-acid silica gel was prepared by mixing silica gel with a saturated aqueous solution 
of sodium bicarbonate (300 mL of solution for 100 g of silica gel) during 24 hours and 
subsequent evaporation of water in an oven at 80 °C for 72 hours.  
6.1.4. Melting points 
Melting points were determined in open capillaries on a Stuart SHP3 or Fisher-Johns 
12-144 melting point apparatus and a microscope and were uncorrected. 
                                                     
222 Armarego, W. L. F.; Chai, C. Purification of Laboratory Chemicals, 6th ed.; Butterworth-Heinemann: 
Oxford, U.K., 2009. 
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6.1.5. Infrared spectra 
Infrared spectra were recorded on a Bruker Alpha FT-IR spectrometer as a thin film. 
Only selected maximum absorbances are reported. 
6.1.6. NMR spectra 
NMR spectra were recorded on Bruker AV-300, AV-400, AV-500, AMX-400, DRX-500 
and DRX-600 instruments and are calibrated using residual undeuterated solvent (CHCl3 
at 7.26 ppm 1H NMR, 77.16 ppm 13C NMR; CH3OH at 3.31 ppm 1H NMR, 49.0 ppm 13C 
NMR). 19F NMR spectra were recorded using fluorobenzene (δ –113.15 ppm) as internal 
standard. The following abbreviations were used to explain multiplicities: s = singlet, d 
= doublet, t = triplet, q = quartet, m = multiplet, br = broad. 
MestReNova Mnova 11.0 program was used to process and edit the registered spectra. 
6.1.7. Mass spectra 
Mass spectra were recorded on a UPLC-DAD-QTOF spectrometer (Ultra High 
Performance Liquid Chromatograph-Mass spectrometer; Waters UPLC ACQUITY, 
Waters PDA Detector, Waters Synapt G2). Mass-spectrometry analyses were performed 
in the General Research Service (SGIKer) of the University of the Basque Country (EHU-
UPV) for chapters 2 and 3. For chapter 4, high-resolution mass spectra (HRMS) were 
recorded on an Agilent LC/MSD-ESI-QTOF mass spectrometer. 
6.1.8. Determination of enantiomeric excesses 
Enantiomeric excesses in chapters 2 and 3 were determined using analytical high 
performance liquid chromatography (HPLC) performed on Waters-600E (equipped with 
2996 and 2998 photodiode array UV detector) employing Daicel columns (4.6 x 250 mm, 
5 μm particle size). Enantiomeric excesses in chapter 4 were determined using 
supercritical fluid chromatography (SFC) performed on Waters UPC2 SFC (equipped with 
a photodiode array detector) employing Daicel columns (4.6 x 250 mm, 3 μm particle 
size) under isocratic conditions at 30 °C. 
6.1.9. Optical rotations 
Optical rotations were recorded using a Jasco P-2000 or a Rudolph Research Analytical 
Autopol III automatic polarimeter; specific rotations (SR) ([α]DT) are reported in 10-1 
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deg∙cm2∙g-1; concentrations (c) are quoted in g/100 mL; D refers to the D-line of sodium 
(589 nm); temperatures (T) are given in Celsius degrees (°C). 
6.1.10. X-Ray diffraction analysis 
X-ray diffraction analysis experiments were conducted in the General Research Service 
(SGIKer) of the University of the Basque Country (EHU-UPV) using difractometers for 
monocrystals. 
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6.2. Synthesis of catalysts 
Catalysts C9,223 C19224 and C20225 were prepared following reported procedures and 
Takemoto’s thiourea C21 was purchased from Strem Chemicals. 
6.2.1. Preparation of chiral amines 
6.2.1.1. Preparation of Cinchona alkaloid derived amines 
 
1st step:226 A mixture of the corresponding Cinchona alkaloid (1 equiv., 100 mmol) and 
triethylamine (3.6 equiv., 360 mmol, 50.0 mL) in dry THF (500 mL) was cooled to 0 °C 
and then methanesulfonyl chloride (1.8 equiv., 180 mmol, 13.9 mL) was added 
dropwise. The mixture was stirred at room temperature for 14 hours. The reaction was 
quenched with water (40 mL) and then THF was removed under vacuum. The residue 
was dissolved in CH2Cl2 (60 mL) and washed with water (40 mL) and saturated NaHCO3 
(2 x 40 mL). The organic layer was dried over MgSO4, filtered and concentrated under 
vacuum to afford the crude product (96% yield) which was used in the next step without 
further purification. 
2nd step:227 The crude of the corresponding mesylated Cinchone (1 equiv., 48 mmol) 
was dissolved in DMF (150 mL). The solution was cooled to 0 °C and sodium azide (2 
equiv., 96 mmol, 6.2 g) was added portionwise. The mixture was stirred at 70 °C for 16 
hours and after this time the reaction mixture was quenched with water (80 mL) and 
                                                     
223 Yang, W.; Du, D.-M. Org. Lett. 2010, 12, 5450–5453. 
224 Vakulya, B.; Varga, S.; Csámpai, A.; Soós, T. Org. Lett. 2005, 7, 1967–1969. 
225 Greenaway, K.; Dambruoso, P.; Ferrali, A.; Hazelwood, A. J.; Sladojevich, F.; Dixon, D. J. Synthesis 2011, 
12, 1880–1886. 
226 Adapted from: Zielińska-Blajet, M.; Kucharska, M.; Skarzewski, J. Synthesis 2006, 7, 1176–1182. 
227 Adapted from: Sundermeier, U.; Döbler, C.; Mehltretter, G. M.; Baumann, W.; Beller, M. Chirality 2003, 
15, 127–134. 
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diluted with ethyl acetate (150 mL). The organic layer was separated and washed with 
saturated NaCl thoroughly (5 x 60 mL), dried over MgSO4, filtered and evaporated under 
reduced pressure to afford the crude azide in quantitative yield, which was used in the 
next step without further purification. 
3rd step:227 The crude azide product was dissolved in dry THF (250 mL) and PPh3 (12.6 
g, 48 mmol, 1 equiv.) was added. The reaction mixture was heated to 40 °C and stirred 
until the gas evolution ceased (≈5 hours). Then H2O (8 mL) was added and the mixture 
was stirred overnight at 40 °C. The solvent was removed under vacuum and the residue 
was dissolved in CH2Cl2 (150 mL). HCl 6M (250 mL) was added and the aqueous phase 
was extracted and washed with dichloromethane (2 × 100 mL). Then the aqueous layer 
was cooled to 0 °C and basified until pH > 10 with NaOH 40%. The aqueous phase was 
then extracted with CH2Cl2 (3 × 150 mL), dried over MgSO4 and concentrated under 
reduced pressure to afford the corresponding 9-amino-9-deoxy-9-epicinchone. 
9-Amino-9-deoxy-9-epiquinine228 
9-Amino-9-deoxy-epiquinine was synthetized following the 
general procedure employing quinine as starting material. 
Yield: 9.06 g (56%). Brown viscous oil. [αD25= 80 (c=1.1, 
CHCl3). 1H NMR (400 MHz, CDCl3) δ 8.75 (d, J= 4.6 Hz, 1H), 
7.36–8.05 (m, 4H), 5.79 (m, 1H), 4.97 (m, 2H), 4.57 (d, J= 10.4 
Hz, 1H), 3.97 (s, 3H), 3.02–3.34 (m, 3H), 2.77 (m, 2H), 2.27 (m, 1H), 2.08 (s, 2H), 1.26–
1.63 (m, 4H), 0.80 (m, 1H).  
9-Amino-9-deoxy-9-epiquinidine228b,229 
9-Amino-9-deoxy-epiquinidine was synthetized following the 
general procedure employing quinidine as starting material. 
Yield: 8.25 g (51%). Brown viscous oil. [αD22= 69 (c=2.5, CHCl3). 
1H NMR (400 MHz, CDCl3) δ 8.75 (d, J= 4.3 Hz, 1H), 7.64–8.14 (m, 
2H), 7.55 (d, J= 4.6 Hz, 1H), 7.35 (m, 1H), 5.79–5.87 (m, 1H), 5.09 
(m, 2H), 4.67 (d, J= 9.9 Hz, 1H), 3.97 (s, 3H), 2.79–3.01 (m, 5H), 2.28 (m, 1H), 2.16 (s, 2H), 
1.46–1.56 (m, 3H), 1.14–1.32 (m, 1H), 0.78–0.96 (m, 1H). 
                                                     
228 Physical and spectroscopic data were coincident with the previously reported: a) Brunner, H.; Büegler, 
J.; Nuber, B. Tetrahedron: Asymmetry 1995, 6, 1699–1702. b) He, W.; Liu, P.; Zhang, B. L.; Sun, X. L.; Zhang, 
S. Y. Appl. Organometal. Chem. 2006, 20, 328–334. 
229 Physical and spectroscopic data were coincident with the previously reported: Brunner, H.; Schmidt, P. 
Eur. J. Org. Chem. 2000, 2119–2133. 
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6.2.1.2. Preparation of 9-epiquinine230 
 
A solution of mesylated quinine (1 equiv., 30 mmol, 12.1 g) and L-tartaric acid (1.1 
equiv., 33 mmol, 5.0 g) in H2O (140 mL) was stirred at reflux for 1.5 hours. Then, the 
reaction mixture was cooled to room temperature and a saturated solution of NaHCO3 
(200 mL) was added and it was extracted with CH2Cl2 (3 x 150 mL). The combined organic 
layers were dried over MgSO4 and concentrated under reduced pressure to afford 9-
epiquinine. Yield: 9.08 g (93%). Brown solid. [αD24= 25.8 (c=1.1, CHCl3). 1H NMR (300 
MHz, CDCl3) δ 8.73 (d, J= 4.5 Hz, 1H), 8.02 (d, J= 9.2 Hz, 1H), 7.65 (d, J= 2.7 Hz, 1H), 7.43–
7.34 (m, 2H), 5.83–5.67 (m, 1H), 5.07–4.92 (m, 3H), 3.94 (s, 3H), 3.34–3.03 (m, 3H), 2.88–
2.72 (m, 2H), 2.33 (m, J= 9.6, 6.7, 5.3, 3.7, 1.5 Hz, 1H), 1.72 (ddd, J= 4.2, 3.2, 2.2 Hz, 4H), 
1.67–1.56 (m, 2H), 1.47 (dddd, J= 13.6, 9.6, 4.0, 2.0 Hz, 1H), 0.96 (ddt, J= 13.6, 7.9, 1.8 
Hz, 1H). 
6.2.1.3. Preparation of 9-amino-9-deoxyhydroquinines 
 
To a solution of 9-amino(9-deoxy)quinine (10 mmol, 3.23 g) in MeOH (40 mL) at inert 
atmosphere, Pd/C (10% w/w, 323 mg) was added. It was subjected to H2 atmosphere at 
room temperature for 16 hours. Then, the reaction mixture was filtered through celite 
and concentrated under reduced pressure to afford the corresponding saturated 9-
amino-9-deoxy-hydroquinine. 
                                                     
230 Adapted from: Braje, W. M.; Holzgrefe, J.; Wartchow, R.; Hoffmann, H. M. R. Angew. Chem. Int. Ed. 
2000, 39, 2085–2087. 
Chapter 6 
196 
 
9-Amino-9-deoxyhydroquinine 
9-Amino-9-deoxyhydroquinine was prepared following the 
general procedure for the preparation of chiral amines (see 
page 193) and subsequent hydrogenation employing 9-
epiquinine. Overall yield: 8.10 g (50%). Brown viscous oil. 
[αD23= -57.7 (c=0.3, MeOH). 1H NMR (300 MHz, CDCl3) δ 8.72 
(d, J= 4.6 Hz, 1H), 8.00 (d, J= 9.2 Hz, 1H), 7.46–7.24 (m, 3H), 4.58 (d, J= 9.1 Hz, 1H), 3.94 
(s, 3H), 3.16 (q, J= 8.8 Hz, 1H), 3.08–2.82 (m, 2H), 2.58–2.44 (m, 1H), 2.39–2.30 (m, 1H), 
2.06 (tdd, J= 12.3, 5.6, 3.3 Hz, 1H), 1.83 (dq, J= 4.0, 2.0 Hz, 1H), 1.71–1.56 (m, 2H), 1.54–
1.29 (m, 5H), 0.96–0.74 (m, 3H). 
9-Amino-9-deoxy-9-epihydroquinine 
9-Amino-9-deoxy-9-epihydroquinine was prepared following 
the general procedure for the hydrogenation employing 9-
amino-9-deoxy-9-epiquinine. Yield: 3.24 g (>99%). Brown 
viscous oil. [αD25= 56 (c=1, CHCl3). 1H NMR (300 MHz, CDCl3) 
δ 8.75 (d, J= 4.3 Hz, 1H), 7.64–8.14 (m, 2H), 7.55 (d, J= 4.6 Hz, 1H), 7.35 (m, 1H), 5.79–
5.87 (m, 1H), 5.09 (m, 2H), 4.67 (d, J= 9.9 Hz, 1H), 3.97 (s, 3H), 2.79–3.01 (m, 5H), 2.28 
(m, 1H), 2.16 (s, 2H), 1.46–1.56 (m, 3H), 1.14–1.32 (m, 1H), 0.78–0.96 (m, 1H). 
6.2.1.4. Preparation of (1S,2S)-2-(piperidin-1-yl)cyclohexanamine231 
To a mixture of (1S,2S)-cyclohexane-1,2-diamine (1 equiv., 10 mmol, 1.14 g) and 
NaBH(OAc)3 (4 equiv., 40 mmol, 8.50 g) in 1,2-dichloroethane (60 mL), glutaraldehyde 
(1.04 equiv., 50% w/w in H2O, 10.4 mmol, 1.9 mL) was added dropwise at room 
temperature and stirred for 3 hours. The mixture was quenched with NaOH 6M solution 
(30 mL), the organic layer was separated and the aqueous phase was extracted with 
CH2Cl2 (3 x 30 mL). The combined organic layers were concentrated. The residue was 
dissolved in CH2Cl2 (50 mL), washed with brine (20 mL), dried over MgSO4, filtered and 
concentrated under reduced pressure to give (1S,2S)-2-(piperidin-1-yl)cyclohexanamine 
which was used in next step without further purification. Yellow oil. Yield: 1.62 g (89%). 
1H NMR (300 MHz, CDCl3) δ 2.87 – 2.68 (m, 1H), 2.67 – 2.49 (m, 3H), 2.41 – 2.19 (m, 2H), 
2.16 –1.92 (m, 2H), 1.88 – 1.34 (m, 8H), 1.31 – 0.97 (m, 4H). 
                                                     
231 Adapted from: Zhu, Y.; Malerich, J. P.; Rawal, V. H. Angew. Chem. Int. Ed. 2010, 49, 153–156. 
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6.2.2. Synthesis of ureidopeptide-based Brønsted base catalysts 
Ureidopeptide-based Brønsted base catalysts were prepared according to the 
following general scheme: 
 
6.2.2.1. Preparation of N-carbamate protected α-amino acids 
The aminoacids N-(9-fluorenylmethoxycarbonyl)-L-valine (Fmoc-Val-OH) and and N-
tert-butoxycarbonyl-L-tert-leucine (Boc-Tle-OH) were bought from Fluka. 
6.2.2.1.1. Procedure A using chloroformates232 
 
To a stirred solution of the corresponding amino acid (1 equiv., 10 mmol) in 10% 
aqueous Na2CO3 (25 mL) and dioxane (10 mL), a solution of the corresponding 
chloroformate (1 equiv., 10 mmol) in dioxane (30 mL) was slowly added at 0 °C. The 
mixture was stirred in an ice bath for 1 hour, then allowed to warm to room temperature 
and stirred at the same temperature for 15 hours. After that, the mixture was poured 
into water (100 mL) and washed with Et2O (3 x 50 mL). The aqueous layer was cooled in 
an ice bath and acidified with concentrated HCl, followed by extraction with EtOAc (3 x 
50 mL) and washed with brine (5 x 50 mL). The combined extracts were dried over 
MgSO4 and concentrated under reduced pressure to afford the corresponding N-
protected amino acid, which was used in the next step without further purification. 
                                                     
232 Adapted from: Bain, J. D.; Wacker, D. A.; Kuo, E. E.; Chamberlin, A. R. Tetrahedron 1991, 47, 2389–
2400. 
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N-(((9H-Fluoren-9-yl)methoxy)carbonyl)-L-phenylalanine 
The title compound was prepared from (9H-fluoren-9-
yl)methyl chloroformate and L-phenylalanine according 
to the general procedure A. Yield: 3.60 g (93%). White 
foam. 1H NMR (300 MHz, CDCl3) δ 7.87 (d, 2H), 7.71 (d, 
1H), 7.64 (t, 2H), 7.40 (t, 2H), 7.33 – 7.19 (m, 8H), 4.20 – 
4.16 (m, 4H), 3.10-3.06 (m, 1H), 2.90-2.84 (m, 1H) 1H NMR (300 MHz, CD3OD) δ 7.78 (d, 
J = 7.5, 2H), 7.68 (d, J = 6.7, 2H), 7.39 (t, J = 7.5, 2H), 7.33 – 7.18 (m, 7H), 4.50 (s, 2H), 
4.39 – 4.33 (m, 2H), 4.23 (t, J = 6.9, 1H), 4.05 (brs, 1H), 3.04 (s, 1H). 
N-(((9H-Fluoren-9-yl)methoxy)carbonyl)-L-tert-leucine 
The title compound was prepared from (9H-fluoren-9-
yl)methyl chloroformate and L-tert-leucine according to 
the general procedure A. Yield: 3.39 g (95%). White 
foam. 1H NMR (300 MHz, CD3OD) δ 7.78 (d, J = 7.5, 2H), 
7.68 (d, J = 6.7, 2H), 7.39 (t, J = 7.5, 2H), 7.30 (dt, J = 7.5, 
1.0, 2H), 4.50 (s, 2H), 4.39 – 4.33 (m, 2H), 4.23 (t, J = 6.9, 1H), 4.05 (brs, 1H), 3.66 (s, 1H), 
1.03 (s, 9H). 
N-(tert-butoxycarbonyl)-L-tert-leucine 
The title compound was prepared from tert-butyl chloroformate 
and L-tert-leucine according to the general procedure A. White 
foam. Yield: 2.29 g (99%). 1H NMR (300 MHz, CDCl3) δ 5.07 (d, J = 
8.5, 1H), 4.18 – 4.07 (m, 1H), 1.45 (s, 9H), 1.02 (s, 9H). 
N-(Carboxybenzyl)-L-tert-leucine 
The title compound was prepared from benzyl 
chloroformate and L-tert-leucine according to the general 
procedure A. Yield: 2.38 g (91%). White foam. 1H NMR (300 
MHz, CDCl3) δ 7.35 (m, 5H), 5.33 (d, J = 9.6, 1H), 5.12 (s, 2H), 
4.21 (d, J = 9.5, 1H), 1.02 (s, 9H). 
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6.2.2.1.2. Procedure B using 4-nitrophenyl carbonates233 
 
1st step: To a stirred solution of p-nitrophenylchloroformate (1.1 equiv., 11 mmol, 2.2 
g) in CH2Cl2 (13.6 mL) was added pyridine (1.1 equiv., 11 mmol, 0.9 mL). The formed 
white slurry was cooled to 0 °C, and the corresponding alcohol (1 equiv., 10 mmol) was 
added in several portions to keep the temperature at 0 °C. After complete addition, the 
yellow mixture was allowed to warm to room temperature and stirred for 15 hours. The 
reaction mixture was diluted with CH2Cl2 (40 mL) and subsequently washed with 1 M 
HCl (20 mL), water (20 mL) and brine (20 mL), dried with MgSO4 and concentrated under 
reduced pressure. The residue was used in the next step without further purification. 
 
2nd step: To a stirred solution of L-tert-leucine (1 equiv., 10 mmol, 1.31 g) in 10% 
aqueous Na2CO3 (26 mL) and N-dimethylformamide (10 mL), the solution of the 
corresponding 4-nitrophenyl carbonate (1 equiv., 10 mmol) in N-dimethylformamide (30 
mL) was slowly added at 0 °C. The mixture was stirred in an ice bath for 1 hour, then 
allowed to warm to room temperature and stirred at the same temperature for 15 
hours. After that, the mixture was poured into H2O (100 mL) and washed with Et2O (3 x 
50 mL). The aqueous layer was cooled in an ice bath and acidified with concentrated 
HCl, followed by extraction with EtOAc (3 x 50 mL) and washed with brine (5 x 50 mL). 
The combined extracts were dried over MgSO4 and concentrated under reduced 
pressure. The residue was purified by flash column chromatography on silica gel 
(Hex/EtOAc, 80:20) to afford the corresponding N-protected-L-tert-leucine. 
 (S)-3,3-Dimethyl-2-(((phenanthren-9-ylmethoxy)carbonyl)amino)butanoic acid 
The title compound was prepared from phenanthren-
9-ylmethanol and L-tert-leucine according to the 
general procedure B. Yield: 2.74 g (75%). White foam. 
1H NMR (300 MHz, CDCl3) δ 8.73 (d, J = 7.5, 1H), 8.66 
(d, J = 8.0, 1H), 8.07 (d, J = 7.0, 1H), 7.88 (d, J = 7.5, 1H), 
                                                     
233 Adapted from: Lan, P.; Porco, J. A. Jr.; South, M. S.; Parlow, J. J. J. Comb. Chem. 2003, 5, 660–669. 
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7.81 (s, 1H), 7.61 (dd, J = 18.5, 10.7, 4H), 5.63 (q, J = 12.4, 2H), 5.37 (d, J = 9.4, 1H), 4.26 
(d, J = 9.5, 1H), 1.02 (s, 9H). 
(S)-2-((((3,5-Bis(trifluoromethyl)benzyl)oxy)carbonyl)amino)-3,3-dimethylbutanoic 
acid 
The title compound was prepared from 3,5-
bis(trifluoromethyl)benzyl alcohol and L-tert-leucine 
according to the general procedure B. Yield: 3.25 g 
(81%). White foam. 1H NMR (300 MHz, CDCl3) δ 7.83 
(s, 1H), 7.30 (s, 2H), 5.33 (d, J = 9.6, 1H), 5.12 (s, 2H), 
4.21 (d, J = 9.5, 1H), 1.02 (s, 9H). 
6.2.2.2. Preparation of ureidopeptide-based catalysts 
To a cooled solution of the corresponding N-protected α-amino acid (1 equiv., 5 mmol) 
in dry THF (20 mL), isobutyl chloroformate (1 equiv., 5 mmol, 0.65 mL) and N-
methylmorpholine (1 equiv., 5 mmol, 0.6 mL) were added at –20 °C and the mixture was 
stirred for 20 minutes. Then, a suspension of NaN3 (1.5 equiv., 7.5 mmol, 0.48 g in 5 mL 
of H2O) was added and the reaction mixture was stirred at the same temperature. After 
30 minutes, the organic layer was separated, evaporated and the residue was dissolved 
in CH2Cl2 (30 mL) and washed with water (15 mL). The organic phase was dried over 
MgSO4, and concentrated in vacuo to give a yellow oil, which was redissolved in dry 
CH2Cl2 (10 mL). The resulting solution was heated at 40 °C under nitrogen atmosphere 
for 1–2 hours. The reaction was monitored by infrared analysis until disappearance of 
the azide band (λ = 2140 cm-1) –isocyanate band is observed (λ = 2240 cm-1)–. After 
completion, the corresponding amine was added (0.7 equiv., 3.5 mmol) and the reaction 
mixture was stirred at room temperature for 15 hours. The solvent was evaporated and 
the residue was purified by flash column chromatography on silica gel (CH2Cl2–
CH2Cl2/MeOH, 80:20) or by non-acid silica gel (Hex/EtOAc, 80:20 to 0:100) to afford the 
desired catalysts C1–C8, C22 and C23. 
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(9H-Fluoren-9-yl)methyl ((S)-1-(3-((R)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-
vinylquinuclidin-2-yl)methyl)ureido)-2-methylpropyl)carbamate (C1) 
The title compound was prepared from N-
Fmoc-L-Val-OH and 9-amino-9-deoxy-9-
epiquinidine. Yield: 1.69 g (73%). White solid. 
m. p.= 115–127 °C. [αD25= +104.8 (c= 0.86, 
CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 8.71 (d, 
J= 4.5 Hz, 1H), 8.03 (d, J= 9.2 Hz, 1H), 7.80 (d, 
J= 7.4 Hz, 2H), 7.66 (s, 1H), 7.58 (s, 2H), 7.46–
7.38 (m, 4H), 7.35–7.30 (m, 3H), 6.47–6.26 (brs, 1H), 6.00–5.81 (m, 1H), 5.68–5.49 (m, 
2H), 5.10 (d, J= 11.8 Hz, 3H), 4.67–4.54 (m, 1H), 4.53–4.42 (m, 1H), 4.38–4.27 (m, 1H), 
4.22 (t, J= 6.6 Hz, 1H), 3.97 (s, 3H), 2.94–2.83 (m, 6H), 2.31–2.18 (m, 1H), 1.64 (s, 1H), 
1.64–1.42 (m, 2H), 1.36–1.22 (m, 1H), 0.98–0.89 (m, 2H), 1.87–0.77 (m, 5H). 13C NMR 
(75 MHz, CDCl3) δ 157.7, 155.9, 147.6, 144.8, 143.9, 143.8, 141.3, 141.3, 140.4, 131.7, 
127.7, 127.1, 125.1, 125.0, 121.9, 120.0, 114.7, 101.5, 66.8, 65.4, 55.5, 49.2, 47.2, 47.0, 
39.2, 32.0, 27.4, 26.6, 25.3, 18.7, 18.6. UPLC (DAD-QTOF [M+H]+) calcd for C40H46N5O4: 
660.3550; found: 660.3559. 
(9H-Fluoren-9-yl)methyl ((S)-1-(3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-
vinylquinuclidin-2-yl)methyl)ureido)-2-methylpropyl)carbamate (C2) 
The title compound was prepared from N-
Fmoc-L-Val-OH and 9-amino-9-deoxy-9-
epiquinine. Yield: 1.76 g (76%). White solid. 
m. p.= 129–140 °C. [αD25= –35.8 (c= 1.1, 
CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 8.66 (d, 
J= 3.8 Hz, 1H), 8.02 (d, J= 9.2 Hz, 1H), 7.86–
7.69 (m, 3H), 7.79–7.73 (m, 2H), 7.49–7.20 
(m, 7H), 6.47–6.28 (bs, 1H), 5.79–5.68 (m, 2H), 5.65–5.46 (bs, 1H), 5.40–5.19 (m, 1H), 
5.03–4.95 (m, 2H), 4.80–4.57 (m, 1H), 4.48–4.26 (m, 2H), 4.19–4.15 (m, 1H), 3.96 (s, 3H), 
3.28–3.20 (m, 2H), 3.17–3.02 (m, 1H), 2.75–2.70 (m, 2H), 2.60–2.54 (m, 1H), 2.38–2.22 
(m, 1H), 1.66–1.58 (m, 3H), 1.53–1.35 (m, 1H), 0.87 (s, 7H). 13C NMR (75 MHz, CDCl3) δ 
157.8, 157.4, 156.1, 147.5, 145.7, 144.7, 143.9, 143.7, 141.2, 131.6, 128.4, 127.7, 127.0, 
125.0, 121.5, 119.9, 114.6, 102.0, 66.7, 65.1, 60.1, 55.8, 55.6, 47.1, 40.9, 39.4, 31.9, 27.7, 
27.4, 26.1, 18.7, 18.5. UPLC (DAD-QTOF [M+H]+) calcd for C40H46N5O4: 660.3550; found: 
660.3557. 
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(9H-Fluoren-9-yl)methyl ((S)-1-(3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-
vinylquinuclidin-2-yl)methyl)ureido)-2-phenylethyl)carbamate (C3) 
The title compound was prepared from N-
Fmoc-L-Phe-OH and 9-amino-9-deoxy-9-
epiquinine. Yield: 1.66 g (67%). White solid. 
m. p.= 135–146 °C. [αD25= –12.1 (c= 1, 
CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 8.72 (d, 
J= 4.5, 1H), 8.03 (d, J= 9.2, 1H), 7.79 (d, J= 7.5, 
2H), 7.69 (d, J= 2.5, 1H), 7.57–7.52 (m, 2H), 
7.48–7.39 (m, 3H), 7.38–7.33 (m, 4H), 7.26–7.23 (m, 4H), 7.14 (s, 2H), 6.08 (bs, 1H), 5.82–
5.66 (m, 2H), 5.16 (bs, 2H), 5.03–4.96 (m, 3H), 4.41–4.33 (m, 2H), 4.22–4.12 (m, 1H), 3.97 
(s, 3H), 3.27–3.04 (m, 5H) 2.77 – 2.68 (m, 2H), 2.34–2.27 (m, 1H), 1.69–1.62 (m, 1H), 
1.45–1.36 (m, 1H), 1.00–0.93 (m, 1H). 13C NMR (75 MHz, CDCl3) δ 157.8, 156.9, 155.7, 
147.5, 144.8, 143.9, 143.8, 141.3,  141.2, 136.8, 131.7, 129.3, 128.5, 127.7, 127.1, 126.7, 
125.0, 121.5, 120.0, 114.6, 102.0, 66.6, 60.8, 60.1, 55.7, 55.6, 47.1, 40.8, 40.2, 39.4, 27.8, 
27.3, 26.01. UPLC (DAD-QTOF [M+H]+) calcd for C44H46N5O4 708.3550; found 708.3560. 
(9H-Fluoren-9-yl)methyl ((S)-1-(3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-
vinylquinuclidin-2-yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C4) 
The title compound was prepared from N-
Fmoc-L-Tle-OH and 9-amino-9-deoxy-9-
epiquinine. Yield: 1.67 g (71%). White solid. 
m. p.= 130–139 °C. [αD25= –16.2 (c= 1, 
CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 8.63 (d, 
J= 4.4 Hz, 1H), 8.01 (d, J= 9.2 Hz, 1H), 7.83–
7.72 (m, 3H), 7.62–7.55 (m, 2H), 7.47–7.31 
(m, 7H), 6.41–6.26 (bs, 1H), 5.84–5.69 (m, 1H), 5.40–5.25 (m, 1H), 5.09–5.05 (bs, 1H), 
5.07–4.95 (m, 3H), 4.47–4.41 (m, 1H), 4.35– 4.30 (m, 1H), 4.26–4.11 (m, 1H), 3.97 (s, 
3H), 3.32–3.24 (m, 2H), 3.17–3.02 (m, 1H), 2.81–2.69 (m, 2H), 2.36–2.25 (m, 1H), 1.66–
157 (m, 3H), 1.48–1.38 (m, 1H), 0.92 (s, 10H). 13C NMR (75 MHz, CDCl3) δ 158.2, 157.8, 
156.8, 147.9, 146.3, 145.1, 144.3, 144.1, 141.8, 141.7, 132.00, 128.9, 128.1, 127.5, 125.5, 
122.0, 120.4, 114.9, 102.5, 67.4, 67.1, 60.8, 56.8, 56.3, 56.0, 47.6, 41.4, 39.9, 35.8, 28.3, 
27.9, 26.5, 25.8. UPLC (DAD-QTOF [M+H]+) calcd for C41H47N5O4 674.3726; found 
674.3726. 
Experimental section 
203 
 
tert-Butyl ((S)-1-(3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-
yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C5) 
The title compound was prepared from N-Boc-L-Tle-
OH and 9-amino-9-deoxy-9-epiquinine. Yield: 1.50 g 
(78%). White solid. m. p.= 118–130 °C. [αD25= –26.7 
(c= 1, CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 8.73 (d, J= 
4.6 Hz, 1H), 8.02 (d, J= 9.2 Hz, 1H), 7.79 (d, J= 2.5 Hz, 
1H), 7.39 (dd, J= 3.5, 8.4 Hz, 2H), 6.62–6.43 (bs, 1H), 
5.86–5.74 (m, 1H), 5.46–5.33 (m, 1H), 5.07–5.07 (m, 
1H), 5.04–4.95 (m, 2H), 4.93–4.90 (m, 2H), 4.87–4.79 (bs, 1H), 4.01 (s, 3H), 3.38–3.21 
(m, 2H), 3.18–3.08 (m, 1H), 2.89–2.69 (m, 2H), 2.37–2.28 (m, 1H), 1.69–1.66 (m, 1H), 
1.66–1.57 (m, 2H), 1.42 (s, 10H), 0.91 (s, 10H). 13C NMR (75 MHz, CDCl3) δ 157.8, 157.5, 
156.0, 147.5, 146.2, 144.8, 141.6, 131.5, 128.7, 121.7, 119.1, 114.4, 102.1, 80.1, 66.2, 
60.5, 56.0, 55.7, 41.1, 39.7, 35.3, 28.3, 28.0, 27.6, 26.2, 25.4. UPLC (DAD-QTOF [M+H]+) 
calcd for C31H46N5O4 552.3550; found 552.3559. 
Benzyl ((S)-1-(3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-
yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C6) 
The title compound was prepared from N-Cbz-L-
Tle-OH and 9-amino-9-deoxy-9-epiquinine. 
Yield: 1.48 g (72%). White solid. m. p.= 101–126 
°C. [αD25= –29.8 (c= 1, CH2Cl2). 1H NMR (300 
MHz, CDCl3) δ 8.62 (d, J= 4.3 Hz, 1H), 8.01 (d, J= 
9.2 Hz, 1H), 7.74 (d, J= 2.6 Hz, 1H), 7.39 (d, J= 2.7 
Hz, 1H), 7.36 (d, J= 7.0 Hz, 5H), 7.22 (d, J= 4.4 Hz, 
1H), 6.48–6.35 (bs, 1H), 5.84–5.73 (m, 1H), 5.32–5.29 (m, 1H), 5.20 (d, J= 9.4 Hz, 1H), 
5.08–5.05 (m, 2H), 5.04–4.95 (m, 3H), 3.97 (s, 3H), 3.30–3.23 (m, 2H), 3.12–2.99 (m, 1H), 
2.80–2.70 (m, 2H), 2.34–2.27 (s, 1H), 1.68–1.64 (m, 2H), 1.62–1.56 (m, 1H), 1.45–1.38 
(m, 1H), 0.82 (s, 10H). 13C NMR (75 MHz, CDCl3) δ 158.2, 157.8, 156.8, 148.0, 146.5, 
145.1, 141.9, 136.6, 132.6, 132.0, 129.0, 128.7, 128.6, 122.0, 119.6, 114.8, 102.5, 67.4, 
67.5, 60.8, 57.0 56.4, 56.1, 41.4, 40.0, 35.8, 28.4, 27.9, 26.5, 25.7. UPLC (DAD-QTOF 
[M+H]+) calcd for C34H44N5O4 586.3399; found 586.3393. 
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Benzyl ((S)-1-(3-((R)-((1S,2S,4S,5R)-5-ethylquinuclidin-2-yl)(6-methoxyquinolin-4-
yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C7) 
The title compound was prepared from N-Cbz-L-
Tle-OH and 9-amino-9-deoxyhydroquinine. 
Yield: 1.18 g (65%). White solid. m. p.= 105–134 
°C. [αD24= +59.4 (c= 1.1, CHCl3). 1H NMR (300 
MHz, CDCl3) δ 8.66 (d, J= 4.5 Hz, 1H), 7.93 (d, J= 
9.2 Hz, 1H), 7.70 (d, J= 2.8 Hz, 1H), 7.49–7.14 (m, 
7H), 6.42 (s, 1H), 5.72 (t, J= 9.9 Hz, 1H), 5.31 (d, 
J= 9.9 Hz, 1H), 5.25–5.01 (m, 3H), 4.71 (t, J= 9.6 Hz, 1H), 3.93 (s, 3H), 3.40–3.31 (m, 1H), 
3.10–2.83 (m, 2H), 2.55–2.33 (m, 2H), 1.97–1.82 (m, 1H), 1.80–1.63 (m, 2H), 1.57–1.30 
(m, 5H), 0.88 (t, J= 7.0 Hz, 3H), 0.81 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 157.74, 154.55, 
147.90, 147.38, 144.64, 140.88, 140.56, 140.41, 131.51, 127.93, 121.84, 121.60, 120.95, 
120.52, 116.30, 114.99, 114.81, 114.49, 102.19, 102.03, 55.56, 55.04, 53.85, 49.58, 
47.90, 39.77, 30.57, 29.78, 28.87, 27.30. UPLC (DAD-QTOF [M+H]+) calcd for C34H46N5O4 
588.3550; found 588.3549. 
(9H-Fluoren-9-yl)methyl ((S)-1-(3-((S)-((1S,2S,4S,5R)-5-ethylquinuclidin-2-yl)(6-
methoxyquinolin-4-yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C8) 
The title compound was prepared from N-
Fmoc-L-Tle-OH and 9-amino-9-deoxy-9-
epihydroquinine. Yield: 1.44 g (61%). White 
solid. m. p.= 135–149 °C. [αD24= –29.8 (c= 1, 
CHCl3). 1H NMR (300 MHz, CDCl3) δ 8.61 (d, J= 
4.5 Hz, 1H), 7.97 (d, J= 9.2 Hz, 1H), 7.81–7.69 
(m, 3H), 7.62–7.49 (m, 2H), 7.44–7.27 (m, 
7H), 6.28 (s, 1H), 5.27 (d, J= 15.7 Hz, 1H), 5.01 (s, 2H), 4.85 (s, 1H), 4.41 (dd, J= 10.6, 7.1 
Hz, 1H), 4.30 (dd, J= 10.6, 6.7 Hz, 1H), 4.17 (t, J= 6.8 Hz, 1H), 3.94 (s, 3H), 3.22 (dd, J= 
13.6, 9.9 Hz, 1H), 3.01 (s, 1H), 2.78–2.60 (m, 1H), 2.45 (d, J= 13.7 Hz, 1H), 1.60 (d, J= 12.1 
Hz, 5H), 1.52–1.37 (m, 2H), 1.09–0.95 (m, 1H), 0.89 (s, 9H), 0.79 (t, J= 7.3 Hz, 3H). 13C 
NMR (75 MHz, CDCl3) δ 157.93, 157.44, 156.42, 147.68, 144.90, 143.97, 141.46, 131.76, 
127.89, 127.20, 125.11, 121.80, 120.15, 102.15, 66.69, 66.00, 57.78, 55.78, 47.32, 41.18, 
37.47, 35.63, 28.75, 27.65, 26.12, 25.60, 25.36, 15.43, 12.15. UPLC (DAD-QTOF [M+H]+) 
calcd for C41H50N5O4 696.3863; found 676.3876. 
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Phenanthren-9-ylmethyl ((S)-1-(3-((S)-((1S,2S,4S,5R)-5-ethylquinuclidin-2-yl)(6-
methoxyquinolin-4-yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C22) 
The title compound was prepared from (S)-
3,3-dimethyl-2-(((phenanthren-9-
ylmethoxy)carbonyl)amino)butanoic acid 
and 9-amino-9-deoxy-9-hydroepiquinine. 
Yield: 1.66 g, (69%). Yellow solid. m. p.= 
152–159 °C. [αD25 = 8.7 (c=1, CH2Cl2). 1H 
NMR (300 MHz, CDCl3) δ 8.66 (dd, J = 21.2, 
8.1, 2H), 8.53 (s, 1H), 8.05 – 7.49 (m, 9H), 7.37 – 7.31 (m, 1H), 7.21 (s, 1H), 6.35 (s, 1H), 
5.55 (t, J = 10.6, 2H), 5.11 (dd, J = 28.1, 15.1, 4H), 3.93 (s, 3H), 3.24 – 3.06 (m, 2H), 2.99 
(s, 1H), 2.56 (s, 1H), 2.42 (d, J = 11.1, 1H), 2.21 (s, 1H), 1.36 (dd, J = 58.1, 27.4, 7H), 0.92 
– 0.72 (m, 12H). 13C NMR (75 MHz, CDCl3) δ 157.9, 157.6, 156.7, 147.7, 146.5, 144.9, 
131.8, 131.5, 131.2, 129.2, 126.8, 125.3, 124.2, 121.8, 119.4, 102.3, 66.7, 60.6, 59.6, 
57.8, 55.8, 41.1, 37.5, 35.6, 28.8, 27.6, 25.9, 25.4, 21.2, 14.4, 12.2. UPLC (DAD-QTOF 
[M+H]+) calcd for C42H50N5O4 688.3863, found 688.3863. 
3,5-Bis(trifluoromethyl)benzyl ((S)-1-(3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-
vinylquinuclidin-2-yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C23) 
The title compound was prepared from (S)-
2-((((3,5-(CF3)2-benzyloxycarbonyl-amino-
3,3-dimethylbutanoic acid and 9-amino-9-
deoxy-9-epiquinine. Yield: 2.3 g (65%). 
White solid. m. p. = 125–131 °C. [αD24 = – 
9.5 (c = 1.00, CH2Cl2). 1H NMR (300 MHz, 
CDCl3) δ 8.58 (d, J = 4.5 Hz, 1H), 7.94 (d, J = 
9.2 Hz, 1H), 7.85 – 7.61 (m, 4H), 7.30 (dd, J = 9.2, 2.6 Hz, 1H), 7.25 (d, J = 4.4 Hz, 1H), 6.46 
(s, 1H), 5.91 – 5.54 (m, 3H), 5.13 (d, J = 13.3 Hz, 2H), 5.08 – 4.81 (m, 3H), 3.89 (s, 3H), 
3.38 – 3.01 (m, 3H), 2.68 (d, J = 16.8 Hz, 2H), 2.25 (h, J = 5.3, 4.7 Hz, 1H), 1.70 – 1.28 (m, 
4H), 0.76 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 158.0, 157.6, 155.7, 147.4, 145.9, 144.7, 
141.0, 139.3, 131.78 (q, J = 35.7 Hz), 131.5, 128.5, 127.6, 125.0, 121.7, 121.4, 119.2, 
114.8, 102.2, 66.7, 64.9, 60.2, 55.8, 55.7, 41.0, 39.3, 35.5, 27.6, 27.4, 27.2, 26.1, 25.3. 
UPLC-DAD-QTOF: C36H41N5O4F6 [M+H]+ calcd.: 722.3136, found: 722.3138. 
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6.2.3. Synthesis of squaramide-based Brønsted base catalysts 
6.2.3.1. Preparation of (chloromethyl)silyl derivatives234 
(Chloromethyl)dimethyl(phenyl)silane was purchased from Sigma-Aldrich. 
(Chloromethyl)(methyl)diphenylsilane 
 
To a solution of dichloro(chloromethyl)methylsilane (1 equiv., 60 mmol, 7.62 mL) in 
anhydrous diethyl ether (30 mL), phenylmagnesium bromide (3.0 M in ether) (2 equiv., 
120 mmol, 40 mL) was added dropwise at room temperature and the reaction mixture 
was refluxed for 16 hours. Then, the mixture was cooled to 0 oC, saturated solution of 
NH4Cl (20 mL) was added and it was extracted with ethyl acetate (3 x 30 mL). The 
combined extracts were dried over MgSO4 and concentred under reduced pressure. The 
crude material was purified by flash column chromatography on silica gel (eluting with 
hexane) to afford the title compound. Yield: 8.22 g (55 %). Colorless liquid. 1H NMR (300 
MHz, CDCl3) δ 7.64 – 7.52 (m, 4H), 7.49 – 7.32 (m, 6H), 3.26 (s, 2H), 0.72 (s, 3H). 
(Chloromethyl)triphenylsilane 
 
The title compound was prepared according to the procedure shown above from 
trichloro(chloromethyl)silane (1 equiv., 10 mmol, 1.25 mL) and phenylmagnesium 
bromide (3.0 M in ether) (3 equiv., 30 mmol, 10 mL). The crude material was purified by 
crystallization on methanol. The crystals were washed with petroleum ether to afford 
the title compound. Yield: 1.40 g (45 %). White solid. m. p. 110–113 oC. 1H NMR (300 
MHz, CDCl3) δ 7.68 – 7.52 (m, 6H), 7.53 – 7.29 (m, 9H), 3.53 (s, 2H). 
                                                     
234 Procedures adapted from: a) Larson, G. L.; Prieto, J. A.; Ortiz, E. Tetrahedron, 1988, 44, 3781-3790. b) 
Allen, J. M.; Aprahamian, S. L.; Sans, E. A.; Shechter, H. J. Org. Chem., 2002, 67, 3561. 
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(Chloromethyl)dimethyl(naphthalen-2-yl)silane 
 
To a solution of chloro(chloromethyl)dimethylsilane (1 equiv., 20 mmol, 2.63 mL) in 
anhydrous diethyl ether (15 mL), 2-naphthylmagnesium bromide (0.5 M in THF) (1.4 
equiv., 28 mmol, 56 mL) was added dropwise at room temperature and the reaction 
mixture was refluxed for 16 hours. Then, the mixture was cooled to 0 oC, saturated 
solution of NH4Cl (20 mL) was added and it was extracted with ethyl acetate (3 x 30 mL). 
The combined extracts were dried over MgSO4 and concentred under reduced pressure. 
The crude material was purified by flash column chromatography on silica gel (eluting 
with hexane) to afford the title compound. Yield: 2.34 g (50 %). Colorless liquid. 1H NMR 
(300 MHz, CDCl3) δ 8.04 (s, 1H), 7.86 – 7.45 (m, 6H), 3.02 (s, 2H), 0.50 (s, 6H). 
(Chloromethyl)(methyl)di(naphthalen-2-yl)silane 
 
To a solution of dichloro(chloromethyl)methylsilane (1 equiv., 20 mmol, 2.54 mL) in 
anhydrous diethyl ether (15 mL), 2-naphthylmagnesium bromide (0.5 M in ether) (2.4 
equiv., 48 mmol, 96 mL) was added dropwise at room temperature and the reaction 
mixture was refluxed for 16 hours. Then, the mixture was cooled to 0 oC, saturated 
solution of NH4Cl (20 mL) was added and it was extracted with ethyl acetate (3 x 30 mL). 
The combined extracts were dried over MgSO4 and concentred under reduced pressure. 
The crude material was purified by flash column chromatography on silica gel (eluting 
with hexane) to afford the title compound. Yield: 4.17 g (61 %). Colorless liquid. 1H NMR 
(300 MHz, CDCl3) δ 8.02 (s, 2H), 7.80 – 7.42 (m, 12H), 3.07 (s, 2H), 0.56 (s, 3H). 
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6.2.3.2. Preparation of aminomethyl silanes235 
(Trimethylsilyl)methylamine was purchased Fluka. The other aminomethyl silanes 
were prepared following the general procedure: 
 
1st step: To a solution of the corresponding chloromethyl silane (20.0 mmol) in HMPA 
(10 mL) was added sodium azide (1.43 g, 22 mmol) and the reaction mixture was stirred 
for 5 hours at room temperature. Then, the mixture was poured into H2O (30 mL) and 
extracted with hexane (3 x 30 mL). The combined extracts were washed with saturated 
solution of NH4Cl, dried over MgSO4 and concentred under reduced pressure. The 
residue was used in the next step without further purification. 
2nd step: To a suspension of LiAlH4 (1 equiv., 10.0 mmol) in dry Et2O (10 mL) was slowly 
added at 0 oC a solution of the corresponding azide (10.0 mmol) in dry diethyl ether (5 
ml). The mixture was stirred in an ice bath for 10 min and then stirred at room 
temperature until liberation of nitrogen ceased (30 min). The, the reaction was 
quenched with 1 mL of NH4OH 1 % aqueous solution. The mixture was filtered through 
celite, the filtered was dried over MgSO4 and solvent was evaporated under reduced 
pressure. The residue was used in the next step without further purification. 
(Dimethyl(phenyl)silyl)methanamine 
The title compound was prepared according to the general 
procedure. Yield: 2.97 g (90 %) Colorless liquid. 1H NMR (300 MHz, 
CDCl3) δ 7.57-7.53 (m, 2H), 7.38-7.36 (m, 3H), 2.40 (s, 2H), 0.33 (s, 6H). 
(Methyldiphenylsilyl)methanamine 
The title compound was prepared according to the general 
procedure. Yield: 3.68 g (81 %). Colorless liquid. 1H NMR (300 MHz, 
CDCl3) δ 7.60-7.55 (m, 4H), 7.41-7.34 (m, 6H), 2.72 (s, 2H), 0.63 (s, 3H). 13C NMR (75 MHz, 
CDCl3) δ 135.4, 134.5, 133.9, 129.4, 129.2, 127.8, 127.6, 29.1, -5.7. UPLC-DAD-QTOF: 
C14H18NSi [M+H]+ calcd.: 228.1209, found: 228.1197. 
                                                     
235 Adapted from: Lettelier, M.; McPhee, D. J.; Griller, D. Synthetic Commun. 1988, 18, 1975. 
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(Dimethyl(naphthalen-2-yl)silyl)methanamine  
The title compound was prepared according to the general 
procedure. Yield: 3.68 g (80 %). Colorless liquid. 1H NMR (300 
MHz, CDCl3) δ 8.04 (s, 1H), 7.87-7.81 (m, 3H), 7.63-7.60 (m, 1H), 
7.51-7.48 (m, 2H), 2.49 (s, 2H), 0.42 (s, 6H).  
(Methyl(naphthalen-2-yl)silyl)methanamine  
The title compound was prepared according to the general 
procedure. Yield: 3.68 g (80 %). Colorless liquid. 1H NMR (300 
MHz, CDCl3) δ 8.01 (s, 2H), 7.86-7.78 (m, 6H), 7.64-7.59 (m, 2H), 
7.53-7.45 (m, 4H), 2.51 (s, 2H), 0.40 (s, 3H).  
 
(Methyldiphenylsilyl)methanamine 
The title compound was prepared according to the general procedure. 
Yield: 4.85 g (84 %). Colorless liquid. 1H NMR (300 MHz, CDCl3) δ 7.66 – 
7.54 (m, 6H), 7.54 – 7.31 (m, 9H), 3.04 (s, 2H). 
6.2.3.3. Preparation of squaramide-type catalysts 
1st STEP: 
 
To a solution of 3,4-dimethoxycyclobut-3-ene-1,2-dione (0.71 g, 5.0 mmol) in 10 mL 
MeOH was added the corresponding (aminomethyl)silane. The reaction mixture was 
stirred for 48 hours at room temperature and white precipitate was generated. The 
reaction product was filtered and the filtration residue was washed with Et2O to give the 
corresponding monosubstituted secondary amine. 
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3-Methoxy-4-((trimethylsilyl)methylamino)cyclobut-3-ene-1,2-dione 
The title compound was prepared according to the general 
procedure. Yield: 0.884 g (83 %). White solid. m. p. 119–122 °C. 
IR (ν/cm-1): 3205, 3014, 2969, 2948, 2357, 1790, 1692, 1576, 
1493, 1366, 1228, 862, 584. 1H NMR (300 MHz, CDCl3) δ 5.68 (s, 1H), 4.40 (s, 3H), 3.02 – 
2.96 (m, 2H), 0.12 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 189.4, 182.1, 176.9, 172.1, 60.1, 
35.8, –3.42. UPLC-DAD-QTOF: C9H16NO3Si [M+H]+ calcd.: 214.0899, found: 214.0892. 
3-((Dimethyl(phenyl)silyl)methylamino)-4-methoxycyclobut-3-ene-1,2-dione 
The title compound was prepared according to the general 
procedure. Yield: 0.963 g (70 %). White solid. m. p. 117–120 
°C. IR (ν/cm-1): 3247, 3135, 3046, 2968, 2359, 1799, 1691, 
1586, 1357, 1229, 1112, 1051, 980, 934, 807, 697, 587, 467. 
1H NMR (300 MHz, CDCl3) δ 7.53 – 7.48 (m, 2H), 7.42 – 7.35 (m, 3H), 6.20 (s, 1H), 4.32 (s, 
3H), 3.22 – 3.15 (m, 2H), 0.40 (s, 6H). 13C NMR (75 MHz, CDCl3) δ: 189.5, 182.6, 177.4, 
172.5, 134.9, 133.9, 130.2, 128.4, 60.5, 35.6,–4.6.  UPLC-DAD-QTOF: C14H18NO3Si [M+H]+ 
calcd.: 276.1056, found: 276.1058. 
3-(((Dimethyl(naphthalen-2-yl)silyl)methyl)amino)-4-methoxycyclobut-3-ene-1,2-
dione  
The title compound was prepared according to the 
general procedure. Yield: 1.14 g (70 %). White solid. m. 
p. 140–144 °C. IR (ν/cm-1): 3277, 3065, 3001, 2939, 
2904, 1803, 1696, 1622, 1495, 1396, 1275, 1109, 918, 
848, 779, 725, 580, 459. 1H NMR (300 MHz, CDCl3) δ 8.00 (s, 1H), 7.86 – 7.81 (m, 3H), 
7.55 – 7.49 (m, 3H), 6.63 (s, 1H), 4.23 (s, 3H), 3.21 (d, J = 6Hz, 1H), 0.48 (s, 6H). 13C NMR 
(75 MHz, CDCl3) δ 189.7, 182.3, 177.3, 172.2, 135.0, 134.1, 132.9, 129.5, 128.2, 127.9, 
127.6, 127.0, 126.4, 60.4, 35.6, –4.5. UPLC-DAD-QTOF: C18H20NO3Si [M+H]+ calcd.: 
326.1212, found: 326.1212. 
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3-(((Dimethyl(naphthalen-2-yl)silyl)methyl)amino)-4-methoxycyclobut-3-ene-1,2-
dione  
The title compound was prepared according to the 
general procedure. Yield: 1.56 g (72 %). White solid. m. 
p. 150–153 °C. IR (ν/cm-1): 3240, 3046, 1801, 1699, 
1605, 1497, 1461, 1396, 1362, 1085, 857, 758, 475. 1H 
NMR (300 MHz, CDCl3) δ 8.12 (s, 2H), 8.00 – 7.77 (m, 
6H), 7.77 – 7.41 (m, 6H), 6.76 (brs, 1H), 4.17 (s, 3H), 3.62 
(m, 6.3 Hz, 2H), 0.85 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 189.3, 182.2, 177.2, 172.2, 136.1, 
134.2, 132.9, 130.6, 130.1, 128.2, 127.8, 127.7, 127.2, 126.4, 60.3, 34.3, –5.4. UPLC-DAD-
QTOF: C27H23NO3Si [M+H]+ calcd.: 438,1520, found: 438,1523. 
3-Methoxy-4-(triphenylsilyl)methylamino)cyclobut-3-ene-1,2-dione 
The title compound was prepared according to the general 
procedure. Yield: 1.70 g (85 %). White solid. m. p. 167-171°C. IR 
(ν/cm-1): 3254, 3046, 1801, 1702, 1601, 1426, 1360, 1111, 698, 
505. 1H NMR (300 MHz, CDCl3) δ 7.63 – 7.35 (m, 15H), 5.32 (s, 1H), 4.28 (s, 3H), 3.76 (s, 
2H). 13C NMR (75 MHz, CDCl3) δ 188.9, 182.9, 177.6, 172.9, 136.0, 135.7, 130.8, 128.7, 
60.5, 27.8. UPLC-DAD-QTOF: C24H21NO3Si [M+H]+ calcd.: 400.1363, found: 400.1360. 
2nd STEP: 
 
To a solution of monosubstituted squarate (1.5 mmol) in 6 mL MeOH was added the 
corresponding cinchona-base chiral amine (3.0 mmol) and the reaction mixture was 
stirred for 48 hours at room temperature. The reaction product was obtained after flash 
column chromatography on basic silica gel (eluting with ethyl acetate) to afford the 
desired catalysts C10–C15. 
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3-(((1S,2S)-2-(Piperidin-1-yl)cyclohexyl)amino)-4-
(((trimethylsilyl)methyl)amino)cyclobut-3-ene-1,2-dione (C10) 
The title compound C10 was prepared according to the 
general procedure. Yield: 0.247 g (45 %). m. p. 239–242 °C. 
[α]D25= +42.1 (c = 0.25, DMSO). IR (ν/cm-1): 3160, 3014, 2929, 
2851, 1791, 1633, 1551, 1462, 1365, 1216, 846, 762. 1H NMR 
(300 MHz, DMSO) δ 7.10 (s, 1H), 3.82 (s, 1H), 3.21 – 3.08 (m, 
2H), 2.63 – 2.47 (m, 2H), 2.30 – 2.20 (m, 2H), 2.04 – 1.99 (m, 1H), 1.83 – 1.63 (m, 2H), 
1.41 – 1.14 (m, 8H), 0.06 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 182.3, 181.6, 168.1, 167.6, 
68.4, 53.8, 49.3, 34.4, 26.4, 24.9, 24.6, 24.6, 23.8, –3.1. UPLC-DAD-QTOF: C19H34N3O2Si 
[M+H]+ calcd.: 364.2420, found: 276.2409. 
3-((S)-(6-Methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methylamino)-4-
((trimethylsilyl)methylamino)cyclobut-3-ene-1,2-dione (C11) 
The title compound C11 was prepared according to the 
general procedure. Yield: 0.514 mg (68 %). White solid. 
m. p. 209–213 °C. [α]D25= –102.6 (c = 0.25, CH2Cl2). IR 
(ν/cm-1): 3203, 3014, 2936, 2871, 1788, 1636, 1545, 
1455, 1366, 1232, 1037, 842. 1H NMR (300 MHz, CDCl3) 
δ 8.66 (d, J = 4.5 Hz, 1H), 8.06 – 8.02 (d, J = 9.2 Hz, 1H), 
7.84 (s, 1H), 7.56 (d, J = 3 Hz, 1H), 7.40 (dd, J = 3,3 Hz, 
1H), 5.85 – 5.73 (m, 1H), 5.01 – 4.91 (m, 2H), 3.92 (s, 3H), 3.51 – 3.06 (m, 6H), 2.78 – 2.68 
(m, 2H), 2.24 (brs, 1H), 1.62 – 1.42 (m, 4H), 0.78 – 0.72 (m, 1H), 0.02 (s, 3H),  –0.06 (s, 
6H). 13C NMR (75 MHz, CDCl3) δ 183.5, 181.8, 181.7, 168.0, 167.7, 158.7, 147.9, 144.9, 
141.5, 132.0, 128.0, 122.3, 114.8, 101.9, 56.1, 41.0, 39.7, 36.0, 35.9, 29.8, 28.0, 27.7, 
26.2, –2.9. UPLC-DAD-QTOF: C28H37N4O3Si [M+H]+ calcd.: 505.2635, found: 505.2597. 
3-((Dimethyl(phenyl)silyl)methylamino)-4-((S)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-
vinylquinuclidin-2-yl)methylamino)cyclobut-3-ene-1,2-dione (C12) 
The title compound C12 was prepared according to 
the general procedure. Yield: 0.594 g (70 %). White 
solid. m. p. 221–224 °C. [α]D25= –106.0 (c = 0.25, 
CH2Cl2). IR (ν/cm-1): 3183, 3047, 2919, 2862, 1788, 
1631, 1542, 1455, 1399, 1232, 1032, 838, 711, 469. 
1H NMR (300 MHz, CDCl3) δ 8.62 (d, J = 3.4 Hz, 1H), 
8.01 (d, J = 9.2 Hz, 1H), 7.77 (s, 1H), 7.42 – 7.38 (m, 
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2H), 7.35 – 7.32 (m, 2H), 7.22 –7.19 (m, 3H), 5.80 – 5.68 (m, 1H), 5.02 – 4.94 (m, 2H), 
3.93 (s, 3H), 3.45-7.39 (m, 2H), 3.29 – 3.12 (m, 3H), 2.77 – 2.67 (m, 2H), 2.29 (s, 1H), 1.68 
– 1.61 (m, 3H), 1.50 – 1.42 (m, 1H), 0.83 – 0.77 (m, 1H), 0.19 (s, 6H). 13C NMR (75 MHz, 
CDCl3) δ 183.4, 181.0, 168.3, 167.2, 158.8, 147.7, 145.0, 140.9, 135.5, 133.8, 132.0, 
129.9, 128.1, 122.6, 115.2, 101.8, 56.2, 41.0, 39.4, 35.1, 27.5, 26.1, –4.5. UPLC-DAD-
QTOF: C33H39N4O3Si [M+H]+ calcd.: 567.2791, found: 567.2800. 
3-(((Dimethyl(naphthalen-2-yl)silyl)methyl)amino)-4-(((S)-(6-methoxyquinolin-4-
yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)amino)cyclobut-3-ene-1,2-dione 
(C13) 
The title compound was C13 prepared according 
to the general procedure. Yield: 0.693 g (75 %). 
White solid. m. p. 229–232 °C. [α]D25= –109.5 (c 
= 0.5, CH2Cl2). IR (ν/cm-1): 3227, 2937, 2862, 
1790, 1637, 1567, 1544, 1264, 1086, 1038, 817. 
1H NMR (300 MHz, CDCl3) δ 8.54 (s, 1H), 8.00 (d, 
J = 9.2 Hz, 1H), 7.84 (s, 1H), 7.75 – 7.70 (m, 4H), 
7.43 – 7.35 (m, 5H), 5.78 – 5.65 (m, 1H), 4.98 – 4.89 (m, 2H), 3.89 (s, 3H), 3.31 – 3.06 (m, 
5H), 2.71 – 2.61 (m, 2H), 2.25 – 2.19 (m, 1H), 1.62 – 1.52 (m, 3H), 1.41 – 1.32 (m, 1H), 
0.77 – 0.70 (m, 1H), 0.20 – 0.18 (m, 6H). 13C NMR (75 MHz, CDCl3) δ 184.0, 182.8, 167.7, 
159.2, 148.1, 145.5, 141.9, 135.3, 134.5, 133.3, 132.5, 130.0, 128.5, 128.3, 128.0, 127.4, 
126.8, 122.9, 115.2, 102.2, 56.5, 41.3, 40.1, 35.2, 28.4, 28.0, 26.7, –4.0. UPLC-DAD-QTOF: 
C37H41N4O3Si [M+H]+ calcd.: 617.2948, found: 617.2961. 
3-(((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)amino)-
4-(((methyldi(naphthalen-2-yl)silyl)methyl)amino)cyclobut-3-ene-1,2-dione (C14) 
The title compound was C14 prepared 
according to the general procedure. Yield: 
0.830 g (76 %). White solid. m. p. 245–252 °C. 
[α]D25= –124.6 (c = 0.7, CH2Cl2). IR (ν/cm-1): 
3230, 3048, 2939, 1792, 1584, 1535, 1457, 
1241, 1086, 908, 854, 730, 475. 1H NMR (300 
MHz, CDCl3) δ 8.47 (s, 1H), 8.00 – 7.88 (m, 3H), 
7.87 – 7.59 (m, 8H), 7.55 – 7.35 (m, 6H), 7.31 
(dd, J = 9.2, 2.5 Hz, 1H), 5.64 (dt, J = 18.4, 9.7 Hz, 1H), 5.02 – 4.81 (m, 2H), 3.88 (s, 3H), 
3.76 (d, J = 16.0 Hz, 1H), 3.50 (s, 1H), 3.16 (d, J = 42.3 Hz, 3H), 2.61 (s, 2H), 2.22 (s, 1H), 
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1.35 (s, 1H), 0.72 (dd, J = 13.5, 7.4 Hz, 1H), 0.55 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 183.3, 
181.5, 167.8, 167.5, 158.6, 147.5, 144.6, 140.7, 135.9, 135.2, 134.0, 132.8, 131.6, 131.1, 
131.0, 130.2, 128.1, 128.1, 127.7, 127.5, 126.9, 126.2, 122.5, 115.0, 101.7, 60.0, 56.0, 
55.6, 53.3, 40.7, 39.1, 33.7, 27.4, 25.8, -5.5. UPLC-DAD-QTOF: C46H44N4O3Si [M+H]+ 
calcd.: 729.3255, found: 729.3251. 
3-((S)-(6-Methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methylamino)-4-
((methyldiphenylsilyl)methylamino)cyclobut-3-ene-1,2-dione (C15) 
The title compound C15 was prepared according to 
the general procedure. Yield: 0.560 g (60 %). m. p. 
152–156 °C. [α]D23= –105.3 (c = 1. 0, CH2Cl2). IR    
(ν/cm-1): 3193, 2929, 2859, 1788, 1628, 1547, 1456, 
1230, 1114, 803, 760, 730, 700, 489. 1H NMR (300 
MHz, CDCl3) δ 8.49 (d, J = 5.1 Hz, 1H), 8.00 (d, J = 9.2 
Hz, 1H), 7.79 (s, 1H), 7.48 – 6.97 (m, 12H), 5.75 (ddd, 
J = 17.6, 10.9, 7.6 Hz, 1H), 5.08 – 4.80 (m, 2H), 3.89 (s, 3H), 3.43 (ddd, J = 32.6, 16.8, 9.5 
Hz, 4H), 3.15 (dd, J = 13.8, 10.0 Hz, 1H), 2.68 (dq, J = 14.9, 7.5, 6.1 Hz, 2H), 2.15 (s, 2H), 
1.73 – 1.18 (m, 4H), 0.86 – 0.65 (m, 1H), 0.44 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 183.6, 
181.9, 167.8, 158.7, 147.6, 144.9, 141.6, 134.6, 133.6, 133.5, 131.9, 130.1, 128.2, 128.2, 
122.5, 114.7, 101.9, 56.1, 40.9, 39.7, 33.7, 28.0, 27.7, 26.3, –5.7. UPLC-DAD-QTOF: 
C38H41N4O3Si [M+H]+ calcd.: 629.2948, found:  629.2956. 
3-((S)-(6-Methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methylamino)-
4-((triphenylsilyl)methylamino)cyclobut-3-ene-1,2-dione (C16) 
The title compound C16 was prepared according to the 
general procedure. Yield: 0.688 g (67 %). White solid. m. 
p. 252–256 °C. [α]D23= –58.9 (c = 1. 0, CH2Cl2). 1H NMR 
(300 MHz, CDCl3) δ 8.40 (s, 1H), 7.96 (d, J = 9.2 Hz, 1H), 
7.77 (s, 1H), 7.61 – 7.08 (m, 19H), 5.71 (dt, J = 17.4, 9.3 
Hz, 1H), 5.03 – 4.83 (m, 2H), 3.90 (s, 3H), 3.72 (td, J = 
20.5, 20.0, 10.0 Hz, 3H), 3.36 – 3.01 (m, 3H), 2.63 (dt, J = 14.6, 7.5 Hz, 2H), 2.23 (dt, J = 
10.8, 6.3 Hz, 1H), 1.72 – 1.28 (m, 4H), 0.72 (q, J = 7.6, 6.5 Hz, 1H). 13C NMR (75 MHz, 
CDCl3) δ 183.6, 182.0, 167.9, 167.8, 158.7, 147.4, 144.9, 141.5, 135.9, 135.7, 135.4, 
131.8, 130.3, 128.4, 128.3, 128.2, 128.0, 122.7, 114.7, 101.9, 56.2, 40.8, 39.6, 32.6, 28.0, 
27.8, 27.7, 26.4. UPLC-DAD-QTOF: C43H43N4O3Si [M+H]+ calcd.: 691.3104, found:  
691.3129. 
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6.2.4. Synthesis of thiourea- or urea-based Brønsted base catalysts 
6.2.4.1. Preparation of silyl-thiourea type catalyst C17 
6.2.4.1.1. Synthesis of 9-deoxy-9-epiquinine isocyanate derivative 
 
To a solution of 9-amino-9-deoxy-9-epiquinine (1 equiv., 1 mmol, 0.323 g) in anhydrous 
THF (1 mL) at –10 °C, carbon disulfide (6 equiv., 6 mmol, 0.36 mL) and DCC (1 equiv., 1 
mmol, 0.206 g) were successively added. The reaction mixture was slowly warmed to 
room temperature in 3 hours and then, it was stirred at the same temperature for 16 
hours. After that, the mixture was concentrated under reduced pressure and purified by 
flash chromatography column in silica gel (CH2Cl2:MeOH, 97:3 to 90:10). Yield: 0.329 g 
(90 %). Yellow solid. 1H NMR (300 MHz, CDCl3) δ 8.77 (d, J = 4.5 Hz, 1H), 8.07 (d, J = 9.2 
Hz, 1H), 7.49 – 7.32 (m, 3H), 5.72 (ddd, J = 17.1, 10.4, 6.6 Hz, 1H), 5.30 (d, J = 10.0 Hz, 
1H), 5.14 – 5.03 (m, 2H), 3.98 (s, 3H), 3.65 (dd, J = 13.7, 10.2 Hz, 1H), 3.47 – 3.23 (m, 3H), 
3.08 (dt, J = 13.5, 2.9 Hz, 1H), 2.58 (s, 1H), 2.02 (s, 1H), 1.88 – 1.72 (m, 3H), 1.38 (dd, J = 
13.5, 8.9 Hz, 1H).13C NMR (75 MHz, CDCl3) δ 164.16, 157.86, 147.72, 144.46, 141.92, 
138.54, 131.81, 127.18, 121.46, 119.86, 116.76, 101.48, 66.56, 65.69, 57.19, 55.81, 
46.23, 38.73, 27.65, 26.19, 25.42. UPLC-DAD-QTOF: C21H24NOS [M+H]+ calcd.: 366.1640, 
found: 366.1644. 
6.2.4.1.2. Synthesis of silyl-thiourea catalyst C17 
 
(Methyldiphenylsilyl)methanamine (1 equiv., 1.4 mmol, 0.32 g) was added to a solution 
of 9-isocyanate-9-deoxy-9-epiquinine (1 equiv., 1.4 mmol, 0.51 g) in anhydrous THF (2 
mL) and the mixture was stirred at room temperature for 3 hours. After that, the mixture 
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was concentrated under reduced pressure and purified by flash chromatography column 
in silica gel (CH2Cl2:MeOH, 90:10) to afford catalyst C17. Yield: 0.746 g (90 %). White 
solid. m. p. 136–145 °C. [α]D23= –106.7 (c = 1. 0, CH2Cl2). IR (ν/cm-1): 2932, 1620, 1508, 
1422, 1227, 1113, 1029, 910, 818, 730, 699, 483. 1H NMR (300 MHz, CDCl3) δ 8.57 (s, 
1H), 8.00 (d, J = 9.2 Hz, 1H), 7.65 – 7.51 (m, 2H), 7.44 – 7.28 (m, 12H), 6.03 (s, 1H), 5.71 
– 5.52 (m, 1H), 5.00 – 4.84 (m, 2H), 3.91 (s, 3H), 3.44 (s, 2H), 3.24 – 2.85 (m, 4H), 2.72 – 
2.53 (m, 2H), 2.24 (s, 1H), 1.70 – 1.46 (m, 3H), 1.27 (td, J = 12.4, 10.4, 3.7 Hz, 1H), 0.95 – 
0.81 (m, 1H), 0.37 (s, 3H).13C NMR (75 MHz, CDCl3) δ 183.68, 158.00, 147.60, 144.87, 
141.11, 134.56, 134.51, 134.10, 131.98, 129.78, 128.29, 128.23, 127.93, 122.09, 114.79, 
101.88, 60.77, 55.77, 55.59, 40.78, 39.48, 33.43, 31.00, 27.87, 27.40, 25.89, –5.31. UPLC-
DAD-QTOF: C35H41N4OSSi [M+H]+ calcd.: 593.2770, found: 593.2776. 
6.2.4.2. Preparation of silyl-urea type catalyst C18 
 
To a solution of N,N’-carbonyldiimidazole (1.1 equiv., 1.1 mmol, 0.178 g) in anhydrous 
CH2Cl2 (1 mL), a solution of 9-amino-9-deoxy-9-epiquinine (1.0 equiv., 1.0 mmol, 0.323 
g) in CH2Cl2 (1 mL) was added at room temperature. The reaction was monitorized by 
TLC and once the reaction was finished –30 minutes aprox.–,   
(methyldiphenylsilyl)methanamine (1 equiv., 1.4 mmol, 0.23 g) was added and stirred at 
room temperature for 16 hours. After that, the mixture was concentrated under 
reduced pressure and purified by flash chromatography column in silica gel 
(CH2Cl2:MeOH, 90:10) to afford catalyst C18. Yield, 0.346 g (60 %). White solid. m. p. 
129–135 °C. [α]D23= –36.3 (c = 1. 0, CH2Cl2). IR (ν/cm-1): 2931, 1621, 1546, 1508, 1427, 
1228, 1113, 1028, 910, 821, 730, 699, 484. 1H NMR (300 MHz, CDCl3) δ 8.66 (d, J = 4.5 
Hz, 1H), 8.02 (d, J = 9.2 Hz, 1H), 7.69 (d, J = 2.8 Hz, 1H), 7.46 – 7.22 (m, 12H), 5.86 (s, 1H), 
5.77 – 5.60 (m, 1H), 5.04 (s, 1H), 5.02 – 4.87 (m, 2H), 4.23 (t, J = 5.5 Hz, 1H), 3.93 (s, 3H), 
3.25 – 2.91 (m, 5H), 2.74 – 2.56 (m, 2H), 2.33 – 2.20 (m, 1H), 1.70 – 1.52 (m, 3H), 1.41 – 
1.26 (m, 1H), 1.00 – 0.85 (m, 1H), 0.44 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 159.09, 157.84, 
147.65, 144.92, 141.35, 134.60, 134.47, 134.11, 131.86, 129.90, 128.20, 127.95, 121.77, 
119.89, 114.67, 101.99, 60.22, 55.97, 55.71, 40.86, 39.63, 28.01, 27.49, 26.11, –5.26. 
UPLC-DAD-QTOF: C35H41N4O2Si [M+H]+ calcd.: 577.2999, found: 577.3004. 
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6.2.4.3. Preparation of achiral thiourea catalyst C24236 
To a solution of 3,5-bis(trifluoromethyl)phenyl 
isocianate (0.91 mL, 5 mmol, 1 equiv.) in anhydrous 
CH2Cl2 (5 mL), N,N-dimethylelthylenediamine (0.55 mL, 5 
mmol, 1 equiv.) was added. The mixture was stirred at 
room temperature for 2 hours and then, the solvent was 
eliminated under reduced pressure to afford catalyst C24. Yield: 1.76 g (98%). White 
solid. 1H RMN (300 MHz, MeOD-d4) δ 8.15 (s, 2H), 7.58 (s, 1H), 3.79 – 3.56 (m, 2H), 2.56 
(t, J= 6.3 Hz, 2H), 2.27 (s, 6H). 13C RMN (75 MHz, MeOD-d4) δ 182.8, 143.2, 132.7 (q, J= 
33.2 Hz), 126.5, 123.6, 117.8, 58.6, 45.5, 43.0. Spectroscopic data were coincident with 
the previously reported.236 
                                                     
236 Procedure adapted from: a) Pratt, R. C.; Lohmeijer, B. G.; Long, D. A.; Lundberg, P. N.; Dove, A. P.; Li, 
H. B.; Wade, C. G.; Waymouth, R. M.; Hedrick, J. L. Macromolecules, 2006, 39, 7863. b) Opalka, S. M.; 
Steinbacher, J. L.; Lambiris, B. A.; McQuade. D. T. J. Org. Chem. 2011, 76, 6503-6571. 
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6.3. Experimental section for Chapter 2 
6.3.1. Preparation of 2-nitroethyl sulfones237 
1st STEP: 
 
A solution of 2-nitroethanol (1.0 equiv., 50 mmol, 3.5 mL), pyridine (1.0 equiv., 50 
mmol, 4.0 mL) and acetic anhydride (1.0 equiv., 50 mmol, 4.7 mL) in CH2Cl2 (80 mL) was 
stirred under nitrogen atmosphere at room temperature in the dark. After 7 hours, the 
reaction mixture was poured into 1M HCl (80 mL). The organic solvent was removed 
under reduced pressure and the aqueous phase was extracted with Et2O (3 x 50 mL). 
The combined organic extracts were dried over MgSO4 and the solvent was removed 
under reduced pressure to afford pure 2-nitroethyl acetate. Yield: 6.0 g (91%). Brown 
oil. 1H NMR (300 MHz, CDCl3) δ 4.60 (s, 4H), 2.08 (s, 3H). 
2nd STEP: 
 
To a solution of 2-nitroethyl acetate (1.0 equiv., 15 mmol, 1.99 g) and the 
corresponding thiol (1.0 equiv., 15 mmol) in acetonitrile (40 mL), a solution of Et3N (1.1 
equiv., 16.5 mmol, 2.20 mL) in CH3CN (10 mL) was added dropwise at 0 °C. The resulting 
mixture was stirred at 0 °C for 1 hour and then poured into 1M HCl (20 mL). The organic 
solvent was eliminated under reduced pressure and the aqueous phase was extracted 
with hexane (3 x 30 mL). The organic layer was washed with H2O (100 mL), dried over 
MgSO4 and the removal of the solvent under reduced pressure afforded the 
corresponding thioether, which was used in the following step without further 
purification. 
(2-Nitroethyl)(phenyl)sulfane 
The title compound was prepared from thiophenol following the 
general procedure. Yield: 2.55 g (93%). Yellow oil. 1H NMR (300 MHz, 
                                                     
237 Procedure adapted from: Mukhina, E. S.; Pavlova, Z. F.; Nekrasova, G. V.; Lipina, E. S.; Perekalin, V. V. 
Russ. J. Org. (Chem. Zhurnal Organicheskoi Khimii) 1990, 26, 2285-2290. 
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CDCl3) δ 7.47 – 7.40 (m, 2H), 7.39 – 7.27 (m, 3H), 4.50 (t, J= 7.2 Hz, 2H), 3.44 (t, J= 7.2 Hz, 
2H). 
Naphthalen-2-yl(2-nitroethyl)sulfane 
The title compound was prepared from 2-naphthalenethiol 
following the general procedure. Yield: 2.70 g (77%). White 
solid. 1H NMR (300 MHz, CDCl3) δ 7.90 (d, J= 1.6 Hz, 1H), 7.88 – 7.74 (m, 3H), 7.59 – 7.44 
(m, 3H), 4.54 (t, J= 6.8 Hz, 2H), 3.53 (t, J= 6.8 Hz, 2H). 
2-((2-Nitroethyl)thio)pyridine 
The title compound was prepared from 2-mercaptopyridine 
following the general procedure. Yield: 2.45 g (89%). Yellow oil. 1H 
NMR (300 MHz, CDCl3) δ 8.11 – 8.02 (m, 1H), 7.90 – 7.72 (m, 2H), 
7.01 (ddd, J = 6.9, 4.7, 2.0 Hz, 1H), 4.48 (t, J = 6.8 Hz, 2H), 3.46 (t, J = 6.8 Hz, 2H). 
(3,5-Bis(trifluoromethyl)phenyl)(2-nitroethyl)sulfane 
The title compound was prepared from 3,5-
bis(trifluoromethyl)benzenethiol following the general 
procedure. Yield: 4.26 g (89%). Yellow oil. 1H NMR (300 MHz, 
CDCl3) δ 7.81 (s, 2H), 7.77 (s, 1H), 4.58 (t, J= 6.8 Hz, 2H), 3.58 
(t, J= 6.8 Hz, 2H). 
3rd STEP: 
 
To a solution of the corresponding thioether (1.0 equiv., 10 mmol) in CH2Cl2 (100 mL), 
m-CPBA (2.0 equiv, 20 mmol, 6.4 g (70%)) was added in portions and the resulting 
solution was stirred overnight at room temperature. The reaction mixture was then 
cooled to 0°C and treated with 10% aqueous Na2SO3 (80 mL) for 15 minutes. The 
aqueous layer was separated and the organic phase was successively washed with a 
saturated NaHCO3 solution (80 mL) and brine (80 mL), dried over MgSO4 and the solvent 
was removed under reduced pressure to afford the corresponding pure 2-nitroethyl 
sulfone. 
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((2-Nitroethyl)sulfonyl)benzene (2a) 
The title compound 2a was prepared from (2-
nitroethyl)(phenyl)sulfane according to the general procedure. Yield: 
2.00 g (93%). White solid. m. p.= 99–101 °C. 1H NMR (300 MHz, CDCl3) 
δ 7.95 – 7.91 (m, 2H), 7.78 – 7.67 (m, 1H), 7.66 – 7.57 (m, 2H), 4.74 (t, J= 7.0 Hz, 2H), 
3.81 (t, J= 7.0 Hz, 2H). 13C NMR (75 MHz, CDCl3) δ 138.2, 134.9, 129.9, 128.2, 68.2, 52.5. 
Elem. Anal. calcd for C8H9NO4S (215.23): C, 44.64; H, 4.21; N, 6.51. Found: C, 44.71; H, 
4.21; N, 6.34. 
2-((2-Nitroethyl)sulfonyl)naphthalene (2b) 
The title compound 2b was prepared from naphthalen-2-yl(2-
nitroethyl)sulfane according to the general procedure. Yield: 
2.23 g (84%). White solid. m. p.= 135–137 °C. 1H NMR (300 
MHz, CDCl3) δ 8.55 – 8.48 (m, 1H), 8.12 – 7.81 (m, 4H), 7.80 – 
7.50 (m, 2H), 4.78 (d, J= 7.3 Hz, 2H), 3.89 (t, J= 7.3 Hz, 2H). 13C NMR (75 MHz, CD2Cl2) δ 
136.20, 135.47, 132.69, 130.83, 130.72, 130.38, 130.04, 128.61, 122.72, 68.78, 52.90. 
UPLC-DAD-QTOF: C12H11NO4S [M+H]+ calcd.: 266.0482, found: 266.0479. 
2-((2-Nitroethyl)sulfonyl)pyridine (2c) 
The title compound 2c was prepared from 2-((2-
nitroethyl)thio)pyridine according to the general procedure. Yield: 
1.56 g (72%). Yellow solid. m. p.= 116–120 °C. 1H NMR (300 MHz, 
CDCl3) δ 8.74 – 8.62 (m, 1H), 8.07 – 7.90 (m, 2H), 7.58 (ddd, J = 6.9, 
4.7, 2.0 Hz, 1H), 4.87 (t, J = 6.8 Hz, 2H), 4.06 (t, J = 6.8 Hz, 2H). 13C NMR (75 MHz, CDCl3) 
δ 156.5, 150.3, 138.7, 128.2, 122.0, 68.3, 48.7. UPLC-DAD-QTOF: C7H9N2O4S [M+H]+ 
calcd.: 217.0286, found: 217.0283; C7H8N2O4SNa [M+Na]+ calcd.: 239.0104, found: 
217.0102. 
1-((2-Nitroethyl)sulfonyl)-3,5-bis(trifluoromethyl)benzene (2d) 
The title compound 2d was prepared from (3,5-
bis(trifluoromethyl)phenyl)(2-nitroethyl)sulfane according to 
the general procedure. Yield: 3.06 g (87%). White solid. m. p.= 
138–140 °C. 1H NMR (300 MHz, CDCl3) δ 8.43 (s, 2H), 8.26 (s, 
1H), 4.90 (t, J= 6.6 Hz, 2H), 3.94 (t, J= 6.6 Hz, 2H). 13C NMR (75 MHz, CD2Cl2) δ 141.77, 
134.00 (q, J= 34.9 Hz), 129.34, 129.03, 124.71, 68.22, 53.08. UPLC-DAD-QTOF: 
C10H7F6NO4S [M+H]+ calcd.: 352.0073, found: 352.0075. 
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6.3.2. Enantioselective synthesis of γ-sulfonyl allyl amines 
 
To a solution of the corresponding N-Boc imine 4 (1.0 equiv., 0.5 mmol) and catalyst 
C8 (0.20 equiv., 0.1 mmol, 0.067 g) in CH2Cl2 (5 mL), was added the 2-nitroethyl sulfone 
2 (1.5 equiv., 0.75 mmol) at 60 °C. The reaction mixture was stirred for 15 hours, then 
quenched with HCl 1 M (3 mL) and extracted with CH2Cl2 (3 x 5 mL). The combined 
organic layers were dried over MgSO4 and concentrated under reduced pressure. 
Impurities were removed by trituration with Et2O. Then, the nitro-Mannich adduct was 
dissolved in dichloromethane (20 mL, from a commercial bottle) and KOH (2.0 equiv., 1 
mmol, 0.056 g) was added and stirred at room temperature. The reaction was 
moniterized by IR, observing the disappearence of the band at 1560 cm-1 in 1–2 hours. 
The reaction mixture was quenched with HCl 1 M (20 mL) and extracted with CH2Cl2 (3 x 
20 mL). The organic layers were combined, dried over MgSO4 and concentrated under 
reduced pressure to give the crude product. The corresponding products were 
purified238 by trituration in Et2O or flash column chromatography (hexane:ethyl acetate) 
to afford the corresponding γ-sulfonyl allyl amines 5. 
Racemic adducts for the determination of the enantiomeric excesses were prepared 
following the general procedure employing achiral catalyst C23. 
tert-Butyl (S,E)-(3-(phenylsulfonyl)-1-(p-tolyl)allyl)carbamate (5aa) 
The title compound 5aa was prepared from 2-nitroethyl 
sulfone 2a and N-Boc imine 4a following the general 
procedure. Yield: 0.081 g (42%). White solid. m. p.= 120–
123 °C. [αD25= –64.2 (c= 0.05, CH2Cl2). 1H NMR (300 MHz, 
                                                     
238 Some adducts decomposed during isolation and purification procedures. 
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CDCl3) δ 7.88 (d, J= 7.2 Hz, 2H), 7.65 – 7.49 (m, 2H), 7.20 – 7.05 (m, 5H), 6.49 (dd, J= 15.0, 
1.7 Hz, 1H), 5.41 (s, 1H), 4.86 (d, J= 7.3 Hz, 1H), 2.34 (s, 3H), 1.38 (s, 9H). 13C NMR (75 
MHz, CDCl3) δ 154.8, 145.8, 140.5, 138.7, 135.2, 133.6, 131.2, 130.1, 129.5, 127.9, 127.3, 
80.6, 55.1, 28.4, 21.3. UPLC-DAD-QTOF: C21H26NO4S [M+H]+ calcd.: 388.1577, found: 
388.1574. Chiral HPLC (Chiralpak AD-H; 90:10 hexane:iPrOH; 0.50 mL/min, λ = 230 nm) 
tR (major.) = 41.5 min, tR (minor.) = 54.3 min. 85% ee. 
tert-Butyl (S,E)-(1-phenyl-3-(phenylsulfonyl)allyl)carbamate (5ab) 
The title compound 5ab was prepared from 2-nitroethyl sulfone 
2a and N-Boc imine 4b following the general procedure. Yield: 
0.105 g (56%). White solid. m. p.= 131–135 °C. [αD25= –46.9 (c= 
2.5, CHCl3) ([αD23= +31.5 (c= 1.04, CHCl3) for R-enantiomer).239 
1H NMR (300 MHz, CDCl3) δ 7.96 – 7.83 (m, 2H), 7.67 – 7.59 (m, 1H), 7.55 (ddt, J= 8.4, 
6.7, 1.4 Hz, 2H), 7.36 (dtd, J= 7.0, 5.2, 2.3 Hz, 3H), 7.25 – 7.19 (m, 2H), 7.11 (dd, J= 15.0, 
4.8 Hz, 1H), 6.50 (dd, J= 15.0, 1.8 Hz, 1H), 5.47 (s, 1H), 4.84 (s, 1H), 1.39 (s, 9H). 13C NMR 
(75 MHz, CDCl3) δ 154.8, 145.6, 140.4, 138.2, 133.7, 131.4, 129.7, 129.6, 129.5, 128.9, 
127.9, 127.4, 77.4, 55.6, 28.4. UPLC-DAD-QTOF: C20H24NO4S [M+H]+ calcd.: 374.1421, 
found: 374.1419. Chiral HPLC (Chiralpak IA; 90:10 hexane:iPrOH; 0.50 mL/min, λ = 230 
nm) tR (major.) = 35.8 min, tR (minor.) = 43.2 min. 61% ee. 
tert-Butyl (S,E)-(1-(4-methoxyphenyl)-3-(phenylsulfonyl)allyl)carbamate (5ac) 
The title compound 5ac was prepared from 2-nitroethyl 
sulfone 2a and N-Boc imine 4c following the general 
procedure. Yield: 0.042 g (56%). White solid. m. p.= 115–
119 °C. [αD24= –16.0 (c= 0.5, CHCl3). 1H NMR (300 MHz, 
CDCl3) δ 7.97 – 7.82 (m, 2H), 7.71 – 7.45 (m, 3H), 7.13 (d, J= 8.7 Hz, 2H), 7.11 – 7.04 (m, 
1H), 6.87 (d, J= 8.7 Hz, 2H), 6.48 (dd, J= 15.0, 1.8 Hz, 1H), 5.40 (s, 1H), 4.88 (s, 1H), 3.79 
(s, 3H), 1.49 – 1.29 (m, 9H). 13C NMR (75 MHz, CDCl3) δ 159.9, 154.8, 145.9, 140.5, 133.7, 
131.0, 130.2, 129.5, 128.7, 127.9, 114.7, 80.6, 55.5, 54.7, 28.4. UPLC-DAD-QTOF: 
C21H26NO5S [M+H]+ calcd.: 404.1526, found: 404.1529. Chiral HPLC (Chiralpak AD-H; 
90:10 hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR (major.) = 35.5 min, tR (minor.) = 50.8 
min. 77% ee. 
                                                     
239 Ref. 156a, page 88. 
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tert-Butyl (S,E)-(3-(naphthalen-2-ylsulfonyl)-1-(p-tolyl)allyl)carbamate (5ba) 
The title compound 5ba was prepared from 2-
nitroethyl sulfone 2b and N-Boc imine 4a following 
the general procedure. Yield: 0.044 g (20%). White 
solid. m. p.= 160–162 °C. [αD25= –33.7 (c= 0.8, 
CHCl3). 1H NMR (300 MHz, CDCl3) δ 8.49 (d, J= 1.8 Hz, 1H), 8.03 – 7.95 (m, 2H), 7.95 – 
7.89 (m, 1H), 7.81 (dd, J= 8.7, 1.9 Hz, 1H), 7.72 – 7.57 (m, 2H), 7.21 – 7.06 (m, 5H), 6.53 
(dd, J= 15.1, 1.8 Hz, 1H), 5.44 (s, 1H), 4.83 (s, 1H), 2.34 (s, 3H), 1.36 (s, 9H). 13C NMR (75 
MHz, CDCl3) δ 154.7, 145.9, 138.6, 137.1, 135.3, 135.1, 132.4, 131.0, 130.0, 129.8, 129.5, 
129.5, 129.4, 128.1, 127.8, 127.2, 122.6, 80.5, 55.0, 28.3, 21.2. UPLC-DAD-QTOF: 
C25H28NO4S [M+H]+ calcd.: 438.1734, found: 438.1730. Chiral HPLC (Chiralpak AD-H; 
90:10 hexane:iPrOH; 0.50 mL/min, λ = 230 nm) tR (major.) = 59.5 min, tR (minor.) = 66.2 
min. 77% ee. 
tert-Butyl (S,E)-(3-(pyridin-2-ylsulfonyl)-1-(p-tolyl)allyl)carbamate (5ca) 
The title compound 5ca was prepared from 2-nitroethyl 
sulfone 2c and N-Boc imine 4a following the general 
procedure. Yield: 0.031 g (16%). White solid. 1H NMR (300 
MHz, CDCl3) δ 8.90 – 8.66 (m, 1H), 8.21 – 7.90 (m, 2H), 
7.71 – 7.47 (m, 1H), 7.42 – 7.02 (m, 5H), 6.79 (dd, J = 15.1, 1.9 Hz, 1H), 5.52 (s, 1H), 4.98 
(d, J = 8.3 Hz, 1H), 2.36 (s, 3H), 1.42 (s, 9H). UPLC-DAD-QTOF: C20H24N2O4SNa [M+H]+ 
calcd.: 411.1349, found: 411.1358. Chiral HPLC (Chiralpak AD-H; 90:10 hexane:iPrOH; 
1.00 mL/min, λ = 210 nm) tR (major.) = 25.0 min, tR (minor.) = 31.5 min. 92% ee. 
tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(p-
tolyl)allyl)carbamate (5da) 
The title compound 5da was prepared from 2-
nitroethyl sulfone 2d and N-Boc imine 4a following 
the general procedure. Yield: 0.141 g (54%). White 
solid. m. p.= 149–152 °C. [αD25= –8.9 (c= 0.28, 
CHCl3). 1H NMR (300 MHz, CDCl3) δ 8.40 – 8.29 (m, 
2H), 8.12 (dd, J= 2.0, 1.1 Hz, 1H), 7.25 (dd, J= 15.0, 4.9 Hz, 1H), 7.19 (d, J= 8.0 Hz, 2H), 
7.10 (d, J= 8.1 Hz, 2H), 6.52 (dd, J= 15.0, 1.7 Hz, 1H), 5.41 (s, 1H), 4.85 (s, 1H), 2.35 (s, 
3H), 1.38 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 154.8, 149.6, 143.6, 139.2, 134.4, 133.5 (q, 
J= 35.4, 33.7 Hz), 130.3, 129.2, 128.2, 127.4, 124.4, 120.8, 80.9, 55.6, 28.4, 21.3. UPLC-
DAD-QTOF: C23H24NO4SF6 [M+H]+ calcd.: 524.1330, found: 524.1332. Chiral HPLC 
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(Chiralpak IC; 98:2 hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR (major.) = 28.1 min, tR 
(minor.) = 36.4 min. >99% ee. 
tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-phenylallyl)carbamate 
(5db) 
The title compound 5db was prepared from 2-nitroethyl 
sulfone 2d and N-Boc imine 4b following the general 
procedure. Yield: 0.153 g (60%). White solid. m. p.= 131–
135 °C. [αD24= –32.0 (c=1, CHCl3). 1H NMR (300 MHz, 
CDCl3) δ 8.34 (d, J= 1.9 Hz, 2H), 8.12 (d, J= 2.0 Hz, 1H), 
7.45 – 7.18 (m, 6H), 6.53 (dd, J= 15.0, 1.7 Hz, 1H), 5.46 (s, 1H), 4.87 (s, 1H), 1.55 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ 154.8, 149.3, 143.4, 137.4, 133.4 (q, J= 34.9 Hz), 129.6, 129.3, 
129.1, 128.2, 127.4, 125.2, 120.1, 81.0, 55.7, 28.3. UPLC-DAD-QTOF: C22H21NO4SF6Na 
[M+Na]+ calcd.: 532.0993, found: 532.1001. Chiral HPLC (Chiralpak IC; 99:1 
hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR (major.) = 60.5 min, tR (minor.) = 73.1 min. 
>99% ee. 
tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(4-
methoxyphenyl)allyl)carbamate (5dc) 
The title compound 5dc was prepared from 2-
nitroethyl sulfone 2d and N-Boc imine 4c following 
the general procedure. Yield: 0.194 g (72%). White 
solid. m. p.= 139–142 °C. [αD24= –39.6 (c=1, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 8.34 (d, J= 1.6 Hz, 2H), 
8.12 (s, 1H), 7.25 (dd, J= 14.9, 4.9 Hz, 1H), 7.14 (d, J= 8.7 Hz, 2H), 6.90 (d, J= 8.7 Hz, 2H), 
6.51 (dd, J= 15.0, 1.8 Hz, 1H), 5.39 (s, 1H), 4.82 (s, 1H), 3.81 (s, 3H), 1.38 (s, 9H). 13C NMR 
(75 MHz, CDCl3) δ 160.1, 154.7, 149.6, 143.5, 133.4 (q, J= 34.7 Hz), 128.9, 128.7, 128.2, 
127.2, 124.3, 120.7, 114.9, 80.8, 55.5, 55.2, 28.3. UPLC-DAD-QTOF: C23H24NO5SF6 [M+H]+ 
calcd.: 540.1279, found: 540.1277. Chiral HPLC (Chiralpak IC; 98:2 hexane:iPrOH; 1.00 
mL/min, λ = 230 nm) tR (major.) = 40.9 min, tR (minor.) = 49.8 min. >99% ee. 
Experimental section 
225 
 
Methyl (S,E)-4-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-((tert-
butoxycarbonyl)amino)allyl)benzoate (5dd) 
The title compound 5dd was prepared from 2-
nitroethyl sulfone 2d and N-Boc imine 4d 
following the general procedure. Yield: 0.142 g 
(50%). White solid. 1H NMR (300 MHz, CDCl3) δ 
8.35 (s, 2H), 8.13 (s, 1H), 8.06 (d, J = 8.3 Hz, 2H), 
7.32 (d, J = 8.2 Hz, 2H), 7.26 (dd, J = 15.0, 5.0 Hz, 1H), 6.53 (dd, J = 15.0, 1.8 Hz, 1H), 5.53 
(s, 1H), 4.90 (s, 1H), 3.94 (s, 3H), 1.39 (s, 9H). UPLC-DAD-QTOF: C24H23NO6SF6Na [M+Na]+ 
calcd.: 590.1048, found: 590.1051. Chiral HPLC (Chiralpak IC; 95:5 hexane:iPrOH; 1.00 
mL/min, λ = 230 nm) tR (minor.) = 34.0 min, tR (major.) = 38.1 min. 90% ee. 
tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(4-
chlorophenyl)allyl)carbamate (5de) 
The title compound 5de was prepared from 2-
nitroethyl sulfone 2d and N-Boc imine 4e following 
the general procedure. Yield: 0.138 g (51%). White 
solid. 1H NMR (300 MHz, CDCl3) δ 8.34 (s, 2H), 8.13 
(s, 1H), 7.36 (dd, J = 8.5, 2.0 Hz, 2H), 7.25 – 7.21 (m, 
1H), 7.18 (dd, J = 8.5, 2.0 Hz, 2H), 6.52 (dd, J = 15.0, 1.8 Hz, 1H), 5.46 (d, J = 7.1 Hz, 1H), 
4.89 (d, J = 7.4 Hz, 1H), 1.38 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 154.6, 148.4, 143.3, 
136.0, 135.1, 133.5 (q, J = 34.8 Hz), 129.9, 129.8, 128.7, 128.2, 127.4, 124.3, 120.7, 81.2, 
55.0, 28.3. UPLC-DAD-QTOF: C22H20NO4SF6ClNa [M+Na]+ calcd.: 566.0603, found: 
566.0601. Chiral HPLC (Chiralpak AD-H; 98:2 hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR 
(major.) = 16.6 min, tR (minor.) = 19.2 min. >99% ee. 
tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(2-
chlorophenyl)allyl)carbamate (5df) 
The title compound 5df was prepared from 2-nitroethyl 
sulfone 2d and N-Boc imine 4f following the general 
procedure. Yield: 0.027 g (10%). White solid. 1H NMR 
(300 MHz, CDCl3) δ 8.36 (d, J = 1.5 Hz, 2H), 8.15 (s, 1H), 
7.46 – 7.26 (m, 4H), 6.53 (d, J = 15.1 Hz, 1H), 5.96 – 5.79 
(m, 1H), 5.22 (d, J = 8.1 Hz, 1H), 1.43 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 154.7, 148.6, 
143.3, 135.3, 133.4 (q, J = 34.6 Hz), 130.8, 130.4, 129.8, 129.3, 128.2, 127.9, 127.3, 124.3, 
120.7, 81.1, 53.7, 28.3. UPLC-DAD-QTOF: C22H21NO4SF6Cl [M+H]+ calcd.: 544.0779, 
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found: 544.0783 Chiral HPLC (Chiralpak AD-H; 98:2 hexane:iPrOH; 1.00 mL/min, λ = 230 
nm) tR (minor.) = 29.2 min, tR (major.) = 47.7 min. 68% ee. 
tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(4-methoxy-3-
methylphenyl)allyl)carbamate (5dg) 
The title compound 5dg was prepared from 2-
nitroethyl sulfone 2d and N-Boc imine 4g following 
the general procedure. Yield: 0.194 g (72%). White 
solid. m. p.= 144–149 °C. [αD24= –42.6 (c=1, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 8.35 (s, 2H), 8.11 (s, 
1H), 7.21 (dd, J = 15.0, 4.9 Hz, 1H), 7.04 – 6.95 (m, 2H), 6.80 (d, J = 8.2 Hz, 1H), 6.51 (dd, 
J = 15.0, 1.7 Hz, 1H), 5.34 (brs, 1H), 4.79 (brs, 1H), 3.83 (s, 3H), 2.20 (s, 3H), 1.38 (s, 9H). 
13C NMR (75 MHz, CDCl3) δ 158.3, 154.7, 149.9, 143.7, 142.2, 133.4 (q, J = 34.9 Hz), 129.7, 
128.8, 128.2, 127.2, 126.0, 124.3, 120.7, 110.6, 80.8, 55.6, 31.1, 28.3, 16.4. UPLC-DAD-
QTOF: C24H26NO4SF6 [M+H]+ calcd.: 554.1436, found: 554.1439. Chiral HPLC (Chiralpak 
IC; 98:2 hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR (major.) = 32.1 min, tR (minor.) = 
38.5 min. >99% ee. 
tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(3,4-
dimethoxyphenyl)allyl)carbamate (5dh) 
The title compound 5dh was prepared from 2-
nitroethyl sulfone 2d and N-Boc imine 4h following 
the general procedure. Yield: 0.170 g (60%). White 
solid. m. p.= 147–151 °C. [αD24= –40.3 (c=1, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 8.35 (s, 2H), 8.12 (s, 
1H), 7.27 (dd, J = 15.0, 4.8 Hz, 1H), 6.90 – 6.81 (m, 1H), 6.80 – 6.70 (m, 2H), 6.52 (dd, J = 
15.0, 1.8 Hz, 1H), 5.38 (s, 1H), 4.82 (s, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 1.39 (s, 9H). UPLC-
DAD-QTOF: C24H26NO6SF6 [M+H]+ calcd.: 570.1385, found: 570.1389. Chiral HPLC 
(Chiralpak IC; 95:5 hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR (minor.) = 15.1 min, tR 
(major.) = 17.2 min. >99% ee. 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(naphthalen-2-
yl)allyl)carbamate (5di) 
The title compound 5di was prepared from 2-
nitroethyl sulfone 2d and N-Boc imine 4i following 
the general procedure. Yield: 0.126 g (45%). White 
solid. m. p.= 121–124 °C. [αD23= –39.4 (c=1, CHCl3). 
1H NMR (300 MHz, CDCl3) δ 8.36 (s, 2H), 8.13 (s, 1H), 
7.82 (ddd, J = 13.5, 7.3, 3.9 Hz, 3H), 7.68 (s, 1H), 7.53 (dt, J = 6.2, 3.4 Hz, 2H), 7.37 (dd, J 
= 15.0, 4.8 Hz, 1H), 7.31 (dd, J = 8.5, 1.9 Hz, 1H), 6.60 (dd, J = 15.0, 1.6 Hz, 1H), 5.64 (brs, 
1H), 5.13 (brs, 1H), 1.40 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 154.7, 149.0, 143.3, 134.6, 
133.2 (q, J = 34.6 Hz), 133.2, 133.1, 129.5, 128.0, 127.9, 127.7, 127.1, 126.8, 126.4, 124.5, 
124.1, 120.5, 80.8, 55.6, 28.1. UPLC-DAD-QTOF: C26H24NO4SF6 [M+H]+ calcd.: 560.1330, 
found: 560.1334. Chiral HPLC (Chiralpak AD-H; 99:1 hexane:iPrOH; 1.00 mL/min, λ = 230 
nm) tR (minor.) = 41.7  min, tR (major.) = 60.5 min. 88% ee. 
tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(thiophen-2-
yl)allyl)carbamate (5dj) 
The title compound 5dj was prepared from 2-nitroethyl 
sulfone 2d and N-Boc imine 4j following the general 
procedure. Yield: 0.103 g (40%). White solid. 1H NMR (300 
MHz, CDCl3) δ 8.35 (s, 2H), 8.13 (s, 1H), 7.34 – 7.30 (m, 
1H), 7.26 (d, J = 5.0 Hz, 1H), 7.04 – 6.96 (m, 2H), 6.58 (dd, 
J = 15.0, 1.7 Hz, 1H), 5.74 (s, 1H), 4.90 (s, 1H), 1.40 (s, 9H). UPLC-DAD-QTOF: 
C20H20NO4S2F6 [M+H]+ calcd.: 516.0738, found: 516.0737. Chiral HPLC (Chiralpak IC; 98:2 
hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR (major.) = 24.5 min, tR (minor.) = 31.1 min. 
94% ee. 
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6.4. Experimental section for Chapter 3 
6.4.1. Enantioselective α-amination of 2-(cyanomethyl)pyridine N-oxides 
with azodicarboxylates 
6.4.1.1. Preparation of 2-(cyanomethyl)pyridine N-oxides 
6.4.1.1.1. Oxidation of 2-bromo pyridines 
6.4.1.1.1.1. Synthesis of 2-bromopyridine N-oxide240 
 
To a solution of 2-bromopyridine (1 equiv., 10 mmol, 1.58 g) in CHCl3 (20 mL), m-CPBA 
(1.4 equiv., 14 mmol, 4.35 g (70% w/w)) was added and the resulting mixture was stirred 
at 50 oC for 16 hours. The organic layer was removed under reduced pressure and the 
crude was purified by flash column chromatography on silica gel (Hexane:AcOEt, 50:50 
to 0:100) to afford pure 2-bromopyridine N-oxide. Yield: 4.15 g (80%). Grey oil. IR (ν/cm-
1): 3096, 3035, 1697, 1589, 1541, 1411, 1251, 1121, 1065, 1037, 838, 762, 674, 565, 519, 
446. 1H NMR (300 MHz, CDCl3) δ 8.40 – 8.38 (m, 1H), 7.68 – 7.64 (m, 1H), 7.28 – 7.22 (m, 
1H), 7.14 – 7.08 (m, 1H). 
6.4.1.1.1.2. Synthesis of 2,6-dibromopyridine N-oxide241 
 
To an ice-cold solution of 2,6-dibromopyridine (1 equiv., 10 mmol, 2.37 g) in 
trifluoroacetic acid (12 mL) was added drop-wise an aqueous solution of H2O2 (30 %) 
(0.33 mL/mmol, 3.3 mL). The reaction mixture was stirred at 100 oC for 16 hours and 
then cooled to rt, poured into 50 mL of water and the precipitate was filtered. The solid 
                                                     
240 Adapted from: Brasse, M.; Cámpora, J.; Palma, P.; Álvarez, E. Organometallics 2008, 27, 4711–4723. 
241 Adapted from: Palmer, J. T.; Luniss, C. J.; Offermann, D. A.; Axford, L. C.; Blair, M.; Mitchell, D.; Palmer, 
M.; Steele, C.; Atherall, F.; Watson, D.; Haydon, D.; Czaplewski, L.; Davies, D.; Collins, I.; Tyndall, E. M.; 
Andrau, L.; Pitt, G. R. W. Bacteria topoisomerase II inhibiting 2-ethylcarbamoylamino-1,3-benzothiazol-5-
yls. WO 2012045124, 2012. 
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obtained was the starting material. The filtrate was extracted with CH2Cl2 (3 x 20 mL) 
and the combined organic layers were washed with 0.5 M K2CO3 solution (3 x 20 mL). 
The organic layer was dried over MgSO4, filtered and concentrated under reduced 
pressure to afford 2,6-dibromopyridine N-oxide. Yield: 2.10 g (84%). White solid. m. p.= 
180–183 °C. IR (ν/cm-1): 3090, 3034, 1696, 1554, 1403, 1268, 1125, 1066, 1032, 808, 743, 
660, 567, 528, 444. 1H NMR (300 MHz, CDCl3) δ 7.64 (d, J = 9 Hz, 2H), 6.93 (t, J = 6, 9 Hz, 
1H). 
6.4.1.1.2. Synthesis of 2-(cyanomethyl)pyridine N-oxides 13(a–f) 
 
GENERAL PROCEDURE A 
To a solution of potassium tert-butoxide (2 equiv., 6 mmol, 0.673 g) in dry THF (10 mL) 
at room temperature, the corresponding 2-arylacetonitrile (1.5 equiv., 4.5 mmol) was 
added and the resulting mixture was stirred for 45 minutes at the same temperature. 
Afterwards, the corresponding 2-bromopyridine N-oxide (1 equiv., 3 mmol) was added 
as a solution in dry THF (5 mL) and the mixture was stirred for additional 3 hours at the 
same temperature. The reaction mixture was quenched with H2O and diluted with 
CH2Cl2. The aqueous layer was extracted with CH2Cl2 and the combined organic extracts 
were dried over MgSO4 and concentrated to afford the crude product which was purified 
by flash column chromatography on silica gel.  
GENERAL PROCEDURE B 
To a solution of potassium tert-butoxide (2 equiv., 6 mmol, 0.673 g) in dry THF (10 mL) 
at –40 oC, the corresponding 2-arylacetonitrile (1.5 equiv.) was added and the resulting 
mixture was stirred for 45 minutes at the same temperature. A solution of the 
corresponding 2-bromopyridine N-oxide (1 equiv., 3 mmol) in dry THF (5 mL) was added 
and the mixture was stirred for additional 3 hours at –40 oC and then allowed to warm 
to room temperature over 30 minutes. The reaction mixture was quenched with H2O 
and diluted with CH2Cl2. The aqueous layer was extracted with CH2Cl2 and the combined 
organic extracts were dried over MgSO4 and concentrated to afford the crude product 
which was purified by flash column chromatography on silica gel.  
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Note: Pyridine N-oxides 13(a–f) decompose over time and should be stored in a 
refrigerator (at –30 oC they are stable for several months). 
2-(Cyano(phenyl)methyl)pyridine N-oxide (13a) 
The title compound 13a was prepared from 2-bromopyridine N-oxide 
and 2-phenylacetonitrile according to general procedure A. The crude 
material was purified by flash column chromatography on silica gel 
(hexane:ethyl acetate, 50:50 to 0:100). Yield: 0.567 g (90 %). Yellow 
solid. m. p.= 112–115 oC. IR (ν/cm-1): 3110, 3052, 2894, 2246, 1489, 1438, 1246, 884, 
794, 696. 1H NMR (300 MHz, CDCl3) δ 8.29 – 8.27 (m, 1H), 7.52 – 7.28 (m, 8H), 6.11 (s, 
1H). 13C NMR (75 MHz, CDCl3) δ 146.2, 139.6, 132.0, 129.3, 12.9, 128.1, 125.8, 125.7, 
125.4, 117.5, 36.8. UPLC-DAD-QTOF: C13H11N2O3 [M+H]+ calcd.: 211.0871, found: 
211.0863. 
2-(Cyano(p-tolyl)methyl)pyridine N-oxide (13b) 
The title compound 13b was prepared from 2-bromopyridine N-
oxide and 2-(p-tolyl)acetonitrile according to general procedure 
A. The crude material was purified by flash column 
chromatography on silica gel (hexane:ethyl acetate, 50:50 to 
0:100). Yield: 0.565 g (84%). Yellow solid. m. p.= 96–99 oC. IR (ν/cm-1): 3082, 3042, 3013, 
2909, 2247, 1687, 1513, 1488, 1429, 1279, 1242, 837, 798, 765, 705. 1H NMR (300 MHz, 
CDCl3) δ 8.26 – 8.23 (m, 1H), 7.43 – 7.33 (m, 3H), 7.27 – 7.24 (m, 2H), 7.20 – 7.17 (m, 
2H), 6.03 (s, 1H), 2.33 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 146.5, 139.6, 138.9, 130.0, 
129.0, 128.1, 125.8, 125.6, 125.4, 117.7, 36.5, 21.1. UPLC-DAD-QTOF: C14H13N2O [M+H]+ 
calcd.: 225.1028, found: 225.1046. 
2-(Cyano(4-methoxyphenyl)methyl)pyridine N-oxide (13c) 
The title compound 13c was prepared from 2-bromopyridine N-
oxide and 2-(4-methoxyphenyl)acetonitrile according to general 
procedure A. The crude material was purified by flash column 
chromatography on silica gel (hexane:ethyl acetate, 50:50 to 
0:100). Yield: 0.511 mg (71%). Red oil. IR (ν/cm-1): 3110, 3071, 3013, 2934, 2837, 2245, 
1607, 1583, 1509, 1429, 1365, 1178, 1027, 830, 762. 1H NMR (300 MHz, CDCl3) δ 8.21 – 
8.19 (m, 1H), 7.38 – 7.33 (m, 3H), 7.23 – 7.20 (m, 2H), 6.87 – 6.84 (m, 2H), 5.95 (s, 1H), 
3.73 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 159.8, 146.3, 139.5, 129.3, 125.8, 125.5, 125.1, 
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123.7, 117.7, 114.6, 55.3, 36.1. UPLC-DAD-QTOF: C14H13N2O2 [M+H]+ calcd.: 241.0977, 
found: 241.0974. 
2-((4-Bromophenyl)(cyano)methyl)pyridine N-oxide (13d) 
The title compound 13d was prepared from 2-bromopyridine N-
oxide and 2-(4-bromophenyl)acetonitrile according to general 
procedure A. The crude material was purified by flash column 
chromatography on silica gel (hexane:ethyl acetate, 50:50 to 
0:100). Yield: 0.760 g (88 %). Red oil. IR (ν/cm-1): 3112, 3078, 3050, 3023, 2896, 2247, 
1692, 1587, 1484, 1428, 1404, 1237, 1047, 1010, 824, 782, 729, 625. 1H NMR (300 MHz, 
CDCl3) δ 8.27 – 8.24 (m, 1H), 7.53 – 7.50 (m, 3H), 7.39 – 7.39 (m, 2H), 7.32 – 7.29 (m, 
2H), 6.05 (s, 1H). 13C NMR (75 MHz, CDCl3) δ 145.9, 139.8, 132.6, 131.2, 129.9, 125.3, 
123.3, 117.3, 36.6. UPLC-DAD-QTOF: C13H10N2OBr [M+H]+ calcd.: 288.9977, found: 
288.9973. 
2-(Cyano(4-(methoxycarbonyl)phenyl)methyl)pyridine N-oxide (13e) 
The title compound 13e was prepared from 2-bromopyridine 
N-oxide and methyl 4-(cyanomethyl)benzoate according to 
general procedure B. The crude material was purified by flash 
column chromatography on silica gel (hexane:ethyl acetate, 
50:50 to 0:100). Yield: 0.643 g (80 %). Red oil. IR (ν/cm-1): 3111, 3080, 3013, 2926, 2245, 
1710, 1620, 1590, 1469, 1240, 1113, 1054, 840, 631. 1H NMR (300 MHz, CDCl3) δ 8.28 – 
8.25 (m, 1H), 8.06 – 8.02 (m, 2H), 7.58 – 7.49 (m, 3H), 7.32 – 7.29 (m, 2H), 6.16 (s, 1H), 
3.90 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 166.3, 145.7, 139.8, 136.9, 130.9, 130.6, 128.3, 
126.1, 126.0, 125.5, 117.2, 52.4, 36.9. UPLC-DAD-QTOF: C15H13N2O3 [M+H]+ calcd.: 
269.0926, found: 269.0923. 
2-Bromo-6-(cyano(4-(trifluoromethyl)phenyl)methyl)pyridine N-oxide (13f) 
The title compound 13f was prepared from 2,6-
dibromopyridine N-oxide and 2-(4-
(trifluoromethyl)phenyl)acetonitrile according to general 
procedure B. The crude material was purified by flash 
column chromatography on silica gel (hexane:ethyl acetate, 70:30 to 0:100). Yield: 0.897 
g (84%). Red solid. m. p.= 92–96 °C. IR (ν/cm-1): 3086, 3043, 2984, 2893, 2248, 1691, 
1618, 1576, 1556, 1462, 1378, 1322, 1240, 1163, 1113, 1066, 857, 844, 783. 1H NMR 
(300 MHz, CDCl3) δ 7.73 – 7.55 (m, 6H), 7.18 (t, J = 8.1 Hz, 1H), 6.12 (s, 1H). 13C NMR (75 
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MHz, CDCl3) δ 146.9, 135.7, 133.9, 133.0, 128.9, 126.4, 126.4, 125.5, 124.1, 117.0, 38.0. 
UPLC-DAD-QTOF: C14H9N2OF3Br [M+H]+ calcd.: 356.9850, found: 356.9843. 
2-(Cyano(thiophen-3-yl)methyl)pyridine 1-oxide (13g) 
The title compound 13g was prepared from 2-bromopyridine N-oxide 
and 2-(thiophen-3-yl)acetonitrile according to general procedure B. 
The crude material was purified by flash column chromatography on 
silica gel (hexane:ethyl acetate, 50:50 to 0:100). Yield: 0.383 g (60%). 
Red oil. IR (ν/cm-1): 3114, 3083, 2890, 2240, 1711, 1604, 1483, 1427, 1272, 1237, 1142, 
943, 837, 762, 621. 1H NMR (300 MHz, CDCl3) δ 8.30 – 8.28 (m, 1H), 7.51 – 7.50 (m, 1H), 
7.45 – 7.42 (m, 1H), 7.38 – 7.35 (m, 1H), 7.32 – 7.26 (m, 2H), 7.15 – 7.13 (m, 1H), 6.18 (s, 
1H). 13C NMR (75 MHz, CDCl3) δ 145.8, 139.6, 131.5, 127.6, 126.7, 126.0, 125.8, 125.2, 
124.6, 117.3, 32.5. UPLC-DAD-QTOF: C11H9N2OS [M+H]+ calcd.: 217.0436, found: 
217.0428. 
6.4.1.2. General procedure for the enantioselective α-amination 
 
To a solution of the corresponding pyridine N-oxide 13 (1 equiv., 0.2 mmol) in 
methylene chloride (1 mL), catalyst C16 (0.1 equiv, 0.02 mmol, 0.014 g) and the 
corresponding azodicarboxylate 14 (1.5 equiv., 0.3 mmol) were added at 0 oC. The 
resulting mixture was stirred for 15 hours at the same temperature. Then, the reaction 
mixture was quenched with HCl 0.1 M (7 mL) and extracted with CH2Cl2 (3 x 10 mL). The 
combined organic layers were dried over MgSO4 and concentrated under reduced 
pressure. The residues were purified by flash column chromatography on silica gel 
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(Hex:EtOAc 80:20 to 0:100) to afford the expected adducts. In general, these compounds 
were detected as a 1:1 mixture of rotamers by 1H NMR analysis (in DMSO-d6 at 70 oC). 
Racemic adducts for the determination of the enantiomeric excesses were prepared 
following the general procedure employing DBU as aquiral Brønsted base. 
(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(phenyl)methyl)pyridine N-
oxide (15aa) 
The title compound 15aa was prepared from 2-
(cyano(phenyl)methyl)pyridine N-oxide 13a and   di-tert-butyl 
azodicarboxylate 14a according to the general procedure. Yield: 
0.078 g (88 %). White foam. [α]D22= +41.3 (c = 1.96, CH2Cl2). IR (ν/cm-
1): 3330, 2977, 2931, 2251, 1717, 1604, 1428, 1366, 1245, 1149, 1051, 912, 839, 729. 1H 
NMR (500 MHz, 70 °C, DMSO-d6) δ 8.26 (d, J = 6.1 Hz, 1H) (rotamer A), 8.18 (d, J = 6.1 
Hz, 1H) (rotamer B), 7.59 – 7.30 (m, 8H), 1.37 (s, 9H), 1.26 (brs, 9H). 13C NMR (126 MHz, 
70°C, DMSO-d6) δ 154.5, 153.7, 152.2, 152.0, 145.2, 144.7, 139.6, 139.1, 132.5, 131.8, 
128.3, 128.3, 127.9, 127.8, 127.4, 127.4, 126.0, 125.7, 125.5, 124.1, 123.7, 115.1, 114.7, 
82.2, 82.1, 79.5, 66.67, 66.4, 27.4, 27.4, 27.1. UPLC-DAD-QTOF: C23H28N4O5 [M+H]+ 
calcd.: 441.2138, found: 441.2141. Elem. Anal. calcd for C23H28N4O5 (440.50): C, 62.71; 
H, 6.41; N, 12.72. Found: C, 62.47; H, 6.35; N, 12.99. Chiral HPLC (Chiralpak IC; 60:40 
hexane:EtOH; 0.50 mL/min, λ = 210 nm) tR (minor.) = 8.1 min, tR (major.) = 10.4 min. 90% 
ee. 
(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(p-tolyl)methyl)pyridine N-
oxide (15ba) 
The title compound 15ba was prepared from 2-(cyano(p-
tolyl)methyl)pyridine N-oxide 13b and di-tert-butyl 
azodicarboxylate 14a according to the general procedure. Yield: 
0.072 g (79%). White foam. [α]D23= +50.9 (c = 1.01, CH2Cl2). IR 
(ν/cm-1): 3174, 2976, 2930, 2252, 1716, 1607, 1428, 1365, 1248, 1150, 1050, 1025, 1008, 
765. 1H NMR (500 MHz, 70 °C, DMSO-d6) δ 8.25 (brs, 1H) (rotamer A), 8.17 (d, J = 6.3 Hz, 
1H) (rotamer B), 7.58 – 7.44 (m, 3H), 7.25 (d, J = 7.7 Hz, 1H), 7.20 (d, J = 8.0 Hz, 1H), 7.15 
(dd, J = 11.6, 8.1 Hz, 2H), 2.30 (s, 3H) (rotamer A), 2.30 (s, 3H) (rotamer B), 1.45 – 1.32 
(s, 9H), 1.29 (brs, 9H). 13C NMR (126 MHz, 70°C, DMSO-d6) δ 155.3, 154.3, 153.9, 152.6, 
145.5, 145.0, 140.0, 139.8, 139.5, 138.6, 138.4, 129.5, 129.0, 128.7, 128.6, 128.5, 128.4, 
128.1, 126.6, 126.4, 126.2, 125.4, 125.1, 124.9, 124.8, 124.6, 124.3, 116.4, 115.2, 82.9, 
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82.4, 80.7, 80.5, 79.7, 79.6, 66.9, 66.2, 27.8, 27.8, 27.6, 20.6. UPLC-DAD-QTOF: 
C24H31N4O5 [M+H]+ calcd.: 455.2294, found: 455.2297. Chiral HPLC (Chiralpak IA; 80:20 
hexane:EtOH; 0.50 mL/min, λ = 210 nm) tR (minor.) = 21.8 min, tR (major.) = 48.7 min. 
82% ee. 
(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(4-
methoxyphenyl)methyl)pyridine N-oxide (15ca) 
The title compound 15ca was prepared from 2-(cyano(4-
methoxy)methyl)pyridine N-oxide 13c and di-tert-butyl 
azodicarboxylate 14a according to the general procedure. Yield: 
0.074 g (79%). White foam. [α]D23= +47.0 (c = 1.02, CH2Cl2). IR 
(ν/cm-1): 3325, 2976, 2932, 2839, 2233, 1720, 1607, 1512, 1429, 1367, 1253, 1152, 1031, 
841, 766. 1H NMR (500 MHz, 70°C, DMSO-d6) δ 8.25 (brs, 1H) (rotamer A), 8.18 (d, J = 
6.1 Hz, 1H) (rotamer B), 7.49 (m, 3H), 7.26 (m, 2H), 6.90 (m, 2H), 3.77 (s, 3H) (rotamer 
A), 3.76 (s, 3H) (rotamer B), 1.36 (s, 9H), 1.31 (brs, 9H). 13C NMR (126 MHz, CDCl3) δ 
159.4, 153.8, 152.3, 152.1, 145.5, 139.7, 139.2, 129.4, 126.0, 125.7, 125.3, 124.2, 123.8, 
123.6, 115.3, 115.0, 113.2, 113.2, 82.2, 82.0, 79.3, 66.1, 65.9, 54.9, 27.5, 27.5, 27.2, 27.2. 
UPLC-DAD-QTOF: C24H31N4O6 [M+H]+ calcd.: 471.2244, found: 471.2247. Chiral HPLC 
(Chiralpak IA; 80:20 hexane:EtOH; 0.50 mL/min, λ = 210 nm) tR (minor.) = 28.3 min, tR 
(major.) = 65.7 min. 76% ee. 
(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(4 
bromophenyl)(cyano)methyl)pyridine 1-oxide (15da) 
The title compound 15da was prepared from 2-((4-
bromophenyl)(cyano)methyl)pyridine 1-oxide 13d and di-tert-
butyl azodicarboxylate 14a according to the general procedure. 
Yield: 0.094 g (90%). White foam. [α]D23= +18.0 (c = 1.00, CH2Cl2). 
IR (ν/cm-1): 3307, 2976, 2931, 2239, 1717, 1587, 1366, 1245, 1147, 1010, 763, 734. 1H 
NMR (500 MHz, 70 °C, DMSO-d6) δ 8.27 (d, J = 6.0 Hz, 1H) (rotamer A), 8.21 (d, J = 6.2 
Hz, 1H) (rotamer B), 7.67 – 7.43 (m, 5H), 7.31 (d, J = 8.0 Hz, 1H), 7.25 (d, J = 8.3 Hz, 1H), 
1.37 (s, 9H), 1.28 (brs, 9H). 13C NMR (126 MHz, 70°C, DMSO-d6) δ 154.7, 153.9, 152.2, 
152.0, 144.7, 144.2, 139.7, 139.3, 132.1, 131.4, 130.5, 130.0, 129.8, 126.3, 126.1, 125.5, 
125.1, 124.4, 124.1, 122.0, 114.9, 114.3, 82.6, 82.4, 79.5, 66.2, 65.9, 27.5, 27.4, 27.2, 
27.2. UPLC-DAD-QTOF: C23H27N4O5Br [M+H]+ calcd.: 519.1243, found: 519.1255. Elem. 
Anal. calcd for C23H27N4O5Br (519.40): C, 53.19; H, 5.24; N, 10.79. Found: C, 52.92; H, 
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5.16; N, 10.10. Chiral HPLC (Chiralpak IA; 90:10 hexane:EtOH; 1.00 mL/min, λ = 210 nm) 
tR (minor.) = 26.8 min, tR (major.) = 56.6 min. 92% ee. 
(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(4-
(methoxycarbonyl)phenyl)methyl)pyridine N-oxide (15ea) 
The title compound 15ea was prepared from 2-(cyano(4-
(methoxycarbonyl)phenyl)methyl)pyridine N-oxide 13e and 
di-tert-butyl azodicarboxylate 14a according to the general 
procedure. Yield: 0.085 g (86%). White foam. [α]D23= +20.1 (c 
= 1.79, CH2Cl2). IR (ν/cm-1): 3309, 2976, 2931, 2870, 2288, 
1719, 1609, 1367, 1277, 1248, 1150, 1112, 764. 1H NMR (500 MHz, 70 °C, DMSO-d6) δ 
8.27 (brs, 1H) (rotamer A), 8.21 (d, J = 6.3 Hz, 1H) (rotamer B), 7.92 (t, J = 9.0 Hz, 2H), 
7.65 – 7.42 (m, 5H), 3.87 (s, 3H), 1.38 (s, 9H), 1.26 (brs, 9H). 13C NMR (126 MHz, 70°C, 
DMSO-d6) δ 165.2, 152.2, 152.0, 144.6, 139.7, 139.3, 136.8, 130.0, 128.3, 128.1, 126.4, 
126.2, 125.7, 125.2, 124.5, 124.2, 114.9, 114.3, 82.6, 82.5, 79.6, 66.0, 51.7, 27.5, 27.4, 
27.2. UPLC-DAD-QTOF: C25H31N4O7 [M+H]+ calcd.: 499.2193, found: 499.2196. Chiral 
HPLC (Chiralpak IA; 60:40 hexane:EtOH; 0.50 mL/min, λ = 210 nm) tR (minor.) = 13.9 min, 
tR (major.) = 23.0 min. 93% ee. 
(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(4-
(trifluoromethyl)phenyl)methyl)-6-bromopyridine N-oxide (15fa) 
The title compound 15fa was prepared from 2-bromo-6-
(cyano(4-(trifluoromethyl)phenyl)methyl)pyridine N-oxide 
13f and di-tert-butyl azodicarboxylate 14a according to the 
general procedure. Yield: 0.099 g (84 %). White foam. [α]D23= 
+42.3 (c= 1.98, CH2Cl2). IR (ν/cm-1): 3323, 2978, 2932, 2296, 1719, 1618, 1367, 1323, 
1244, 1122, 1068, 844, 733, 702. 1H NMR (300 MHz, 70 °C, DMSO-d6) δ 8.05 (dt, J = 8.3, 
2.0 Hz, 1H), 7.73 (d, J = 8.3 Hz, 2H), 7.55 (m, 4H), 1.40 (s, 9H) (rotamer B), 1.38 (s, 9H) 
(rotamer A), 1.28 (brs, 9H). 13C NMR (75 MHz, DMSO) δ 154.6, 153.7, 152.1, 152.0, 145.9, 
145.6, 136.3, 136.0, 132.7, 132.2, 130.9, 130.7, 129.3 (q, J = 31.8 Hz), 128.8, 128.6, 125.2, 
125.0, 124.7, 124.2, 121.6, 114.6, 113.9, 82.9, 82.7, 79.7, 66.8, 66.5, 27.4, 27.3, 27.2. 
UPLC-DAD-QTOF: C24H27BrF3N4O5 [M+H]+ calcd.: 587.1117, found: 587.1119. Chiral HPLC 
(Chiralpak IA; 95:5 hexane:EtOH; 1.00 mL/min, λ = 230 nm) tR (minor.) = 35.7 min, tR 
(major.) = 91.0 min. 88% ee. 
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(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(thiophen-3-yl)methyl)pyridine 
N-oxide (15ga) 
The title compound 15ga was prepared from 2-(cyano(thiophen-3-
yl)methyl)pyridine N-oxide 13g and di-tert-butyl azodicarboxylate 
14a according to the general procedure. Yield: 0.072 g (81%). White 
foam. [α]D23= +49.3 (c = 0.88, CH2Cl2). IR (ν/cm-1): 3198, 2976, 2931, 
2244, 1719, 1586, 1429, 1367, 1249, 1152, 771. 1H NMR (300 MHz, CDCl3) δ 8.34 (d, J = 
5.9 Hz, 1H), 8.17 (d, J = 6.1, 1H) (minor),  8.00 (brs, 1H), 7.59 (d, J = 5.3 Hz, 1H), 7.46 – 
7.15 (m, 4H), 6.99 (dd, J = 8.3, 2.1 Hz, 1H), 1.38 (s, 9H) (minor), 1.35 (s, 9H) (minor), 1.33 
(s, 9H), 1.25 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 155.4, 152.4, 145.3, 140.5, 140.0, 136.5, 
128.0, 127.5, 127.2, 126.8, 126.7, 126.4, 126.1, 125.9, 125.7, 125.4, 116.3, 84.0, 81.7, 
81.2, 64.3, 28.1, 28.0. UPLC-DAD-QTOF: C21H27N4O5S [M+H]+ calcd.: 447.1702, found: 
447.1707. Chiral HPLC (Chiralpak IA; 70:30 hexane:EtOH; 0.50 mL/min, λ = 210 nm) tR 
(minor.) = 15.1 min, tR (major.) = 23.8 min. 90% ee. 
(S)-2-((1,2-bis((benzyloxy)carbonyl)hydrazinyl)(4-
bromophenyl)(cyano)methyl)pyridine N-oxide (15db) 
The title compound 15db was prepared from 2-((4-
bromophenyl)(cyano)methyl)pyridine N-oxide 13d and dibenzyl 
azodicarboxylate 14b according to the general procedure. Yield: 
0.094 g (80%). White foam. [α]D23= +47.1 (c = 1.02, CH2Cl2). IR 
(ν/cm-1): 3330, 2976, 2931, 2250, 1716, 1604, 1365, 1244, 1147, 755, 732, 695. 1H NMR 
(500 MHz, 70 °C, DMSO-d6) δ 8.26 (d, J = 6.4 Hz, 1H) (rotamer A), 8.19 (d, J = 6.4 Hz, 1H) 
(rotamer B), 7.78 – 6.88 (m, 17H), 5.19 (s, 2H), 5.08 – 4.91 (m, 2H). 13C NMR (126 MHz, 
70 °C, DMSO-d6) δ 153.4, 153.3, 143.7, 143.5, 139.7, 139.3, 135.5, 134.9, 131.4, 130.9, 
130.6, 129.8, 129.7, 127.8, 127.5, 127.4, 127.0, 126.4, 126.1, 125.3, 124.9, 124.4, 124.1, 
122.3, 114.4, 113.9, 78.1, 67.9, 67.8, 66.1. UPLC-DAD-QTOF: C29H24BrN4O5 [M+H]+ calcd.: 
587.0930, found: 587.0948. Elem. Anal. calcd for C29H23BrN4O5 (586.08): C, 59.30; H, 
3.95; N, 9.54. Found: C, 59.37; H, 3.87; N, 9.41. Chiral HPLC (Chiralpak IA; 60:40 
hexane:EtOH; 0.80 mL/min, λ = 210 nm) tR (minor.) = 17.3 min, tR (major.) = 27.6 min. 
90% ee. 
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(S)-2-((1,2-bis((benzyloxy)carbonyl)hydrazinyl)(cyano)(4-
(methoxycarbonyl)phenyl)methyl)pyridine N-oxide (15eb) 
The title compound 15eb was prepared from 2-(cyano(4-
(methoxycarbonyl)phenyl)methyl)pyridine N-oxide 13e and 
dibenzyl azodicarboxylate 14b according to the general 
procedure. Yield: 0.096 g (85%). White foam. [α]D23= +13.7 (c 
= 1.39, CH2Cl2). IR (ν/cm-1): 3301, 2951, 2236, 1721, 1609, 
1430, 1278, 1111, 733, 697. 1H NMR (500 MHz, 70°C, DMSO-d6) δ 8.26 (d, J = 6.4 Hz, 1H) 
(rotamer A), 8.19 (d, J = 6.3 Hz, 1H) (rotamer B), 7.87 (d, J = 8.2 Hz, 2H), 7.46 (m, 6H), 
7.38 – 7.21 (m, 7H), 7.15 (bs, 1H), 5.19 (m, 2H), 4.98 (m, 2H), 3.94 – 3.79 (m, 3H). 13C 
NMR (126 MHz, 70°C, DMSO-d6) δ 165.1, 153.4, 153.3, 143.6, 143.4, 139.7, 139.2, 136.6, 
136.2, 135.4, 134.9, 130.1, 128.4, 128.1, 127.9, 127.8, 127.7, 127.5, 127.4, 127.0, 126.5, 
126.2, 125.4, 125.0, 124.5, 124.2, 114.4, 113.8, 67.9, 67.9, 66.0, 51.5. UPLC-DAD-QTOF: 
C31H27BrN4O7 [M+H]+ calcd.: 567.1880, found: 567.1876. Elem. Anal. calcd for 
C31H26N4O7 (566.57): C, 65.72; H, 4.63; N, 9.89. Found: C, 65.53; H, 4.67; N, 9.34. Chiral 
HPLC (Chiralpak IA; 70:30 hexane:EtOH; 0.50 mL/min, λ = 210 nm) tR (minor.) = 52.3 min, 
tR (major.) = 63.2 min. 90% ee. 
6.4.1.3. Elaboration of adducts 
6.4.1.3.1. Reduction of N-oxide group on adduct 15aa242 
 
A solution of adduct 15aa (0.440 g, 1 mmol, 1 equiv.) in acetonitrile (10 mL) was stirred 
in an oven-dried reaction vial, bis(pinacolato)diboron ((pinB)2) (0.762 g, 3 mmol, 3 
equiv.) was added and the mixture was stirred at 70 oC for 24 h. Afterwards 3 equiv. 
more of (pinB)2 were added and the reaction stirred at 70 oC for additional 24 hours. 
Then, ethylenediamine (8 mL, 120 mmol, 120 equiv.) was added to the mixture, and the 
stirring was continued for 1 hour at room temperature. The reaction mixture was then 
diluted with water (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The organic phase was 
                                                     
242 Procedure adapted from: Kokatla, H. P.; Thompson, P. F.; Bae, S.; Doddi, V. R.; Lakshman, M. K. J. Org. 
Chem. 2011, 76, 7842–7848. 
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dried over MgSO4, filtered and concentrated under reduced pressure. The crude 
material was purified by flash column chromatography on silica gel (eluting with 
Hex/EtOAc 80/20 to 50/50) to give the desired compound as a colourless oil. Yield: 0.327 
g (77 %). [α]D25= +22.6 (c = 1.00, CH2Cl2). IR (ν/cm-1): 2977, 2931, 2252, 1720, 1451, 1367, 
1244, 1149, 912, 729, 697. 1H NMR (300 MHz, CDCl3) δ 8.72 – 8.54 (m, 1H), 7.81 (td, J = 
7.7, 1.8 Hz, 1H), 7.65 (dd, J = 23.5, 7.0 Hz, 1H), 7.50 – 7.31 (m, 5H), 6.65 (s, 1H), 1.45 – 
1.18 (m, 18H). UPLC-DAD-QTOF: C23H29N4O4 [M+H]+ calcd.: 425.2183, found: 425.2179. 
6.4.1.3.2. Acylation of adduct 15aa.243 Determination of the absolute configuration. 
 
To a solution of 15aa (1 equiv., 0.30 mmol, 0.130 g) in CH2Cl2 (4 mL), Et3N (16 equiv., 
4.8 mmol, 0.67 mL) and 4-dimethylaminopyridine (DMAP) (0.1 equiv., 0.03 mmol, 0.037 
g) were added at 0 oC. After stirring the reaction mixture at room temperature for 16 
hours, CH2Cl2 was evaporated under reduce pressure. The crude product was purified 
by flash column chromatography on silica gel (hexane:EtOAc 50:50 to 20:80) to give the 
desired compound as a white solid. The solid was recrystallized in a benzene/hexane 
mixture; Yield: 106 mg (60%). White solid. m. p.= 163–165 oC. IR (ν/cm-1): 2976, 2922, 
2851, 2273, 1759, 1730, 1520, 1427, 1346, 1304, 1259, 1134, 838, 779, 756. [α]D25= 
+143.0 (c = 1.1, 90% ee, CH2Cl2). 1H NMR (300 MHz, CDCl3) δ 8.70 – 8.51 (m, 1H), 8.52 – 
8.24 (m, 1H), 8.24 – 7.92 (m, 3H), 7.79 – 7.57 (m, 1H), 7.57 – 7.21 (m, 4H), 7.15 – 6.82 
(m, 1H), 6.82 – 6.57 (m, 1H), 6.57 – 6.26 (m, 1H), 1.59 – 1.37 (m, 18H). UPLC-DAD-QTOF: 
C30H32N5O8 [M+H]+ calcd.: 590.2251, found: 590.2255. 
Compound 16 was synthetized for X-Ray analysis purpose. CCDC 1453241 contains the 
supplementary crystallographic data for its structural analysis. These data can be 
obtained free of charge from The Cambridge Crystallographic Data Centre via 
http://www.ccdc.cam.ac.uk/deposit/. 
                                                     
243 Procedure adapted from: Ji, C.-B.; Liu, Y.-L.; Zhao, X.-L.; Guo, Y.-L.; Wang, H.-Y.; Zhou, J. Org. Biomol. 
Chem. 2012, 10, 1158. 
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6.4.2. Enantioselective Mannich reaction of 2-azaaryl N-oxides to N-Boc 
imines 
6.4.2.1. Preparation of pronucleophiles 
6.4.2.1.1. Synthesis of pyridyl N-oxide acetates 17, 19 and 20 
 
To a solution of the corresponding pyridyl acetate (5.5 mmol, 1.1 equiv) in CHCl3 (20 
mL), m-CPBA (75 %) (1.15 g, 5 mmol, 1.0 equiv.) was added at 0 °C and the resulting 
mixture was stirred at the same temperature for 16 hours. Solvent was removed under 
reduce pressure and the corresponding N-oxide was purified by flash column 
chromatography on silica gel (CH2Cl2:MeOH, 98:2). 
Note: The oxidation reaction gives the α-hydroxyl compound as a side product. 
2-(2-(Benzyloxy)-2-oxoethyl)pyridine N-oxide (17) 
The title compound 17 was prepared according to the general 
procedure using benzyl 2-(pyridin-2-yl)acetate244 (5% of II was 
obtained). Yield: 0.81 g (66%). White solid. m. p. = 101 – 104 C. IR 
                                                     
244 Prepared following the reported procedure: Sahoo, B.; Hopkinson, M. N.; Glorius, F. Angew. Chem. Int. 
Ed. 2015, 54, 15545–15549. 
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(ν/cm-1): 3062, 1733, 1493, 1439, 1252, 1160, 994, 753, 699.  1H NMR (300 MHz, CDCl3) 
δ 8.29 – 8.22 (m, 1H), 7.39 – 7.28 (m, 6H), 7.26 – 7.17 (m, 2H), 5.20 (s, 2H), 3.93 (s, 
2H).13C NMR (75 MHz, CDCl3) δ 168.42, 145.49, 139.29, 135.65, 128.53, 128.23, 128.17, 
127.20, 125.38, 124.93, 77.58, 77.16, 76.74, 66.97, 36.95. UPLC-DAD-QTOF: C14H14NO3 
[M+H]+ calcd.: 244.0979, found: 244.0974. 
2-(2-(tert-Butoxy)-2-oxoethyl)pyridine N-oxide (19) 
The title compound 19 was prepared according to the general 
procedure using tert-butyl 2-(pyridin-2-yl)acetate244 (10% of II was 
obtained). Yield: 0.59 g (56%). White solid. m. p. = 49 – 52 C. IR 
(ν/cm-1): 2977, 1725, 1491, 1438, 1367, 1344, 1247, 1146, 766, 731. 1H NMR (300 MHz, 
CDCl3) δ 8.32 – 8.19 (m, 1H), 7.36 – 7.27 (m, 1H), 7.27 – 7.11 (m, 2H), 3.79 (s, 2H), 1.45 
(s, 9H).13C NMR (75 MHz, CDCl3) δ 167.7, 146.1, 139.3, 127.1, 125.3, 124.6, 81.6, 38.0, 
28.0. UPLC-DAD-QTOF: C11H16NO3 [M+H]+ calcd.: 210.1130, found: 210.1127. 
2-(2-Methoxy-2-oxoethyl)pyridine N-oxide (20a) 
The title compound 20a was prepared according to the general 
procedure using methyl 2-(pyridin-2-yl)acetate245 (50% of II was 
obtained). Yield: 0.33 g (40%). White solid. m. p. = 88 – 93 C. IR 
(ν/cm-1): 2953, 1731, 1492, 1436, 1348, 1220, 1166, 1001, 771, 681, 
562, 488. 1H NMR (300 MHz, CDCl3) δ 8.34 – 8.25 (m, 1H), 7.41 – 7.32 (m, 1H), 7.28 – 
7.23 (m, 2H), 3.91 (s, 2H), 3.75 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 169.0, 145.5, 139.3, 
127.2, 125.6, 124.9, 52.3, 36.8. UPLC-DAD-QTOF: C8H10NO3 [M+H]+ calcd.: 168.0661, 
found: 168.0664. 
                                                     
245 Prepared following the reported procedure: Nacsa, E. D.; Lambert, T. H. J. Am. Chem. Soc. 2015, 137, 
10246–10253. 
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4-Bromo-2-(2-methoxy-2-oxoethyl)pyridine N-oxide (20b) 
The title compound 20b was prepared according to the general 
procedure using methyl 2-(4-bromopyridin-2-yl)acetate246 (30% of II 
was obtained). Yield: 0.55 g (45%). White solid. m. p. = 93 – 97 C. IR 
(ν/cm-1): 3047, 2952, 1734, 1461, 1425, 1339, 1248, 1164, 1003, 821, 
730, 649, 547, 494. 1H NMR (300 MHz, CDCl3) δ 8.09 (d, J = 6.9 Hz, 1H), 7.50 (d, J = 2.3 
Hz, 1H), 7.35 (dd, J = 6.9, 2.8 Hz, 1H), 3.72 (s, 2H), 3.42 (s, 3H). 13C NMR (75 MHz, CDCl3) 
δ 168.5, 146.8, 140.1, 130.2, 128.2, 118.6, 52.6, 36.6. UPLC-DAD-QTOF: C8H8NO3Br 
[M+H]+ calcd.: 245.9766, found: 245.9769. 
4-(tert-Butyl)-2-(2-methoxy-2-oxoethyl)pyridine N-oxide (20c) 
The title compound 20c was prepared according to the general 
procedure using methyl 2-(4-(tert-butyl)pyridin-2-yl)acetate246 (20% 
of II was obtained). Yield: 0.61 g (55%). Colorless oil. IR (ν/cm-1): 2955, 
1739, 1438, 1245, 773. 1H NMR (300 MHz, CDCl3) δ 8.15 (d, J = 6.8 Hz, 
1H), 7.27 (d, J = 2.8 Hz, 1H), 7.18 (dd, J = 6.8, 2.8 Hz, 1H), 3.85 (s, 2H), 3.70 (s, 3H), 1.27 
(s, 9H). 13C NMR (75 MHz, CDCl3) δ 169.2, 150.5, 144.5, 138.6, 124.2, 122.1, 52.4, 37.1, 
34.6, 30.6. UPLC-DAD-QTOF: C12H18NO3 [M+H]+ calcd.: 244.1287, found: 244.1293. 
6.4.2.1.2. Synthesis of 2-(2-(tert-butoxy)-2-oxoethyl)quinoline N-oxide (28)247 
To a solution of tert-butyl acetate (2.7 mL, 20 mmol, 2.0 equiv.) 
in t-BuNH2 (25 mL) at –15 °C, n-BuLi (2.5 M in hexane) (10 mL, 
25 mmol, 2.5 equiv.) was added. After 10 minutes stirring at the 
same temperature, quinoline N-oxide (1.45 g, 10 mmol, 1.0 
equiv.) was added and reaction mixture was allowed to warm to room temperature. 
After 4 hours, the reaction was quenched with HCl 2M (20 mL) and extracted with ethyl 
acetate (3 x 25 mL). The combined organic layers were dried over MgSO4 and solvent 
was removed under reduced pressure. The residue was purified by flash column 
                                                     
246 Prepared following the reported procedure: Londregan, A. T.; Burford, K.; Conn, E. L.; Hesp, K. D. Org. 
Lett. 2014, 16, 3336–3339. 
247 Procedure adapted from: Hamana, M.; Genji, I.; Saeki, S. Heterocycles 1982, 17, 177–181. 
Chapter 6 
242 
 
chromatography on silica gel (AcOEt, 100%) to afford pure compound 28. Yield: 0.80 g 
(31%). Brown solid. m. p. = 88–92 C. IR (ν/cm-1): 2978, 2235, 1726, 1339, 1220, 1148, 
907, 724, 644, 562. 1H NMR (300 MHz, CDCl3) δ 8.54 (dd, J = 8.7, 1.2 Hz, 1H), 7.60 (dd, J 
= 8.1, 1.3 Hz, 1H), 7.50 (ddd, J = 8.6, 6.9, 1.4 Hz, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.40 – 7.32 
(m, 1H), 7.18 (d, J = 8.6 Hz, 1H), 3.87 (s, 2H), 1.33 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 
167.5, 142.1, 141.0, 129.8, 129.3, 127.8, 127.8, 124.5, 122.7, 119.2, 81.2, 38.6, 27.8. 
UPLC-DAD-QTOF: C15H17NO3 [M+H]+ calcd.: 260.1287, found: 260.1286. 
6.4.2.1.3. Synthesis of tert-butyl 2-(quinolin-2-yl)acetate (28’) 
To a solution of 28 (1 equiv., 1 mmol, 0.259 g) in CH2Cl2 (9 mL), 
bis(pinacolato)diboron (3 equiv., 3 mmol, 0.762 g) was added 
and the reaction mixture was stirred at room temperature for 
16 hours. Then, ethylendiamine (120 equiv., 120 mmol, 8 mL) was added to the mixture, 
and the stirring was continued for 1 hour at room temperature. The reaction mixture 
was then diluted with water (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The organic 
phase was dried over MgSO4, filtered and concentrated under reduced pressure. The 
crude material was purified by flash column chromatography on silica gel 
(Hexane:EtOAc, 90:10). Yield: 0.181 g (75%). 1H NMR (300 MHz, CDCl3) δ 8.12 (d, J = 8.6 
Hz, 1H), 8.06 (d, J = 8.4 Hz, 1H), 7.80 (dd, J = 8.0, 1.4 Hz, 1H), 7.70 (ddd, J = 8.4, 6.9, 1.5 
Hz, 1H), 7.52 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.43 (d, J = 8.5 Hz, 1H), 3.96 (s, 2H), 1.46 (s, 
8H). Physical and spectroscopic data were coincident with the previously reported.248 
                                                     
248 Bruno, N. C.; Tudge, M. T.; Buchwald, S. L. Chem. Sci. 2013, 4, 916–920. 
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6.4.2.2. General procedure for the enantioselective Mannich reaction of pyridyl N-
oxide acetate with N-protected imines 
 
To a solution of the corresponding azaaryl N-oxide acetate (1 equiv., 0.12 mmol) and 
catalyst C6 (0.2 equiv., 0.024 mmol, 0.014 g), unless otherwise stated, in anhydrous 
CH2Cl2 (0.5 mL) at 0 °C, the corresponding N-protected imine (2 equiv., 0.24 mmol) was 
added. The resulting solution was stirred at the same temperature until complete 
disappearance of N-oxide and then poured into a flash column chromatography 
(Hexane:EtOAc, 50:50 to 0:100) to afford the corresponding pure Mannich adducts. 
Racemic adducts for the determination of the enantiomeric excesses were prepared 
following the general procedure employing DBU as aquiral Brønsted base. 
2-((1S,2R)-1-((tert-Butoxycarbonyl)amino)-3-oxo-3-phenoxy-1-(p-tolyl)propan-
2yl)pyridine N-oxide (18a) 
The title compound 18a was prepared according to the general 
procedure employing N-oxide 17 and N-Boc imine 4a at 1 
mmol scale. Reaction time: 48 hours. Yield: 0.46 g (95%). White 
solid. m. p.= 42–45 C. [αD25= –46.1 (c = 0.55, CHCl3). IR (ν/cm-
1): 2973, 1706, 1514, 1434, 1365, 1286, 1250, 1164, 764, 697. 
1H NMR (300 MHz, CDCl3) δ 8.32 (dd, J = 4.7, 3.1 Hz, 1H), 7.46 (dd, J = 6.1, 4.0 Hz, 1H), 
7.39 – 7.17 (m, 6H), 7.14 – 6.96 (m, 4H), 6.83 (d, J = 8.3 Hz, 1H), 5.37 (t, J = 9.2 Hz, 1H), 
5.16 (d, J = 10.0 Hz, 1H), 5.06 – 4.92 (m, 2H), 2.33 (s, 3H), 1.27 (s, 9H). 13C NMR (75 MHz, 
CDCl3) δ 169.2, 155.4, 147.2, 139.5, 137.6, 137.4, 135.1, 129.3, 128.4, 128.2, 128.1, 
127.0, 126.5, 126.4, 124.5, 79.2, 67.1, 57.5, 51.1, 28.3, 21.2. UPLC-DAD-QTOF: 
C27H31N2O5 [M+H]+ calcd.: 463.2233, found: 463.2241. Chiral HPLC (Chiralpack IC; 50:50 
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Hexane:Ethanol; 0.7 mL/min,  = 210 nm) tR = 10.1 min (anti, major.), 11.4 min (anti, 
minor.), 14.0 min (syn), 23.7 min (syn). dr 99:1; 99% ee. 
2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-1-oxo-3-phenylpropan-2-
yl)pyridine N-oxide (18b) 
The title compound 18b was prepared according to the general 
procedure employing N-oxide 17 and N-Boc imine 4b. Reaction 
time: 28 hours. Yield: 0.053 g (98%). White solid. m. p.= 170–172 
C. [αD25= –12.2 (c = 2.5, CHCl3). IR (ν/cm-1): 2974, 1704, 1495, 
1434, 1365, 1250, 1165, 982, 698. 1H NMR (300 MHz, CDCl3) δ 8.36 
– 8.28 (m, 1H), 7.48 – 7.34 (m, 3H), 7.33 – 7.16 (m, 8H), 7.13 – 6.98 (m, 2H), 6.90 (d, J = 
7.9 Hz, 1H), 5.41 (t, J = 9.0 Hz, 1H), 5.07 (d, J = 40.3 Hz, 3H), 1.27 (s, 9H). 13C NMR (75 
MHz, CDCl3) δ 169.10, 155.45, 147.17, 140.70, 139.64, 135.15, 128.72, 128.52, 128.30, 
128.20, 127.91, 127.16, 126.63, 126.40, 125.00, 79.35, 67.28, 58.07, 51.23, 28.37. UPLC-
DAD-QTOF: C26H29N2O5 [M+H]+ calcd.: 449.2076 found: 449.2082. Chiral HPLC 
(Chiralpack IC; 60:40 Hexane:Ethanol; 0.5 mL/min,  = 210 nm) tR = 15.6 min (anti, 
major.), 17.0 min (anti, minor.), 31.9 min (both syn enantiomers). dr 99:1; 99% ee. 
2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(4-methoxyphenyl)-1-
oxopropan-2-yl)pyridine N-oxide (18c) 
The title compound 18c was prepared according to the 
general procedure employing N-oxide 17 and N-Boc imine 4c. 
Reaction time: 48 hours. Yield: 0.052 g (90%). White solid. m. 
p.= 40–43 C. [αD25= –67.26 (c = 2, CH2Cl2). IR (ν/cm-1): 2973, 
1705, 1512, 1433, 1246, 1165, 1031, 767. 1H NMR (300 MHz, 
CDCl3) δ 8.31 (dd, J = 4.7, 3.1 Hz, 1H), 7.46 (t, J = 5.0 Hz, 1H), 7.38 – 7.14 (m, 6H), 7.10 – 
7.01 (m, 2H), 6.81 (d, J = 8.7 Hz, 3H), 5.33 (t, J = 9.2 Hz, 1H), 5.15 (d, J = 10.1 Hz, 1H), 5.00 
(q, J = 12.3 Hz, 2H), 3.78 (s, 3H), 1.26 (s, 9H).13C NMR (75 MHz, CDCl3) δ 169.2, 159.2, 
155.4, 147.2, 139.6, 135.1, 132.8, 128.4, 128.3, 128.2, 128.1, 126.4, 124.9, 114.0, 79.2, 
67.1, 57.4, 55.3, 51.1, 28.3. UPLC-DAD-QTOF: C27H31N2O6 [M+H]+ calcd.: 479.2182, 
found: 479.2187. Chiral HPLC (Chiralpak AD-H; 20:80 Hexane:Ethanol; 0.5 mL/min,  = 
270 nm) tR = 16.0 min (anti, major.), 30.2 min (anti, minor.), 68.0 min (syn), 111.0 min 
(syn). dr 99:1; 99% ee. 
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CCDC 1559084 contains the supplementary crystallographic data for the structural 
analysis of 18c. These data can be obtained free of charge from The Cambridge 
Crystallographic Data Centre via http://www.ccdc.cam.ac.uk/deposit/. 
 
2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(4-
(methoxycarbonyl)phenyl)-1-oxopropan-2-yl)pyridine N-oxide (18d) 
The title compound 18d was prepared according to the 
general procedure employing N-oxide 17, N-Boc imine 4d 
and catalyst C6 (0.1 equiv., 0.012 mmol, 0.007 g). Reaction 
time: 20 hours. Yield: 0.059 g (98%). White solid. m. p.= 
68–70 C. [αD25 = –27.0 (c = 2.5, CH2Cl2). IR (ν/cm-1): 2972, 1717, 1490, 1434, 1278, 1164, 
1104, 1018, 764, 698. 1H NMR (300 MHz, CDCl3) δ 8.30 (d, J = 6.1, 1.6 Hz, 1H), 7.92 (d, J 
= 7.9 Hz, 2H), 7.42 (d, J = 8.1 Hz, 2H), 7.34 – 7.12 (m, 6H), 7.12 – 6.94 (m, 2H), 5.42 (t, J = 
8.4 Hz, 1H), 5.09 – 4.87 (m, 3H), 3.90 (s, 3H), 1.26 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 
168.6, 166.8, 155.5, 146.8, 145.8, 139.7, 135.0, 130.0, 129.8, 129.6, 128.5, 128.3, 128.2, 
127.2, 126.7, 125.2, 79.5, 67.4, 57.7, 52.1, 51.2, 28.3. UPLC-DAD-QTOF: C28H31N2O7 
[M+H]+ calcd.: 507.2131, found: 507.2141. Chiral HPLC (Chiralpack IC; 70:30 
Hexane:Ethanol; 0.5 mL/min,  = 210 nm) tR = 30.2 min (anti, minor.), 31.6 min (anti, 
major.), 42.7 min (syn), 58.0 min (syn). dr 99:1; 99% ee. 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(4-methoxy-3-
methylphenyl)-1-oxopropan-2-yl)pyridine N-oxide (18g) 
The title compound 18g was prepared according to the 
general procedure employing N-oxide 17 and N-Boc imine 
4g. Reaction time: 48 hours. Yield: 0.51 g (87%). White solid. 
m. p.= 58–61 C. [αD24 = –37.3 (c = 0.58, CH2Cl2). IR (ν/cm-1): 
2966, 2924, 2853, 1728, 1705, 1503, 1253, 1163, 1029, 766. 1H NMR (300 MHz, CDCl3) δ 
8.35 – 8.24 (m, 1H), 7.53 – 7.41 (m, 1H), 7.27 – 7.20 (m, 5H), 7.17 (d, J = 7.0 Hz, 2H), 7.08 
– 6.94 (m, 2H), 6.75 – 6.65 (m, 1H), 6.44 (d, J = 6.6 Hz, 1H), 5.28 (t, J = 9.3 Hz, 1H), 5.22 – 
5.10 (m, 1H), 5.03 (d, J = 12.3 Hz, 1H), 4.93 (d, J = 12.3 Hz, 1H), 3.80 (s, 3H), 2.17 (s, 3H), 
1.23 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 169.3, 157.5, 155.3, 147.4, 139.6, 135.2, 132.2, 
129.4, 128.4, 128.3, 126.9, 126.5, 125.7, 124.9, 109.9, 79.3, 67.2, 57.6, 55.4, 51.0, 28.4, 
16.4. UPLC-DAD-QTOF: C28H32N2O6 [M+H]+ calcd.: 493.2339, found: 493.2345. Chiral 
HPLC (Chiralpack IC; 50:50 Hexane:Ethanol; 0.5 mL/min,  = 210 nm) tR = 14.0 min (anti, 
minor.), 16.8 min (syn), 17.8 min (anti, major.), 27.7 min (syn). dr 99:1; 99% ee. 
2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(3,4-dimethoxyphenyl)-1-
oxopropan-2-yl)pyridine N-oxide (18h) 
The title compound 18h was prepared according to the 
general procedure employing N-oxide 17 and N-Boc imine 
4h. Reaction time: 48 hours. Yield: 0.54 g (88%). White solid. 
m. p.= 55–59 C. [αD24 = –45.0 (c = 0.79, CH2Cl2). IR (ν/cm-1) 
= 2969, 2930, 1728, 1706, 1515, 1257, 1162, 1026, 765. 1H NMR (300 MHz, CDCl3) δ 8.36 
– 8.25 (m, 1H), 7.40 (dd, J = 6.7, 3.4 Hz, 1H), 7.30 – 7.18 (m, 5H), 7.11 – 7.00 (m, 2H), 
6.93 (dd, J = 8.3, 2.0 Hz, 1H), 6.86 (d, J = 2.1 Hz, 1H), 6.75 (d, J = 8.2 Hz, 1H), 6.72 (brs, 
1H), 5.32 (t, J = 9.0 Hz, 1H), 5.14 – 5.01 (m, 2H), 4.96 (d, J = 12.3 Hz, 1H), 3.85 (s, 3H), 
3.80 (s, 3H), 1.25 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 169.2, 155.4, 149.1, 148.6, 147.2, 
139.6, 135.2, 133.3, 128.5, 128.3, 128.1, 126.7, 126.5, 125.0, 119.4, 111.2, 110.1, 79.3, 
67.3, 57.9, 56.0, 56.0, 51.2, 28.4. UPLC-DAD-QTOF: C28H32N2O7 [M+H]+ calcd.: 509.2288 
found: 509.2299. Chiral HPLC (Chiralpack IC; 70:30 Hexane:Ethanol; 0.7 mL/min,  = 210 
nm) tR = 21.3 min (anti, major.), 23.1 min (anti, minor.), 32.1 min (syn), 46.2 min (syn). 
dr 99:1; 99% ee. 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(naphthalen-2-yl)-1-
oxopropan-2-yl)pyridine N-oxide (18i) 
The title compound 18i was prepared according to the general 
procedure employing N-oxide 17 and N-Boc imine 4i. Reaction 
time: 48 hours. Yield: 0.055 g (92%). White solid. m. p.= 83–87 
C. [αD24 = –69.5 (c = 0.88, CH2Cl2). IR (ν/cm-1) = 2974, 2929, 
1703, 1490, 1433, 1365, 1250, 1163, 1050, 1019, 984, 858, 765, 746, 697, 479. 1H NMR 
(300 MHz, CDCl3) δ 8.39 – 8.26 (m, 1H), 7.87 – 7.72 (m, 4H), 7.54 (dd, J = 8.5, 1.8 Hz, 1H), 
7.51 – 7.37 (m, 3H), 7.25 – 7.16 (m, 2H), 7.16 – 7.10 (m, 1H), 7.05 (t, J = 7.5 Hz, 2H), 6.98 
(d, J = 8.0 Hz, 1H), 6.89 (d, J = 7.5 Hz, 2H), 5.55 (t, J = 8.9 Hz, 1H), 5.24 (d, J = 9.9 Hz, 1H), 
4.98 (d, J = 12.4 Hz, 1H), 4.91 (d, J = 12.3 Hz, 1H), 1.25 (s, 9H). 13C NMR (75 MHz, CDCl3) 
δ 169.1, 155.5, 147.1, 139.6, 138.0, 134.9, 133.3, 133.2, 128.7, 128.3, 128.3, 128.2, 
128.0, 127.7, 126.6, 126.5, 126.4, 126.2, 126.1, 125.0, 124.9, 79.4, 67.3, 58.2, 51.1, 28.4. 
UPLC-DAD-QTOF: C30H30N2O5 [M+H]+ calcd.: 499.2233, found: 499.2237. Chiral HPLC 
(Chiralpack IC; 50:50 Hexane:Ethanol; 0.7 mL/min,  = 210 nm) tR = 9.2 min (anti, minor.), 
10.4 min (anti, major.), 12.1 min (syn), 15.4 min (syn). dr 99:1; 99% ee. 
2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-1-oxo-3-(thiophen-2-
yl)propan-2-yl)pyridine N-oxide (18j) 
The title compound 18j was prepared according to the general 
procedure employing N-oxide 17 and N-Boc imine 4j. Reaction time: 
48 hours. Yield: 0.051 g (94%). Yellow solid. m. p = 49–53 C. [αD24 
= –21.4 (c = 0.85, CH2Cl2). IR (ν/cm-1): 2975, 2928, 1706, 1489, 1433, 
1365, 1251, 1163, 766, 734, 698. 1H NMR (300 MHz, CDCl3) δ 8.34 – 8.25 (m, 1H), 7.38 – 
7.22 (m, 4H), 7.24 – 7.09 (m, 5H), 6.99 (d, J = 3.6 Hz, 1H), 6.87 (dd, J = 5.0, 3.5 Hz, 1H), 
6.76 (d, J = 8.0 Hz, 1H), 5.70 (t, J = 8.7 Hz, 1H), 5.17 – 4.99 (m, 3H), 1.27 (s, 9H). 13C NMR 
(75 MHz, CDCl3) δ 168.9, 155.4, 146.8, 144.7, 139.7, 135.2, 128.6, 128.4, 128.3, 126.9, 
126.6, 126.4, 125.2, 125.0, 124.7, 79.6, 67.5, 53.3, 51.8, 28.3. UPLC-DAD-QTOF: 
C24H26N2O5S [M+H]+ calcd.: 455.1641, found: 455.1645. Chiral HPLC (Chiralpack IC; 80:20 
Hexane:Ethanol; 0.5 mL/min,  = 210 nm) tR = 32.7 min (anti, minor.), 34.8 min (anti, 
major.), 69.0 min (syn), 89.2 min (syn). dr 99:1; 99% ee. 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-1-oxo-3-(o-tolyl)propan-2-
yl)pyridine N-oxide (18l) 
The title compound 18l was prepared according to the general 
procedure employing N-oxide 17 and N-Boc imine 4l. Reaction 
time: 48 hours. Yield: 0.051 g (92%). White solid. m. p.= 61–63 C. 
[αD25 = –62.3 (c = 2, CH2Cl2). IR (ν/cm-1): 2973, 1702, 1492, 1433, 
1365, 1287, 1250, 1164, 1045, 729, 697.   1H NMR (300 MHz, CDCl3) 
δ 8.37 – 8.28 (m, 1H), 7.50 – 7.39 (m, 2H), 7.30 – 7.09 (m, 8H), 7.07 – 6.93 (m, 2H), 6.49 
(d, J = 8.7 Hz, 1H), 5.70 (t, J = 9.4 Hz, 1H), 5.31 (d, J = 4.3 Hz, 1H), 5.00 (q, 2H), 2.50 (s, 
3H), 1.24 (s, 9H).13C NMR (75 MHz, CDCl3) δ 169.2, 155.3, 147.3, 139.5, 138.9, 136.0, 
135.2, 130.8, 128.5, 128.2, 128.1, 127.7, 126.6, 126.5, 126.47, 126.2, 124.9, 79.2, 67.2, 
53.5, 50.0, 28.3, 19.5. UPLC-DAD-QTOF: C27H31N2O5 [M+H]+ calcd.: 463.2233, found: 
463.2247. Chiral HPLC (Chiralpack IC; 50:50 Hexane:Ethanol; 0.5 mL/min,  = 210 nm) tR 
= 12.2 min (anti, major.), 13.7 min (anti, minor.), 16.7 min (syn), 31.9 min (syn). dr 99:1; 
99% ee. 
2-((2R,3S)-1-(Benzyloxy)-3-(4-bromophenyl)-3-((tert-butoxycarbonyl)amino)-1-
oxopropan-2-yl)pyridine N-oxide (18m) 
The title compound 18m was prepared according to the general 
procedure employing N-oxide 17 and N-Boc imine 4m. Reaction 
time: 21 hours. Yield: 0.060 g (95%). White solid. m. p.= 44–46 
C. [αD25 = –17.5 (c = 3.0, CH3Cl3). IR (ν/cm-1): 2974, 1705, 1488, 
1434, 1365, 1283, 1250, 1165, 1010, 765.  1H NMR (300 MHz, 
CDCl3) 1H NMR (300 MHz, CDCl3) δ 8.35 – 8.24 (m, 1H), 7.55 – 6.89 (m, 13H), 5.31 (t, J = 
8.9 Hz, 1H), 5.11 – 4.88 (m, 3H), 1.26 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 168.9, 155.4, 
146.9, 139.8, 139.6, 134.9, 131.7, 128.9, 128.5, 128.4, 128.2, 126.6, 126.5, 125.1, 121.8, 
79.5, 67.4, 57.4, 51.0, 28.3. UPLC-DAD-QTOF: C26H28N2O5Br [M+H]+ calcd.: 527.1182, 
found: 527.1183. Chiral HPLC (Chiralpack IC; 60:40 Hexane:Ethanol; 0.5 mL/min,  = 210 
nm) tR = 12.1 min (anti, major.), 13.4 min (anti, minor.), 15.0 min (syn), 22.4 min (syn). 
dr 99:1; 99% ee. 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(3-chlorophenyl)-1-
oxopropan-2-yl)pyridine N-oxide (18n) 
The title compound 18n was prepared according to the general 
procedure employing N-oxide 17, N-Boc imine 4n and catalyst 
C6 (0.05 equiv., 0.006 mmol, 0.004 g). Reaction time: 30 hours. 
Yield: 0.104 g (90%). White solid. m. p.= 51–53C. [αD25 = –58.9 
(c = 1.45, CH2Cl2). IR (ν/cm-1): 2974, 1706, 1490, 1434, 1365, 
1250, 1164, 767, 697. 1H NMR (300 MHz, CDCl3) δ 8.42 – 8.23 (m, 1H), 7.59 – 6.91 (m, 
12H), 5.36 (t, J = 8.6 Hz, 1H), 5.23 – 4.83 (m, 3H), 1.28 (s, 9H).13C NMR (75 MHz, CDCl3) δ 
168.7, 155.5, 146.8, 142.9, 139.7, 135.0, 134.5, 129.9, 128.5, 128.4, 128.3, 128.2, 128.1, 
127.3, 126.7, 125.4, 125.2, 79.5, 67.4, 57.6, 51.2, 28.3. UPLC-DAD-QTOF: C26H28Cl N2O5 
[M+H]+ calcd.: 483.1687, found: 483.1691. Chiral HPLC (Chiralpak IC; 20:80 
Hexane:Ethanol; 0.5 mL/min,  = 210 nm) tR = 25.5 min (anti, major.), 27.0 min (anti, 
minor.), 43.5 min (syn), 48.1 min (syn). dr 99:1; 99% ee. 
2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(2-nitrophenyl)-1-
oxopropan-2-yl)pyridine N-oxide (18o) 
The title compound 18o was prepared according to the general 
procedure employing N-oxide 17 and N-Boc imine 4o. Reaction 
time: 10 hours. Yield: 0.056 g (95%). Yellow solid. m. p.= 170–173 
C. [αD25 = 28.8 (c = 0.63, CH2Cl2). IR (ν/cm-1): 2975, 1706, 1525, 
1437, 1364, 1249, 1166, 1052, 746. 1H NMR (300 MHz, CDCl3) δ 8.29 (d, J = 6.5, 1.2 Hz, 
1H), 8.08 (brs, 1H), 7.92 (d, J = 7.9 Hz, 1H), 7.44 – 7.19 (m, 9H), 7.11 (t, J = 7.7 Hz, 1H), 
6.86 (d, J = 8.0 Hz, 1H), 6.11 (t, J = 5.9 Hz, 1H), 5.23 (d, J = 12.4 Hz, 1H), 5.14 (d, J = 12.5 
Hz, 1H), 4.80 (d, J = 6.2 Hz, 1H), 1.32 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 167.4, 155.7, 
148.2, 146.5, 139.8, 136.5, 135.4, 129.4, 129.0, 128.5, 128.1, 128.1, 126.6, 125.5, 125.0, 
79.4, 67.4, 53.5, 51.8, 28.3. UPLC-DAD-QTOF: C26H28N3O7 [M+H]+ calcd.: 494.1927, 
found: 494.1941. Chiral HPLC (Chiralpack IA; 20:80 Hexane:Ethanol; 0.5 mL/min,  = 210 
nm) tR = 14.0 min (anti, minor.), 17.4 min (anti, major.), 32.3 min (syn), 48.8 min (syn). 
dr 99:1; 99% ee. 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(furan-2-yl)-1-oxopropan-
2-yl)pyridine N-oxide (18p) 
The title compound 18p was prepared according to the general 
procedure employing N-oxide 17 and N-Boc imine 4p. Reaction 
time: 44 hours. Yield: 0.049 g (93%). White solid. m. p = 52–55 C. 
[αD25 = –34.74 (c = 1.75, CH2Cl2). IR (ν/cm-1): 2969, 1707, 1498, 
1434, 1366, 1255, 1165, 1022, 874, 768. 1H NMR (300 MHz, CDCl3) δ 8.30 (dd, J = 5.0, 2.7 
Hz, 1H), 7.56 – 7.43 (m, 1H), 7.38 (s, 1H), 7.33 – 7.27 (m, 3H), 7.26 – 7.12 (m, 4H), 6.51 – 
6.33 (m, 2H), 5.42 (t, J = 9.5 Hz, 1H), 5.21 – 5.02 (m, 4H), 1.28 (s, 9H). 13C NMR (75 MHz, 
CDCl3) δ 169.3, 155.4, 147.0, 143.3, 140.0, 139.6, 135.1, 128.5, 128.4, 128.3, 126.3, 
125.3, 125.2, 125.0, 109.1, 79.4, 67.4, 50.2, 49.4, 28.3. UPLC-DAD-QTOF: C24H27N2O6 
[M+H]+ calcd.: 439.1869, found: 439.1878. Chiral HPLC (Chiralpack IC; 80:20 
Hexane:Ethanol; 0.5 mL/min,  = 210 nm) tR = 26.0 min (anti, major.), 27.1 min (anti, 
minor.), 43.6 min (syn), 48.4 min (syn). dr 99:1; 99% ee. 
2-((2R,3S)-1-(Benzyloxy)-3-(((benzyloxy)carbonyl)amino)-1-oxo-3-(p-tolyl)propan-2-
yl)pyridine N-oxide (22) 
The title compound 22 was prepared according to the general 
procedure employing N-oxide 17 and N-Cbz imine 21. Reaction 
time: 24 hours. Yield: 0.052 g (88%). White solid. m. p = 50–53 
C. [αD25 = – 21.7 (c = 1.5, CH2Cl2). IR (ν/cm-1): 3030, 1721, 
1514, 1433, 1258, 1174, 1042, 764, 697. 1H NMR (300 MHz, CDCl3) δ 8.34 – 8.13 (m, 1H), 
7.50 – 6.84 (m, 17H), 5.35 (t, J = 8.6 Hz, 1H), 5.11 – 4.82 (m, 5H), 2.32 (s, 3H).13C NMR 
(75 MHz, CDCl3) δ 169.0, 156.0, 147.1, 139.7, 137.7, 137.4, 136.8, 135.1, 129.4, 128.5, 
128.4, 128.3, 128.2, 128.0, 127.9, 127.1, 126.7, 126.4, 125.0, 67.3, 66.4, 58.6, 51.2, 21.3. 
UPLC-DAD-QTOF: C30H29N2O5 [M+H]+ calcd.: 497.2076, found: 497.2072. Chiral HPLC 
(Chiralpak IC; 50:50 Hexane:Ethanol; 0.5 mL/min,  = 210 nm) tR = 21.5 min (anti, minor.), 
24.3 min (anti, major.), 31.0 min (syn), 41.3 min (syn). dr 99:1; 99% ee. 
2-((1S,2R)-1-(((Benzyloxy)carbonyl)amino)-3-(tert-butoxy)-3-oxo-1-(p-tolyl)propan-2-
yl)pyridine N-oxide (23) 
The title compound 23 was prepared according to the general 
procedure employing N-oxide 19 and N-Cbz imine 21. Reaction 
time: 48 hours. Yield: 0.049 g (89 %). White solid. m. p. = 63–
65 C. [αD25 = – 58.4 (c = 0.43, CH2Cl2). IR (ν/cm-1): 2972, 1716, 
1646, 1540, 1433, 1255, 1152, 1027, 736. 1H NMR (300 MHz, CDCl3) δ 8.20 (d, J = 6.5 Hz, 
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1H), 7.69 (d, J = 7.7 Hz, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.40 – 6.92 (m, 10H), 5.32 – 5.20 (m, 
1H), 5.08 – 4.79 (m, 3H), 2.31 (s, 3H), 1.21 (s, 9H).13C NMR (75 MHz, CDCl3) δ 168.0, 
155.9, 147.8, 139.6, 137.5, 136.8, 129.1, 128.3, 128.0, 127.8, 127.4, 126.7, 126.1, 124.7, 
82.2, 66.3, 58.7, 51.6, 27.7, 21.2. UPLC-DAD-QTOF: C24H27N2O6 [M+H]+ calcd.: 463.2233, 
found: 463.2240. Chiral HPLC (Chiralpak IC; 60:40 Hexane:Ethanol; 0.5 mL/min,  = 210 
nm) tR = 18.7 min (anti, major.), 30.9 min (anti, minor.), 35.1 min (syn), 44.9 min (syn). 
dr 99:1; 99% ee. 
2-((1S,2R)-1-((tert-Butoxycarbonyl)amino)-3-methoxy-3-oxo-1-(p-tolyl)propan-2-
yl)pyridine N-oxide (24) 
The title compound 24 was prepared according to the general 
procedure employing N-oxide 20a and N-Boc imine 4a. 
Reaction time: 72 hours. Yield: 0.045 g (96 %). White solid. m. 
p. = 126–130 C. [αD25 = – 64.0 (c = 1.00, CH2Cl2). IR (ν/cm-1): 
2975, 1734, 1705, 1513, 1489, 1432, 1365, 1250, 1165, 1051, 1020, 995, 768. 1H NMR 
(300 MHz, CDCl3) δ 8.28 (dd, J = 4.9, 2.8 Hz, 1H), 7.39 (dd, J = 6.3, 3.7 Hz, 1H), 7.32 – 7.15 
(m, 4H), 7.10 (d, J = 7.9 Hz, 2H), 6.70 (d, J = 8.2 Hz, 1H), 5.35 (t, J = 9.0 Hz, 1H), 5.02 (d, J 
= 9.5 Hz, 1H), 3.54 (s, 3H), 2.30 (s, 3H), 1.24 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 169.8, 
155.4, 147.3, 139.6, 137.7, 137.5, 129.3, 126.9, 126.6, 126.4, 124.9, 79.2, 57.4, 52.5, 
51.2, 28.3, 21.2. UPLC-DAD-QTOF: C21H27N2O5 [M+H]+ calcd.: 387.1920, found: 
387.1929. Chiral HPLC (Chiralpak IC; 50:50 Hexane:Ethanol; 0.5 mL/min,  = 210 nm) tR 
= 12.6 min (anti, minor.), 15.0 min (anti, major.), 20.9 min (syn), 22.8 min (syn). dr 99:1; 
99% ee. 
4-Bromo-2-((1S,2R)-1-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxo-1-(p-
tolyl)propan-2-yl)pyridine N-oxide (25) 
The title compound 25 was prepared according to the general 
procedure employing N-oxide 20b and N-Boc imine 21 and 
catalyst C6 (0.1 equiv., 0.012 mmol, 0.007 g). Reaction time: 36 
hours. Yield: 0.055 g (98 %). White solid. m. p. = 85–89 C. 
[αD25 = – 28.4 (c = 1.75, CH2Cl2). IR (ν/cm-1): 2974, 2248, 1731, 
1701, 1513, 1458, 1410, 1365, 1247, 1162, 729, 650. 1H NMR (300 MHz, CDCl3) δ 8.12 
(d, J = 6.9 Hz, 1H), 7.64 (d, J = 2.8 Hz, 1H), 7.33 (dd, J = 6.9, 2.8 Hz, 1H), 7.27 (d, J = 8.5 
Hz, 2H), 7.12 (d, J = 7.9 Hz, 2H), 6.43 (d, J = 8.6 Hz, 1H), 5.32 (t, J = 9.4 Hz, 1H), 5.00 (d, J 
= 9.9 Hz, 1H), 3.52 (s, 3H), 2.31 (s, 3H), 1.27 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 169.4, 
155.3, 148.5, 140.1, 137.8, 137.3, 129.4, 128.1, 126.9, 126.2, 119.7, 79.6, 57.1, 52.6, 
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51.1, 28.3, 21.3. UPLC-DAD-QTOF: C21H26N2O5Br [M+H]+ calcd.: 465.1025, found: 
465.1030. Chiral HPLC (Chiralpak IC; 50:50 Hexane:Ethanol; 0.7 mL/min,  = 210 nm) tR 
= 8.3 min (anti, minor.), 10.3 min (anti, major.), 12.5 min (syn), 15.6 min (syn). dr 99:1; 
99% ee. 
2-((1S,2R)-1-((tert-Butoxycarbonyl)amino)-1-(3-chlorophenyl)-3-methoxy-3-
oxopropan-2-yl)-4-(tert-butyl)pyridine N-oxide (26) 
The title compound 26 was prepared according to the general 
procedure employing N-oxide 20c and N-Boc imine 4m and 
catalyst C6 (0.1 equiv., 0.012 mmol, 0.007 g). Reaction time: 84 
hours. Yield: 0.050 g (90 %). White solid. m. p. = 77–80 C. [αD24 
= – 49.7 (c = 0.73, CH2Cl2). IR (ν/cm-1): 2966, 2926, 2248, 1734, 
1705, 1480, 1365, 1282, 1244, 1165, 732. 1H NMR (300 MHz, CDCl3) δ 8.24 (d, J = 6.8 Hz, 
1H), 7.54 (brs, 1H), 7.27 – 7.20 (m, 5H), 6.95 (brs, 1H), 5.44 (t, J = 7.1 Hz, 1H), 4.53 (brs, 
1H), 3.66 (s, 3H), 1.34 (s, 9H), 1.22 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 169.1, 155.9, 152.1, 
145.5, 143.3, 139.1, 134.6, 130.0, 127.9, 127.1, 125.1, 124.7, 122.5, 79.5, 57.6, 52.7, 
34.8, 30.4, 29.8, 28.4. UPLC-DAD-QTOF: C24H32N2O5Cl [M+H]+ calcd.: 463.2020, found: 
463.2000. Chiral HPLC (Chiralpak IC; 50:50 Hexane:Ethanol; 0.7 mL/min,  = 210 nm) tR 
= 7.5 min (anti, minor.), 10.8 min (anti, major.), 13.4 min (syn), 19.3 min (syn). dr 99:1; 
98% ee. 
2-((1S,2R)-1-(((Benzyloxy)carbonyl)amino)-3-methoxy-3-oxo-1-(p-tolyl)propan-2-yl)-
4-(tert-butyl)pyridine N-oxide (27) 
The title compound 27 was prepared according to the general 
procedure employing N-oxide 20c and N-Boc imine 21 and 
catalyst C6 (0.1 equiv., 0.012 mmol, 0.007 g). Reaction time: 84 
hours. Yield: 0.051 g (89 %). White solid. m. p. = 75–79 C. [αD24 
= – 21.7 (c = 0.19, CH2Cl2). IR (ν/cm-1): 3030, 2959, 2924, 2852, 
1715, 1514, 1482, 1434, 1246, 1049, 698. 1H NMR (300 MHz, CDCl3) δ 8.20 (d, J = 6.9 Hz, 
1H), 7.39 – 7.34 (m, 1H), 7.25 (s, 4H), 7.17 (td, J = 5.6, 5.1, 3.0 Hz, 3H), 7.08 (d, J = 7.9 Hz, 
2H), 7.00 (brs, 1H), 5.44 (t, J = 7.4 Hz, 1H), 5.04 – 4.86 (m, 2H), 4.67 (s, 1H), 3.61 (s, 3H), 
2.29 (s, 3H), 1.18 (s, 9H). 13C NMR (126 MHz, CDCl3) δ 169.4, 156.3, 152.2, 145.9, 139.0, 
138.6, 137.5, 133.0, 129.4, 128.4, 128.0, 127.9, 126.8, 122.3, 66.4, 58.4, 52.6, 30.4, 30.4, 
29.9, 21.2. UPLC-DAD-QTOF: C28H32N2O5 [M+H]+ calcd.: 477.2389, found: 477.2398. 
Chiral HPLC (Chiralpak IC; 50:50 Hexane:Ethanol; 0.7 mL/min,  = 210 nm) tR = 14.0 min 
(anti, minor.), 28.0 min (syn), 40.2 min (anti, major.), 80.4 min (syn). dr 99:1; 98% ee. 
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2-((1S,2R)-1-(((Benzyloxy)carbonyl)amino)-3-(tert-butoxy)-3-oxo-1-(p-tolyl)propan-2-
yl)quinoline N-oxide (29) 
The title compound 29 was prepared according to the 
general procedure employing N-oxide 28 and N-Boc imine 
21 and catalyst C6 (0.1 equiv., 0.012 mmol, 0.007 g). 
Reaction time: 48 hours. Yield: 0.051 g (89 %). Yellow oil. 
[αD24 = – 22.9 (c = 1.96, CH2Cl2). IR (ν/cm-1): 3030, 2976, 1717, 1514, 1327, 1282, 1241, 
1046, 736, 697. 1H NMR (300 MHz, CDCl3) 1H NMR (300 MHz, CDCl3) δ 8.82 (d, J = 8.8 Hz, 
1H), 7.97 – 7.76 (m, 2H), 7.76 – 7.62 (m, 2H), 7.57 (d, J = 8.8 Hz, 1H), 7.44 – 7.31 (m, 5H), 
7.25 – 7.08 (m, 4H), 7.08 – 6.94 (m, 1H), 5.53 – 5.16 (m, 2H), 4.87 (d, J = 12.5 Hz, 1H), 
4.80 (d, J = 12.5 Hz, 1H), 2.35 (s, 3H), 1.26 (s, 9H). 13C NMR (75 MHz, CDCl3) 13C NMR (75 
MHz, CDCl3) δ 168.2, 156.0, 144.6, 141.5, 137.7, 137.6, 130.9, 129.6, 129.2, 129.1, 128.7, 
128.6, 128.3, 128.2, 127.7, 127.6, 127.4, 126.4, 121.3, 120.2, 82.4, 66.2, 59.2, 52.3, 27.8, 
21.3. UPLC-DAD-QTOF: C31H32N2O5 [M+H]+ calcd.: 513.2389, found: 513.2393. Chiral 
HPLC (Chiralpak IC; 70:30 Hexane:Ethanol; 0.7 mL/min,  = 210 nm) tR = 8.6 min (anti, 
minor.), 11.9 min (syn, minor.), 13.0 min (anti, major.), 16.2 min (syn, major.). dr 10:1; 
92% ee. 
6.4.2.3. General procedure for the Mannich reaction of pyridyl acetate N-oxide with 
N-Boc isatin ketimines 
 
To a solution of pyridyl acetate N-oxide 17 (1 equiv., 0.12 mmol, 0.029 g) and catalyst 
C23 (0.2 equiv., 0.024 mmol, 0.017 g) in anhydrous CH2Cl2 (0.5 mL) at 0 °C, the 
corresponding N-Boc isatin ketimine (0.36 mmol, 3 equiv.) was added. The resulting 
solution was stirred at the same temperature for 72 hours and then poured into a flash 
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column chromatography (Hexane:EtOAc, 50:50 to 0:100) to afford the corresponding 
pure Mannich adducts. 
Racemic adducts for the determination of the enantiomeric excesses were prepared 
following the general procedure employing DBU as aquiral Brønsted base. 
2-(2-(Benzyloxy)-1-(3-((tert-butoxycarbonyl)amino)-2-oxoindolin-3-yl)-2-
oxoethyl)pyridine N-oxide (32)  
The title compound 32 was prepared according to the general 
procedure employing ketimine 30. Yield: 0.047 g (84 %). Yellow 
solid. m. p. = 108–113 C. [αD24  = +43.5 (c = 0.45, CH2Cl2). IR (ν/cm-
1): 2963, 2926, 1741, 1716, 1619, 1473, 1257, 1157, 751. 1H NMR 
(300 MHz, CDCl3) δ 8.64 (s, 1H), 8.42 – 8.27 (m, 1H), 8.01 (s, 1H), 
7.72 – 7.57 (m, 1H), 7.42 (d, J = 7.3 Hz, 1H), 7.31 – 7.14 (m, 6H), 7.04 – 6.94 (m, 3H), 6.76 
(d, J = 7.7 Hz, 1H), 5.76 (s, 1H), 4.81 – 4.69 (m, 2H), 1.25 (s, 9H). 13C NMR (75 MHz, CDCl3) 
δ 174.9, 167.3, 154.0, 143.4, 141.7, 140.0, 134.5, 129.7, 129.4, 128.6, 128.5, 128.4, 
126.8, 125.7, 123.4, 122.5, 121.9, 110.0, 80.1, 67.6, 64.2, 49.5, 28.3. UPLC-DAD-QTOF: 
C27H27N3O6 [M+H]+ calcd.: 490.1978, found: 490.1985. Chiral HPLC (Chiralpak IC + 
Chiralpak IC; 50:50 Hexane:Ethanol; 0.5 mL/min,  = 210 nm) tR = 28.9 min (diast. A, 
major.), 36.1 min (diast. B, minor.), 37.8 min (diast. A, minor.), 41.8 min (diast. B, major). 
dr 10:1; 80% ee. 
2-(2-(Benzyloxy)-1-(3-((tert-butoxycarbonyl)amino)-5-methoxy-2-oxoindolin-3-yl)-2-
oxoethyl)pyridine N-oxide (33) 
The title compound 33 was prepared according to the general 
procedure employing ketimine 31. Yield: 0.048 g (77 %). 
Yellow solid. m. p. = 118–122 C. [αD24 = +44.2 (c = 1.28, 
CH2Cl2). IR (ν/cm-1): 2976, 1712, 1489, 1215, 1161, 733. 1H 
NMR (300 MHz, CDCl3) δ 8.67 (s, 1H), 8.47 – 8.29 (m, 1H), 7.96 
(d, J = 8.6 Hz, 1H), 7.72 (dd, J = 6.3, 3.8 Hz, 1H), 7.27 (dddd, J = 12.9, 10.6, 6.0, 3.2 Hz, 
6H), 7.10 – 6.89 (m, 2H), 6.73 (qd, J = 8.5, 2.1 Hz, 2H), 5.76 (s, 1H), 4.91 – 4.63 (m, 2H), 
3.73 (d, J = 1.7 Hz, 3H), 1.26 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 174.9, 167.2, 155.9, 
154.0, 143.3, 140.0, 134.9, 134.5, 128.6, 128.6, 128.4, 126.9, 125.7, 115.3, 114.2, 110.6, 
109.5, 80.3, 67.6, 64.7, 55.9, 49.4, 28.3. UPLC-DAD-QTOF: C28H29N3O7 [M+H]+ calcd.: 
520.2084, found: 520.2087. Chiral HPLC (Chiralpak IC; 80:20 Hexane:Ethanol; 0.7 
mL/min,  = 210 nm) tR = 43.1 min (diast. A, major.), 62.6 min (diast. B, minor.), 66.4 min 
(diast. A, minor.), 73.7 min (diast. B, major). dr 6.1:1; 78% ee. 
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6.4.2.4. General procedure for the Mannich reaction of azaaryl acetates with N-
protected imines 
 
To a solution of the corresponding azaaryl acetate (0.12 mmol, 1 equiv.) and catalyst 
C6 in anhydrous CH2Cl2 (0.5 mL) at 0 °C, the corresponding N-protected imine (0.24 
mmol, 2 equiv.) was added and stirred at the same temperature for 120 hours and then 
poured into a flash column chromatography (Hexane:EtOAc, 70:30) to afford the 
corresponding pure Mannich adducts. 
Racemic adducts for the determination of the enantiomeric excesses were prepared 
following the general procedure employing DBU as aquiral Brønsted base. 
Benzyl 3-((tert-butoxycarbonyl)amino)-2-(pyridin-2-yl)-3-(p-tolyl)propanoate (18’a) 
The title compound 18’a was prepared according to the 
general procedure employing benzyl 2-(pyridin-2-yl)acetate 
17’, N-Boc imine 4a and catalyst C6 (0.2 equiv., 0.024 mmol, 
0.014 g). Reaction time: 120 hours. Purification with flash 
column chromatography (Hexane:EtOAc, 90:10). Yield: 0.046 g 
(86 %). Colorless oil. 1H NMR (300 MHz, CDCl3) δ 7.85 (d, J = 8.1 Hz, 1H), 7.64 – 6.86 (m, 
13H), 5.30 – 4.98 (m, 2H), 4.25 (m, 1H), 3.97 (m, 1H), 2.46 (s, 3H), 1.63 (s, 9H). Chiral 
HPLC (Chiralpak IC; 50:50 Hexane:iPrOH; 0.5 mL/min,  = 210 nm) tR = 10.9 min (anti), 
12.7 min (anti), 19.1 min (syn), 24.1 min (syn). dr 2.6:1; 0/0% ee. 
tert-Butyl 3-(((benzyloxy)carbonyl)amino)-2-(quinolin-2-yl)-3-(p-tolyl)propanoate 
(29’) 
The title compound 29’ was prepared according to the 
general procedure employing tert-butyl 2-(quinolin-2-
yl)acetate, N-Cbz imine 21 and catalyst C6 (0.1 equiv., 
0.012 mmol, 0.007 g). After 120 hours, the reaction 
conversion was 45 %. Chiral HPLC (Chiralpak IC; 80:20 
Hexane:iPrOH; 0.5 mL/min,  = 210 nm) tR = 13.4 min (diast. A, minor.), 18.5 min (diast. 
A, major.), 26.6 min (diast. B, major.), 30.0 min (diast. B, minor.). dr 1.1:1; 31/9% ee. 
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6.4.2.5. Elaboration of adducts 
6.4.2.5.1. Reduction of the N-oxide group to afford 18’b 
To a solution of adduct 18b (1 equiv., 0.25 mmol, 0.114 g) in CH2Cl2 
(3 mL) was added bis(pinacolato)diboron (3 equiv., 0.75 mmol, 
0.190 g) and the reaction mixture was stirred at room temperature 
for 16 hours. Then, the solution was concentrated under reduced 
pressure and poured into a neutral aluminium oxide flash column 
chromatography (Hexane:EtOAc, 80:20) to afford the corresponding Mannich adduct 
which was further purified by grinding with a mixture of solvents (Hexane:MeOH:, 95:5) 
to produce pure 18’b. Yield: 0.087 g (80%). White solid. m. p = 117–120 C. [αD24 = –
22.8 (c = 0.5, CH2Cl2). IR (ν/cm-1): 2975, 1711, 1591, 1497, 1365, 1288, 1164, 753, 699. 
1H NMR (300 MHz, CDCl3) δ 8.56 (d, J = 5.0, 1.8 Hz, 1H), 7.51 (td, J = 7.7, 1.9 Hz, 1H), 7.34 
– 6.96 (m, 12H), 6.38 (s, 1H), 5.53 (s, 1H), 5.13 – 4.90 (m, 2H), 4.19 (d, J = 7.1 Hz, 1H), 
1.27 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 170.4, 155.7, 155.2, 149.2, 140.9, 136.8, 135.6, 
128.5, 128.4, 128.2, 128.1, 127.4, 126.8, 124.5, 122.8, 79.4, 67.0, 58.9, 56.4, 28.4. UPLC-
DAD-QTOF: C26H29N2O4 [M+H]+ calcd.: 433.2049, found: 433.2124. Chiral HPLC 
(Chiralpak IC; 80:20 Hexane:Isopropanol; 0.5 mL/min,  = 210 nm) tR= 16.6 min (anti, 
minor.), 19 min (anti, major.), 39.5 min (syn), 42.2 min (syn). dr 99:1; 99% ee. 
6.4.2.5.2. Synthesis of β2,3-amino acid 34 
To a solution of adduct 18a (1 equiv., 0.25 mmol, 0.115 g) in 
MeOH (3 mL) palladium on carbon (Pd/C) (0.0115 g, 10 % w/w.) 
was added and the reaction mixture was stirred under H2 
pressure (30 bar) at room temperature for 1.5 hours. Then, the 
solution was filtrated and concentrated under reduced pressure to give the deprotected 
carboxylic acid 34.  Yield: 0.087 g (89%). White solid. m. p = 72–77 C. [αD24 = –2.4 (c = 
1.94, CH2Cl2). IR (ν/cm-1): 2975, 2927, 1700, 1512, 1365, 1249, 1165, 1018, 768. 1H NMR 
(300 MHz, MeOD) δ 8.38 (d, J = 4.9 Hz, 1H), 7.62 – 7.31 (m, 3H), 7.24 (q, J = 6.5, 5.4 Hz, 
2H), 7.11 (d, J = 7.6 Hz, 2H), 5.40 (d, J = 9.1 Hz, 1H), 4.88 (d, J = 9.6 Hz, 1H), 2.29 (s, 3H), 
1.28 (s, 9H). 13C NMR (75 MHz, MeOD) δ 157.3, 149.5, 140.8, 138.3, 130.3, 130.0, 128.2, 
127.3, 126.5, 125.6, 123.2, 80.2, 57.4, 54.1, 28.6, 21.1. UPLC-DAD-QTOF: C20H24N2O5 
[M+H]+ calcd.: 373.1763, found: 373.1771; [M+Na]+ calcd.: 395.1583, found: 395.1581. 
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6.4.2.5.3. Synthesis of amino alcohol 35 
To a solution of adduct 24 (1 equiv., 0.25 mmol, 0.097 g) in THF 
(2.5 mL), lithium aluminium hydride (0.190 g, 0.75 mmol, 3 
equiv.) was added at 0 °C. The reaction mixture was stirred at 
that temperature for 1 hour. The reaction mixture was then 
quenched with water (2 mL) and NaOH (20 %) (3 mL) and  extracted with CH2Cl2 (3 x 7 
mL). The organic phase was dried over MgSO4, filtered and concentrated under reduced 
pressure. The crude material was purified by flash column chromatography on silica gel 
(Hexane:EtOAc, 90:10 to 70:30) to give compound 35. Yield: 0.061 g (71%). White solid. 
m. p = 81–86 C. [αD25 = –39.2 (c = 0.14, CH2Cl2). IR (ν/cm-1): 3342, 3007, 2975, 2925, 
2867, 1693, 1594, 1503, 1365, 1252, 1168, 1053. 1H NMR (300 MHz, CDCl3) δ 8.53 (ddd, 
J = 4.9, 1.9, 0.9 Hz, 1H), 7.48 (td, J = 7.7, 1.8 Hz, 1H), 7.12 (t, J = 6.3 Hz, 1H), 7.00 (s, 4H), 
6.87 (d, J = 7.8 Hz, 1H), 6.49 (brs, 1H), 5.30 (brs, 1H), 3.98 (dd, J = 11.5, 7.3 Hz, 1H), 3.82 
(dd, J = 11.5, 5.5 Hz, 1H), 3.39 (brs, 1H), 3.32 (brs, 1H), 2.26 (s, 3H), 1.42 (s, 9H). 13C NMR 
(75 MHz, CDCl3) δ 160.9, 150.0, 139.3, 137.5, 137.4, 130.0, 127.4, 126.2, 123.1, 111.1, 
80.7, 65.2, 55.4, 55.1, 29.5, 22.1. UPLC-DAD-QTOF: C20H27N2O3 [M+H]+ calcd.: 343.2022, 
found: 343.2042. 
6.4.2.5.4. Synthesis of benzyl amine 36a 
To a solution of adduct 18a (1 equiv., 0.25 mmol, 0.115 g) in 
MeOH (3 mL) palladium on carbon (Pd/C) (0.0115 g, 10 % w/w.) 
was added and the reaction mixture was stirred under H2 
pressure (30 bar) at room temperature for 1.5 hours. Then, the 
solution was filtrated and concentrated under reduced pressure to give the deprotected 
carboxylic acid as white foam. The acid was dissolved in CH2Cl2 (3 mL) and 
bis(pinacolato)diboron (3 equiv., 0.75 mmol, 0.190 g) was added. The reaction mixture 
was stirred at room temperature for 16 hours. Then, ethylendiamine (2 mL, 30 mmol, 
120 equiv.) was added to the mixture, and the stirring was continued for 1 hour at room 
temperature. The reaction mixture was then diluted with water (10 mL) and extracted 
with CH2Cl2 (3 x 10 mL). The organic phase was dried over MgSO4, filtered and 
concentrated under reduced pressure. The crude material was purified by flash column 
chromatography on silica gel (Hexane:EtOAc, 90:10 to 80:20) to give compound 36a. 
Yield: 0.070 g (90%). White solid. m. p = 121–124 C. [αD25 = –28.7 (c = 1.2, CH2Cl2). IR 
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(ν/cm-1): 3006, 2974, 2924, 2867, 1695, 1511, 1364, 1247, 1164, 1018, 810, 751, 541. 1H 
NMR (300 MHz, CDCl3) δ 8.53 (dd, J = 5.2, 1.7 Hz, 1H), 7.51 (td, J = 7.7, 1.9 Hz, 1H), 7.17 
– 7.00 (m, 4H), 6.97 (dd, J = 7.8, 1.4 Hz, 1H), 5.88 (brs, 1H), 5.03 (brs, 1H), 3.26 (dd, J = 
13.6, 5.2 Hz, 1H), 3.11 (dd, J = 13.9, 7.9 Hz, 1H), 2.29 (s, 3H). 13C NMR (75 MHz, CDCl3) δ 
158.4, 155.3, 149.2, 136.6, 136.4, 129.1, 126.2, 124.1, 121.7, 79.3, 54.8, 44.9, 28.4, 21.2. 
UPLC-DAD-QTOF: C19H25N2O2 [M+H]+ calcd.: 313.1916, found: 313.1929. 
6.4.2.5.5. Synthesis of Lanicemine (AZD6765) dihydrochoride (38) 
To a solution of adduct 18b (1 equiv., 0.25 mmol, 0.115 g) in MeOH 
(3 mL) palladium on carbon (Pd/C) (0.0115 g, 10 % w/w.) was added 
and the reaction mixture was stirred under H2 pressure (30 bar) at 
room temperature for 1.5 hours. Then, the solution was filtrated 
and concentrated under reduced pressure to give the deprotected carboxylic acid as 
white foam. The acid was dissolved in CH2Cl2 (3 mL) and bis(pinacolato)diboron (3 equiv., 
0.75 mmol, 0.190 g) was added. The reaction mixture was stirred at room temperature 
for 16 hours. Then, ethylendiamine (120 equiv., 30 mmol, 2 mL) was added to the 
mixture, and the stirring was continued for 1 hour at room temperature. The reaction 
mixture was then diluted with water (10 mL) and extracted with CH2Cl2 (3 x 10 mL). The 
organic phase was dried over MgSO4, filtered and concentrated under reduced pressure. 
The crude material was purified by flash column chromatography on silica gel 
(Hexane:EtOAc, 90:10 to 80:20) to give compound 36b. This compound was redissolved 
in MeOH (10 mL) and TMSCl (0.64 mL, 5.0 mmol, 20.0 equiv.) was added at room 
temperature. After 4 hours, the reaction mixture was concentrated under reduced 
pressure. THF (3 mL) was added and a white solid precipitated. Centrifugation and 
solvent elimination gave pure lanicemine dihydrochloride (38). Overall yield: 0.052 g 
(76%). White solid. 1H NMR (300 MHz, MeOD-d4) δ 8.74 (dd, J = 5.7, 0.9 Hz, 1H), 8.43 (td, 
J = 7.9, 1.7 Hz, 1H), 8.00 – 7.80 (m, 2H), 7.47 (dtt, J = 6.2, 3.7, 1.9 Hz, 5H), 4.95 (dd, J = 
9.5, 6.3 Hz, 1H), 3.94 (dd, J = 14.4, 6.3 Hz, 1H), 3.72 (dd, J = 14.4, 9.6 Hz, 1H). Physical 
and spectroscopic data were coincident with the previously reported.249 
                                                     
249 Ref. 203a, page 151. 
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6.5. Experimental section for Chapter 4 
Products in chapter 4 were synthetized following this general synthetic pathway: 
 
6.5.1. Desymmetrization of meso-anhydrides250 
 
Benzyl alcohol (3.0 equiv., 45.0 mmol, 4.66 mL) was added dropwise to a stirred 
suspension of the corresponding anhydride (1.0 equiv., 15.0 mmol) and quinidine (1.1 
                                                     
250 Ref. 218, page 165. 
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equiv., 16.5 mmol, 5.35 g) in a 1:1 mixture of toluene and tetrachloromethane (75 mL) 
at –55 °C under argon. The reaction mixture was stirred at this temperature for 60 hours. 
During this period, the material gradually dissolved. Subsequently, the resulting clear 
solution was concentrated in vacuo to dryness, and the resulting residue was then 
dissolved in Et2O (40 mL). The solution was washed with 2 M HCl (3 x 15 mL), followed 
by extraction of the aqueous phase with Et2O (5 x 20 mL) and the combined organic 
layers extracted with saturated solution of sodium carbonate (5 x 25 mL). The resulting 
aqueous phase was washed with Et2O (1 x 40 mL) in order to remove traces of benzyl 
alcohol, acidified with concentrated HCl, extracted with methylene chloride (5 x 30 mL) 
and the organic layer was dried over MgSO4, filtered, and concentrated providing the 
corresponding hemiester. 
(1S,3R)-3-((Benzyloxy)carbonyl)-2,2-dimethylcyclopropane-1-carboxylic acid 
The title compound was prepared according to the general procedure 
employing caronic acid 45. Yield: 3.5 g (94 %). Colorless oil. [αD20 =     
–2.2 (c = 1.04, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.52 – 7.41 (m, 5H), 
5.28 (AB-system, 2H), 2.13 (d, J = 8.7 Hz, 1H), 2.09 (d, J = 8.7 Hz, 1H), 
1.49 (s, 3H), 1.40 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 172.7, 171.7, 135.3, 128.8, 128.6, 
67.6, 33.8, 33.0, 28.4, 27.9, 15.4. Spectroscopic data matched with literature.250 
(1R,2S)-2-((Benzyloxy)carbonyl)cyclopropane-1-carboxylic acid 
The title compound was prepared according to the general procedure 
employing 3-oxabicyclo[3.1.0]hexane-2,4-dione 46. Yield: 3.0 g (92 %). 
Colorless oil. [αD20 = –5.2 (c = 1.00, CHCl3). 1H NMR (500 MHz, CDCl3) δ 
10.52 (brs, 1H), 7.40 – 7.28 (m, 5H), 5.13 (AB-system, 2H), 2.23 – 2.14 (m, 
1H), 2.13 – 2.05 (m, 1H), 1.73 (td, J = 6.8, 5.1 Hz, 1H), 1.34 (td, J = 8.4, 5.1 Hz, 1H). 13C 
NMR (126 MHz, CDCl3) δ 175.9, 169.9, 135.6, 128.7, 128.5, 128.5, 67.3, 22.6, 21.5, 12.7. 
Spectroscopic data matched with literature.251 
                                                     
251 Jnoff, E.; Albrecht, C.; Barker, J. J.; Barker, O.; Beaumont, E.; Bromidge, S.; Brookfield, F.; Brooks, M.; 
Bubert, C.; Ceska, T.; Corden, V.; Dawson, G.; Duclos, S.; Fryatt, T.; Genicot, C.; Jigorel, E.; Kwong, J.; 
Maghames, R.; Mushi, I.; Pike, R.; Sands, Z. A.; Smith, M. A.; Stimson, C. C.; Courade, J.-P. ChemMedChem 
2014, 9, 699–705. 
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6.5.2. Synthesis of redox-active esters (General procedure A) 
 
Redox-active esters were prepared according to the previously reported procedure.252 
The corresponding carboxylic acid (1.0 equiv.) was dissolved in methylene chloride (0.1 
– 0.2 M) and N-hydroxytetrachlorophthalimide (1.1 equiv.), DIC (1.1 equiv.) and DMAP 
(0.1 equiv.) were added. The mixture was stirred vigorously at room temperature for 1 
hour. After completion of reaction, the mixture was filtered over silica gel and rinsed 
with additional CH2Cl2. The solvent was removed under reduced pressure, and 
purification by crystallization in Et2O afforded the desired pure TCNHPI redox-active 
ester. 
6.5.3. Decarboxylative cross-coupling reactions 
6.5.3.1. Ni catalyzed Negishi reactions 
Preparation of organozinc reagents 
Mg insertion for the preparation of non-comercial Grignard reagents (10 mmol scale):  
LiCl (1.25 equiv., 12.5 mmol, 0.530 g) was flame-dried under vacuum. After cooling, 
the flask was placed under Ar atmosphere, and Mg turnings (2.5 equiv., 25 mmol, 0.608 
g) were added. In a separate flask under Ar atmosphere, a solution of the corresponding 
aryl or alkenyl bromide (1.0 equiv., 10 mmol) in THF (8 mL) was prepared. A small 
amount of THF (ca. 2 mL) was added to the flask containing LiCl and Mg, followed by 
dropwise addition of 1,2-dibromoethane (0.1 equiv., 0.09 mL). Vigorous bubbling 
occurred. If vigorous bubbling did not occur, the mixture was gently heated with a heat 
gun until effervescence ensued. At this time, the solution of alkenyl bromide in THF was 
added dropwise, and the mixture was periodically heated with a heat gun. Upon 
                                                     
252 Ref. 212, page 160. 
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complete addition, the mixture was placed in an oil bath (ca. 70 – 80 °C) and refluxed 
for 1 hour. The Grignard reagent was titrated with I2 before use (see below). Typical 
concentrations were between 0.4 M and 0.8 M. 
Transmetallation with ZnCl2 (5 mmol scale): 
ZnCl2 (1.0 equiv., 5 mmol, 0.680 g) (and LiCl (1.0 equiv., 5 mmol, 0.212 g) for 
commercial Grignard reagents) was flame-dried under vacuum. Upon cooling, the flask 
was placed under Ar atmosphere. Anhydrous THF (5 mL) was added, and the mixture 
was stirred vigorously until all ZnCl2 dissolved. At this time, the Grignard reagent (1 
equiv., 5 mmol) was added slowly to the ZnCl2 solution and the solution was stirred for 
15 minutes. Then, the organozinc reagent solution in THF was concentrated under 
reduced pressure under argon atmosphere, anhydrous MeCN was added and stirred for 
5 minutes. The organozinc reagent was titrated with I2 see below before its use. Typical 
concentrations were between 0.35 M and 0.25 M. 
Titration of arylzinc reagents: 
I2 (approximately 1.0 equiv., 0.1 mmol, 0.025 g) was quickly added to the culture tube. 
THF (anhydrous, 1.0 mL) was added, and the mixture was stirred for 5 min to give a dark 
brown solution. A 1.00 mL syringe was filled with the corresponding RZnCl·LiCl, and the 
solution was added dropwise via the syringe. Over the course of the titration the color 
changed from dark brown to light brown to yellow to clear, indicating complete 
consumption of I2. The concentration of the RZnCl·LiCl solution was then calculated. 
6.5.3.1.1. Negishi arylation (General procedure B1) 
 
Preparation of the nickel/ligand solution: 
A culture tube was charged with NiCl2·glyme (0.25 mmol, 0.055 g) and 4,4’-di-tert-
butyl-2,2’-bipyridine (0.5 mmol, 0.134 g) under argon atmosphere. Anhydrous DMF (10 
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mL) was added and the homogeneous solution was stirred at room temperature for 15 
minutes before use. 
Procedure for 0.1 mmol scale: 
A culture tube was charged with the corresponding TCNHPI redox-active ester (1.0 
equiv., 0.1 mmol) and a stir bar. The tube was then evacuated and backfilled with argon 
from a balloon. Nickel/ligand solution (0.8 mL) was added and stirred at room 
temperature for 5 minutes. After that, a solution of the corresponding arylzinc reagent 
(4.0 equiv.) was added in one portion and stirred at room temperature for 12 hours. 
After the reaction completion, Et2O (2 mL) was added, quenched with 1 M HCl (1 mL), 
washed with brine (2 x 1 mL), dried with MgSO4, filtered, and concentrated under 
reduced pressure. The crude product was purified by silica gel flash column 
chromatography or preparative TLC (pTLC) to yield the pure compound. 
6.5.3.1.2. Negishi alkenylation (General procedure B2) 
 
Preparation nickel/ligand solution: 
A culture tube was charged with Ni(acac)2·xH2O (0.5 mmol, 0.148 g) and 2,2’-bipyridine 
(0.5 mmol, 0.078 g) under argon atmosphere. Anhydrous DMF (10 mL) was added and 
the homogeneous solution was stirred at room temperature for 15 minutes before use. 
Procedure for 0.1 mmol scale: 
A culture tube was charged with the corresponding TCNHPI redox-active ester (1.0 
equiv., 0.1 mmol) and a stir bar. The tube was then evacuated and backfilled with argon 
from a balloon. Nickel/ligand solution (1.0 mL) was added and stirred at room 
temperature for 5 minutes. After that, a solution of the corresponding alkenylzinc 
reagent (5.0 equiv.) was added in one portion and stirred at 80 °C for 12 hours. After the 
reaction completion, Et2O (2 mL) was added, quenched with 1 M HCl (1 mL), washed 
with brine (2 x 1 mL), dried with MgSO4, filtered, and concentrated under reduced 
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pressure. The crude product was purified by preparative TLC (pTLC) to yield the pure 
compound. 
6.5.3.2. Suzuki coupling (General procedure B3) 
 
Preparation of the nickel/ligand solution: 
A culture tube was charged with NiCl2·glyme (0.4 mmol, 0.088 g) and 4,4’-dimethoxy-
2,2’-bipyridine (0.4 mmol, 0.087 g), under argon atmosphere. Anhydrous DMF (10 mL) 
was added and the homogeneous solution was stirred at room temperature for 15 
minutes before use. 
Preparation of R1Bpin·nBuLi solution: 
A flame-dried culture tube was charged with the corresponding R1Bpin (0.3 mmol) 
under argon atmosphere and anhydrous toluene (1.5 mL) was added. A 2.5 M solution 
of n-BuLi in hexane (0.3 mmol, 0.12 mL) was added at 0 °C and the resulting mixture was 
stirred at room temperature for 15 minutes. 
Procedure for 0.1 mmol scale: 
A culture tube was charged with the corresponding TCNHPI redox-active ester (1.0 
equiv., 0.1 mmol) and a stir bar. The tube was then evacuated and backfilled with argon 
from a balloon. Nickel/ligand solution (1.0 mL) was added and stirred at room 
temperature for 5 minutes. After that, the corresponding R1Bpin·nBuLi solution (2 
equiv., 0.2 mmol, 1.0 mL) was added in one portion and stirred at 60 °C for 12 hours. 
After the reaction completion, Et2O (2 mL) was added, quenched with 1 M HCl (1 mL), 
washed with brine (2 x 1 mL), dried with MgSO4, filtered, and concentrated under 
reduced pressure. The crude product was purified by preparative TLC (pTLC) to yield the 
pure compound. 
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6.5.4. Deprotection of benzyl esters (General procedure C) 
 
The corresponding benzylic ester (1.0 mmol) was dissolved in AcOEt (2.0 mL) in argon 
atmosphere. Pd on carbon (10 %) was added and the flask was evacuated and backfilled 
with H2 (g) with a balloon three times. The reaction was stirred under H2 atmosphere at 
room temperature for 12 hours. After that, the reaction mixture was filtrated over celite 
and solvent was evaporated under reduced pressure to afford the corresponding 
deprotected carboxylic acid. 
Caracterization of compounds 
1-Benzyl 2-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl) (1R,2S)-3,3-
dimethylcyclopropane-1,2-dicarboxylate (47) 
The title compound 47 was prepared on a 10.0 mmol scale 
according to general procedure A employing (1S,3R)-3-
((benzyloxy)carbonyl)-2,2-dimethylcyclopropane-1-carboxylic 
acid. Yield: 4.4 g (83 %). Yellow solid. m.p. = 115–117 °C. [αD20 
= +3.7 (c = 1.00, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.26 
(m, 5H), 5.17 – 5.10 (m, 2H), 2.24 (d, J = 9.3 Hz, 1H), 2.18 (d, J 
= 9.3 Hz, 1H), 1.47 (s, 3H), 1.33 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 167.3, 165.1, 157.5, 141.0, 135.6, 130.5, 128.7, 128.6, 
128.4, 124.8, 67.1, 34.1, 28.6, 27.8, 27.8, 15.3. HRMS (ESI-TOF): calcd for C22H16Cl4NO6 
[M+H]+: 529.9726, found: 529.9725. Chiral SFC (Daicel IB; 40% MeOH / CO2 (4 mL/min), 
1600 psi backpressure; λ = 238 nm). tR (major) = 4.14 min, tR (minor) = 5.84 min. 96% ee. 
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1-Benzyl 2-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl) (1R,2S)-cyclopropane-1,2-
dicarboxylate (48) 
The title compound 48 was prepared on a 10.0 mmol scale 
according to general procedure A employing (1R,2S)-2-
((benzyloxy)carbonyl)cyclopropane-1-carboxylic acid. Yield: 4.0 g 
(80 %). Yellow solid. m.p. = 137–140 °C. [αD20 = –66.4 (c = 1.00, 
CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.48 – 7.27 (m, 5H), 5.25 – 5.15 
(m, 2H), 2.45 – 2.35 (m, 2H), 2.00 – 1.89 (m, 1H), 1.57 – 1.47 (m, 
1H). 13C NMR (126 MHz, CDCl3) δ 168.1, 165.9, 157.3, 141.1, 135.6, 
130.6, 128.8, 128.7, 128.5, 124.8, 67.7, 23.5, 18.4, 12.9. HRMS (ESI-
TOF): calcd for C20H12Cl4NO6 [M+H]+: 501.9413, found: 501.9413. 
Chiral SFC (Daicel IA; 40% MeOH / CO2 (4 mL/min), 1600 psi backpressure; λ = 238 nm). 
tR (minor) = 8.91 min, tR (major) = 10.59 min, 96% ee. 
Benzyl (1R,3R)-3-(4-methoxyphenyl)-2,2-dimethylcyclopropane-1-carboxylate (49a) 
The title compound 49a was prepared on a 2.0 mmol scale according 
to general procedure B1 employing 47 and the arylzinc reagent 
derived from 4-bromoanisole. Purification by flash column 
chromatography with gradient elution (4:1 hexane:CH2Cl2 to 1:1 
hexane:CH2Cl2). Yield: 0.292 g (47 %). Yellow oil. [αD20 = +16.2 (c = 
0.65, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.45 – 7.30 (m, 5H), 7.12 – 
7.04 (m, 2H), 6.86 – 6.78 (m, 2H), 5.17 (AB-system, 2H), 3.79 (s, 3H), 
2.67 (d, J = 5.8 Hz, 1H), 1.95 (d, J = 5.8 Hz, 1H), 1.37 (s, 3H), 0.92 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 173.4, 140.1, 136.1, 128.7, 128.6, 128.4, 128.3, 126.7, 126.3, 66.7, 26.5, 
24.3, 17.4. HRMS (ESI-TOF): calcd for C20H23O3 [M+H]+: 311.1642, found: 311.1646. 
Chiral SFC (Daicel IG; 30% MeOH / CO2 (4 mL/min), 1600 psi backpressure; λ = 226 nm). 
tR (minor) = 1.64 min, tR (major) = 1.94 min, 94% ee. 
Benzyl (1R,3R)-2,2-dimethyl-3-phenylcyclopropane-1-carboxylate (49b) 
The title compound 49b was prepared according to general procedure 
B1 employing 47 and the arylzinc reagent derived from 
phenylmagnesium bromide. Purification by pTLC (7:3 hexane:CH2Cl2). 
Yield: 0.015 g (56 %). Colorless oil. [αD20 = +23.6 (c = 0.40, CHCl3). 1H 
NMR (500 MHz, CDCl3) δ 7.43 – 7.32 (m, 5H), 7.28 (dd, J = 8.2, 6.8 Hz, 
2H), 7.23 – 7.18 (m, 1H), 7.18 – 7.14 (m, 2H), 5.19 (d, J = 12.5 Hz, 1H), 
5.17 (d, J = 12.3 Hz, 1H), 2.74 (d, J = 5.8 Hz, 1H), 2.03 (d, J = 5.8 Hz, 1H), 1.39 (s, 3H), 0.93 
Experimental section 
267 
 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 172.3, 137.4, 136.3, 128.9, 128.7, 128.4, 128.3, 
128.3, 126.5, 66.5, 37.9, 31.7, 29.8, 22.1, 20.9. HRMS (ESI-TOF): calcd for C19H21O2 
[M+H]+: 281.1536, found: 281.1539. Chiral SFC (Daicel IG; 5% MeOH / CO2 (4 mL/min), 
1600 psi backpressure; λ = 214 nm). tR (minor) = 2.63 min, tR (major) = 2.94 min, 96% ee. 
Benzyl (1R,3R)-2,2-dimethyl-3-(p-tolyl)cyclopropane-1-carboxylate (49c) 
The title compound 49c was prepared according to general procedure 
B1 employing 47 and the arylzinc reagent derived from 4-
bromotoluene. Purification by pTLC (1:1 hexane:CH2Cl2). Yield: 0.016 g 
(54 %). Yellow oil. [αD20 = +6.4 (c = 0.10, CHCl3). 1H NMR (600 MHz, 
CDCl3) δ 7.41 – 7.32 (m, 5H), 7.09 (d, J = 7.9 Hz, 2H), 7.05 (d, J = 8.0 Hz, 
2H), 5.18 (d, J = 12.3 Hz, 1H), 5.16 (dd, J = 33.7, 12.3 Hz, 1H), 2.69 (d, J 
= 5.9 Hz, 1H), 2.31 (s, 3H), 1.98 (d, J = 5.8 Hz, 1H), 1.38 (d, J = 2.0 Hz, 
3H), 0.92 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 172.5, 136.4, 136.1, 134.3, 129.0, 128.8, 
128.7, 128.4, 128.3, 66.5, 37.6, 31.7, 29.7, 22.1, 21.2, 20.9. HRMS (ESI-TOF): calcd for 
C20H23O2 [M+H]+: 295.1693, found: 295.1696. Chiral SFC (Daicel IC; 5% MeOH / CO2 (4 
mL/min), 1600 psi backpressure; λ = 214 nm). tR (minor) = 1.59 min, tR (major) = 1.72 
min, 94% ee. 
Benzyl (1S,2S)-2-(4-methoxyphenyl)cyclopropane-1-carboxylate (50a) 
The title compound 50a was prepared according to general procedure B1 
employing 48 and the arylzinc reagent derived from 4-bromoanisole. 
Purification by pTLC (1:1 hexane:CH2Cl2). Yield: 0.011 g (40 %). Yellow oil. 
[αD20 = +101.5 (c = 0.27, CHCl3). 1H NMR (600 MHz, CDCl3) δ 7.39 – 7.35 
(m, 4H), 7.35 – 7.31 (m, 1H), 7.05 – 7.00 (m, 2H), 6.84 – 6.79 (m, 2H), 5.17 
(d, J = 12.3 Hz, 1H), 5.14 (d, J = 12.3 Hz, 1H), 3.78 (s, 3H), 2.52 (ddd, J = 
9.2, 6.6, 4.1 Hz, 1H), 1.89 (ddd, J = 8.3, 5.2, 4.1 Hz, 1H), 1.59 (ddd, J = 9.2, 
5.2, 4.6 Hz, 3H), 1.28 (ddd, J = 8.4, 6.6, 4.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 173.6, 
158.6, 136.2, 132.1, 128.8, 128.5, 128.4, 127.6, 114.2, 66.8, 55.6, 26.1, 24.1, 17.2. HRMS 
(ESI-TOF): calcd for C18H19O3 [M+H]+: 283.1329, found: 383.1335. Chiral SFC (Daicel IG; 
35% MeOH / CO2 (4 mL/min), 1600 psi backpressure; λ = 231 nm). tR (minor) = 2.57 min, 
tR (major) = 3.19 min, 94% ee. 
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Benzyl (1S,2S)-2-phenylcyclopropane-1-carboxylate (50b) 
The title compound 50b was prepared according to general procedure B1 
employing 48 and the arylzinc reagent derived from phenylmagnesium 
bromide. Purification by pTLC (1:1 hexane:CH2Cl2). Yield: 0.013 g (50 %). 
Colorless oil. [αD20 = +168.2 (c = 0.75, CHCl3). 1H NMR (500 MHz, CDCl3) δ 
7.41 – 7.30 (m, 5H), 7.32 – 7.24 (m, 2H), 7.25 – 7.17 (m, 1H), 7.14 – 7.07 (m, 
2H), 5.18 (d, J = 15.0 Hz, 1H), 5.15 (d, J = 15.0 Hz, 1H), 2.57 (ddd, J = 9.2, 6.6, 
4.2 Hz, 1H), 1.98 (ddd, J = 8.4, 5.3, 4.1 Hz, 1H), 1.64 (ddd, J = 9.2, 5.3, 4.6 Hz, 1H), 1.35 
(ddd, J = 8.4, 6.5, 4.5 Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 173.4, 140.1, 136.1, 128.7, 
128.6, 128.4, 128.3, 126.7, 126.3, 66.7, 26.5, 24.3, 17.4. HRMS (ESI-TOF): calcd for 
C17H17O2 [M+H]+: 253.1223, found: 253.1219. Chiral SFC (Daicel IBN; 5% MeOH / CO2 (4 
mL/min), 1600 psi backpressure; λ = 214 nm). tR (minor) = 2.51 min, tR (major) = 2.65 
min, 94% ee. 
Benzyl (1S,2S)-2-(4-fluorophenyl)cyclopropane-1-carboxylate (50d) 
The title compound 50d was prepared on a 2.0 mmol scale according to 
general procedure B1 employing 48 and the arylzinc reagent derived from 
4-bromofluorobenzene. Purification by flash column chromatography with 
gradient elution (4:1 hexane:CH2Cl2 to 3:2 hexane:CH2Cl2). Yield: 0.227 g (42 
%). Yellow oil. [αD20 = +161.6 (c = 0.19, CHCl3). 1H NMR (600 MHz, CDCl3) δ 
7.40 – 7.30 (m, 5H), 7.08 – 7.03 (m, 2H), 6.98 – 6.93 (m, 2H), 5.17 (d, J = 12.3 
Hz, 1H), 5.14 (d, J = 12.3 Hz, 1H), 2.54 (ddd, J = 9.3, 6.6, 4.2 Hz, 1H), 1.91 
(ddd, J = 8.5, 5.3, 4.2 Hz, 1H), 1.62 (dt, J = 9.2, 5.0 Hz, 1H), 1.29 (ddd, J = 8.5, 6.5, 4.6 Hz, 
1H).13C NMR (126 MHz, CDCl3) δ 173.3, 161.8 (d, J = 244.6 Hz), 136.0, 135.7 (d, J = 3.3 
Hz), 128.7, 128.4, 128.4, 127.9 (d, J = 7.7 Hz), 115.55 (d, J = 21.5 Hz), 66.8, 25.8, 24.1, 
17.2. 19F NMR (376 MHz, CDCl3) δ -116.3. GC/MS (EI): m/z (%) 270 (1%), 225 (5%), 133 
(14%), 91 (100%). Chiral SFC (Daicel IG; 15% MeOH / CO2 (4 mL/min), 1600 psi 
backpressure; λ = 214 nm). tR (minor) = 2.04 min, tR (major) = 2.37 min, 94% ee. 
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Benzyl (1R,3R)-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropane-1-carboxylate 
(54a) 
The title compound 54a was prepared according to general procedure 
B2 employing 47 and the arylzinc reagent derived from 2-methyl-1-
propenylmagnesium bromide. Purification by pTLC (7:3 
hexane:CH2Cl2). Yield: 0.010 g (40 %). Yellow oil. [αD20 = –9.5 (c = 0.48, 
CHCl3). 1H NMR (600 MHz, CDCl3) δ 7.39 – 7.35 (m, 4H), 7.35 – 7.31 (m, 
1H), 7.05 – 7.00 (m, 2H), 6.84 – 6.79 (m, 2H), 5.17 (d, J = 12.3 Hz, 1H), 
5.14 (d, J = 12.3 Hz, 1H), 3.78 (s, 3H), 2.52 (ddd, J = 9.2, 6.6, 4.1 Hz, 1H), 1.89 (ddd, J = 
8.3, 5.2, 4.1 Hz, 1H), 1.59 (ddd, J = 9.2, 5.2, 4.6 Hz, 3H), 1.28 (ddd, J = 8.4, 6.6, 4.5 Hz, 
1H). 13C NMR (126 MHz, CDCl3) δ 172.6, 136.5, 135.7, 128.7, 128.3, 128.2, 121.2, 66.3, 
34.9, 33.1, 29.0, 25.7, 22.3, 20.6, 18.6. HRMS (ESI-TOF): calcd for C17H23O2 [M+H]+: 
259.1693, found: 259.1692. Chiral SFC (Daicel IG; 3% MeOH / CO2 (2.8 mL/min), 1600 psi 
backpressure; λ = 214 nm). tR (minor) = 2.51 min, tR (major) = 2.80 min, 93% ee. 
Benzyl (1R,3R)-2,2-dimethyl-3-(prop-1-en-2-yl)cyclopropane-1-carboxylate (54b) 
The title compound 54b was prepared according to general procedure 
B2 employing 47 and the arylzinc reagent derived from 
isopropenylmagnesium bromide. Purification by pTLC (7:3 
hexane:CH2Cl2). Yield: 0.013 g (55 %). Yellow oil. [αD20 = +10.2 (c = 0.55, 
CHCl3). 1H NMR (600 MHz, CDCl3) δ 7.42 – 7.29 (m, 5H), 5.16 – 5.10 (m, 
2H), 4.85 (h, J = 1.5 Hz, 1H), 4.63 (td, J = 1.7, 0.9 Hz, 1H), 2.00 (d, J = 5.9 
Hz, 1H), 1.77 (dt, J = 1.6, 0.8 Hz, 3H), 1.73 (d, J = 5.9 Hz, 1H), 1.29 (s, 3H), 1.06 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 172.3, 141.7, 136.4, 128.7, 128.4, 128.3, 111.5, 66.4, 39.7, 31.1, 
28.9, 23.8, 20.8, 20.6. HRMS (ESI-TOF): calcd for C16H21O2+ [M+H]+: 245.1536; found: 
245.1537. Chiral SFC (Daicel IG; 5% MeOH / CO2 (4 mL/min), 1600 psi backpressure; λ = 
214 nm). tR (minor) = 1.71 min, tR (major) = 1.95 min, 92% ee. 
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Benzyl (1R,3R)-3-(cyclohex-1-en-1-yl)-2,2-dimethylcyclopropane-1-carboxylate (54c) 
The title compound 54c was prepared according to general 
procedure B2 employing 47 and the arylzinc reagent derived from 1-
bromocyclohexene.253 Purification by pTLC (7:3 hexane:CH2Cl2). Yield: 
0.022 g (72 %). Yellow oil. [αD20 = +26.7 (c = 0.33, CHCl3). 1H NMR (400 
MHz, CDCl3) δ 7.42 – 7.28 (m, 5H), 5.28 (dd, J = 15.2, 8.2 Hz, 1H), 5.16 
– 5.09 (m, 2H), 2.06 – 1.99 (m, 1H), 1.68 – 1.55 (m, 1H), 1.54 (d, J = 5.3 
Hz, 1H), 1.46 – 1.28 (m, 2H), 1.28 (s, 1H), 1.25 (s, 3H), 1.16 (d, J = 1.8 Hz, 3H), 0.72 – 0.64 
(m, 2H), 0.34 (dddd, J = 6.7, 5.2, 3.3, 1.4 Hz, 2H). 13C NMR (126 MHz, CDCl3) δ 172.6, 
136.5, 133.9, 128.7, 128.3, 128.2, 122.9, 66.3, 40.0, 30.2, 29.9, 28.8, 25.2, 23.0, 22.6, 
20.9, 20.8. HRMS (ESI-TOF): calcd for C19H25O2+ [M+H]+: 285.1849; found: 285.1852. 
Chiral SFC (Daicel IA; 3% iPrOH / CO2 (4 mL/min), 1600 psi backpressure; λ = 214 nm). tR 
(minor) = 2.29 min, tR (major) = 2.45 min, 94% ee. 
Benzyl (1R,3R)-3-((E)-2-cyclopropylvinyl)-2,2-dimethylcyclopropane-1-carboxylate 
(54f) 
The title compound 54f was prepared according to general procedure 
B3 employing 47 and (trans)-2-cyclopropylvinylboronic acid pinacol 
ester. Purification by pTLC (7:3 hexane:CH2Cl2). Yield: 0.022 g (55 %). 
Yellow oil. [αD20 = –7.8 (c = 0.51, CHCl3). 1H NMR (400 MHz, CDCl3) δ 
7.42 – 7.28 (m, 5H), 5.28 (dd, J = 15.2, 8.2 Hz, 1H), 5.13 (dd, J = 14.8, 
8.7 Hz, 1H), 5.12 (d, J = 8.0 Hz, 1H), 5.08 (d, J = 12.4 Hz, 1H), 2.02 (dd, 
J = 8.2, 5.3 Hz, 1H), 1.54 (d, J = 5.3 Hz, 1H), 1.44 – 1.32 (m, 1H), 1.25 (s, 3H), 1.15 (s, 3H), 
0.71 – 0.65 (m, 2H), 0.34 (dtd, J = 6.7, 3.6, 1.1 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 172.2, 
136.8, 136.4, 128.7, 128.4, 128.3, 124.4, 77.5, 77.2, 76.8, 66.3, 36.5, 34.0, 29.0, 22.1, 
20.5, 14.0, 6.8, 6.7. HRMS (ESI-TOF): calcd for C18H23O2+ [M+H]+: 271.1693; found: 
271.1693. Chiral SFC (Daicel IG; 5% MeOH / CO2 (4 mL/min), 1600 psi backpressure; λ = 
214 nm). tR (minor) = 1.87 min, tR (major) = 2.27 min, 95% ee. 
                                                     
253 Prepared following the procedure in: Likhite, N.; Ramasamy, S.; Tendulkar, S.; Sathasivam, S.; Luzung, 
M.; Zhu, Y.; Strotman, N.; Nye, J.; Ortiz, A.; Kiau, S.; Eastgate, M. D.; Vaidyanathan, R. Org. Process Res. 
Dev. 2016, 20, 977–981.  
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(1R,3R)-3-(4-Methoxyphenyl)-2,2-dimethylcyclopropane-1-carboxylic acid (71) 
The title compound 71 was prepared according to general procedure 
C employing 49a. Yield: 0.220 g (99 %). Colorless oil. [αD20 = +9.8 (c 
= 0.56, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.14 – 7.03 (m, 2H), 6.88 
– 6.79 (m, 2H), 3.79 (s, 3H), 2.69 (d, J = 5.7 Hz, 1H), 1.89 (d, J = 5.8 Hz, 
1H), 1.42 (s, 3H), 0.95 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 179.2, 
158.3, 129.8, 129.1, 113.7, 55.3, 37.8, 31.8, 30.6, 22.2, 20.7. 
(1S,2S)-2-(4-Fluorophenyl)cyclopropane-1-carboxylic acid (72) 
The title compound 72 was prepared according to general procedure C 
employing 50d. Yield: 0.180 g (99 %). Colorless oil. [αD20 = +9.8 (c = 0.56, 
CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.08 (ddt, J = 8.2, 5.2, 2.5 Hz, 2H), 7.01 
– 6.94 (m, 2H), 2.59 (ddd, J = 9.3, 6.7, 4.1 Hz, 1H), 1.85 (ddd, J = 8.4, 5.2, 4.1 
Hz, 1H), 1.71 – 1.60 (m, 1H), 1.36 (ddd, J = 8.4, 6.7, 4.7 Hz, 1H). 13C NMR (151 
MHz, CDCl3) δ 178.5, 161.87 (d, J = 245.0 Hz), 135.25 (d, J = 2.8 Hz), 128.06 
(d, J = 8.2 Hz), 115.54 (d, J = 21.4 Hz) 26.5, 23.7, 17.5. 19F NMR (376 MHz, 
CDCl3) δ -116.0. 
4,5,6,7-Tetrachloro-1,3-dioxoisoindolin-2-yl (1R,3R)-3-(4-methoxyphenyl)-2,2-
dimethylcyclopropane-1-carboxylate (73) 
The title compound 73 was prepared on a 1.0 mmol scale 
according to general procedure A employing carboxylic acid 
71. Yield: 0.45 g (90 %). Yellow solid. m.p. = 170–173 °C. [αD24 
= +57.5 (c = 1.00, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.17 – 
7.09 (m, 2H), 6.91 – 6.82 (m, 2H), 3.81 (s, 3H), 2.82 (d, J = 5.7 
Hz, 1H), 2.18 (d, J = 5.7 Hz, 1H), 1.44 (s, 3H), 1.06 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 172.2, 136.8, 136.4, 128.7, 128.4, 
128.3, 124.4, 66.4, 36.5, 34.0, 29.0, 22.1, 20.5, 14.0, 6.8, 6.7. 
HRMS (ESI-TOF): calcd for C21H16Cl4NO5 [M+H]+: 501.9777, 
found: 501.9776. 
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4,5,6,7-Tetrachloro-1,3-dioxoisoindolin-2-yl (1S,2S)-2-(4-fluorophenyl)cyclopropane-
1-carboxylate (74) 
The title compound 74 was prepared on a 1.0 mmol scale according 
to general procedure A employing carboxylic acid 72. Yield: 0.42 g 
(91 %). Yellow solid. m.p. = 148–150 °C. [αD23 = +97.6 (c = 1.00, 
CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.20 – 7.14 (m, 2H), 7.07 – 7.01 
(m, 2H), 2.80 (ddd, J = 9.4, 6.9, 4.1 Hz, 1H), 2.18 (ddd, J = 8.4, 5.2, 
4.1 Hz, 1H), 1.85 (dt, J = 9.4, 5.2 Hz, 1H), 1.65 (ddd, J = 8.5, 7.0, 5.1 
Hz, 1H). 13C NMR (126 MHz, CDCl3) δ 169.3, 162.15 (d, J = 246.0 Hz), 
157.7, 141.2, 133.96 (d, J = 3.1 Hz), 130.7, 128.30 (d, J = 7.9 Hz), 
124.8, 115.76 (d, J = 21.7 Hz), 28.1, 20.9, 18.4. 19F NMR (376 MHz, 
CDCl3): δ –115.1. HRMS (ESI-TOF): calcd for C18H8FNNaO4 [M+Na]+: 
483.9084, found: 483.9079. 
1-((1R,3R)-2,2-dimethyl-3-(p-tolyl)cyclopropyl)-4-methoxybenzene (66) 
The title compound 66 was prepared according to general procedure 
B3 from redox-active ester 73 and p-toluenboronic acid pinacol ester 
employing NiCl2·glyme (60 mol%) and 4,4’-dimethoxy-2,2’-bipyridine 
(60 mol%). Purification by pTLC (7:3 hexane:CH2Cl2). Yield: 0.015 g 
(55 %). Yellow oil. [αD20 = +38.0 (c = 0.30, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ 7.21 – 7.18 (m, 2H), 7.16 (d, J = 7.8 Hz, 2H), 7.11 (d, J = 7.9 
Hz, 2H), 6.87 – 6.83 (m, 2H), 3.81 (s, 3H), 2.34 (s, 3H), 2.29 (d, J = 6.0 
Hz, 1H), 2.26 (d, J = 6.2 Hz, 1H), 0.96 (s, 6H). 13C NMR (101 MHz, 
CDCl3) δ 158.0, 136.9, 135.4, 132.0, 130.2, 129.1, 128.9, 113.6, 77.5, 77.2, 76.8, 55.4, 
34.3, 33.6, 25.5, 22.5, 22.4, 21.2. GC/MS (EI): m/z (%) 266 (75%), 251 (100%), 159 (33%), 
143 (38%). Chiral SFC (Daicel IA; 10% MeOH / CO2 (4 mL/min), 1600 psi backpressure; λ 
= 229 nm). tR (minor) = 1.38 min, tR (major) = 2.13 min, 94% ee. 
1-((1R,3R)-3-(4-methoxyphenyl)-2,2-dimethylcyclopropyl)furan (67) 
The title compound 67 was prepared according to general procedure 
B3 from redox-active ester 73 and 3-furanboronic acid pinacol ester 
employing NiCl2·glyme (60 mol%) and 4,4’-dimethoxy-2,2’-bipyridine 
(60 mol%). Purification by pTLC (7:3 hexane:CH2Cl2). Yield: 0.013 g 
(54 %). Yellow oil. [αD20 = +16.0 (c = 0.30, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ 7.36 (t, J = 1.7 Hz, 1H), 7.28 (dd, J = 1.7, 0.9 Hz, 1H), 7.21 – 
7.10 (m, 2H), 6.89 – 6.79 (m, 2H), 6.31 (dd, J = 1.8, 0.9 Hz, 1H), 3.80 
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(s, 3H), 2.06 (d, J = 5.8 Hz, 1H), 1.94 (d, J = 6.0 Hz, 1H), 1.06 (s, 3H), 0.91 (s, 3H). 13C NMR 
(101 MHz, CDCl3) δ 158.0, 142.6, 140.1, 131.6, 130.0, 124.1, 113.6, 112.1, 77.5, 77.2, 
76.8, 55.4, 34.7, 24.9, 24.7, 22.3, 22.0. GC/MS (EI): m/z (%) 242 (50%), 227 (100%), 199 
(40%), 121 (60%). Chiral SFC (Daicel IG; 7% MeOH / CO2 (4 mL/min), 1600 psi 
backpressure; λ = 226 nm). tR (minor) = 1.50 min, tR (major) = 2.38 min, 95% ee. 
1-((1R,3R)-3-((E)-2-cyclopropylvinyl)-2,2-dimethylcyclopropyl)-4-methoxybenzene 
(68) 
The title compound 68 was prepared according to general procedure 
B3 from redox-active ester 73 and (trans)-2-cyclopropylvinylboronic 
acid pinacol ester employing NiCl2·glyme (60 mol%) and 4,4’-
dimethoxy-2,2’-bipyridine (60 mol%). Purification by pTLC (7:3 
hexane:CH2Cl2). Yield: 0.016 g (64 %). Yellow oil. [αD20 = +90.3 (c = 
0.36, CHCl3). 1H NMR (400 MHz, CDCl3) δ 7.08 (d, J = 8.8 Hz, 2H), 6.80 
(d, J = 8.7 Hz, 2H), 5.44 (dd, J = 15.2, 8.2 Hz, 1H), 5.15 (dd, J = 15.2, 
8.6 Hz, 1H), 3.78 (s, 3H), 1.80 (d, J = 5.7 Hz, 1H), 1.60 (dd, J = 8.2, 5.6 Hz, 1H), 1.41 (dtd, 
J = 13.2, 8.4, 4.8 Hz, 1H), 1.20 (s, 3H), 0.82 (s, 3H), 0.74 – 0.60 (m, 2H), 0.41 – 0.29 (m, 
2H). 13C NMR (101 MHz, CDCl3) δ 157.8, 134.4, 132.0, 130.0, 127.4, 113.5, 55.4, 36.2, 
32.7, 24.9, 22.5, 22.1, 14.0, 6.8, 6.7. HRMS (ESI-TOF): calcd for C17H23O+ [M+H]+: 
243.1743; found: 243.1743. Chiral SFC (Daicel IA; 2% MeOH / CO2 (4 mL/min), 1600 psi 
backpressure; λ = 220 nm). tR (minor) = 1.47 min, tR (major) = 1.76 min, 94% ee. 
1-Fluoro-4-((1S,2S)-2-phenylcyclopropyl)benzene (69) 
The title compound 69 was prepared according to general procedure B1 
from redox-active ester 74 and the arylzinc derived from phenylmagnesium 
bromide employing NiCl2·glyme (40 mol%) and 4,4’-di-tert-butyl-2,2’-
bipyridine (40 mol%). Purification by pTLC (9:1 hexane:CH2Cl2). Yield: 0.013 
g (62 %). Yellow oil. [αD20 = +125.5 (c = 0.44, CHCl3). 1H NMR (400 MHz, 
CDCl3) δ 7.34 – 7.27 (m, 2H), 7.23 – 7.16 (m, 1H), 7.16 – 7.07 (m, 4H), 7.02 – 
6.94 (m, 2H), 2.13 (dddd, J = 19.0, 8.7, 6.0, 4.6 Hz, 2H), 1.42 (dddd, J = 16.2, 
8.7, 6.0, 5.3 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 161.4 (d, J = 243.7 Hz), 142.5, 138.2 (d, 
J = 3.3 Hz), 128.6, 127.4 (d, J = 7.8 Hz), 126.0, 125.9, 115.3 (d, J = 21.4 Hz), 27.9, 27.4, 
18.2. 19F NMR (376 MHz, CDCl3) δ -117.7. GC/MS (EI): m/z (%) 197 (40%), 133 (35%), 115 
(49%). Chiral SFC (Daicel IA; 10% MeOH / CO2 (4 mL/min), 1600 psi backpressure; λ = 226 
nm). tR (major) = 1.30 min, tR (minor) = 1.43 min, 93% ee. 
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1-((1S,2S)-2-(Cyclohex-1-en-1-yl)cyclopropyl)-4-fluorobenzene (70) 
The title compound 70 was prepared according to general procedure B2 
from redox-active ester 74 and the alkenylzinc derived from 1-
bromocyclohexene253 employing Ni(acac)2·xH2O (60 mol%) and 2,2’-
bipyridine (60 mol%). Purification by pTLC (9:1 hexane:CH2Cl2). Yield: 0.010 
g (44 %). Yellow oil. [αD20 = +61.3 (c = 0.38, CHCl3). 1H NMR (500 MHz, CDCl3) 
δ 7.07 – 7.00 (m, 2H), 6.97 – 6.90 (m, 2H), 5.49 (ddq, J = 3.9, 2.5, 1.3 Hz, 1H), 
2.04 – 1.98 (m, 2H), 1.94 – 1.90 (m, 2H), 1.88 (dt, J = 8.7, 5.1 Hz, 1H), 1.64 
(qd, J = 6.2, 3.4 Hz, 2H), 1.57 (ddd, J = 7.2, 5.7, 3.0 Hz, 2H), 1.51 (dd, J = 9.2, 5.1 Hz, 1H), 
1.16 (ddd, J = 8.7, 6.1, 4.9 Hz, 1H), 0.94 (dt, J = 8.8, 5.2 Hz, 1H). 13C NMR (151 MHz, CDCl3) 
δ 161.2 (d, J = 243.2 Hz), 139.1 (d, J = 3.3 Hz), 137.1, 127.3 (d, J = 7.7 Hz), 120.6, 115.1 
(d, J = 21.4 Hz), 30.1, 27.1, 25.3, 23.0, 22.8, 22.5, 14.2. 19F NMR (376 MHz, CDCl3) δ -
118.3. HRMS (ESI-TOF): calcd for C15H18F+ [M+H]+: 217.1387; found: 217.1384. Chiral SFC 
(Daicel IG; 2% iPrOH / CO2 (3.3 mL/min), 1600 psi backpressure; λ = 229 nm). tR (major) 
= 2.24 min, tR (minor) = 2.46 min, 95% ee. 
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6.6. NMR spectra 
6.6.1. Catalysts 
 (9H-Fluoren-9-yl)methyl ((S)-1-(3-((R)-(6-methoxyquinolin-4-yl)((1S,2R,4S,5R)-5-
vinylquinuclidin-2-yl)methyl)ureido)-2-methylpropyl)carbamate (C1) 
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(9H-Fluoren-9-yl)methyl ((S)-1-(3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-
vinylquinuclidin-2-yl)methyl)ureido)-2-methylpropyl)carbamate (C2) 
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(9H-Fluoren-9-yl)methyl ((S)-1-(3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-
vinylquinuclidin-2-yl)methyl)ureido)-2-phenylethyl)carbamate (C3) 
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(9H-Fluoren-9-yl)methyl ((S)-1-(3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-
vinylquinuclidin-2-yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C4) 
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tert-Butyl ((S)-1-(3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-
yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C5) 
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Benzyl ((S)-1-(3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-
yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C6) 
 
 
 
Chapter 6 
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COSY: 
 
HSQC: 
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HMBC: 
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Benzyl ((S)-1-(3-((R)-((1S,2S,4S,5R)-5-ethylquinuclidin-2-yl)(6-methoxyquinolin-4-
yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C7) 
 
  
Experimental section 
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(9H-Fluoren-9-yl)methyl ((S)-1-(3-((S)-((1S,2S,4S,5R)-5-ethylquinuclidin-2-yl)(6-
methoxyquinolin-4-yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C8) 
 
 
  
Chapter 6 
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Phenanthren-9-ylmethyl ((S)-1-(3-((S)-((1S,2S,4S,5R)-5-ethylquinuclidin-2-yl)(6-
methoxyquinolin-4-yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C22) 
 
 
 
Experimental section 
286 
 
3,5-Bis(trifluoromethyl)benzyl ((S)-1-(3-((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-
vinylquinuclidin-2-yl)methyl)ureido)-2,2-dimethylpropyl)carbamate (C23) 
 
 
Chapter 6 
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3-(((1S,2S)-2-(Piperidin-1-yl)cyclohexyl)amino)-4-
(((trimethylsilyl)methyl)amino)cyclobut-3-ene-1,2-dione (C10) 
 
  
Experimental section 
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3-((S)-(6-Methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methylamino)-4-
((trimethylsilyl)methylamino)cyclobut-3-ene-1,2-dione (C11) 
 
  
Chapter 6 
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3-((Dimethyl(phenyl)silyl)methylamino)-4-((S)-(6-methoxyquinolin-4-yl)((2S,4S,8R)-8-
vinylquinuclidin-2-yl)methylamino)cyclobut-3-ene-1,2-dione (C12) 
 
  
Experimental section 
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3-(((Dimethyl(naphthalen-2-yl)silyl)methyl)amino)-4-(((S)-(6-methoxyquinolin-4-
yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)amino)cyclobut-3-ene-1,2-dione 
(C13) 
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3-(((S)-(6-methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)amino)-
4-(((methyldi(naphthalen-2-yl)silyl)methyl)amino)cyclobut-3-ene-1,2-dione (C14) 
 
 
  
Experimental section 
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3-((S)-(6-Methoxyquinolin-4-yl)((2S,4S,8R)-8-vinylquinuclidin-2-yl)methylamino)-4-
((methyldiphenylsilyl)methylamino)cyclobut-3-ene-1,2-dione (C15) 
 
 
3-((S)-(6-Methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methylamino)-
4-((triphenylsilyl)methylamino)cyclobut-3-ene-1,2-dione (C16) 
Chapter 6 
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1-((S)-(6-Methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)-3-
((methyldiphenylsilyl)methyl)thiourea (C17) 
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1-((S)-(6-Methoxyquinolin-4-yl)((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)methyl)-3-
((methyldiphenylsilyl)methyl)urea (C18) 
 
 
  
Experimental section 
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1-(3,5-Bis(trifluoromethyl)phenyl)-3-(2-(dimethylamino)ethyl)thiourea (C24) 
 
  
Chapter 6 
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6.6.2. NMR spectra for Chapter 2 
 ((2-Nitroethyl)sulfonyl)benzene (2a) 
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2-((2-Nitroethyl)sulfonyl)naphthalene (2b) 
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2-((2-Nitroethyl)sulfonyl)pyridine (2c) 
 
 
  
Experimental section 
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1-((2-Nitroethyl)sulfonyl)-3,5-bis(trifluoromethyl)benzene (2d) 
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tert-Butyl (S,E)-(3-(phenylsulfonyl)-1-(p-tolyl)allyl)carbamate (5aa) 
 
 
  
Experimental section 
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tert-Butyl (S,E)-(1-phenyl-3-(phenylsulfonyl)allyl)carbamate (5ab) 
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tert-Butyl (S,E)-(1-(4-methoxyphenyl)-3-(phenylsulfonyl)allyl)carbamate (5ac) 
 
 
  
Experimental section 
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tert-Butyl (S,E)-(3-(naphthalen-2-ylsulfonyl)-1-(p-tolyl)allyl)carbamate (5ba) 
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tert-Butyl (S,E)-(3-(pyridin-2-ylsulfonyl)-1-(p-tolyl)allyl)carbamate (5ca) 
 
  
Experimental section 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(p-
tolyl)allyl)carbamate (5da) 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-phenylallyl)carbamate 
(5db) 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(4-
methoxyphenyl)allyl)carbamate (5dc) 
 
 
  
Chapter 6 
309 
 
Methyl (S,E)-4-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-((tert-
butoxycarbonyl)amino)allyl)benzoate (5dd) 
  
Experimental section 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(4-
chlorophenyl)allyl)carbamate (5de) 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(2-
chlorophenyl)allyl)carbamate (5df) 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(4-methoxy-3-
methylphenyl)allyl)carbamate (5dg) 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(3,4-
dimethoxyphenyl)allyl)carbamate (5dh) 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(naphthalen-2-
yl)allyl)carbamate (5di) 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(thiophen-2-
yl)allyl)carbamate (5dj) 
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6.6.3. NMR spectra for Chapter 3 
2-(Cyano(phenyl)methyl)pyridine N-oxide (13a) 
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2-(Cyano(p-tolyl)methyl)pyridine N-oxide (13b) 
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2-(Cyano(4-methoxyphenyl)methyl)pyridine N-oxide (13c) 
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2-((4-Bromophenyl)(cyano)methyl)pyridine N-oxide (13d) 
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2-(Cyano(4-(methoxycarbonyl)phenyl)methyl)pyridine N-oxide (13e) 
 
 
  
Chapter 6 
321 
 
2-Bromo-6-(cyano(4-(trifluoromethyl)phenyl)methyl)pyridine N-oxide (13f) 
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2-(Cyano(thiophen-3-yl)methyl)pyridine 1-oxide (13g) 
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(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(phenyl)methyl)pyridine N-
oxide (15aa)  
 
 
 
1H NMR (300 MHz, CDCl3, rt) 
1H NMR (500 MHz, DMSO-d6, rt) 
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1H NMR experiments in CDCl3 (at room temperature and at 55°C) and DMSO-d6 (at room 
temperature) showed a mixture of rotamers 15aa, whose ratio could not be determined. 
A simpler 1H NMR was obtained in DMSO-d6 at 70°C, in which a 1:1 mixture of rotamers 
was observed.  
 
 
 
1H NMR (500 MHz, DMSO-d6, 70°C) 
Rotameric ratio: 1:1 
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(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(p-tolyl)methyl)pyridine N-
oxide (15ba) 
 
 
 
 1H NMR (500 MHz, DMSO-d6, 70°C) 
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(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(4-
methoxyphenyl)methyl)pyridine N-oxide (15ca) 
 
 
  
1H NMR (500 MHz, DMSO-d6, 70°C) 
13C NMR (126 MHz, DMSO-d6, 70°C) 
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(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(4 
bromophenyl)(cyano)methyl)pyridine 1-oxide (15da) 
 
 
  
1H NMR (500 MHz, DMSO-d6, 70°C) 
13C NMR (126 MHz, DMSO-d6, 70°C) 
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(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(4-
(methoxycarbonyl)phenyl)methyl)pyridine N-oxide (15ea) 
 
 
  
1H NMR (500 MHz, DMSO-d6, 70°C) 
 
13C NMR (126 MHz, DMSO-d6, 70°C) 
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(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(4-
(trifluoromethyl)phenyl)methyl)-6-bromopyridine N-oxide (15fa) 
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(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(thiophen-3-yl)methyl)pyridine 
N-oxide (15ga) 
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(S)-2-((1,2-bis((benzyloxy)carbonyl)hydrazinyl)(4-
bromophenyl)(cyano)methyl)pyridine N-oxide (15db) 
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(S)-2-((1,2-bis((benzyloxy)carbonyl)hydrazinyl)(cyano)(4-
(methoxycarbonyl)phenyl)methyl)pyridine N-oxide (15eb) 
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2-(2-(Benzyloxy)-2-oxoethyl)pyridine N-oxide (17) 
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2-(2-(tert-Butoxy)-2-oxoethyl)pyridine N-oxide (19) 
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2-(2-Methoxy-2-oxoethyl)pyridine N-oxide (20a) 
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4-Bromo-2-(2-methoxy-2-oxoethyl)pyridine N-oxide (20b) 
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4-(tert-Butyl)-2-(2-methoxy-2-oxoethyl)pyridine N-oxide (20c) 
 
 
 
Experimental section 
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2-(2-(tert-Butoxy)-2-oxoethyl)quinoline N-oxide (28) 
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2-((1S,2R)-1-((tert-Butoxycarbonyl)amino)-3-oxo-3-phenoxy-1-(p-tolyl)propan-
2yl)pyridine N-oxide (18a) 
 
 
Experimental section 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-1-oxo-3-phenylpropan-2-
yl)pyridine N-oxide (18b) 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(4-methoxyphenyl)-1-
oxopropan-2-yl)pyridine N-oxide (18c) 
 
 
 
Experimental section 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(4-
(methoxycarbonyl)phenyl)-1-oxopropan-2-yl)pyridine N-oxide (18d) 
 
 
Chapter 6 
343 
 
2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(4-methoxy-3-
methylphenyl)-1-oxopropan-2-yl)pyridine N-oxide (18g) 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(3,4-dimethoxyphenyl)-1-
oxopropan-2-yl)pyridine N-oxide (18h) 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(naphthalen-2-yl)-1-
oxopropan-2-yl)pyridine N-oxide (18i) 
 
 
Experimental section 
346 
 
2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-1-oxo-3-(thiophen-2-
yl)propan-2-yl)pyridine N-oxide (18j) 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-1-oxo-3-(o-tolyl)propan-2-
yl)pyridine N-oxide (18l) 
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2-((2R,3S)-1-(Benzyloxy)-3-(4-bromophenyl)-3-((tert-butoxycarbonyl)amino)-1-
oxopropan-2-yl)pyridine N-oxide (18m) 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(3-chlorophenyl)-1-
oxopropan-2-yl)pyridine N-oxide (18n) 
 
 
Experimental section 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(2-nitrophenyl)-1-
oxopropan-2-yl)pyridine N-oxide (18o) 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(furan-2-yl)-1-oxopropan-
2-yl)pyridine N-oxide (18p) 
 
 
Experimental section 
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2-((2R,3S)-1-(Benzyloxy)-3-(((benzyloxy)carbonyl)amino)-1-oxo-3-(p-tolyl)propan-2-
yl)pyridine N-oxide (22) 
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2-((1S,2R)-1-(((Benzyloxy)carbonyl)amino)-3-(tert-butoxy)-3-oxo-1-(p-tolyl)propan-2-
yl)pyridine N-oxide (23) 
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2-((1S,2R)-1-((tert-Butoxycarbonyl)amino)-3-methoxy-3-oxo-1-(p-tolyl)propan-2-
yl)pyridine N-oxide (24) 
 
 
4-Bromo-2-((1S,2R)-1-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxo-1-(p-
tolyl)propan-2-yl)pyridine N-oxide (25) 
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2-((1S,2R)-1-((tert-Butoxycarbonyl)amino)-1-(3-chlorophenyl)-3-methoxy-3-
oxopropan-2-yl)-4-(tert-butyl)pyridine N-oxide (26) 
Experimental section 
356 
 
 
 
2-((1S,2R)-1-(((Benzyloxy)carbonyl)amino)-3-methoxy-3-oxo-1-(p-tolyl)propan-2-yl)-
4-(tert-butyl)pyridine N-oxide (27) 
Chapter 6 
357 
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2-((1S,2R)-1-(((benzyloxy)carbonyl)amino)-3-(tert-butoxy)-3-oxo-1-(p-tolyl)propan-2-
yl)quinoline N-oxide (29) 
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2-(2-(Benzyloxy)-1-(3-((tert-butoxycarbonyl)amino)-2-oxoindolin-3-yl)-2-
oxoethyl)pyridine N-oxide (32)  
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2-(2-(Benzyloxy)-1-(3-((tert-butoxycarbonyl)amino)-5-methoxy-2-oxoindolin-3-yl)-2-
oxoethyl)pyridine N-oxide (33) 
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Benzyl (2R,3S)-3-((tert-butoxycarbonyl)amino)-3-phenyl-2-(pyridin-2-yl)propanoate 
(18’b) 
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2-((1R,2S)-2-((tert-butoxycarbonyl)amino)-1-carboxy-2-(p-tolyl)ethyl)pyridine N-
oxide (34) 
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tert-Butyl ((1S,2R)-3-hydroxy-2-(pyridin-2-yl)-1-(p-tolyl)propyl)carbamate (35) 
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tert-butyl (S)-(2-(pyridin-2-yl)-1-(p-tolyl)ethyl)carbamate (36a) 
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6.6.4. NMR spectra for Chapter 4 
 (1S,3R)-3-((Benzyloxy)carbonyl)-2,2-dimethylcyclopropane-1-carboxylic acid 
 
 
Experimental section 
366 
 
(1R,2S)-2-((Benzyloxy)carbonyl)cyclopropane-1-carboxylic acid 
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1-Benzyl 2-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl) (1R,2S)-3,3-
dimethylcyclopropane-1,2-dicarboxylate (47) 
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1-Benzyl 2-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl) (1R,2S)-cyclopropane-1,2-
dicarboxylate (48) 
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Benzyl (1R,3R)-3-(4-methoxyphenyl)-2,2-dimethylcyclopropane-1-carboxylate (49a) 
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Benzyl (1R,3R)-2,2-dimethyl-3-phenylcyclopropane-1-carboxylate (49b) 
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Benzyl (1R,3R)-2,2-dimethyl-3-(p-tolyl)cyclopropane-1-carboxylate (49c) 
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Benzyl (1S,2S)-2-(4-methoxyphenyl)cyclopropane-1-carboxylate (50a) 
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Benzyl (1S,2S)-2-phenylcyclopropane-1-carboxylate (50b) 
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Benzyl (1S,2S)-2-(4-fluorophenyl)cyclopropane-1-carboxylate (50d) 
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19F NMR: 
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Benzyl (1R,3R)-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropane-1-carboxylate 
(54a) 
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Benzyl (1R,3R)-2,2-dimethyl-3-(prop-1-en-2-yl)cyclopropane-1-carboxylate (54b) 
 
 
Experimental section 
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Benzyl (1R,3R)-3-(cyclohex-1-en-1-yl)-2,2-dimethylcyclopropane-1-carboxylate (54c) 
 
 
Chapter 6 
379 
 
Benzyl (1R,3R)-3-((E)-2-cyclopropylvinyl)-2,2-dimethylcyclopropane-1-carboxylate 
(54f) 
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(1R,3R)-3-(4-Methoxyphenyl)-2,2-dimethylcyclopropane-1-carboxylic acid (71) 
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 (1S,2S)-2-(4-Fluorophenyl)cyclopropane-1-carboxylic acid (72) 
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19F NMR: 
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4,5,6,7-Tetrachloro-1,3-dioxoisoindolin-2-yl (1R,3R)-3-(4-methoxyphenyl)-2,2-
dimethylcyclopropane-1-carboxylate (73)  
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4,5,6,7-Tetrachloro-1,3-dioxoisoindolin-2-yl (1S,2S)-2-(4-fluorophenyl)cyclopropane-
1-carboxylate (74) 
 
 
  
Chapter 6 
385 
 
19F NMR: 
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386 
 
1-((1R,3R)-2,2-dimethyl-3-(p-tolyl)cyclopropyl)-4-methoxybenzene (66) 
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1-((1R,3R)-3-(4-methoxyphenyl)-2,2-dimethylcyclopropyl)furan (67) 
 
 
Experimental section 
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1-((1R,3R)-3-((E)-2-cyclopropylvinyl)-2,2-dimethylcyclopropyl)-4-methoxybenzene 
(68) 
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1-Fluoro-4-((1S,2S)-2-phenylcyclopropyl)benzene (69) 
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19F NMR: 
 
  
Chapter 6 
391 
 
1-((1S,2S)-2-(Cyclohex-1-en-1-yl)cyclopropyl)-4-fluorobenzene (70) 
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19F NMR: 
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6.7. Determination of enantiomeric excesses 
6.7.1. HPLC Chromatograms for Chapter 2 
tert-Butyl (S,E)-(3-(phenylsulfonyl)-1-(p-tolyl)allyl)carbamate (5aa) 
The enantiomeric purity of compound 5aa was determined 
by chiral HPLC analysis (Chiralpak AD-H; 90:10 
hexane:iPrOH; 0.50 mL/min, λ = 230 nm) tR (major.) = 41.5 
min, tR (minor.) = 54.3 min. 85% ee. 
 
 Retention Time % Area 
1 52.270 51.83 
2 67.952 48.17 
 
 
 Retention Time % Area 
1 41.574 92.39 
2 54.284 7.61 
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tert-Butyl (S,E)-(1-phenyl-3-(phenylsulfonyl)allyl)carbamate (5ab) 
The enantiomeric purity of compound 5ab was determined by 
chiral HPLC analysis (Chiralpak IA; 90:10 hexane:iPrOH; 0.50 
mL/min, λ = 230 nm) tR (major.) = 35.8 min, tR (minor.) = 43.2 
min. 61% ee. 
 
 
 Retention Time % Area 
1 37.572 49.12 
2 44.698 50.88 
 
 
 
 
 
 
 Retention Time % Area 
1 35.821 80.74 
2 43.201 19.26 
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tert-Butyl (S,E)-(1-(4-methoxyphenyl)-3-(phenylsulfonyl)allyl)carbamate (5ac) 
The enantiomeric purity of compound 5ac was 
determined by chiral HPLC analysis (Chiralpak AD-H; 90:10 
hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR (major.) = 35.5 
min, tR (minor.) = 50.8 min. 77% ee. 
 
 
 Retention Time % Area 
1 34.161 49.01 
2 50.431 50.99 
 
 
 
 Retention Time % Area 
1 35.578 88.42 
2 50.817 11.58 
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tert-Butyl (S,E)-(3-(naphthalen-2-ylsulfonyl)-1-(p-tolyl)allyl)carbamate (5ba) 
The enantiomeric purity of compound 5ba was 
determined by chiral HPLC analysis (Chiralpak AD-H; 
90:10 hexane:iPrOH; 0.50 mL/min, λ = 230 nm) tR 
(major.) = 59.5 min, tR (minor.) = 66.2 min. 77% ee. 
 
 
 Retention Time % Area 
1 59,537 49,24 
2 66,201 50,76 
 
 
 
 Retention Time % Area 
1 66,033 88,47 
2 69,480 11,53 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(p-
tolyl)allyl)carbamate (5da) 
The enantiomeric purity of compound 5da was 
determined by chiral HPLC analysis (Chiralpak IC; 
98:2 hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR 
(major.) = 28.1 min, tR (minor.) = 36.4 min. >99% ee. 
 
 
 Retention Time % Area 
1 26.565 50.28 
2 33.577 49.72 
 
 
 
 
 
 
 
 Retention Time % Area 
1 28.187 99.96 
2 36.403 0.04 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-phenylallyl)carbamate 
(5db) 
The enantiomeric purity of compound 5db was 
determined by chiral HPLC analysis (Chiralpak IC; 99:1 
hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR (major.) = 
60.5 min, tR (minor.) = 73.1 min. >99% ee. 
 
 
 
 Retention Time % Area 
1 57.294 53.90 
2 69.770 46.10 
 
 
 
 
 Retention Time % Area 
1 60.460 100.00 
2 71.341 0.00 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(4-
methoxyphenyl)allyl)carbamate (5dc) 
The enantiomeric purity of compound 5dc was 
determined by chiral HPLC analysis (Chiralpak IC; 
98:2 hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR 
(major.) = 40.9 min, tR (minor.) = 49.8 min. >99% 
ee. 
 
 
 
 
 
 Retention Time % Area 
1 42.251 50.46 
2 51.197 49.54 
 
 
 
 
 
 
 
 
 
 
 
 Retention Time % Area 
1 40.584 99.77 
2 50.158 0.23 
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Methyl (S,E)-4-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-((tert-
butoxycarbonyl)amino)allyl)benzoate (5dd) 
The enantiomeric purity of compound 5dd was 
determined by chiral HPLC analysis (Chiralpak 
IC; 95:5 hexane:iPrOH; 1.00 mL/min, λ = 230 nm) 
tR (minor.) = 34.0 min, tR (major.) = 38.1 min. 
90% ee. 
 
 Retention Time % Area 
1 34.728 50.04 
2 39.483 49.96 
 
 
 Retention Time % Area 
1 33.996 5.36 
2 38.071 94.64 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(4-
chlorophenyl)allyl)carbamate (5de) 
The enantiomeric purity of compound 5de was 
determined by chiral HPLC analysis (Chiralpak AD-H; 
98:2 hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR 
(major.) = 16.6 min, tR (minor.) = 19.2 min. >99% ee. 
 
 Retention Time % Area 
1 16.602 51.92 
2 19.211 48.08 
 
 Retention Time % Area 
1 16.858 99.94 
2 19.297 0.06 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(2-
chlorophenyl)allyl)carbamate (5df) 
The enantiomeric purity of compound 5df was 
determined by chiral HPLC analysis (Chiralpak AD-H; 98:2 
hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR (minor.) = 
29.2 min, tR (major.) = 47.7 min. 68% ee. 
 
 Retention Time % Area 
1 29.083 50.49 
2 47.835 49.51 
 
 
 Retention Time % Area 
1 29.190 16.26 
2 47.710 83.74 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(4-methoxy-3-
methylphenyl)allyl)carbamate (5dg) 
The enantiomeric purity of compound 5dg was 
determined by chiral HPLC analysis (Chiralpak IC; 
98:2 hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR 
(major.) = 32.1 min, tR (minor.) = 38.5 min. >99% 
ee. 
 
 Retention Time % Area 
1 32.480 50.07 
2 38.511 49.93 
 
 
 Retention Time % Area 
1 32.127 99.72 
2 37.927 0.28 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(3,4-
dimethoxyphenyl)allyl)carbamate (5dh) 
The enantiomeric purity of compound 5dh was 
determined by chiral HPLC analysis (Chiralpak IC; 
95:5 hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR 
(minor.) = 15.1 min, tR (major.) = 17.2 min. >99% 
ee. 
 
 Retention Time % Area 
1 15.096 49.58 
2 17.231 50.42 
 
 
 Retention Time % Area 
1 15.207 0.39 
2 17.224 99.61 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(naphthalen-2-
yl)allyl)carbamate (5di) 
The enantiomeric purity of compound 5di was 
determined by chiral HPLC analysis (Chiralpak AD-
H; 99:1 hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR 
(minor.) = 41.7  min, tR (major.) = 60.5 min. 88% ee. 
 
 Retention Time % Area 
1 41.729 50.18 
2 60.525 49.82 
 
 
 Retention Time % Area 
1 38.899 6.39 
2 56.052 93.61 
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tert-Butyl (S,E)-(3-((3,5-bis(trifluoromethyl)phenyl)sulfonyl)-1-(thiophen-2-
yl)allyl)carbamate (5dj) 
The enantiomeric purity of compound 5dj was 
determined by chiral HPLC analysis (Chiralpak IC; 98:2 
hexane:iPrOH; 1.00 mL/min, λ = 230 nm) tR (major.) = 
24.5 min, tR (minor.) = 31.1 min. 94% ee. 
 
 Retention Time % Area 
1 25.096 48.29 
2 30.913 51.71 
 
 
 Retention Time % Area 
1 24.446 96.34 
2 31.127 3.66 
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6.7.2. HPLC Chromatograms for Chapter 3 
(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(phenyl)methyl)pyridine N-
oxide (15aa) 
The enantiomeric purity of compound 15aa was determined by 
chiral HPLC analysis (Chiralpak IC; 60:40 hexane:EtOH; 0.50 mL/min, 
λ = 210 nm) tR (minor.) = 8.1 min, tR (major.) = 10.4 min. 90% ee. 
 
 Retention Time % Area 
1 8.125 50.46 
2 10.430 49.54 
 
 
 
 
 Retention Time % Area 
1 7.999 94.67 
2 10.267 5.33 
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(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(p-tolyl)methyl)pyridine N-
oxide (15ba) 
The enantiomeric purity of compound 15ba was determined by 
chiral HPLC analysis (Chiralpak IA; 80:20 hexane:EtOH; 0.50 
mL/min, λ = 210 nm) tR (minor.) = 21.8 min, tR (major.) = 48.7 min. 
82% ee. 
 
 
 Retention Time % Area 
1 20.819 48.64 
2 47.922 51.36 
 
 
 
 Retention Time % Area 
1 21.715 8.92 
2 48.798 91.08 
 
  
2
0
.8
1
9
4
7
.9
2
2
A
U
0.00
0.02
0.04
0.06
0.08
0.10
Minutes
0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 55.00 60.00
2
1
.7
1
5
4
8
.7
9
8
A
U
0.00
0.02
0.04
0.06
0.08
0.10
0.12
Minutes
0.00 5.00 10.00 15.00 20.00 25.00 30.00 35.00 40.00 45.00 50.00 55.00 60.00
Chapter 6 
409 
 
(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(4-
methoxyphenyl)methyl)pyridine N-oxide (15ca) 
The enantiomeric purity of compound 15ca was determined by 
chiral HPLC analysis (Chiralpak IA; 80:20 hexane:EtOH; 0.50 
mL/min, λ = 210 nm) tR (minor.) = 28.3 min, tR (major.) = 65.7 
min. 76% ee. 
 
 
 Retention Time % Area 
1 27.748 50.31 
2 66.646 49.69 
 
 
 
 
 Retention Time % Area 
1 28,347 11,91 
2 65,686 88,09 
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(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(4 
bromophenyl)(cyano)methyl)pyridine 1-oxide (15da) 
The enantiomeric purity of compound 15da was determined by 
chiral HPLC analysis (Chiralpak IA; 90:10 hexane:EtOH; 1.00 
mL/min, λ = 210 nm) tR (minor.) = 26.8 min, tR (major.) = 56.6 min. 
92% ee. 
 
 
 Retention Time % Area 
1 28.336 50.27 
2 59.940 49.73 
 
 
 
 
 Retention Time % Area 
1 26.792 3.93 
2 56.633 96.07 
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(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(4-
(methoxycarbonyl)phenyl)methyl)pyridine N-oxide (15ea) 
The enantiomeric purity of compound 15ea was determined 
by chiral HPLC analysis (Chiralpak IA; 60:40 hexane:EtOH; 
0.50 mL/min, λ = 210 nm) tR (minor.) = 13.9 min, tR (major.) = 
23.0 min. 93% ee. 
 
 
 Retention Time % Area 
1 13.800 50.70 
2 22.772 49.30 
 
 
 
 
 Retention Time % Area 
1 13.895 3.46 
2 22.964 96.54 
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(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(4-
(trifluoromethyl)phenyl)methyl)-6-bromopyridine N-oxide (15fa) 
The enantiomeric purity of compound 15fa was determined 
by chiral HPLC analysis (Chiralpak IA; 95:5 hexane:EtOH; 1.00 
mL/min, λ = 230 nm) tR (minor.) = 35.7 min, tR (major.) = 91.0 
min. 88% ee. 
 
 
 Retention Time % Area 
1 35.001 47.20 
2 92.321 52.80 
 
 
 
 
 Retention Time % Area 
1 35.717 6.36 
2 91.023 93.64 
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(S)-2-((1,2-bis(tert-butoxycarbonyl)hydrazinyl)(cyano)(thiophen-3-yl)methyl)pyridine 
N-oxide (15ga) 
The enantiomeric purity of compound 15ga was determined by 
chiral HPLC analysis (Chiralpak IA; 70:30 hexane:EtOH; 0.50 mL/min, 
λ = 210 nm) tR (minor.) = 15.1 min, tR (major.) = 23.8 min. 90% ee. 
 
 
 Retention Time % Area 
1 15.385 50,46 
2 24.941 49,54 
 
 
 
 Retention Time % Area 
1 15.039 5,43 
2 23.821 94,57 
 
  
A
U
0,00
0,02
0,04
0,06
0,08
Minutes
0,00 5,00 10,00 15,00 20,00 25,00 30,00 35,00 40,00
1
5
,3
8
5
2
4
,9
4
1
A
U
0,00
0,05
0,10
0,15
Minutes
0,00 5,00 10,00 15,00 20,00 25,00 30,00 35,00 40,00
1
5
,0
3
9 2
3
,8
2
1
Experimental section 
414 
 
(S)-2-((1,2-bis((benzyloxy)carbonyl)hydrazinyl)(4-
bromophenyl)(cyano)methyl)pyridine N-oxide (15db) 
The enantiomeric purity of compound 15db was determined by 
chiral HPLC analysis (Chiralpak IA; 60:40 hexane:EtOH; 0.80 
mL/min, λ = 210 nm) tR (minor.) = 17.3 min, tR (major.) = 27.6 min. 
90% ee. 
 
 
 Retention Time % Area 
1 14.700 51.01 
2 23.833 48.99 
 
 
 
 Retention Time % Area 
1 17.251 5.19 
2 27.593 94.81 
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(S)-2-((1,2-bis((benzyloxy)carbonyl)hydrazinyl)(cyano)(4-
(methoxycarbonyl)phenyl)methyl)pyridine N-oxide (15eb) 
The enantiomeric purity of compound 15eb was determined 
by chiral HPLC analysis (Chiralpak IA; 70:30 hexane:EtOH; 
0.50 mL/min, λ = 210 nm) tR (minor.) = 52.3 min, tR (major.) = 
63.2 min. 90% ee. 
 
 
 Retention Time % Area 
1 52.137 50.72 
2 64.057 49.28 
 
 
 
 Retention Time % Area 
1 52.257 5.43 
2 63.225 94.57 
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2-((1S,2R)-1-((tert-Butoxycarbonyl)amino)-3-oxo-3-phenoxy-1-(p-tolyl)propan-
2yl)pyridine N-oxide (18a) 
The enantiomeric purity of compound 18a was determined by 
chiral HPLC analysis (Chiralpack IC; 50:50 Hexane:Ethanol; 0.7 
mL/min,  = 210 nm) tR = 10.1 min (anti, major.), 11.4 min (anti, 
minor.), 14.0 min (syn), 23.7 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
10.963 33.59 
12.334 31.64 
15.278 17.32 
25.985 17.45 
 
 
Retention Time % Area 
10.076 98.33 
11.350 0.65 
13.977 0.51 
23.723 0.51 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-1-oxo-3-phenylpropan-2-
yl)pyridine N-oxide (18b) 
The enantiomeric purity of compound 18b was determined by 
chiral HPLC analysis (Chiralpack IC; 60:40 Hexane:Ethanol; 0.5 
mL/min,  = 210 nm) tR = 15.6 min (anti, major.), 17.0 min (anti, 
minor.), 31.9 min (both syn enantiomers). dr 99:1; 99% ee. 
 
Retention Time % Area 
15.602 31.22 
16.995 31.20 
31.928 37.58 
 
 
Retention Time % Area 
15.447 100.00 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(4-methoxyphenyl)-1-
oxopropan-2-yl)pyridine N-oxide (18c) 
The enantiomeric purity of compound 18c was determined 
by chiral HPLC analysis (Chiralpak AD-H; 20:80 
Hexane:Ethanol; 0.5 mL/min,  = 270 nm) tR = 16.0 min (anti, 
major.), 30.2 min (anti, minor.), 68.0 min (syn), 111.0 min 
(syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
15.887 33.60 
30.249 32.67 
67.951 16.84 
111.014 16.90 
 
 
Retention Time % Area 
16.103 100.00 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(4-
(methoxycarbonyl)phenyl)-1-oxopropan-2-yl)pyridine N-oxide (18d) 
The enantiomeric purity of compound 18d was 
determined by chiral HPLC analysis (Chiralpack IC; 70:30 
Hexane:Ethanol; 0.5 mL/min,  = 210 nm) tR = 30.2 min 
(anti, minor.), 31.6 min (anti, major.), 42.7 min (syn), 58.0 
min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
30.210 30.56 
31.590 31.05 
42.665 20.43 
57.988 17.96 
 
 
Retention Time % Area 
31.577 100.00 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(4-methoxy-3-
methylphenyl)-1-oxopropan-2-yl)pyridine N-oxide (18g) 
The enantiomeric purity of compound 18g was determined 
by chiral HPLC analysis (Chiralpack IC; 50:50 Hexane:Ethanol; 
0.5 mL/min,  = 210 nm) tR = 14.0 min (anti, minor.), 16.8 min 
(syn), 17.8 min (anti, major.), 27.7 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
14.059 36.74 
16.849 13.03 
17.780 37.14 
27.772 13.09 
 
 
Retention Time % Area 
13.979 0.30 
16.771 0.02 
17.766 99.59 
27.743 0.09 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(3,4-dimethoxyphenyl)-1-
oxopropan-2-yl)pyridine N-oxide (18h) 
The enantiomeric purity of compound 18h was determined 
by chiral HPLC analysis (Chiralpack IC; 70:30 Hexane:Ethanol; 
0.7 mL/min,  = 210 nm) tR = 21.3 min (anti, major.), 23.1 min 
(anti, minor.), 32.1 min (syn), 46.2 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
21.408 40.11 
23.535 41.04 
32.077 9.49 
46.262 9.36 
 
 
Retention Time % Area 
21.346 99.69 
23.069 0.28 
32.127 0.03 
46.223 0.01 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(naphthalen-2-yl)-1-
oxopropan-2-yl)pyridine N-oxide (18i) 
The enantiomeric purity of compound 18i was determined by 
chiral HPLC analysis (Chiralpack IC; 50:50 Hexane:Ethanol; 0.7 
mL/min,  = 210 nm) tR = 9.2 min (anti, minor.), 10.4 min (anti, 
major.), 12.1 min (syn), 15.4 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
9.129 32.85 
10.253 32.27 
11.642 17.60 
15.140 17.28 
 
 
Retention Time % Area 
9.217 0.26 
10.356 99.65 
12.057 0.06 
15.413 0.03 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-1-oxo-3-(thiophen-2-
yl)propan-2-yl)pyridine N-oxide (18j) 
The enantiomeric purity of compound 18j was determined by chiral 
HPLC analysis (Chiralpack IC; 80:20 Hexane:Ethanol; 0.5 mL/min,  
= 210 nm) tR = 32.7 min (anti, minor.), 34.8 min (anti, major.), 69.0 
min (syn), 89.2 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
32.804 30.37 
35.254 30.34 
68.708 19.64 
89.617 19.66 
 
 
Retention Time % Area 
32.718 0.48 
34.761 96.94 
68.963 0.19 
89.224 2.39 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-1-oxo-3-(o-tolyl)propan-2-
yl)pyridine N-oxide (18l) 
The enantiomeric purity of compound 18l was determined by chiral 
HPLC analysis (Chiralpack IC; 50:50 Hexane:Ethanol; 0.5 mL/min,  
= 210 nm) tR = 12.2 min (anti, major.), 13.7 min (anti, minor.), 16.7 
min (syn), 31.9 min (syn). dr 99:1; 99% ee. 
 
 
Retention Time % Area 
12.247 34.18 
13.707 34.61 
16.706 15.96 
31.850 15.25 
 
 
Retention Time % Area 
12.208 100.00 
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2-((2R,3S)-1-(Benzyloxy)-3-(4-bromophenyl)-3-((tert-butoxycarbonyl)amino)-1-
oxopropan-2-yl)pyridine N-oxide (18m) 
The enantiomeric purity of compound 18m was determined by 
chiral HPLC analysis (Chiralpack IC; 60:40 Hexane:Ethanol; 0.5 
mL/min,  = 210 nm) tR = 12.1 min (anti, major.), 13.4 min (anti, 
minor.), 15.0 min (syn), 22.4 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
12.092 31.40 
13.355 31.10 
14.999 18.79 
22.413 18.71 
 
 
Retention Time % Area 
12.672 100.00 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(3-chlorophenyl)-1-
oxopropan-2-yl)pyridine N-oxide (18n) 
The enantiomeric purity of compound 18n was determined by 
chiral HPLC analysis (Chiralpak IC; 20:80 Hexane:Ethanol; 0.5 
mL/min,  = 210 nm) tR = 25.5 min (anti, major.), 27.0 min (anti, 
minor.), 43.5 min (syn), 48.1 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
25.502 30.31 
26.932 30.24 
43.510 19.75 
48.098 19.71 
 
 
Retention Time % Area 
25.939 100.00 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(2-nitrophenyl)-1-
oxopropan-2-yl)pyridine N-oxide (18o) 
The enantiomeric purity of compound 18o was determined by 
chiral HPLC analysis (Chiralpack IA; 20:80 Hexane:Ethanol; 0.5 
mL/min,  = 210 nm) tR = 14.0 min (anti, minor.), 17.4 min (anti, 
major.), 32.3 min (syn), 48.8 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
13.984 11.66 
17.304 39.23 
32.322 11.33 
48.842 37.78 
 
 
Retention Time % Area 
17.488 100.00 
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2-((2R,3S)-1-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)-3-(furan-2-yl)-1-oxopropan-
2-yl)pyridine N-oxide (18p) 
The enantiomeric purity of compound 18p was determined by chiral 
HPLC analysis (Chiralpack IC; 80:20 Hexane:Ethanol; 0.5 mL/min,  
= 210 nm) tR = 26.0 min (anti, major.), 27.1 min (anti, minor.), 43.6 
min (syn), 48.4 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
25.958 27.32 
27.149 28.88 
43.645 21.46 
48.444 22.34 
 
 
Retention Time % Area 
25.960 100.00 
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2-((2R,3S)-1-(Benzyloxy)-3-(((benzyloxy)carbonyl)amino)-1-oxo-3-(p-tolyl)propan-2-
yl)pyridine N-oxide (22) 
The enantiomeric purity of compound 22 was determined by 
chiral HPLC analysis (Chiralpak IC; 50:50 Hexane:Ethanol; 0.5 
mL/min,  = 210 nm) tR = 21.5 min (anti, minor.), 24.3 min 
(anti, major.), 31.0 min (syn), 41.3 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
21.176 33.58 
24.214 34.69 
30.609 16.01 
40.776 15.72 
 
 
Retention Time % Area 
21.476 0.25 
24.348 99.68 
31.002 0.05 
41.304 0.02 
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2-((1S,2R)-1-(((Benzyloxy)carbonyl)amino)-3-(tert-butoxy)-3-oxo-1-(p-tolyl)propan-2-
yl)pyridine N-oxide (23) 
The enantiomeric purity of compound 23 was determined by 
chiral HPLC analysis (Chiralpak IC; 60:40 Hexane:Ethanol; 0.5 
mL/min,  = 210 nm) tR = 18.7 min (anti, major.), 30.9 min (anti, 
minor.), 35.1 min (syn), 44.9 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
21.434 34.79 
30.898 34.31 
35.089 15.60 
44.911 15.31 
 
 
Retention Time % Area 
18.682 100.00 
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2-((1S,2R)-1-((tert-Butoxycarbonyl)amino)-3-methoxy-3-oxo-1-(p-tolyl)propan-2-
yl)pyridine N-oxide (24) 
The enantiomeric purity of compound 24 was determined by 
chiral HPLC analysis (Chiralpak IC; 50:50 Hexane:Ethanol; 0.5 
mL/min,  = 210 nm) tR = 12.6 min (anti, minor.), 15.0 min (anti, 
major.), 20.9 min (syn), 22.8 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
12.157 35.39 
14.406 35.86 
19.966 14.34 
22.067 14.41 
 
 
Retention Time % Area 
12.617 0.33 
15.073 99.30 
20.940 0.33 
22.817 0.04 
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4-Bromo-2-((1S,2R)-1-((tert-butoxycarbonyl)amino)-3-methoxy-3-oxo-1-(p-
tolyl)propan-2-yl)pyridine N-oxide (25) 
The enantiomeric purity of compound 25 was determined by 
chiral HPLC analysis (Chiralpak IC; 50:50 Hexane:Ethanol; 0.7 
mL/min,  = 210 nm) tR = 8.3 min (anti, minor.), 10.3 min (anti, 
major.), 12.5 min (syn), 15.6 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
8.255 27.80 
10.250 27.79 
12.420 22.24 
15.521 22.17 
 
 
Retention Time % Area 
8.283 0.42 
10.263 98.59 
12.499 0.88 
15.643 0.11 
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2-((1S,2R)-1-((tert-Butoxycarbonyl)amino)-1-(3-chlorophenyl)-3-methoxy-3-
oxopropan-2-yl)-4-(tert-butyl)pyridine N-oxide (26) 
The enantiomeric purity of compound 26 was determined by 
chiral HPLC analysis (Chiralpak IC; 50:50 Hexane:Ethanol; 0.7 
mL/min,  = 210 nm) tR = 7.5 min (anti, minor.), 10.8 min (anti, 
major.), 13.4 min (syn), 19.3 min (syn). dr 99:1; 98% ee. 
 
Retention Time % Area 
7.632 13.22 
11.138 12.40 
13.877 37.32 
19.800 37.06 
 
 
Retention Time % Area 
7.521 1.10 
10.806 98.77 
13.436 0.13 
19.306 0.00 
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2-((1S,2R)-1-(((Benzyloxy)carbonyl)amino)-3-methoxy-3-oxo-1-(p-tolyl)propan-2-yl)-
4-(tert-butyl)pyridine N-oxide (27) 
The enantiomeric purity of compound 27 was determined by 
chiral HPLC analysis (Chiralpak IC; 50:50 Hexane:Ethanol; 0.7 
mL/min,  = 210 nm) tR = 14.0 min (anti, minor.), 28.0 min (syn), 
40.2 min (anti, major.), 80.4 min (syn). dr 99:1; 98% ee. 
 
Retention Time % Area 
13.735 19.02 
26.280 31.10 
39.049 18.01 
79.805 31.87 
 
 
Retention Time % Area 
14.006 1.37 
28.017 0.10 
40.211 98.51 
80.350 0.02 
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2-((1S,2R)-1-(((Benzyloxy)carbonyl)amino)-3-(tert-butoxy)-3-oxo-1-(p-tolyl)propan-2-
yl)quinoline N-oxide (29) 
The enantiomeric purity of compound 29 was determined 
by chiral HPLC analysis (Chiralpak IC; 70:30 
Hexane:Ethanol; 0.7 mL/min,  = 210 nm) tR = 8.6 min 
(anti, minor.), 11.9 min (syn, minor.), 13.0 min (anti, 
major.), 16.2 min (syn, major.). dr 10:1; 92% ee. 
 
Retention Time % Area 
8.229 42.55 
11.296 7.27 
12.378 42.93 
15.403 7.25 
 
 
Retention Time % Area 
8.652 3.95 
11.929 0.55 
12.977 86.88 
16.273 8.62 
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2-(2-(Benzyloxy)-1-(3-((tert-butoxycarbonyl)amino)-2-oxoindolin-3-yl)-2-
oxoethyl)pyridine N-oxide (32)  
The enantiomeric purity of compound 32 was determined by 
chiral HPLC analysis (Chiralpak IC + Chiralpak IC; 50:50 
Hexane:Ethanol; 0.5 mL/min,  = 210 nm) tR = 28.9 min (diast. A, 
major.), 36.1 min (diast. B, minor.), 37.8 min (diast. A, minor.), 41.8 
min (diast. B, major). dr 10:1; 80% ee. 
 
Retention Time % Area 
29.317 27.72 
36.716 21.78 
38.269 28.28 
42.471 22.23 
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2-(2-(Benzyloxy)-1-(3-((tert-butoxycarbonyl)amino)-5-methoxy-2-oxoindolin-3-yl)-2-
oxoethyl)pyridine N-oxide (33) 
The enantiomeric purity of compound 33 was determined by 
chiral HPLC analysis (Chiralpak IC; 80:20 Hexane:Ethanol; 0.7 
mL/min,  = 210 nm) tR = 43.1 min (diast. A, major.), 62.6 min 
(diast. B, minor.), 66.4 min (diast. A, minor.), 73.7 min (diast. 
B, major). dr 6.1:1; 78% ee. 
 
Retention Time % Area 
43.129 28.81 
54.307 21.16 
58.058 21.40 
64.186 28.63 
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Benzyl 3-((tert-butoxycarbonyl)amino)-2-(pyridin-2-yl)-3-(p-tolyl)propanoate (18’a) 
The enantiomeric purity of compound 18’a was determined by 
chiral HPLC analysis (Chiralpak IC; 50:50 Hexane:iPrOH; 0.5 
mL/min,  = 210 nm) tR = 10.9 min (anti), 12.7 min (anti), 19.1 
min (syn), 24.1 min (syn). dr 2.6:1; 0/0% ee. 
 
Retention Time % Area 
10.855 30.29 
12.557 30.71 
18.793 19.56 
24.117 19.44 
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tert-Butyl 3-(((benzyloxy)carbonyl)amino)-2-(quinolin-2-yl)-3-(p-tolyl)propanoate 
(29’) 
The enantiomeric purity of compound 29’ was 
determined by chiral HPLC analysis (Chiralpak IC; 80:20 
Hexane:iPrOH; 0.5 mL/min,  = 210 nm) tR = 13.4 min 
(diast. A, minor.), 18.5 min (diast. A, major.), 26.6 min 
(diast. B, major.), 30.0 min (diast. B, minor.). dr 1.1:1; 
31/9% ee. 
 
Retention Time % Area 
13.681 30.13 
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Benzyl (2R,3S)-3-((tert-butoxycarbonyl)amino)-3-phenyl-2-(pyridin-2-yl)propanoate 
(18’b) 
The enantiomeric purity of compound 18’b was determined by 
chiral HPLC analysis (Chiralpak IC; 80:20 Hexane:Isopropanol; 0.5 
mL/min,  = 210 nm) tR= 16.6 min (anti, minor.), 19 min (anti, 
major.), 39.5 min (syn), 42.2 min (syn). dr 99:1; 99% ee. 
 
Retention Time % Area 
16.624 30.26 
19.360 30.23 
39.508 19.56 
42.177 19.95 
 
 
Retention Time % Area 
16.617 0.05 
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6.7.3. SFC Chromatograms for Chapter 4 
1-Benzyl 2-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl) (1R,2S)-3,3-
dimethylcyclopropane-1,2-dicarboxylate (47) 
The enantiopurity of compound 47 was determined by chiral 
SFC analysis (Daicel IB; 40% MeOH / CO2 (4 mL/min), 1600 psi 
backpressure; λ = 238 nm). tR (major) = 4.14 min, tR (minor) = 
5.84 min. 96% ee. 
 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 47.rac 49.70 50.30 -0.59 1001432 1013351 
2 47 2.10 97.90 -95.81 59016 2757971 
Experimental section 
442 
 
1-Benzyl 2-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl) (1R,2S)-cyclopropane-1,2-
dicarboxylate (48) 
The enantiopurity of compound 48 was determined by chiral SFC 
analysis (Daicel IA; 40% MeOH / CO2 (4 mL/min), 1600 psi 
backpressure; λ = 238 nm). tR (minor) = 8.91 min, tR (major) = 
10.59 min, 96% ee. 
 
 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 48.rac 49.81 50.19 -0.37 810298 816337 
2 48 97.93 2.07 95.87 1409889 29746 
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Benzyl (1R,3R)-3-(4-methoxyphenyl)-2,2-dimethylcyclopropane-1-carboxylate (49a) 
The enantiopurity of compound 49a was determined by chiral SFC 
analysis (Daicel IG; 30% MeOH / CO2 (4 mL/min), 1600 psi 
backpressure; λ = 226 nm). tR (minor) = 1.64 min, tR (major) = 1.94 
min, 94% ee. 
 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 49a.rac 50.08 49.92 0.16 1004427 1001168 
2 49a 3.02 96.98 -93.96 37897 1216276 
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Benzyl (1R,3R)-2,2-dimethyl-3-phenylcyclopropane-1-carboxylate (49b) 
The enantiopurity of compound 49b was determined by chiral SFC 
analysis (Daicel IG; 5% MeOH / CO2 (4 mL/min), 1600 psi backpressure; 
λ = 214 nm). tR (minor) = 2.63 min, tR (major) = 2.94 min, 96% ee. 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 49b.rac 50.81 49.19 1.63 2535829 2454532 
2 49b 98.31 1.69 96.62 631958 10873 
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Benzyl (1R,3R)-2,2-dimethyl-3-(p-tolyl)cyclopropane-1-carboxylate (49c) 
The enantiopurity of compound 49c was determined by chiral SFC 
analysis (Daicel IC; 5% MeOH / CO2 (4 mL/min), 1600 psi backpressure; 
λ = 214 nm). tR (minor) = 1.59 min, tR (major) = 1.72 min, 94% ee. 
 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 49c.rac 49.48 50.52 -1.03 19158 19557 
2 49c 2.17 97.83 -95.66 55005 2478703 
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Benzyl (1S,2S)-2-(4-methoxyphenyl)cyclopropane-1-carboxylate (50a) 
The enantiopurity of compound 50a was determined by chiral SFCa 
analysis (Daicel IG; 35% MeOH / CO2 (4 mL/min), 1600 psi backpressure; 
λ = 231 nm). tR (minor) = 2.57 min, tR (major) = 3.19 min, 94% ee. 
 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 50a.rac 50.03 49.97 0.06 1441439 1439750 
2 50a 96.83 3.17 93.65 3113934 102106 
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Benzyl (1S,2S)-2-phenylcyclopropane-1-carboxylate (50b) 
The enantiopurity of compound 50b was determined by chiral SFC analysis 
(Daicel IBN; 5% MeOH / CO2 (4 mL/min), 1600 psi backpressure; λ = 214 
nm). tR (minor) = 2.51 min, tR (major) = 2.65 min, 94% ee. 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 50b.rac 50.03 49.97 0.06 1220379 1218859 
2 50b 2.98 97.02 -94.03 131289 4267884 
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Benzyl (1S,2S)-2-(4-fluorophenyl)cyclopropane-1-carboxylate (50d) 
The enantiopurity of compound 50d was determined by chiral SFC analysis 
(Daicel IG; 15% MeOH / CO2 (4 mL/min), 1600 psi backpressure; λ = 214 
nm). tR (minor) = 2.04 min, tR (major) = 2.37 min, 94% ee. 
 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 50d.rac 50.11 49.89 0.21 550860 548550 
2 50d 97.09 2.91 94.19 2050447 61378 
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Benzyl (1R,3R)-2,2-dimethyl-3-(2-methylprop-1-en-1-yl)cyclopropane-1-carboxylate 
(54a) 
The enantiopurity of compound 54a was determined by chiral SFC 
analysis (Daicel IG; 3% MeOH / CO2 (2.8 mL/min), 1600 psi 
backpressure; λ = 214 nm). tR (minor) = 2.51 min, tR (major) = 2.80 min, 
93% ee. 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 54a.rac 51.77 48.23 3.54 1404027 1308039 
2 54a 
7 
96.66 3.34 93.32 704365 24339 
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Benzyl (1R,3R)-2,2-dimethyl-3-(prop-1-en-2-yl)cyclopropane-1-carboxylate (54b) 
The enantiopurity of compound 54b was determined by chiral SFC 
analysis (Daicel IG; 5% MeOH / CO2 (4 mL/min), 1600 psi backpressure; 
λ = 214 nm). tR (minor) = 1.71 min, tR (major) = 1.95 min, 92% ee. 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 54b.rac 49.56 50.44 -0.88 698704 711163 
2 54b 96.06 3.94 92.13 1264765 51816 
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Benzyl (1R,3R)-3-(cyclohex-1-en-1-yl)-2,2-dimethylcyclopropane-1-carboxylate (54c) 
The enantiopurity of compound 54c was determined by chiral SFC 
analysis (Daicel IA; 3% iPrOH / CO2 (4 mL/min), 1600 psi backpressure; 
λ = 214 nm). tR (minor) = 2.29 min, tR (major) = 2.45 min, 94% ee. 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 54c.rac 51.46 48.54 2.92 203210 191684 
2 54c 97.24 2.76 94.47 639907 18195 
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Benzyl (1R,3R)-3-((E)-2-cyclopropylvinyl)-2,2-dimethylcyclopropane-1-carboxylate 
(54f) 
The enantiopurity of compound 54f was determined by chiral SFC 
analysis (Daicel IG; 5% MeOH / CO2 (4 mL/min), 1600 psi 
backpressure; λ = 214 nm). tR (minor) = 1.87 min, tR (major) = 2.27 
min, 95% ee. 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 54f.rac 49.99 50.01 -0.02 914357 914778 
2 54f 97.69 2.31 95.38 2147962 50815 
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1-((1R,3R)-2,2-dimethyl-3-(p-tolyl)cyclopropyl)-4-methoxybenzene (66) 
The enantiopurity of compound 66 was determined by chiral SFC 
analysis (Daicel IA; 10% MeOH / CO2 (4 mL/min), 1600 psi 
backpressure; λ = 229 nm). tR (minor) = 1.38 min, tR (major) = 2.13 
min, 94% ee. 
 
 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 66.rac 50.13 49.87 0.25 920447 915827 
2 66 3.18 96.82 -93.64 17343 527747 
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1-((1R,3R)-3-(4-methoxyphenyl)-2,2-dimethylcyclopropyl)furan (67) 
The enantiopurity of compound 67 was determined by chiral SFC 
analysis (Daicel IG; 7% MeOH / CO2 (4 mL/min), 1600 psi 
backpressure; λ = 226 nm). tR (minor) = 1.50 min, tR (major) = 2.38 
min, 95% ee. 
 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 67.rac 50.31 49.69 0.62 91426 90292 
2 67 2.59 97.41 -94.83 19676 741098 
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1-((1R,3R)-3-((E)-2-cyclopropylvinyl)-2,2-dimethylcyclopropyl)-4-methoxybenzene 
(68) 
The enantiopurity of compound 68 was determined by chiral SFC 
analysis (Daicel IA; 2% MeOH / CO2 (4 mL/min), 1600 psi 
backpressure; λ = 220 nm). tR (minor) = 1.47 min, tR (major) = 1.76 
min, 94% ee. 
 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 68.rac 50.29 49.71 0.58 359064 354917 
2 68 2.92 97.08 -94.16 56993 1895962 
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1-Fluoro-4-((1S,2S)-2-phenylcyclopropyl)benzene (69) 
The enantiopurity of compound 69 was determined by chiral SFC analysis 
(Daicel IA; 10% MeOH / CO2 (4 mL/min), 1600 psi backpressure; λ = 226 nm). 
tR (major) = 1.30 min, tR (minor) = 1.43 min, 93% ee. 
 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 69.rac 49.93 50.07 -0.14 717813 719807 
2 69 96.49 3.51 92.97 1223765 44579 
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1-((1S,2S)-2-(Cyclohex-1-en-1-yl)cyclopropyl)-4-fluorobenzene (70) 
The enantiopurity of compound 70 was determined by chiral SFC analysis 
(Daicel IG; 2% iPrOH / CO2 (3.3 mL/min), 1600 psi backpressure; λ = 229 
nm). tR (major) = 2.24 min, tR (minor) = 2.46 min, 95% ee. 
 
 
 
 Compound ent1 ent2 ee Ent1 Ent2 
1 70.rac 50.01 49.99 0.02 222078 222011 
2 70 97.61 2.39 95.22 416652 10208 
  
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Publications 
  
 
 
Base-Catalyzed Asymmetric α‑Functionalization of
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ABSTRACT: A simple, new strategy for the direct
asymmetric α-functionalization of 2-alkyl azaarenes is
described. Speciﬁcally, a Brønsted base catalyzed conjugate
addition of substituted 2-cyanomethylpyridine (and
pyrazine) N-oxides to acrylate equivalents to aﬀord
hitherto elusive 2-tert-alkyl azaaryl adducts with high
enantioselectivity (up to 94% ee) is realized. Extension of
the method to the α-amination reaction by using
azodicarboxylate esters as electrophiles is also demon-
strated. Key for success is the N-oxide functionality of
substrates that acts as a removable activating and
stereodirecting group. A bifunctional Brønsted base
catalyst bearing a squaramide with an attached bulky silyl
group is also disclosed.
Ortho-substituted pyridines, and more generally azaarenes, are
widespread structural motifs,1 with the congeners that are chiral
by virtue of an α-stereogenic o-substituent constituting a relevant
subset. Several catalytic approaches have recently been reported
for the enantioselective synthesis of such chiral units via α-
deprotonation of the corresponding 2-alkylazaarene (Figure
1a).2 With simple 2-alkylazaarenes (R: H, alkyl, etc.), substrate
activation requires a (super)stoichiometric strong base
(LiHMDS),3 thus compromising practicality. Milder conditions
have been developed for the α-functionalization of preactivated
substrates, i.e. those with electron-withdrawing substituents
(EWG) in either the azaarene ring (p-nitroazaarenes, poly-
heteroarenes) or the Cα (α-ester, amide, electron-deﬁcient aryl)
or both (strategy 2).4,5 In these cases, α-stereogenic 2-substituted
azaarenes can be produced with high enantioselectivities by
means of a chiral Pd(II),4a Ni(II),4b or amine5 catalyst and no
base, or only a catalytic weak base, being added. However, none
of these methods address the generation of a quaternary α-
stereocenter,6 an issue of general importance in organic
synthesis,7 and of particular signiﬁcance to the present context
given the interest in 1,1-diaryl quaternary compounds as
potential pharmacophores.8 Here we describe an enantioselec-
tive α-functionalization of o-substituted azaarenes that is
complementary to the known procedures in several aspects: (i)
successfully aﬀords hitherto elusive all-carbon quaternary
stereocenters, (ii) relies on a Brønsted base activation strategy
using newly designed chiral bifunctional organocatalysts, and
(iii) uses azaarene N-oxides, more speciﬁcally substituted 2-
cyanomethyl azaarene N-oxides,9 as enabling substrates (Figure
1b).
Two key elements that make 2-cyanomethyl azaarene N-
oxides perfect substrate candidates a priori are their relatively
high CH Brønsted acidity as compared to most alkylazaarenes10
and the presence of the N → O group as a potentially
coordinating site for catalyst binding.11 Considering this, one
might expect that bifunctional chiral Brønsted bases12 would
suﬃce for an eﬀective α-deprotonation and subsequent stereo-
selective bond formation. As far as we know azaarene N-oxides
have not been investigated within the context of asymmetric
C(sp3)−H functionalizations.13,14
At the outset, we studied the behavior of 2-cyanoalkylpyridine
1 under Brønsted base catalysis conditions and selected as a
reaction partner enone 2, an acrylate surrogate well suited for
organocatalytic conjugate additions.15 As data in Scheme 1 show,
the reactions in the presence of typical cinchona-based
bifunctional Brønsted base catalysts C1−C316 were sluggish,
with low conversion after an extended reaction time (96 h) at
room temperature and poor enantioselectivity. The reactivity
increased substantially when the correspondingN-oxide17 4awas
employed instead (Scheme 2). Thus, conversions of ∼70% were
reached after 2 days at ambient temperature, almost complete at
40 °C, but with yet suboptimal enantioselectivity (75% ee with
C3). After some additional screening,18 we tested the new
Received: December 22, 2015
Published: March 3, 2016
Figure 1. Enantioselective routes to o-substituted azaarenes.
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squaramide catalysts19 C4−C9, which show as a novel feature a
R4Si site that might play a steric function or even participate in
some speciﬁcN−O→ Si interaction.20 Gratifyingly, we observed
that while catalystC4 performed poorly, the reaction between 4a
and 2 catalyzed by C5 and C6 led to the highest selectivity (90%
and 92% ee, respectively) in dichloromethane at temperatures in
the range 20−40 °C.
Catalyst C6 was thus selected to explore the scope of the
reaction with a range of 2-cyanomethyl azaareneN-oxides (Table
1). It was found that under these conditions the reaction
tolerated well pyridine N-oxides 4 with both electron-releasing
and -withdrawing groups attached at diﬀerent positions of the
pyridine ring. Similarly, substrates bearing both electron-rich and
-poor aryl substituents at Cα were equally eﬀective in providing
the corresponding addition adducts 5 in generally very good yield
and high enantioselectivity. Nonetheless, the method was less
tolerant with the corresponding α-alkyl substituted 2-(cyano-
methyl)azaareneN-oxides 4 (R = alkyl, products 5m−o). Then it
was proven that variation of the azaarene system did not
apparently aﬀect the reaction course, as the corresponding 2-
cyanomethylpyrazines 6 added eﬃciently to 2 to aﬀord the
quaternary 1,1′-diaryls 7a−c in good yields. In these latter cases
somewhat lower enantioselectivity was obtained, although they
were still acceptable considering the challenge posed by these
types of targets.9
It was subsequently proven that these 2-cyanomethylpyridine
N-oxides may also work as enabling substrates for stereoselective
α-heterofunctionalization reactions under conditions similar to
those mentioned above. For example, the pyridine N-oxide 4a
reacted with di(tert-butyl) azodicarboxylate 8 in the presence of
10 mol % C8 to aﬀord α-aminated adduct 10a in 90% isolated
yield and 81% ee. The same reaction using catalyst C9 led to
product with 90% ee. The scope of this α-amination process using
either di(tert-butyl) or dibenzyl azodicarboxylate 8 or 9 as the
amination reagent was brieﬂy investigated for a range of 2-
cyanoalkylpyridine N-oxides. As data collected in Table 2 show,
reactions proceeded successfully to give products 10 and 11 in
good yields and ee’s, with catalyst C9 providing the best results
for most of the entries. Once again, the parent pyridine 1 proved
to be less eﬃcient for these transformations. For instance, the
reaction of 1 and di(tert-butyl) azodicarboxylate 8 in the
presence of 10 mol % catalystC8 proceeded to a limited extent of
30% conversion after 15 h at 0 °C.
The detailed mechanism of these catalytic transformations as
well as the precise role played by each element involved remains
unclear. However, data in Figure 2 indicate that the N-oxide
group and its ortho-relationship to the cyanoalkyl substituent are
key for optimal reaction outcome.21 As a general trend, for the
three positional isomers ortho,meta, and para, the corresponding
pyridine N-oxide was more reactive than the parent pyridine in
Scheme 1. Diﬃculties in the Brønsted Base Catalyzed
Reaction of 2-Cyanomethylpyridine 1
Scheme 2. Catalyst Screening for the Reaction of 2-
Cyanomethylpyridine N-Oxide 4a and Enone 2
Table 1. Scope of the Reaction of α-Substituted 2-
(Cyanomethyl)azaarene N-Oxides with 2 Catalyzed by C6a
aReactions conducted on a 0.2 mmol scale in 1 mL of CH2Cl2 (molar
ratio of 4 or 6/2/catalyst 1:3:0.1). Yields of isolated product.
Enantioselectivity determined by HPLC analysis using a chiral
stationary phase. b20 mol % C6 was used.
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both the catalyzed and uncatalyzed reactions. In fact, among the
six experiments involving cyanoalkylpyridines, only that using p-
cyanoalkylpyridine in the presence of C6 provided practical
conversion after 24 h, leading to a racemic product. Equally
important is the position of the N-oxide group relative to the
cyanoalkyl substituent on the ring. Among the three cyanoalkyl-
pyridine N-oxides, the meta and para isomers proved to be
inherently more reactive than the ortho isomer, also in the
presence of catalystC6, although both led to essentially a racemic
product. In contrast, the ortho isomer led to 92% ee.
Adducts obtained from these catalytic transformations can be
modiﬁed in several ways. For instance, reduction of the N-oxide
group on adduct 5a by treatment with (Bpin)2
22 aﬀorded
pyridine 12 in 74% isolated yield and unaltered enantioselectivity
(92% ee, Scheme 3). Furthermore, elaboration of the ketol
moiety in adducts by applying well established protocols allows
the corresponding ketone (13), aldehyde (14), or carboxylic acid
(15) product to be furnished from a common single intermediate
and with formation of acetone as the only organic waste. These
results are of particular interest in that the direct conjugate
addition of azaareneN-oxide 4 to simple enones, i.e. methyl vinyl
ketone, or unsaturated esters, i.e. methyl acrylate, did not work
under the present catalytic conditions. In addition, the reaction
of 4 with acrolein aﬀorded the corresponding 1,4-addition
adduct, but with a poor 15% ee. Another illustration of the
synthetic versatility of adducts is shown by transformation of the
nitrile carboxylic acid 15 into the protected amine 16 and amide
17, respectively. On the other hand, the conﬁguration of adducts
5a and 10a was established by single crystal X-ray analysis,23 and
for the remaining adducts it was assigned by assuming a uniform
reaction mechanism.
In summary, a mild and highly enantioselective carbo- and
hetero-α-functionalization of 2-cyanomethylazaareneN-oxides is
developed as the ﬁrst direct and asymmetric entry to α-
quaternary alkylazaarenes. The N-oxide group plays a strategic
role as a removable activating and stereodirecting element in
conjunction with newly designed bifunctional squaramide-
Brønsted base catalysts bearing a bulky silyl group. While the
speciﬁc role played by the silyl group during catalysis is not clear
yet,24 its easy variation makes this new subclass of squaramides
very attractive for further asymmetric transformations under
proton transfer conditions. Work to address these issues is
currently underway in our laboratory.
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/jacs.5b13385.
Crystallographic data for 5a (CIF)
Crystallographic data for a 10a derivative (CIF)
Experimental details, NMR spectra, HPLC chromato-
grams (PDF)
■ AUTHOR INFORMATION
Corresponding Author
*claudio.palomo@ehu.es
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
Financial support was provided by the University of the Basque
Country UPV/EHU (UFI 11/22), Basque Government (Grant
Table 2. α-Amination Reaction of 4a
aReactions conducted on a 0.2 mmol scale in 1 mL of CH2Cl2 at 0 °C
(molar ratio of 4/8 or 9/catalyst 1:1.5:0.1). Yields of isolated product.
Enantioselectivity determined by HPLC analysis using a chiral
stationary phase.
Figure 2. Conversion after 24 h for the reactions of 2 with o-, m-, and p-
substituted cyanoalkylpyridines and pyridine N-oxides.
Scheme 3. Elaboration of 5a into Quaternary 1,1′-Diarylsa
aReagents and conditions: (a) MeMgBr, 0 °C, 6 h; (b) NaIO4,
MeOH/H2O, rt, 1 h; (c) BH3·THF, THF, 0 °C, 2 h, then MeOH; (d)
Et3N, DPPA, toluene, 80 °C, 2 h; (e)
tBuOH, 50 °C, 16 h; (f) H2SO4
(conc.), rt, overnight.
Journal of the American Chemical Society Communication
DOI: 10.1021/jacs.5b13385
J. Am. Chem. Soc. 2016, 138, 3282−3285
3284
No IT-628-13), and Ministerio de Economiá y Competitividad
(Grant CTQ2013-47925-C2), Spain. J.I. thanks UPV/EHU and
I.B. thanks the Basque Government for fellowships. We also
thank SGIker (UPV/EHU) for providing NMR, HRMS, and X-
ray resources.
■ REFERENCES
(1) Pyridine is the second (near the ﬁrst) most commonly used
nitrogen heterocycle among all U.S. FDA approved pharmaceuticals,
with the pyridine C2-position being the preferred position for
substitution. Vitaku, E.; Smith, D. T.; Njardarson, J. T. J. Med. Chem.
2014, 57, 10257−10274.
(2) Perspective: Best, D.; Lam, H.W. J. Org. Chem. 2014, 79, 831−845.
(3) (a) Trost, B. M.; Thaisrivongs, D. A. J. Am. Chem. Soc. 2008, 130,
14092−14093. (b) Trost, B. M.; Thaisrivongs, D. A. J. Am. Chem. Soc.
2009, 131, 12056−12057. (c) Trost, B. M.; Thaisrivongs, D. A.;
Hartwig, J. J. Am. Chem. Soc. 2011, 133, 12439−12441. Also, see:
(d) Hamana, H.; Sugasawa, T. Chem. Lett. 1984, 13, 1591−1594.
(4) (a) Best, D.; Kujawa, S.; Lam, H. W. J. Am. Chem. Soc. 2012, 134,
18193−18196. (b) Fallan, C.; Lam, H. W. Chem. - Eur. J. 2012, 18,
11214−11218.
(5) (a) Vera, S.; Liu, Y. K.; Marigo, M.; Escudero-Adan, E. C.;
Melchiorre, P. Synlett 2011, 2011, 489−494. (b) Li, T.; Zhu, J.; Wu, D.;
Li, X.; Wang, S.; Li, H.; Li, J.; Wang, W. Chem. - Eur. J. 2013, 19, 9147−
9150. (c)Meazza, M.; Ceban, V.; Pitak, M. B.; Coles, S. J.; Ríos, R.Chem.
- Eur. J. 2014, 20, 16853−16857. For related reactions involving 2-
alkylarenes, see: (d) Cid, M. B.; Duce, S.; Morales, S.; Rodrigo, E.;
García-Ruano, J. L. Org. Lett. 2010, 12, 3586−3589. (e) Duce, S.; Jorge,
M.; Alonso, I.; García-Ruano, J. L.; Cid, M. B. Eur. J. Org. Chem. 2013,
2013, 7067−7075. (f) Dell’Amico, L.; Companyo,́ X.; Naicker, T.;
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Strategy for Stereoselective Metal-free a-Functionalization of
2-Azaaryl Acetates with N-Boc Imines
IÇaki Bastida, Marcos San Segundo, Rosa Ljpez, and Claudio Palomo*[a]
Abstract: We report the first diastereo- and enantioselec-
tive formal Mannich reaction of 2-pyridyl acetates which
gives rise to a- and b-functionalized 2-substituted pyri-
dines. Key for success is the previous azaarene N-oxide
formation enabling a-carbon deprotonation by a mild bi-
functional Brønsted base and subsequent reaction with N-
Boc imines under almost perfect stereocontrol.
ortho-Substituted pyridines are common fragments in chiral
compounds with biological activity.[1] In particular, a- and/or b-
functionalized 2-substituted pyridines containing amino
groups in the b-position constitute a relevant family
(Figure 1).[2] A practical synthesis of these structural motifs is
the addition of 2-alkylazaarene anions to imines, the Mannich-
like reaction.[3] Although several methods relaying on metal
catalyzed approaches have been reported,[4] they have some
limitations. Firstly, the majority of the methods reported until
now are racemic. Secondly, 2-methylazaarenes, for example, 2-
methyl pyridines are the substrates of choice to generate a
single stereocenter, and finally, high temperatures are needed
for reaction success, a condition that may cause subsequent
C@N elimination.[4e,f]
In these methods the metal generally coordinates with the
nitrogen atom of the azaarene ring thus facilitating a-carbon
deprotonation of the 2-alkyl substituent using a Brønsted base,
typically a tertiary amine base. However, the development of
an enantioselective variant of these approaches becomes com-
plicated by competitive metal/amine base self-quenching. Not
surprisingly, there is only one example that documents the
asymmetric synthesis of this kind of motif. The group of Lam[5]
reported that high levels of stereoselectivity may be achieved
in the reaction of 2-alkyl azaarenes with N-Boc imines promot-
ed by a chiral PdII-bis(oxazoline) complex without the need of
a tertiary amine base (Scheme 1a). However, although in this
approach the acetate counterion appears to act as base, the
incorporation of an electron withdrawing group (EWG) into
the azaarene ring is required to facilitate the generation of the
chiral azaallylmetal species.[6] To date, only a few methods to
control reactivity and stereoselectivity in reactions involving 2-
alkyl azaarenes for example, 2-alkyl pyridines and quinolines
have been accomplished through different approaches.[7] Re-
cently, we have reported the enantioselective a-functionaliza-
tion of (cyanomethyl)azaarene N-oxides to generate quaternary
stereogenic centers with high enantioselectivity.[8] In this ap-
proach, the N-oxide functionality plays a dual role. On the one
hand, it facilitates deprotonation at the exocyclic azaarene a-
carbon side chain, and on the other hand, it acts as a powerful
temporary stereodirecting group. Herein we report further util-
ity of this hitherto unknown property of the N-oxide function-
ality[9, 10] by documenting the first catalytic highly diastereo-
and enantioselective Mannich reaction of azaaryl N-oxide ace-
tates (Scheme 1b).
To establish the feasibility of the proposal the reaction of
pyridyl N-oxide acetate 1A with N-Boc imine 2a in the pres-
Figure 1. Drug candidates for the treatment of schizophrenia (Gly-T1 inhibi-
tor), neurodegenerative (lanicemine) and lipid metabolism disorders. Scheme 1. Enantioselective Mannich-like reactions of 2-alkylazarenes.
[a] I. Bastida, M. S. Segundo, Dr. R. Ljpez, Prof. Dr. C. Palomo
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ence of several benchmark Brønsted base catalysts[11] was ex-
amined first. The results (Table 1) soon revealed that not only
the N-oxide group, but also the Brønsted base were critical for
success. For example, using chiral thiourea tertiary amines
C1,[12] and C2,[13] the urea catalyst C3[13] and squaramides C4[14]
and C5,[8] low transformations were observed even when the
reactions were carried out for extended reaction time or at
40 8C (entries 1–5). These catalysts exerted low asymmetric in-
ductions, especially in terms of anti :syn diastereoselectivity,
which was clearly negligible. In particular, catalyst C5, which
efficiently promoted the a-functionalization of 2-(cyanomethy-
l)azaarene N-oxides, performed very poorly in the current Man-
nich reaction (entry 5). Next we examined catalysts C6–9,[15]
which display three consecutive hydrogen bond donors and
would thus provide an additional site for hydrogen-bond-ac-
cepting substrate recognition.[16] It was gratifying to observe
that after 64 hours of stirring at room temperature, these cata-
lysts exhibited high (88%, entry 6) and complete conversion
(entries 7–9). Most remarkably, the corresponding Mannich
adduct 3a was produced with high anti :syn ratio (5.7:1–>9:1)
and enantioselectivity (96–99% ee) regardless the nature of
the R substituent in the catalyst. After some additional screen-
ing,[17] catalyst C8 enabled the production of 3a as the only
detectable diastereomer in 99% ee (entry 10).
Importantly, this result provides new insight on the versatili-
ty of ureidopeptide-based bifunctional Brønsted bases to pro-
mote reactions under mild proton transfer conditions and, for
the first time, their utility for construction of configurationally
labile tertiary stereocenters.[15]
Next, we explored the generality of the optimized procedure
for N-oxide 1A with a range of N-Boc imines under the action
of catalyst C8. As the data in Table 2 show, N-Boc imines 4
with either electron-donating or electron-withdrawing groups
at the ortho, meta or para positions on the aromatic ring, as
well as heteroaromatic groups, were equally tolerated to pro-
duce the corresponding Mannich adducts 6Aa–m as sole dia-
stereomers with excellent enantiomeric excess (99%).
In this study we employed 20 mol% of catalyst but it is im-
portant to note that using 5–10 mol% of catalyst loading the
reactions proceeded equally well without compromising either
selectivity or chemical yield (Table 2, adducts 6Af and 6Ag).
The relative and absolute configuration of the anti enantiomer
were determined by X-ray crystallographic analysis of 6Ad.[18]
Additionally, the reaction with N-Cbz (benzyloxycarbonyl)
imine 5a produced the corresponding Mannich adduct 7Aa
with an identical level of stereocontrol, and the tert-butyl and
methyl pyridyl N-oxide acetates 2A and 3A were also compati-
ble with the reaction conditions and produced the Mannich
adducts 8Aa and 9Aa, respectively, with equal high stereose-
lectivity. This functional group compatibility represents an im-
portant advantage for subsequent adduct manipulations. Fur-
thermore, the methodology was also suitable for substituted
pyridyl N-oxides such as 3B and 3C which reacted with either
N-Boc or N-Cbz imines using 10 mol% of catalyst C8 to afford
adducts 9Ba, 9Cf and 10Ca.
The importance of the N-oxide functionality in these reac-
tions was clearly illustrated from the reaction of 11 with 4a
(Scheme 1a), which proceeded sluggishly and with poor ste-
reoselectivity to give 12 essentially in racemic form. On the
other hand, other azaaryl N-oxide acetates such as 13 per-
formed well to produce the corresponding Mannich adduct 14,
albeit with slightly diminished diastereoselectivity
(Scheme 2b). Again, the presence of the N-oxide functionality
was essential to ensure reactivity and selectivity (Scheme 2b)
as illustrated from the reaction of quinoyl acetate 15 with
imine 5a.
It can be argued that the anti adducts obtained in the Man-
nich reaction are produced under kinetic control, since their
diastereomeric ratio and enantiomeric excess remained con-
stant during the reaction progress despite the basic reaction
conditions. For instance, upon complete transformation into
the Mannich adduct 6Aa, its configurational stability was
maintained at 0 8C and slowly diminished at room tempera-
ture; after 96 hours the diastereomeric ratio turned to 7.3:1
(99% ee) (Figure 2). This stability of the anti adduct 6Aa, could
be explained by the difficulty of the catalyst to remove the re-
maining hydrogen from the exocyclic tertiary a-carbon. Less-
hindered and stronger bases, such as Et3N, DBU (1,8-diazabicy-
Table 1. Catalyst screening for the Mannich reaction of 1A and N-Boc imine
4a.[a]
Entry Cat. T [8C], t [h][b] Conv. [%][c,d] anti :syn ee [%][e]
1 C1 RT, 140 60 0.6:1 17/79
2 C2 40, 70 42 0.8:1 3/16
3 C3 40, 40 28 0.7:1 50/74
4 C4 40, 48 20 0.9:1 4/53
5 C5 RT, 48 21 2:1 30/52
6 C6 RT, 64 88 6.7:1 99/99
7 C7 RT, 64 >95 5.7:1 99/98
8 C8 RT, 64 >95 9:1 96/94
9 C9 RT, 64 >95 9:1 98/55
10 C8 0, 48[f] >95 >20:1 99
[a] Reactions conducted on a 0.12 mmol scale in 0.5 mL of CH2Cl2 (molar
ratio of 1A :4a, 1:1.2). [b] Determined by 1H NMR. [c] Determined by 1H NMR
and corroborated by HPLC. [d] Configuration for the syn isomer not deter-
mined. [e] for both diastereomers determined by chiral HPLC. [f] Molar ratio
of 1A :4a, 1:2.
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clo[5.4.0]undec-7-ene), and even the analogous bifunctional
urea C3 promoted epimerization at shorter reaction times at
room temperature (Figure 2).
Taking into account the diastereo- and enantioselectivity ob-
served, the capacity of the ureidopeptide-based catalyst to ex-
clusively produce anti-configured adducts could be consistent
with a tight transition state (TS), in which multiple hydrogen
bonding interactions may be operating in unison, such as in
the model depicted in Figure 3 for adducts 6A.[19]
The excellent stereoselectivity displayed by the catalytic
system provides a quick access to a- and/or b-functionalized 2-
substituted azaarenes (Scheme 3). For instance, reduction of
the N-oxide group in adduct 6Ac by treatment with (Bpin)2
[20]
afforded the corresponding pyridine derivative 17 in 80% iso-
lated yield with remarkable unaltered diastereoselectivity
(d.r.>20:1). Simple elaborations of the ester moiety, in adduct
6Aa and 9Aa, brought into the corresponding aminoalcohol
18 and b2,3-amino acid 19, respectively.
Furthermore, enantiopure benzylic amines[21] can also be
easily obtained from the Mannich adducts through hydrogena-
tion and subsequent N-oxide group reduction step that pro-
ceeds with concomitant in situ decarboxylation, probably
through intermediate I assisted by the pyridine nitrogen
atom.[22] For instance, 6Aa led to the benzylic amine 20 in
Table 2. Scope for the catalytic Mannich reaction of pyridyl N-oxide ace-
tates.[a]
[a] Reactions conducted on a 0.12 mmol scale in 0.5 mL of CH2Cl2 (molar
ratio of 1–3 :4/5, 1:2). [b] d.r. Determined by 1H NMR and corroborated by
HPLC. [c] ee Determined by chiral HPLC.
Scheme 2. Effect of the N-oxide group on reactivity and stereoselectivity in
the Mannich reaction of a) pyridyl acetate 11 b) quinoline acetates 13 and
15.
Figure 2. Effect of the Brønsted base on the configurational stability of the
anti adduct.
Figure 3. Proposed model that might account for the observed preference
for anti adduct formation.
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90% overall yield and, most importantly, adduct 6Ac was
easily transformed into Lanicemine (AZD-6765), which is a
potent low-trapping NMDA (N-methyl-d-aspartate) receptor
agonist,[2b–e] usually prepared by resolutive methods[2b]
(Scheme 3).
Eventually, the suitability of this highly stereoselective Man-
nich reaction to generate quaternary estereogenic centers was
briefly examined (Scheme 4). For example, the pyridyl N-oxide
acetate 1A reacted with N-Boc imine derived isatines 23 and
24 in the presence of either catalyst C8 or C9 to produce the
corresponding Mannich adducts in good yield and selectivity.
Although it seems that the stereochemical outcome of the re-
action may be improved, what is once again significant is the
essential lack of reactivity observed in the reaction of 24 with
the parent 2-pyridyl acetate 11 to generate the corresponding
quaternary stereocenter.[17]
In summary, we report the first direct catalytic formal Man-
nich reaction of 2-pyridyl acetates to produce b-amino esters
with very high diastereo- and enantioselectivity. This realization
was feasible thanks to an emergent strategy for exocyclic a-
carbon functionalization that employs the azaarene N-oxide
functionality as a powerful activating and stereodirecting
group.[9] We also demonstrated that, in contrast to other
known parent catalysts, ureidopeptide-based Brønsted bases
not only provide excellent levels of asymmetric induction but
also are able to preserve the configurational stability of the
azaarene adducts during reaction. From these results, it may
be anticipated that this new strategy will find future applica-
tions in the field of azaarene chemistry.
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Bifunctional Brønsted Base Catalyzed Mannich Reaction of b-
Alkoxy a-Keto Amides: Stereocontrolled Entry to Functionalized
Amino Diols
Haizea Echave, IÇaki Bastida, Rosa Ljpez, and Claudio Palomo*[a]
Abstract: The potential of b-alkoxy a-keto amides as pro-
nucleophiles in the enantioselective Mannich type reac-
tion with p-nosyl imines is presented. The proper combi-
nation of b-alkoxy a-keto amides and a squaramide-based
Brønsted base catalyst produced highly enantioenriched
Mannich adducts, which may be transformed into func-
tionalized amino diols.
A common feature of enantiopure compounds possessing
therapeutic potential, is their dense functionalization contain-
ing numerous and frequently contiguous stereogenic centers,
with linear polyols[1] and amino polyols[2] being some of the
most frequent fragments contained in this class of molecules.
a-Hydroxyketones are traditionally the pronucleophiles of
choice in direct asymmetric and catalytic aldol[3] and Mannich[4]
reactions to assemble 1,2-diols and 1,2-amino alcohols, which,
after subsequent stereoselective reduction of the ketone
moiety, afford the corresponding enantioenriched fragments
with three contiguous stereogenic centers. In contrast, b-hy-
droxy-1,2-dicarbonyl compounds that present extra reactive
centers and offer the opportunity for the construction of
highly functionalized moieties have been much less explored
(Scheme 1a). The inherent high reactivity of the dicarbonyl
function against nucleophilic 1,2-additions has hampered their
use as pronucleophiles[5] until recently, when progress in selec-
tive activation modes has made it possible to enhance their
nucleophilic character towards cross-condensation instead of
self-condensation.[6] Most examples employ piruvates and
belong to the Michael type reaction, for which metallo- and or-
ganocatalytic approaches have been described,[7] whereas the
aldol[8] and Mannich-type reactions[9] have been scarcely exam-
ined. Trying to fill this gap, we have recently described the first
direct enantioselective cross-aldol reaction of b-alkoxy a-keto
amides with aldehydes catalyzed by a bifunctional Brønsted
base (Scheme 1b).[10] We now document the first direct Man-
nich-type reaction of these b-alkoxy a-keto amides, which fur-
ther proves their utility as efficient pronucleophile partners
and provides a route to highly versatile enantioenriched amino
polyols.
One problem associated with adducts from aldol and Man-
nich reactions with a-keto esters is their high tendency to cy-
clize and produce isotetronic acids and pyrrolones, respective-
ly, which would result in the loss of one of the stereogenic
centers generated during the reaction.[8, 9d,e]
Initially, we evaluated the reaction of a-keto amides 1a and
1b with different N-protected imines in the presence of several
bifunctional Brønsted base catalysts (Table 1). The experiments
soon revealed nosyl[11] protected imines to be the most suita-
ble azometines for this Mannich reaction. Nevertheless, to our
disappointment, ureidopeptide-based Brønsted base catalysts,
which were the most effective in promoting the parent stereo-
selective aldol reaction,[10] displayed poor control over the re-
action selectivity; the addition of either a-ketoamide 1a or 1b
to nosyl imines, promoted by catalysts C1 and C2, afforded
the corresponding Mannich adducts in generally good conver-
sion and high diastereoselectivity but poor enantioselectivities
Scheme 1. Polyols and amino polyols construction by direct catalytic aldol
and Mannich reactions.
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regardless of the reaction temperature (Table 1, entries 5–8).
Likewise, the thiourea catalysts C3[12] and C4[13] provided poor
enantiocontrol in the reaction of 1a with imine 7a (entries 9,
10). However, cyclization of the Mannich adducts was not ob-
served under the described reaction conditions. We were grati-
fied to find out that squaramide based Cinchona bases[14] (cata-
lysts C5–C9) provided high conversions and higher stereoselec-
tivities, being the best result achieved with catalyst C8, which
produced the Mannich adduct 10a with a 97:3 diastereomeric
ratio and 92% ee for the major diastereomer (entry 14).
The influence of solvent and temperature was evaluated
using catalyst C8 and, among the solvents, chloroform gave
the best results in the presence of molecular sieves; adduct
10a was obtained with 99:1 diastereomeric ratio and 92% ee
at @20 8C.[15]
It is also worth noting that catalysts C6–C9 belong to a new
modular subfamily of squaramides, which, by simply fine-
tuning the carboxamide function, offers several options for
better catalyst/substrate recognition compared with common
catalysts such as C5.[16]
Having optimized the reaction conditions, we examined the
scope of the transformation with respect to the azomethine
group. A representative selection of N-p-nosyl imines was sub-
jected to treatment with 1a to afford Mannich adducts 10 in
generally good diastereo- and enantioselectivities.
Again, and most importantly, in none of these reactions was
formation of cyclized product observed, thus enabling subse-
quent carbonyl reduction to produce amino diols in a concise
and simple way. The reduction step performed on the crude
reaction adducts 10 using K-Selectride provided anti,syn-amino
diols 11 (Table 2) in reasonably good yields upon isolation after
the two steps and with essentially complete stereoselectivity,
whereas the opposite syn,syn- isomers could be obtained
using Et3B/NaBH4 (vide infra). The absolute configuration was
determined for compound 11a by single-crystal X-ray structure
analysis and that of the remaining adducts was established by
assuming a uniform reaction mechanism.[17] As data in Table 2
show, N-p-nosyl protected imines with electron-donating or
-withdrawing substituents were equally competent reaction
partners, apparently irrespective of the p- or m-substitution
pattern for adducts monosubstituted (11a–g) and disubstitut-
ed (11 i–k) in the aromatic ring, producing enantiomeric ex-
cesses generally above 90%. Heteroaromatic imine such as 7 l
also produced the corresponding adduct 11 l with excellent
diastereoselectivity and high enantioselectivity. Nevertheless,
o-substitution considerably affected both diastereo- and enan-
tioselectivity of the reaction (adduct 11h). On the other hand,
reactions performed at 3 mmol scale showed no detrimental
effect on the stereochemical outcome (adduct 11a). In addi-
tion, when catalyst loading was lowered to 5 mol%, the reac-
tion occurred with identical levels of selectivity although
longer reaction times were required (adducts 11a, 11 f, and
11g). We also studied the Mannich reaction between a-keto
amide 1a and a representative selection of p-nosyl N-protect-
ed imines derived from aliphatic aldehydes. Imines derived
from a-branched alkyl aldehydes produced the corresponding
adducts 11m and 11n in high enantiomeric excesses and ex-
cellent diastereomeric ratios, whereas the lower asymmetric in-
duction exerted in the reaction with linear imine 7o could be
mitigated by recrystallization of the corresponding anti,syn
adduct 11o.
To further test the efficacy of this protocol, differently substi-
tuted a-keto amides were subjected to Mannich reaction
under the previous conditions. Satisfactorily, variations on the
substitution of both the amide and alkoxy moieties (R and R1,
respectively), were compatible with the methodology and, as
data in Table 3 show, results were consistently good. Diiso-
propyl a-keto amide 1c reacted with both aromatic and ali-
phatic p-nosyl N-protected imines to produce the correspond-
ing Mannich adducts 12 and 13 with high diastereoselectivity,
albeit with moderate enantioselectivity for the aliphatic adduct
13. Interestingly, the methodology resulted also compatible
Table 1. Nitrogen-protecting group in imine and catalyst screening for
the Mannich reaction of a-keto amides.[a–d]
Ent a-keto/Imine Cat T [8C], t [h] Conv [%][b] d.r.[c] ee [%][d]
1 1a/2 C1 0, 72 0 – –
2 1a/3 C1 0, 72 0 – –
3 1a/4 C1 @20, 120 80 85:15 34
4 1a/5 C1 @20, 120 0 – –
5 1a/6 C1 @20, 15 71 82:18 28
6 1a/7a C1 @20, 15 >95 94:6 30
7 1b/7a C2 @20, 17 >95 93:7 30
8 1b/7a C2 @60, 45 90 99:1 40
9 1a/7a C3 @20, 15 >95 94:4 @48
10 1a/7a C4 @20, 15 >95 95:5 @48
11 1a/7a C5 @20, 15 >95 94:6 88
12 1a/7a C6 @20, 15 >95 87:13 64
13 1a/7a C7 @20, 15 >95 95:5 92
14 1a/7a C8 @20, 15 >95 97:3 92
15 1a/7a C9 @20, 15 >95 90:10 80
[a] Reactions conducted on a 0.2 mmol scale in 0.5 mL of CH2Cl2 (mol
ratio of a-keto amide/imine, 1:1.5). [b] Determined by 1H NMR. [c] Deter-
mined by 1H NMR and corroborated by HPLC. [d] ee of the major diaste-
reomer determined by chiral HPLC.
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with morpholine derived a-keto amide 1d to produce the
enantioenriched adducts 14–16. Likewise, modification in the
nature of the alkoxy moiety did not substantially affect either
reactivity or selectivity (adducts 17–19), confirming the high
versatility of the method.
As noted above, the stereochemical outcome of the stereo-
selective reduction of the Mannich adducts, promoted by K-Se-
lectride, could be inverted (Scheme 2) to efficiently produce,
under treatment with Et3B/NaBH4, a 12:88 mixture of
anti,syn :syn,syn diastereoisomers from which the major syn,syn
adduct 20 was isolated in 58% yield. On the other hand, the
cleavage of the p-nosyl protecting group was efficiently pro-
moted in the presence of thiophenol and potassium carbon-
ate, to afford the corresponding amino diol 21 in high yield.[18]
An interesting feature of nosyl protected amines is that they
can be easily transformed in secondary amines through alkyla-
tion followed by deprotection.[19] Methylation of adduct 11a,
and subsequent p-nosyl cleavage, produced the corresponding
secondary amine 22 in 50% overall yield. This approach high-
lights the structural versatility of the catalytic Mannich reaction
displayed, because the nosyl group allows access to either pri-
mary or secondary amines. Also, the reduction of the amide
group, carried out using the borane tetrahydrofuran com-
plex[20] produced diamines 23 and 24 in good yields.
The diastereo- and enantioselectivity observed might be
consistent with a reaction model in which the Re face of the Z
Table 2. Mannich reaction scope of 1a with different N-p-nosyl imines
7.[a–d]
[a] Reactions conducted on a 0.15 mmol scale in 1.5 mL of CHCl3 (mol
ratio of 1a/7, 1:1.5 for aromatic imines; 1:3 for aliphatic imines). [b] Yield
of the isolated anti,syn adduct 11 after Mannich reaction and stereoselec-
tive reduction. [c] Syn,anti ratio determined by 1H NMR spectroscopy and
corroborated by HPLC for the Mannich adducts 10 before reduction.
[d] The ee value of the major diastereomer (syn Mannich adduct), before
reduction, was determined by chiral-phase HPLC. [e] Mannich reaction
carried out at 0 8C. [f] Determined after recrystallization of the corre-
sponding anti,syn adduct.
Table 3. Mannich reaction scope with different b-alkoxy a-keto am-
ides.[a–c]
[a] Reactions conducted on a 0.15 mmol scale in 1.5 mL of CHCl3 (mol
ratio of 1/7, 1:1.5 for aromatic imines; 1:3 for aliphatic imines). Yield of
the syn adduct after purification. [b] Syn,anti ratio determined by 1H NMR
spectroscopy and corroborated by HPLC. [c] The ee value of the major
diastereomer (syn Mannich adduct) was determined by chiral-phase
HPLC. [d] Reaction carried out at @40 8C.
Scheme 2. Elaboration of Mannich adducts into enantioenriched amino
diols.
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enolate approaches the Re face of the N-protected imine
(Figure 1). For this model, we propose that the deprotonated
nucleophile binds to the H-bond network, and the protonated
amine activates the electrophile while orienting its approach
during reaction.[21] As evidence in favor of this assumption, we
found that the chemical shift of the ortho-ArH in C8 is affect-
ed[22] (Dd= +0.06 ppm) by addition of 1 equivalent of a-keto
amide 1c, whereas it remains unaffected by addition of the
imine 7a. Furthermore, the singlet corresponding to the pro-
tons at the enolizable position in 1c splits into two peaks
upon addition of C8. This effect suggests catalyst C8 and the
a-keto amide interact strongly, so that the homotopic protons
in the achiral substrate become heterotopic and distinguisha-
ble in the substrate–catalyst complex.
In summary, we report the first direct catalytic formal Man-
nich reaction of b-alkoxy a-keto amides with p-nosyl N-protect-
ed imines that provides a quick entry for construction of
amino diols. The newly developed squaramide-based Brønsted
base catalyst employed promoted the transient generation of
a-keto amide enolates, regardless of the substitution pattern
at both the amide and alkoxy moieties, which reacted with
either aromatic and aliphatic imines in a highly stereoselective
fashion. The resulting Mannich adducts upon reduction pro-
duced highly enantioenriched linear anti,syn- and syn,syn-
amino diols containing three contiguous stereogenic centers
in an unprecedented way.
Experimental Section
To a cooled solution of the corresponding a-keto amide 1 (1 equiv,
0.15 mmol) squaramide-based catalyst C8 (0.02 equiv, 0.03 mmol)
and molecular sieves (pellets, 3 a, 0.1 g) in CHCl3 (1.5 mL) was
added the corresponding imine 7 (1.5 equiv for aromatic imines;
3 equiv for aliphatic imines) at the indicated temperature. The re-
sulting solution was stirred at the same temperature until com-
plete disappearance of 1. The reaction mixture was quenched with
HCl 0.1m (5 mL), the organic layer was washed with HCl 0.1m (3V
5 mL), dried over MgSO4, filtered, and concentrated in vacuo to
afford the corresponding crude Mannich adduct. To a cooled solu-
tion of the corresponding crude Mannich adduct in THF (1.5 mL)
was added K-Selectride (1m THF, 3–4 equiv) at @78 8C. After stirring
for 2 h, phosphate buffer pH 7 (0.5 mL) and EtOH (1.0 mL) were
successively added, followed by H2O2 (30%, 0.8 mL) five minutes
later. The reaction temperature was allowed to rise to room tem-
perature and the mixture was stirred for ten additional minutes.
Then, it was diluted with EtOAc (5 mL) and water (5 mL). The aque-
ous phase was extracted with EtOAc (3V5 mL), the organic layers
were combined, dried over MgSO4, filtered, and concentrated in
vacuo. The crude product was purified by flash column chromatog-
raphy (Hex/EtOAc) to afford the corresponding pure anti,syn com-
pounds.
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Building C(sp3)-rich complexity by combining 
cycloaddition and C–C cross-coupling reactions
tie–Gen Chen1,3, Lisa M. Barton1,3, Yutong Lin1,3, Jet tsien1, David Kossler1, Iñaki Bastida1, Shota Asai1, Cheng Bi1, Jason S. Chen1, 
Mingde Shan2, Hui Fang2, Francis G. Fang2, Hyeong-wook Choi2, Lynn Hawkins2, tian Qin1 & Phil S. Baran1*
Prized for their ability to rapidly generate chemical complexity 
by building new ring systems and stereocentres1, cycloaddition 
reactions have featured in numerous total syntheses2 and are a 
key component in the education of chemistry students3. Similarly, 
carbon–carbon (C–C) cross-coupling methods are integral to 
synthesis because of their programmability, modularity and 
reliability4. Within the area of drug discovery, an overreliance on 
cross-coupling has led to a disproportionate representation of flat 
architectures that are rich in carbon atoms with orbitals hybridized 
in an sp2 manner5. Despite the ability of cycloadditions to introduce 
multiple carbon sp3 centres in a single step, they are less used6. This 
is probably because of their lack of modularity, stemming from the 
idiosyncratic steric and electronic rules for each specific type of 
cycloaddition. Here we demonstrate a strategy for combining the 
optimal features of these two chemical transformations into one 
simple sequence, to enable the modular, enantioselective, scalable 
and programmable preparation of useful building blocks, natural 
products and lead scaffolds for drug discovery.
Retrosynthetic chemical analysis is built upon the strategic identifi-
cation of the reactions (transforms) that offer the greatest potential to 
simplify target preparation (the ‘T-goal’)3. To this end, the capacity of 
cycloadditions to generate complex ring systems and multiple bonds 
with precise stereochemical control is unmatched. By contrast, C–C 
cross-couplings such as Heck, Suzuki and Negishi reactions are capa-
ble of making only one bond at a time (most often between flat sp2 
systems)4, yet are the most used C–C bond forming methods in the 
patent literature7. To understand this phenomenon, it is worthwhile 
to compare the features of these two diverse reaction classes (Fig. 1a). 
Cycloadditions form two new sigma bonds, generally through con-
certed pathways that follow precise rules for predicting stereo- and 
regiochemistry. Starting with specialized building blocks that are 
designed to enable the reaction to take place cleanly, this process rapidly 
accesses complexity8. On the other hand, C–C cross-couplings form 
one new sigma bond between easily accessible building blocks, using 
a transition-metal catalyst to reliably and controllably produce new 
connections. What C–C cross-coupling lacks in terms of complexity 
generation, it makes up for in terms of sheer reliability and modularity.
These distinct features are illustrated by the syntheses of the alka-
loid epibatidine (1)9 and the commercial antihypertensive medicine 
Cozaar (2)10 (Fig. 1a). Epibatidine, coveted for its pronounced analgesic 
properties, has been prepared by total synthesis more than 60 times 
(see Supplementary Information for a complete listing). Of these 
syntheses, at least 31 have used cycloaddition chemistry as their key 
ring-constructing step. The vast majority of these approaches involve 
formation of the bridged pyrrolidine core, followed by stepwise, 
and often lengthy, pyridine incorporation. Meanwhile, medicinal 
agent 2, bereft of any stereogenic centres or topological complex-
ity, was heralded as one of the first examples of a ‘blockbuster’ drug. 
Both its discovery and its eventual manufacture used C–C cross- 
couplings (Ullmann and Suzuki reactions) for the key bond cleavage11,12. 
This facilitated both a convergent assembly and a modularity that per-
mitted the rapid exploration of hundreds of analogues.
Here, we sought to combine the innate complexity generation of 
cycloaddition with the simplicity and modularity of C–C coupling. 
When applied to structures such as 1, this strategy will permit the rapid 
generation of analogues, and when applied to medicinal programs such 
as 2, it will allow for the rapid exploration of otherwise challenging 
complex chemical space.
Building block 3, of hypothetical value in medicinal chemistry, rep-
resents the manifestation of this idea (Fig. 1b). Although its structure 
would seem to suggest that it could be formed through a Diels–Alder 
reaction, the relevant synthetic building blocks, structures 4 and 5, are 
not electronically matched and therefore one would expect no reaction 
to take place. Even if a workable enantioselective Diels–Alder reaction 
could be invented to achieve this transform, the strategy would suffer 
from a lack of modularity. In order to solve this problem, one could 
envisage using a hypothetical vicinal dihaloethylene (6) in place of 
5, with a fumarate-type dienophile such as 7 serving as a viable syn-
thetic equivalent. The favourable matched electronics of the dienophile 
should allow for a facile Diels–Alder reaction and subsequent radical 
cross-coupling (RCC).
To address the enantioselectivity challenge, a combination of trans-
forms was proposed (Fig. 1c). Maleic anhydride was chosen as a surro-
gate for the hypothetical chiral (pseudo)dihalide 6 given its inexpensive 
nature, ready participation in most cycloaddition modes ([2+1], [2+2], 
[3+2], [4+2]), and known desymmetrization through chiral Lewis-
base-mediated alcoholysis. Our sequence for generating complexity 
in a modular fashion involves five simple steps: first, cycloaddition 
to build a scaffold; second, desymmetrization to set absolute stereo-
chemistry; third, RCC to install a new C–C bond; fourth, hydrolysis; 
and fifth, RCC to forge another new C–C bond. The known versatility 
of RCC enables a range of functionalities to be installed, from aryl13 
and heteroaryl14 systems to alkenes15, alkynes16 and alkyl groups17. We 
describe here the preparation of more than 80 synthetic examples and 
multiple applications, covering a range of natural products (including 
the synthesis of 1) and real-world examples from industrial settings.
Studies commenced with Diels–Alder [4+2] cycloaddition (Fig. 2a), 
by which a large variety of enantiomerically enriched scaffolds could 
be produced in a simple modular fashion. First, scaffolds A1–A6 (A2 
being a Diels–Alder adduct and all others being derived from Diels–
Alder/hydrogenation) were desymmetrized using Deng’s conditions, 
with either quinine or quinidine used as the Lewis base to deliver mixed 
acids/esters in excellent enantioselectivity18. Next, the mono-acid 
substrate was subjected to successive Negishi13,15–17 and Suzuki14 type 
RCC reactions, depending on starting-material availability or individual 
preferences. In this manner, some of the most simple and inexpensive 
Diels–Alder adducts known (A1 costs US$38.54 per mol and A2 is 
US$9.52 per mol) can be transformed into enantioenriched products 
(11–63) of high value. Indeed, none of these products can at present be 
prepared using a Diels–Alder reaction (racemic or enantioenriched), 
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because in most cases the reaction would require both an electron-rich 
diene and an electron-rich dienophile and therefore is electronically 
unfavoured. Furthermore, controlling the chemoselectivity when 
there are multiple alkenes present in the dienophile is challenging 
using traditional Diels–Alder chemistry; however, with our method, 
diverse alkenes and alkynes can be easily installed post-cyclization, 
with excellent isomeric and geometrical purity (accessing 12, 15, 19, 
21, 25 and 31). Typically, scaffolds derived from Diels–Alder adducts 
A1–A6 have a clear retrosynthetic signature, wherein the electron- 
withdrawing groups on the dienophile have been homologated, 
alkylated, or degraded. Therefore, our approach allows access to 
the previously unexplored chemical space of electron-rich, chiral, 
1,2-disubstituted Diels–Alder scaffolds. Using the tactical combination 
outlined above, a virtually limitless array of substituents is now easily 
accessed, including halogenated arenes, Lewis-basic hetero cycles, 
α,β-unsaturated carbonyl groups, cyclopropanes, cyclobutanes, sulfur 
moieties, and alkenes. In the case of exo and endo isomers A4 and A5 
(both commercially available), the sequences converged to an identi-
cal product using the same coupling partners (27 could be prepared 
from A4 or A5).
As shown in Fig. 2b–d, the strategy outlined above could also be 
applied to [3+2], [2+2] and [2+1] cycloadditions. The vast scope 
observed with Diels–Alder chemistry was also seen in these cases, 
accessing substituents such as substituted olefins, terminal alkynes, 
homoallyl groups, and heterocycles. Pyrrolidine-containing systems 
could be derived from simple building blocks B1 and B2 (accessed 
through dipolar cycloaddition)19 to furnish 64–82 with high enanti-
omeric excess. Quick access to pyrrolidine-containing drug scaffolds 
is useful: historically these have been extremely relevant to medicinal 
chemists, with around 40 pharmaceuticals containing this motif20. 
As with the Diels–Alder adducts, none of these structures has been 
accessed before. Therefore, our approach serves as a modular entry to 
chiral variants of these coveted scaffolds.
In a similar vein, enantioenriched cyclopentenes were easily pro-
duced from palladium-catalysed, trimethylenemethane-based, formal 
[3+2] cycloaddition adduct B321. Such structures are highly challenging 
to access in any other way. Scaffolds C1 and C2, representing entry to 
[2+2]-derived systems, could be similarly processed. Modular access 
to enantioenriched cyclobutanes is important and useful given the 
strict electronic requirements for photochemical cycloaddition and the 
documented challenge in achieving general asymmetric induction22. 
Access to 1,2-disubstituted cyclobutanes (83–86, derived from C1) 
compares favourably with photochemical approaches to such systems 
that frequently give inseparable racemic mixtures of regiomers and 
diastereomers. Furthermore, access to tetrasubstituted, chiral cyclobu-
tanes is highly useful, as multiple families of dimeric and pseudodi-
meric cyclobutane natural products contain such structural motifs23. 
Structures such as 87, which would be otherwise extremely difficult to 
access through conventional photochemistry, can be easily prepared 
in enantioenriched manner from maleic anhydride heterodimeri-
zation adducts such as C2. Finally, the strategy outlined above when 
applied to [2+1] cycloadditions using scaffolds D1 and D2 is a major 
departure from the common retrosynthetic logic normally applied to 
such structures. Conventional approaches, usually involving late-stage 
cyclopropanation of an olefin, suffer from lack of enantiocontrol in 
the absence of directing groups or specialized carbenoid donors and 
complex catalysts24. Structures 94 and 95 (D2-derived) are particu-
larly illustrative of this fact: it would be extremely challenging to access 
either of these in an enantioselective fashion with current synthetic 
technology (cyclopropanation or C–C cross-coupling). As testament 
to the power of this strategy to access diverse libraries, we synthesized 
an additional 48 enantioenriched compounds in a similar manner (see 
Extended Data Figs. 1 and 2 for details).
To further demonstrate the potential of this approach to simplify 
synthesis, we present six applications in the total synthesis of natural 
products and in both early- and late-stage medicinal chemistry programs 
(Fig. 3a–f). As mentioned above, alkaloid 1 has been a popular target 
of both academic and industrial scientists. Through the application of 
cycloaddition and cross-coupling, the native carboxylate required for the 
Diels–Alder reaction can be used directly to produce epibatidine (1) in 
five steps (for optimization and in-depth analysis of previous approaches, 
see Supplementary Information) with a 38% gram-scale overall yield 
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(Fig. 3a). It is worth noting that the key decarboxylative cross-coupling 
takes place with 95% isolated yield (gram-scale, 72% yield).
Saphris (asenapine, 102; Fig. 3b), an antipsychotic approved by 
the US Food and Drug Administration (FDA), is currently mar-
keted as a racemic mixture (although the (+)-isomer has superior 
pharmacokinetic properties)25. This near-symmetric molecule has been 
challenging to prepare enantioselectively, as the two aromatic systems 
differ only in one chlorine substituent. It is therefore hard to envisage a 
cycloaddition that could be rendered enantioselective for the prepara-
tion of 102, and only one enantioselective approach has been reported 
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in 16 steps26. However, 102 can be prepared in formally six steps, with 
complete enantiocontrol, from B2, through a strategy that could also 
be used to make an array of near-symmetric analogues.
Epothilone—a famous natural product that inhibits the dynamics 
of cellular microtubules and inspired the FDA-approved medicine 
Ixabepilone27—has been the subject of numerous synthetic studies 
and analogue campaigns28. Intermediate 105 (Fig. 3c) has been used 
during Nicolaou’s synthesis of a cyclobutyl-containing analogue of 
epothilone, but required 15 steps (24% overall yield) to be prepared in 
enantioenriched form from C1, via enzymatic desymmetrization and 
a series of carefully choreographed homologations28. Using the same 
starting material, C1, we have prepared intermediate 105 in only eight 
steps, through sequential desymmetrization, RCC with alkyne 103, 
hydrolysis, RCC with alkyl zinc 104, protecting-group exchange, and 
finally hydroboration/oxidation.
Differentially substituted norbornene rings have been shown to 
be useful phenyl bioisosteres in medicinal chemistry; however, their 
broad implementation is hindered by a lack of methods for their rapid 
modular construction (unlike the construction of aryl systems)29. In 
collaboration with Leo Pharma, we prepared a key target for an ongoing 
program (109; Fig. 3d) from Diels–Alder adduct 106 via alkene hydra-
tion and RCC with the pyrazole-boronic ester 108 in 44% yield. It is 
worth noting that this is, to our knowledge, the first report of a RCC 
reaction using a bis(pinacolato)diboron (Bpin) derivative rather than 
a boronic acid. This advance was achieved using an in situ prepared ate 
complex, prepared by adding one equivalent of n-BuLi relative to the 
aryl-Bpin donor30. We also used this modification of our Suzuki–RCC 
protocol to prepare cyclopropanes 91, 92 and 93.
Finally, an ongoing program at Eisai Pharmaceuticals necessitated 
the preparation of complex scaffold 114 (Fig. 3e), wherein the key 
structure–activity relationship to be explored resided at the aryl (green) 
portion of the molecule. This is a particularly powerful application of 
the strategy outlined herein, because a carboxylate—needed to achieve 
the diastereoselective Diels–Alder reaction to construct the decalin 
framework—served as a gateway for the exploration of chemical space 
at the desired position. Thus, an asymmetric Diels–Alder reaction 
using Corey’s oxazaborolidine31 catalyst, followed by functional group 
manipulations (see Supplementary Information), led to intermediate 
112, which could be cross-coupled with boronic acid 113 in a particu-
larly challenging context to deliver 114 and enable biological follow-up.
The strategy outlined here could be useful for more than just forging 
C–C linkages through cross-coupling. The incorporation of classic 
nucleophilic functionalization (in ketone synthesis) and decarboxy-
lative functionalization (in the Hunsdiecker reaction and in Curtius 
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and Wolff rearrangements) of intermediate adducts opens up innu-
merable possibilities for diversification, rendering access to previously 
inaccessible building blocks (Fig. 3f). As an example, we used a chiral 
2π enamine synthon to prepare 118, an inhibitor of the embryonic 
ectoderm development (EED) protein (Ki = 4 nM), which was previ-
ously prepared by AbbVie32 through a non-modular, racemic [3+2] 
approach in 1.9% overall yield. Our approach began with intermediate 
meso scaffold B2 and used RCC followed by Curtius rearrangement, 
yielding optically pure 118 in 13% overall yield.
The advance that we have described is largely strategic in nature, and 
thus the underlying limitations are tied mainly to individual param-
eters of a particular cycloaddition and ensuing RCC reactions. That 
said, cis-1,2-disubstituted products are not currently accessible unless 
downstream isomerization reactions are pursued, which need to be 
evaluated on a case-by-case basis. Although ligand-controlled RCC 
reactions might eventually address this issue, in its present form this 
platform for modular molecular assembly holds great promise for 
accessing new areas of chemical space. The combination of classic 
cycloaddition chemistry with newly emerging radical C–C coupling 
offers a powerful way to repurpose the most classic skeleton-building 
reactions of organic synthesis, to simplify the enantioselective prepa-
ration of building blocks, natural products and medicines.
Data availability
Metrical parameters for the structures of 11, 19, 23, 25, 28, 44, 45, 49, 65, C2, 
107, 1·2HCl and 118·2HCl are available free of charge from the Cambridge 
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the corresponding author on reasonable request.
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Extended Data Fig. 1 | Complete substrate scope of [4+2] cycloadditions/cross-couplings. See Supplementary Information for synthetic details.  
R1, R2 = (Het)Aryl, alkyl, alkenyl, alkynyl. X-ray structure data are available for compounds 11, 19, 23, 25, 28, 44, 45 and 49.
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Extended Data Fig. 2 | Complete substrate scope of [3+2], [2+2] and [2+1] sections. See Supplementary Information for synthetic details.  
R1, R2 = (Het)Aryl, alkyl, alkenyl, alkynyl. X-ray structure data are available for compounds C2 and 65.
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